<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <title>Paediatric Pain Manual – Nav Preview</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <style>
    * {
      box-sizing: border-box;
    }

    body {
      margin: 0;
      font-family: system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", sans-serif;
      display: flex;
      height: 100vh;
      color: #111827;
    }

    .sidebar {
      width: 320px;
      background: #f3f4f6;
      border-right: 1px solid #e5e7eb;
      padding: 12px;
      overflow-y: auto;
    }

    .sidebar-header {
      font-weight: 600;
      margin-bottom: 8px;
      font-size: 14px;
      text-transform: uppercase;
      letter-spacing: 0.04em;
      color: #6b7280;
    }

    .chapter {
      margin-bottom: 8px;
      border-radius: 8px;
      padding: 6px 8px;
    }

    .chapter-title {
      font-size: 14px;
      font-weight: 600;
      margin-bottom: 4px;
      cursor: pointer;
      display: flex;
      align-items: center;
      justify-content: space-between;
    }

    .chapter-title:hover {
      color: #1d4ed8;
    }

    .chapter-title span.chevron {
      font-size: 11px;
      color: #9ca3af;
      margin-left: 6px;
    }

    .subheading-list {
      margin-top: 4px;
      padding-left: 4px;
      border-left: 2px solid #e5e7eb;
    }

    /* Collapsed chapters hide their subheading list */
    .chapter.collapsed .subheading-list {
      display: none;
    }

    .subheading-btn {
      display: block;
      width: 100%;
      text-align: left;
      padding: 4px 6px;
      margin: 2px 0;
      border: none;
      border-radius: 6px;
      background: transparent;
      font-size: 13px;
      cursor: pointer;
      color: #374151;
    }

    .subheading-btn:hover {
      background: #e5e7eb;
    }

    .subheading-btn.selected {
      background: #dbeafe;
      color: #1d4ed8;
      font-weight: 500;
    }

    .content {
      flex: 1;
      padding: 16px 20px;
      overflow-y: auto;
      background: #ffffff;
    }

    .content h1 {
      margin-top: 0;
      font-size: 22px;
    }

    .content .meta {
      font-size: 13px;
      color: #6b7280;
      margin-bottom: 12px;
    }

    .pill {
      display: inline-flex;
      align-items: center;
      padding: 2px 8px;
      border-radius: 999px;
      background: #eff6ff;
      color: #1d4ed8;
      font-size: 12px;
      margin-right: 6px;
    }

    .placeholder-box {
      margin-top: 16px;
      padding: 16px;
      border-radius: 12px;
      border: 1px dashed #d1d5db;
      background: #f9fafb;
      font-size: 13px;
      color: #4b5563;
    }

    .search-box {
      margin-bottom: 8px;
    }

    .search-input {
      width: 100%;
      padding: 6px 8px;
      border-radius: 6px;
      border: 1px solid #d1d5db;
      font-size: 13px;
    }

    .search-input:focus {
      outline: none;
      border-color: #2563eb;
      box-shadow: 0 0 0 1px #2563eb33;
    }

    .pdf-container {
      margin-top: 16px;
      border: 1px solid #e5e7eb;
      border-radius: 12px;
      background: #0f172a;
      min-height: 420px;
      display: flex;
      align-items: center;
      justify-content: center;
      position: relative;
      overflow: hidden;
    }

    .pdf-container canvas {
      width: 100%;
      height: auto;
      display: block;
      background: #1f2937;
    }

    .pdf-status {
      position: absolute;
      top: 12px;
      left: 12px;
      padding: 4px 10px;
      border-radius: 999px;
      background: rgba(15, 23, 42, 0.8);
      color: #f8fafc;
      font-size: 12px;
    }

    .pdf-container.error {
      background: #fff;
      color: #b91c1c;
      border-color: #fecaca;
      min-height: auto;
      padding: 16px;
      display: block;
    }

    .page-controls {
      display: flex;
      align-items: center;
      justify-content: flex-end;
      gap: 8px;
      margin-top: 8px;
    }

    .page-btn {
      border: 1px solid #d1d5db;
      background: #fff;
      border-radius: 6px;
      padding: 4px 10px;
      font-size: 13px;
      cursor: pointer;
      color: #1f2937;
    }

    .page-btn:hover:not(:disabled) {
      border-color: #2563eb;
      color: #1d4ed8;
    }

    .page-btn:disabled {
      opacity: 0.4;
      cursor: not-allowed;
    }

    .page-indicator {
      font-size: 12px;
      color: #6b7280;
      font-weight: 500;
    }

    .section-text {
      margin-top: 16px;
      padding: 16px;
      border: 1px solid #e5e7eb;
      border-radius: 12px;
      background: #fefefe;
      font-size: 14px;
      line-height: 1.6;
    }

    .section-text p {
      margin: 8px 0;
    }

    .section-text ul {
      margin: 12px 0;
      padding-left: 20px;
    }

    .section-text table {
      width: 100%;
      border-collapse: collapse;
      margin: 12px 0;
      font-size: 13px;
    }

    .section-text td {
      border: 1px solid #e5e7eb;
      padding: 4px 6px;
      vertical-align: top;
    }

    .section-text .text-muted {
      color: #6b7280;
      font-style: italic;
    }
  </style>
</head>
<body>
  <div class="sidebar">
    <div class="sidebar-header">Chapters & Sections</div>
    <div class="search-box">
      <input id="searchInput" class="search-input" placeholder="Search headings..." />
    </div>
    <div id="sidebarContent"></div>
  </div>
  <div class="content">
    <h1>Paediatric Pain Manual – Navigation Preview</h1>
    <p class="meta">
      Click a subheading on the left to see details. In Teams, this is where you'd:
      <span class="pill">Scroll PDF to page X</span>
      <span class="pill">Highlight section</span>
    </p>
    <div class="placeholder-box">
      <strong>No section selected yet.</strong><br/>
      This pane is acting like your future Teams tab content area.<br/>
      When you click a heading on the left, you'll see:
      <ul>
        <li>Heading text + parent chapter</li>
        <li>The PDF page rendered via pdf.js</li>
        <li>Quick metadata chips you can reuse in Teams</li>
        <li>A short description of what the Teams app would do</li>
      </ul>
    </div>
  </div>

  <script src="vendor/pdfjs/pdf.min.js"></script>
  <script>
    const pdfjsBuild = window['pdfjs-dist/build/pdf'];
    if (pdfjsBuild && pdfjsBuild.GlobalWorkerOptions) {
      pdfjsBuild.GlobalWorkerOptions.workerSrc = 'vendor/pdfjs/pdf.worker.min.js';
      window.pdfjsLib = pdfjsBuild;
    } else {
      console.error('pdf.js failed to initialize');
    }
  </script>
  <script>
    // The tree + metadata from detect_headings.py --json
    const headingData = {"pdf": "Pain Management Handbook 2019. palliative (PDF).pdf", "pdf_path": "Pain Management Handbook 2019. palliative (PDF).pdf", "headings": [{"id": 0, "page": 1, "top": 95.6, "level": 1, "font_size": 24.0, "text": "Paediatric Acute Pain", "content_html": "<p class=\"text-muted\">No text detected for this section.<\/p>", "children": []}, {"id": 1, "page": 1, "top": 123.2, "level": 1, "font_size": 24.0, "text": "Management Handbook", "content_html": "<p>Waikato Hospital<\/p><p>Department of Anaesthesia<\/p><p>th<\/p><p>7 edition 2019<\/p><p>Editor: Dr Andrew Muncaster<\/p><p>Contributors: Drs C Buchanan, M Dick, H Douglas, E Johannsen,<\/p><p>A Martin, H Stone, T Watson<\/p><p>Disclaimer:<\/p><p>This material is designed as a guide only for the care of paediatric patients at Waikato<\/p><p>Hospital. It does not replace decisions tailored to individual patients by the clinicians<\/p><p>responsible for their care. No responsibility is taken for factual errors.<\/p><p>Page 1 of 57<\/p><p>CONTENTS<\/p><p>1. Introduction ....................................................................................................................... 4<\/p><p>2. Principles Of Analgesic Administration In Children ........................................................... 5<\/p><p>3. Managing pain using simple and oral analgesics .............................................................. 6<\/p><p>3.1 Paracetamol .............................................................................................................. 6<\/p><p>3.2 Diclofenac (Voltaren)................................................................................................. 7<\/p><p>3.3 Ibuprofen (Brufen) ..................................................................................................... 7<\/p><p>3.4 Parecoxib (Dynastat)................................................................................................. 8<\/p><p>3.3 Celecoxib .................................................................................................................. 9<\/p><p>3.5 Tramadol ................................................................................................................... 9<\/p><p>3.6 Oral Morphine Preparations .................................................................................... 10<\/p><p>3.7 Oxycodone .............................................................................................................. 11<\/p><p>3.8 Codeine Phosphate ................................................................................................ 13<\/p><p>4. Managing Pain Using Parenteral Analgesics .................................................................. 14<\/p><p>4.1 Protocol for Intermittent IV Opioids ......................................................................... 14<\/p><p>4.2 Protocol for Intravenous Opioid Infusions ............................................................... 14<\/p><p>4.3 Protocol for Nurse Controlled Analgesia (NCA) ...................................................... 16<\/p><p>4.4 Protocol for Patient Controlled Analgesia (PCA) ..................................................... 17<\/p><p>4.5 Protocol for Subcutaneous Morphine Boluses ........................................................ 18<\/p><p>5. Managing Pain Using Epidurals ...................................................................................... 20<\/p><p>6. Managing Pain Using Regional Infusions ....................................................................... 24<\/p><p>7. Managing Pain Using Entonox ........................................................................................ 27<\/p><p>8. Managing Adverse Effects &amp; Troubleshooting ................................................................ 29<\/p><p>8.1 LA Toxicity .............................................................................................................. 29<\/p><p>8.1.1 Management of Impending LA Toxicity ........................................................... 29<\/p><p>8.1.2 Cardiac Resuscitation in the Event of Suspected LA Toxicity ......................... 30<\/p><p>8.2 Management of Common Opioid Side-Effects ........................................................ 30<\/p><p>8.2.1 Management of Overdose ............................................................................... 30<\/p><p>8.2.2 Management of Pruritus .................................................................................. 30<\/p><p>8.3 Management of Nausea &amp; Vomiting ....................................................................... 31<\/p><p>8.4 Management of Common Epidural Problems ......................................................... 33<\/p><p>8.4.1 Epidural Disconnection .................................................................................... 33<\/p><p>8.4.2 Inadequate Analgesia ...................................................................................... 33<\/p><p>Page 2 of 57<\/p><p>8.5 Troubleshooting ...................................................................................................... 34<\/p><p>9. Monitoring ....................................................................................................................... 35<\/p><p>9.1 Pain Assessment &amp; Measurement .......................................................................... 35<\/p><p>9.2 Monitoring ............................................................................................................... 36<\/p><p>9.3 Some Normal Physiological Values for Children 0-16 Years .................................. 37<\/p><p>10. Managing Pain from Burns .............................................................................................. 38<\/p><p>11. Other Analgesic Medications .......................................................................................... 40<\/p><p>11.1 Fentanyl Patches .................................................................................................. 40<\/p><p>11.2 Gabapentin ........................................................................................................... 41<\/p><p>11.3 Amitriptyline .......................................................................................................... 42<\/p><p>11.4 Diazepam .............................................................................................................. 43<\/p><p>11.5 Intranasal Fentanyl................................................................................................ 43<\/p><p>12. Preoperative Medications ................................................................................................ 44<\/p><p>12.1 Topical Local Anaesthetics ................................................................................... 44<\/p><p>12.2 Premedications ..................................................................................................... 44<\/p><p>13. Managing Pain Following Tonsillectomy ......................................................................... 47<\/p><p>14. Managing pain following scoliosis surgery ...................................................................... 49<\/p><p>14.1 Intraoperative Analgesia ....................................................................................... 49<\/p><p>14.2 Postoperative Analgesia ....................................................................................... 49<\/p><p>15. Initial treatment of chronic pain in children ...................................................................... 51<\/p><p>15.1 Types of Chronic Pain in Children......................................................................... 51<\/p><p>15.2 Management ......................................................................................................... 51<\/p><p>15.2.1 Referal to the Pain Service ............................................................................ 52<\/p><p>15.2.2 Initial approach and non-drug treatments ...................................................... 52<\/p><p>15.2.3 Drugs ............................................................................................................. 53<\/p><p>16. Palliative Care, Terminal Illness And End-Of-Life ........................................................... 55<\/p><p>16.1 Key Aspects of Care ............................................................................................. 55<\/p><p>16.2 Symptom Management ......................................................................................... 55<\/p><p>16.2.1 General Approach ......................................................................................... 55<\/p><p>16.2.2 Pain Management ......................................................................................... 56<\/p><p>16.3 Resources ............................................................................................................. 57<\/p><p>Page 3 of 57<\/p><p>1. INTRODUCTION<\/p><p>The purpose of this handbook is to assist with the education of hospital staff in the commonly<\/p><p>available methods of acute pain relief at Waikato Hospital.<\/p><p>It is intended to be a guide which medical and nursing staff can refer to when prescribing and<\/p><p>managing pain relief in children.<\/p><p>It is not intended to be exhaustive or to restrict the way individuals practice, but children<\/p><p>admitted to hospital may benefit from a more co-ordinated approach to pain management.<\/p><p>Referrals and advice:<\/p><p>The Department of Anaesthesia provides a Paediatric Acute Pain Management Service<\/p><p>(PAPS) which is involved in the treatment of all types of acute pain. For in-hours<\/p><p>consultation, refer to the \u2018Amion Rostering\u2019 page on the intranet (Look on the Anaesthetics<\/p><p>roster for \u2018Paed Pain\u2019). If this is unsuccessful, phone the Duty Anaesthetist (23322), who will<\/p><p>direct you to the Paediatric Anaesthetist covering pain for the week. The Anaesthetist is likely<\/p><p>to be working in a theatre, but bearing this in mind they will respond to phone calls as soon<\/p><p>as possible. For out-of-hours problems, phone the Anaesthetic Registrar covering Obstetrics<\/p><p>(23470) who will consult with the on-call Paediatric Anaesthetist if unable to resolve the<\/p><p>problem.<\/p><p>Referrals from within the Department of Anaesthesia:<\/p><p>When referring children to the PAPS, it would be appreciated if the Anaesthetist could<\/p><p>please:<\/p><ul><li>\u2022<\/li><\/ul><p>In-hours \u2013 phone the Paediatric Anaesthetist covering pain for the week<\/p><ul><li>\u2022<\/li><\/ul><p>Out-of-hours \u2013 phone the on-call Paediatric Anaesthetist at a reasonable hour<\/p><ul><li>\u2022<\/li><\/ul><p>Place a patient sticker in the PAPS book (Red A4) found in Level 2 PACU<\/p><p>(document the procedure, type of pain relief and ward)<\/p><ul><li>\u2022<\/li><\/ul><p>Please DO NOT fill out an Adult Pain Referral form<\/p><p>Page 4 of 57<\/p><p>2. PRINCIPLES OF ANALGESIC ADMINISTRATION IN CHILDREN<\/p><p>There are some major differences between paediatric pain relief and adult pain relief, and<\/p><p>this may not be readily appreciated by medical and nursing staff who rotate from adult areas.<\/p><p>Some general principles apply in children:<\/p><ul><li>\u2022<\/li><\/ul><p>Paediatric analgesia needs to be calculated on a mg/kg basis and these dosages need to<\/p><p>be rounded off to make volume calculations easy.<\/p><ul><li>\u2022<\/li><\/ul><p>Children do not like intramuscular (IM) injections and they should not be used<\/p><p>IM injections are unpredictable, largely ineffective<\/p><p>unless special circumstances exist.<\/p><p>and many children will deny having pain to avoid injections. Intravenous, oral and rectal<\/p><p>are the preferred routes of administration.<\/p><ul><li>\u2022<\/li><\/ul><p>Techniques such as opioid infusions, Nurse Controlled Analgesia (NCA), Patient<\/p><p>Controlled Analgesia (PCA), epidural infusions, regional infusions and Entonox are freely<\/p><p>available and should be used if indicated.<\/p><ul><li>\u2022<\/li><\/ul><p>Following the administration of oral, subcutaneous (or IM) opioids, 60 minutes should<\/p><p>elapse before starting opioid infusions, NCA, PCA, or epidurals.<\/p><p>No other opioids or<\/p><p>sedatives should be given while using these techniques unless ordered by PAPS.<\/p><ul><li>\u2022<\/li><\/ul><p>Pain is best treated with continuous methods of analgesic administration (e.g. infusions<\/p><p>or PCA). Mild pain can usually be adequately controlled with intermittent bolus dose<\/p><p>administration.<\/p><ul><li>\u2022<\/li><\/ul><p>Neonates and some ex-premature infants (up to 60 weeks post-conceptual age) may be<\/p><p>sensitive to opioids. If they require opioid analgesics then the method and doses should<\/p><p>be discussed with the Consultant involved.<\/p><ul><li>\u2022<\/li><\/ul><p>When faced with unusually high or increasing requirements of pain relief think of<\/p><p>alternative causes of pain (e.g. compartment syndrome, pressure necrosis or other<\/p><p>surgical complications).<\/p><ul><li>\u2022<\/li><\/ul><p>Hospital approved protocols are available for all the common methods and are included<\/p><p>in this handbook.<\/p><p>Page 5 of 57<\/p><p>3. MANAGING PAIN USING SIMPLE AND ORAL ANALGESICS<\/p><p>3.1 Paracetamol<\/p><p>Paracetamol is an analgesic suitable for mild pain or in conjunction with other analgesics<\/p><p>for more severe pain. Its mechanism of action is not clear. Paracetamol\u2019s main strength is<\/p><p>its excellent side effect profile, with serious complications being very rare despite<\/p><p>extensive worldwide use over a long period of time.<\/p><p>Liver damage from Paracetamol is a very rare problem despite its widespread use. Risk<\/p><p>factors include, prolonged fasting, febrile illness, use of P450 inducing drugs (eg isoniazid)<\/p><p>and probably most importantly a unique genetic predisposition. If children are considered<\/p><p>at risk, consideration should be given to decreasing the dose of Paracetamol if given for<\/p><p>more than 1-2 days. Dosing limits will always be controversial.<\/p><p>Tablets (500mg)<\/p><p>Preparations:<\/p><p>Syrup (120mg/5ml and 250mg/5ml)<\/p><p>Suppositories (50, 125, 250, and 500mg)<\/p><p>Intravenous (Perfalgan 1000mg/100ml)<\/p><p>Dosage:<\/p><p>Oral:<\/p><table><tr><td>Neonates 32 weeks \u2013 44 weeks<\/td><td>10mg/kg 6hrly prn<\/td><td>- max 40mg/kg/day<\/td><\/tr><tr><td>Neonates 44 weeks \u2013 6 months<\/td><td>15mg/kg 6hrly prn<\/td><td>- max 60mg/kg/day<\/td><\/tr><tr><td>&gt; 6 months old<\/td><td>15mg/kg 4-6hrly prn<\/td><td>- max 60-90mg/kg/day<\/td><\/tr><\/table><ul><li>\u2022<\/li><\/ul><p>In neonates a single loading dose of 20mg/kg may be given if the neonatologist is<\/p><p>in agreement (paracetamol has a large volume of distribution in neonates)<\/p><ul><li>\u2022<\/li><\/ul><p>Anaesthetist may chart 120 mg/kg/day for a short time period in selected patients<\/p><ul><li>\u2022<\/li><\/ul><p>Review Paracetamol dose after 48 hours<\/p><ul><li>\u2022<\/li><\/ul><p>Suggestions for extended use:<\/p><p>After 8 days:    reduce dose to max 45mg/kg/day<\/p><p>After 14 days:    reduce dose to max 30mg/kg/day<\/p><p>Rectal:<\/p><ul><li>\u2022<\/li><\/ul><p>Absorption is slow and variable \u2013 the oral route should be used when possible<\/p><ul><li>\u2022<\/li><\/ul><p>Max daily dose is same as oral route<\/p><p>Intravenous (Perfalgan):<\/p><table><tr><td>Neonates 32 weeks \u2013 44 weeks<\/td><td>7.5mg/kg 6hrly prn<\/td><td>- max 30mg/kg/day<\/td><\/tr><tr><td>Neonates 44 weeks \u2013 3 months<\/td><td>10mg/kg 6hrly prn<\/td><td>- max 40mg/kg/day<\/td><\/tr><tr><td>&gt; 3 months old<\/td><td>15mg/kg 6hrly prn<\/td><td>- max 60mg/kg/day<\/td><\/tr><\/table><ul><li>\u2022<\/li><\/ul><p>Chart only for 2 days then review<\/p><ul><li>\u2022<\/li><\/ul><p>Convert to oral as soon as possible<\/p><p>Page 6 of 57<\/p><ul><li>\u2022<\/li><\/ul><p>IV Paracetamol may be considered in patients unable to take or absorb oral<\/p><p>Paracetamol. Following major surgery it provides better analgesia and opioid<\/p><p>sparing effect than rectal Paracetamol which has slow, poor and very variable<\/p><p>absorption<\/p><p>3.2 Diclofenac (Voltaren)<\/p><p>Diclofenac is an NSAID that has a low dose suppository preparation that is licensed for<\/p><p>use in children more than 1 year of age. Caution is required in patients with<\/p><p>hypovolaemia, renal dysfunction, coagulopathy, GI bleeding, aminoglycosides and in the<\/p><p>immediate post-operative period.<\/p><p>Tablets (25, 50mg, and 75SRmg)<\/p><p>Preparation:<\/p><p>Suppository (12.5, 25, 50mg)<\/p><p>0.5-1.0mg/kg 12 hourly prn<\/p><p>Dosage:<\/p><p>3.3 Ibuprofen (Brufen)<\/p><p>Ibuprofen is an NSAID that has a syrup preparation and can be used in children older than<\/p><p>6 months. NSAIDS differ in their nociceptive, anti-inflammatory and side effect profiles.<\/p><p>Ibuprofen has been well validated as an analgesic. The usual cautions apply in patients<\/p><p>with hypovolaemia, renal dysfunction, coagulopathy, GI bleeding, aminoglycosides and<\/p><p>the immediate post-operative period.<\/p><p>Syrup (100mg/5ml)<\/p><p>Preparation:<\/p><p>Tablets (200, 400mg)<\/p><p>5-10mg/kg 6 hourly prn (max 40mg/kg/day)<\/p><p>Dosage:<\/p><p>Ibuprofen is an NSAID that is available as a syrup or tablet. It has been well validated as<\/p><p>an analgesic in children. Studies show a safety profile that is at least as good as<\/p><p>paracetamol when used in patients as young as 3 months old. Some centres are using<\/p><p>Ibuprofen down to 1 month of age, however this cannot be recommended at this time.<\/p><p>(There is also limited safety data from studies looking at its use for patent ductus<\/p><p>arteriosus closure in premature neonates - 7% of neonates had renal impairment which<\/p><p>was completely reversible).<\/p><p>There are some developmental concerns when using Ibuprofen in young babies. Like all<\/p><p>NSAIDs, Ibuprofen disrupts prostaglandin production, and prostaglandins are involved in<\/p><p>regulation of cerebral and renal blood flow, non-REM sleep and ductus arteriosus closure.<\/p><p>In addition, it should be remembered that renal maturity is not reached until 6-12 months.<\/p><p>There are also other pharmacokinetic differences in infants which are complex and may<\/p><p>affect dosing.<\/p><p>hypovolaemia, renal dysfunction,<\/p><p>NSAIDs precautions for all children include:<\/p><p>coagulopathy, jaundice, GI bleeding, aminoglycosides and the immediate post-operative<\/p><p>period. Most asthmatic children tolerate NSAIDs well, but caution should be exercised in<\/p><p>older children with severe asthma and nasal polyp disease, where the rate of severe<\/p><p>exacerbation may be as high as 30%.<\/p><p>Suspension (100 mg/5 ml)<\/p><p>Preparation:<\/p><p>Tablets (200 mg, 400 mg)<\/p><p>Page 7 of 57<\/p><p>Dosage:<\/p><p>3-6 months    5mg/kg 8-12 hourly prn (may use 10mg/kg loading dose)<\/p><p>&gt;6 months old    5-10mg/kg 6-8 hourly prn<\/p><ul><li>\u2022<\/li><\/ul><p>Review Ibuprofen dose after 3 days and for consider reducing dose to 5mg/kg<\/p><p>3.4 Parecoxib (Dynastat)<\/p><p>Parecoxib is an NSAID that specifically inhibits the enzyme cyclooxygenase-2 (COX 2).<\/p><p>Paediatric trial data is very limited. It is given intravenously, and in adults, it has been<\/p><p>shown to be as effective or more effective than the older NSAIDs for treatment of acute<\/p><p>pain. It is opioid sparing and associated with less post-operative nausea and vomiting post<\/p><p>tonsillectomy. Advantages of parecoxib over other NSAIDs are that it does not impair<\/p><p>platelet function, and gastrointestinal ulceration is less likely. In addition, the ability to give<\/p><p>the drug intravenously means a more reliable NSAID dose (ie 100% bioavailability in<\/p><p>children with an IV cannula in place), compared with traditional perioperative rectal<\/p><p>NSAID, or where oral dosing is inappropriate. Parecoxib is not licensed for use in children.<\/p><p>However, it may on occasion be a useful analgesic in the paediatric setting. It should only<\/p><p>be charted by PAPS.<\/p><p>The adverse effects of intravenous Parecoxib in adult clinical trials are similar to those for<\/p><p>NSAIDs, with serious adverse effects such as acute renal failure, Stevens-Johnson<\/p><p>syndrome, and hypersensitivity reactions including anaphylaxis and angioedema<\/p><p>occurring at low incidence. The usual cautions apply in patients with hypovolaemia, renal<\/p><p>dysfunction, coagulopathy and GI bleeding.<\/p><p>Contraindications:<\/p><ul><li>\u2022<\/li><\/ul><p>Sulphur allergy<\/p><ul><li>\u2022<\/li><\/ul><p>Severe hepatic impairment<\/p><ul><li>\u2022<\/li><\/ul><p>Concurrent use of another NSAID<\/p><p>Cautions:<\/p><ul><li>\u2022<\/li><\/ul><p>Allergic like reactions with NSAIDs/ aspirin<\/p><p>According to adult data, COX-2 inhibitors are considered safe in most of<\/p><p>o<\/p><p>these patients, but a small percentage have cross-sensitivity, so an oral<\/p><p>challenge under medical supervision is advisable<\/p><p>Considered safe in paediatric patients with NSAID exacerbated respiratory<\/p><p>o<\/p><p>disease<\/p><p>:    Intravenous (Dynastat)<\/p><p>Preparations<\/p><p>2 yrs and older (no studies looking at safety in younger age to date)<\/p><p>Dosage:<\/p><p>1 mg/kg (max 40mg) once daily IV<\/p><ul><li>\u2022<\/li><\/ul><p>Chart only for 2 days then review<\/p><ul><li>\u2022<\/li><\/ul><p>Convert to oral as soon as possible<\/p><p>Page 8 of 57<\/p><p>3.3 Celecoxib<\/p><p>Celecoxib is a COX 2 inhibitor \u2013 it is an NSAID that selectively inhibits the enzyme<\/p><p>cyclooxygenase-2 (COX 2). Being a selective inhibitor it has the same advantages as<\/p><p>Parecoxib, except that Celecoxib is an oral drug. Paediatric trial data is very limited.<\/p><p>See Parecoxib above<\/p><p>Contraindications:<\/p><p>See Parecoxib above<\/p><p>Cautions:<\/p><p>Capsule (100mg, 200mg)<\/p><p>Preparation:<\/p><p>Solution (10mg/ml \u2013 disperse 100mg capsule in 10ml water)<\/p><p>12 months and older<\/p><p>Dosage:<\/p><p>4 mg/kg (max 200mg per dose) BD prn<\/p><p>3.5 Tramadol<\/p><p>Tramadol is used for treatment of moderate to severe pain. Its action is by both opioid and<\/p><p>non-opioid monoaminergic mechanisms (serotoninergic, noradrenergic), and it may also<\/p><p>have some local anaesthetic action on peripheral nerves. It may be given orally and IV,<\/p><p>although both PR and IM preparations have also been used. Advantages over opioids<\/p><p>such as Morphine may include less sedation, less respiratory depression and less<\/p><p>constipation. Tramadol may not be as suitable as opioids for more severe pain.<\/p><p>In New Zealand Tramadol is currently licensed for use in children aged 2 years and older.<\/p><p>However, it has been used internationally for many years in children as young as<\/p><p>newborn.<\/p><p>The risks and benefits of Tramadol use in early life are not straightforward \u2013 there are a<\/p><p>number of important considerations. Both Tramadol and its M1 metabolite (formed by<\/p><p>CYP2D6 liver enzyme) are active and provide analgesia via different pathways. Tramadol<\/p><p>parent drug causes sedation (but does not cause respiratory depression), however the M1<\/p><p>\u00b5<\/p><p>metabolite has is a opioid agonist (200 x more receptor affinity than Tramadol itself) and<\/p><p>may cause both sedation and respiratory depression.<\/p><p>At term, the newborn\u2019s CYP2D6 activity is still immature and the ability to convert<\/p><p>Tramadol to M1 is 50% compared to adult levels. The newborn\u2019s ability to renally excrete<\/p><p>M1 is also reduced, and is 70% compared to adults. However, as a result of the slow<\/p><p>maturation of CYP2D6, the plasma concentrations of M1 are low until infants are 3<\/p><p>months old \u2013 at this point in time the immature renal elimination becomes relevant and<\/p><p>higher M1 levels may occur. Renal excretion and M1 clearance reaches 90% adult levels<\/p><p>by age 1 year.<\/p><p>In addition, it must be remembered that the descending pain tracts in the neonate may not<\/p><p>be functionally mature, hence the serotoninergic/ noradrenergic advantages of the drug<\/p><p>\u00b5<\/p><p>over conventional opioids may not apply, with agonism predominating.<\/p><p>In 2017 in the United Sates, the FDA in started restricting the use of both Tramadol and<\/p><p>codeine in children, after identifying cases involving serious breathing problems and<\/p><p>death. Among other groups, their restrictions and warnings have included: children with<\/p><p>obesity, sleep disordered breathing, and other breathing problems, post-tonsillectomy and<\/p><p>breast feeding mothers.<\/p><p>In response to this, SPANZA (the Society of Paediatric Anaesthesia of New Zealand and<\/p><p>Page 9 of 57<\/p><p>Australia) put out two statements in 2017 regarding Tramadol use. Genetic variation in<\/p><p>CYP2D6 exists and ultra-rapid metabolisers may be more at risk in certain situations,<\/p><p>although this is less certain with Tramadol than with Codeine. Readers are directed to<\/p><p>these statements in the references; their content is acknowledged in the cautions/ dosage<\/p><p>recommendations below.<\/p><p>Key points:<\/p><p>Tramadol is safer than opioids in breast feeding mothers<\/p><p>Tramadol doses should be limited for acute pain after tonsillectomy<\/p><p>Children with obstructive sleep apnea who have undergone tonsillectomy should be<\/p><p>observed overnight to assess response and sensitivity to opioids<\/p><p>SPANZA Advisory on Tramadol - Use during breast feeding and the neonate<\/p><p>SPANZA Advisory on Tramadol - Warning on tramadol use in children<\/p><p>Caution must be used with certain \u201cat risk\u201d patients:<\/p><ul><li>\u2022<\/li><\/ul><p>Day surgery patients<\/p><ul><li>\u2022<\/li><\/ul><p>Post-tonsillectomy patients<\/p><ul><li>\u2022<\/li><\/ul><p>Patients with obstructive sleep apnoea or obesity or severe lung disease<\/p><ul><li>\u2022<\/li><\/ul><p>Patients with severe hepatic and renal impairment<\/p><ul><li>\u2022<\/li><\/ul><p>Patients susceptible to seizures<\/p><ul><li>\u2022<\/li><\/ul><p>Patients on psychotropic medication (SSRI)<\/p><p>Side effects:<\/p><ul><li>\u2022<\/li><\/ul><p>Nausea and vomiting \u2013 around 10% of children<\/p><ul><li>\u2022<\/li><\/ul><p>Dizziness<\/p><ul><li>\u2022<\/li><\/ul><p>Sedation<\/p><ul><li>\u2022<\/li><\/ul><p>Respiratory depression (rare)<\/p><p>Tablets (50mg, and 100SRmg)<\/p><p>Preparation:<\/p><p>Oral solution (10mg/ml)<\/p><p>Intravenous (50mg/ml)<\/p><p>Drops 100 mg/ml delisted in NZ during 2017 after several unintentional overdoses<\/p><p>worldwide<\/p><p>1.5-2mg/kg 6 hourly prn PO<\/p><p>Dosage:<\/p><p>1-2mg/kg 4-6 hourly prn IV in general population (up to 400 mg daily)<\/p><p>0.5-1 mg/kg 6-8 hourly prn IV/PO in post tonsillectomy/at risk patients<\/p><p>Note that Tramadol and Ondansetron may decrease each other\u2019s efficacy to a mild<\/p><p>degree.<\/p><p>3.6 Oral Morphine Preparations<\/p><p>Oral Morphine is widely used and highly effective for acute and chronic severe pain but<\/p><p>requires a functional gastrointestinal tract. It has a low bioavailability (30-40%) and thus<\/p><p>requires higher doses than parenteral Morphine. All oral opioid prescriptions should be for<\/p><p>limited duration. Monitoring of patients is required following doses of oral opioids. (See<\/p><p>Section 9 of the Handbook)<\/p><p>Page 10 of 57<\/p><p>Morphine Elixir<\/p><p>Indicated for children unable to swallow tablets.<\/p><p>Syrup (1mg/ml only)<\/p><p>Preparation:<\/p><p>0.3mg/kg 4 hourly prn<\/p><p>Dosage:<\/p><p>Morphine Tabs \u2013 Immediate Release (Sevredol)<\/p><p>Indicated for children that are comfortable with swallowing tablets.<\/p><p>Tablets (10, 20mg)<\/p><p>Preparation:<\/p><p>0.1-0.3mg/kg 2-4 hourly prn<\/p><p>Dose:<\/p><p>Morphine Tabs \u2013 Controlled Release (LA Morph)<\/p><p>Indicated for children that are able to swallow tablets that have prolonged severe opioid<\/p><p>responsive pain e.g. cancer pain or post-operative pain.<\/p><p>Once swallowed LA Morph is<\/p><p>like an infusion that cannot be stopped!<\/p><p>Tablets (10, 30, 60 &amp; 100mg)<\/p><p>Preparation:<\/p><p>Calculate the amount of parenteral Morphine used in the previous 24<\/p><p>Dose:<\/p><p>hrs, then chart this orally as a divided dose (BD).<\/p><p>Eg, if the patient used 60mg of IV Morphine in the previous 24hrs then<\/p><p>chart LA Morph (controlled release morphine) 30mg BD.<\/p><p>Observations:<\/p><p>Following doses of oral controlled release Morphine, monitoring must continue<\/p><p>until 12 hours after last dose administered.<\/p><p>See Section 9 of the Handbook.<\/p><p>Whenever prescribing slow release preparations, it is useful to prescribe an<\/p><p>immediate release opioid on a PRN basis for \u201cbreak-through pain\u201d. This dose is<\/p><p>usually equal to 10% of the daily Morphine requirement.<\/p><p>3.7 Oxycodone<\/p><p>Oxycodone is a semi-synthetic opioid, useful for treatment of moderate to severe pain.<\/p><p>The analgesic effects of Oxycodone are similar to Morphine, though in adults it is said to<\/p><p>have a more rapid onset and longer duration. Both drugs, Morphine and Oxycodone,<\/p><p>cause typical opioid side-effects but several reports suggest that hallucinations may be<\/p><p>Page 11 of 57<\/p><p>less frequent with Oxycodone. Oxycodone releases significantly less histamine than<\/p><p>Morphine. Oxycodone syrup is not as bitter/ unpleasant tasting as Morphine elixir.<\/p><p>Oxycodone has a good oral bioavailability (80%; compared to Morphine 25% and Codeine<\/p><p>50-60%). Oxycodone is eliminated more slowly (t 3 hrs) than Morphine. Metabolism of<\/p><p>1/2<\/p><p>Oxycodone does not produce significant levels of active metabolites, however clearance<\/p><p>of Oxycodone may be reduced in renal and hepatic impairment. In renal failure clearance<\/p><p>is reduced, with a resultant increase in half-life (t 3.9 hrs in uraemic patients). In liver<\/p><p>1/2<\/p><p>failure changes in clearance and half-life are more marked.<\/p><p>Oxycodone like Morphine comes in both immediate release (Oxynorm/ Endone) and<\/p><p>controlled release (Oxycontin) preparations \u2013<\/p><p>it is important that the two preparations<\/p><p>are not confused.<\/p><p>Oxycodone \u2013 Immediate Release (Oxynorm, Endone)<\/p><p>Syrup (5mg/5ml)<\/p><p>Preparation:<\/p><p>Tablets (5, 10, 20mg)<\/p><p>1-12months 0.05-0.1 mg/kg 4 hourly prn<\/p><p>Dose:<\/p><p>&gt;12months    0.1-0.25mg/kg 4 hourly prn<\/p><p>Suggested uses:<\/p><p>Inpatients - Oxycodone is a useful analgesic for acute post-operative pain and may be<\/p><p>used as an alternative to codeine and for \u2018stepping down\u2019 from intravenous opioids.<\/p><p>Day-stay surgery - Oxycodone may be useful in infants and children who have moderate<\/p><p>to severe pain and who are likely to need only one dose of oral opioids (it should not be<\/p><p>dispensed for \u201cout of hospital use\u201d following day surgery). Typically:<\/p><ul><li>\u2022<\/li><\/ul><p>Hypospadias repair<\/p><ul><li>\u2022<\/li><\/ul><p>Tonsillectomy<\/p><p>Converting to Oxycodone<\/p><p>Total mg/ day Oxycodone = Total mg/ day of Previous Opioid x f<\/p><p>Previous Opioid    Conversion factor ( f )<\/p><p>Intravenous    Oral<\/p><table><tr><td>Morphine<\/td><td>2<\/td><td>0.5<\/td><\/tr><tr><td>Fentanyl<\/td><td>100<\/td><td>NA<\/td><\/tr><tr><td>Codeine<\/td><td>NA<\/td><td>0.1<\/td><\/tr><tr><td>Tramadol<\/td><td>0.2<\/td><td>0.2<\/td><\/tr><tr><td>Methadone<\/td><td>2<\/td><td>1.3<\/td><\/tr><\/table><p>Eg, if the patient used 60mg of IV Morphine in the previous 24hrs then chart Total of<\/p><p>120mg/ day of Oxycodone ie, 60 x ( f = 2) = 120. This could be charted as Oxycodone<\/p><p>(immediate release) 20mg 4 hourly prn, orally.<\/p><p>Page 12 of 57<\/p><p>Oxycodone    Codeine<\/p><p>Parent drug is active \u2013 all patients    Prodrug (must be metabolised to<\/p><p>receive analgesia. Metabolised by    morphine in order to provide analgesia)<\/p><p>CYP3A4 and to lesser extent CYP2D6.    \u2013 not all patients are able to this.<\/p><p>Unclear how much CYP2D6    Metabolised by CYP2D6, which is<\/p><p>polymorphism affects pharmacokinetics.    polymorphic \u2013 some patients (5-10%<\/p><p>Caucasians) poor/ no activity therefore<\/p><p>limited analgesia, while some have<\/p><p>increased activity and therefore<\/p><p>increased morphine levels.<\/p><p>Duration action 3-4 hrs    Duration action 3-4 hrs<\/p><p>Onset action 45 mins    Onset action 1 hr<\/p><p>Oral bioavailability 70-80%    Oral bioavailability 50-60%<\/p><p>(cf morphine 25%)<\/p><p>Lower incidence of hallucinations than    Higher incidence of nausea and<\/p><p>other opioids; kappa action may provide    vomiting than other opioids<\/p><p>good visceral analgesia<\/p><p>3.8 Codeine Phosphate<\/p><p>Codeine is no longer a routine analgesic \u2013 numerous healthy agencies make warnings<\/p><p>about its use in children, and it is very rarely used by PAPS.<\/p><p>Codeine is a partial opioid agonist which is most effective when given with Paracetamol.<\/p><p>Codeine is a pro-drug with variable metabolism (5-15%) to morphine. Some ultra-rapid<\/p><p>metabolisers will achieve higher than average levels of morphine (which has resulted in<\/p><p>mortality and morbidity), while at the other extreme 5-10% of Caucasian patients are<\/p><p>unable to metabolise codeine to its active form i.e. it will not work.<\/p><p>Tablets (30mg)<\/p><p>Preparations:<\/p><p>Syrup (5mg/5ml)<\/p><p>0.5-1.0mg/kg 4 hourly prn<\/p><p>Dosage:<\/p><p>Page 13 of 57<\/p><p>4. MANAGING PAIN USING PARENTERAL ANALGESICS<\/p><p>4.1 Protocol for Intermittent IV Opioids<\/p><p>Introduction:<\/p><p>This technique of analgesia is suitable for minor surgery where there is a need for short<\/p><p>term intravenous analgesic therapy. This is prescribed by medical staff. Administration is<\/p><p>by medical staff or by nursing staff in PACU or PICU.<\/p><p>Prescription:<\/p><p>This is prescribed on the Inpatient Medication Chart.<\/p><p>Protocol:<\/p><p>Morphine 0.025mg/kg IV every 5 minutes until comfortable.<\/p><p>If the patient is in moderate or severe pain, this dose can be given over 5 minutes directly<\/p><p>into the IV port of a running drip and the patient observed closely for the next 15 minutes.<\/p><p>Alternatively if the need is less urgent then the dose should be given in the burette to be<\/p><p>infused.<\/p><p>For patients unable to tolerate Morphine contact PAPS (Fentanyl or Oxycodone may be<\/p><p>used).<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>4.2 Protocol for Intravenous Opioid Infusions<\/p><p>Introduction:<\/p><p>Infusions of Morphine or Fentanyl can provide continuous analgesia without the \u201cups and<\/p><p>downs\u201d of intermittent bolus administration. They are suitable for children of any age<\/p><p>particularly those who are unsuitable for patient controlled analgesia.<\/p><p>Additional prescribed bolus doses may be required to cover additional \u201cincident\u201d pain<\/p><p>which occurs during movement or when the patient is subjected to painful procedures.<\/p><p>Intravenous infusions need close observation as the patient is always receiving the drug<\/p><p>and accumulations may occur.<\/p><p>Prescription:<\/p><p>Opioid infusion orders are prescribed on the PAPS Prescription Form by the Department<\/p><p>of Anaesthesia only. Syringe changes are recorded in the Drug Administration Record of<\/p><p>the PAPS Prescription Form.<\/p><p>Page 14 of 57<\/p><p>Protocol:<\/p><p>Use CADD Solis pump<\/p><p>Mix drug into 50ml bag of Normal Saline or Dextrose 5%<\/p><p>An anti-reflux valve is necessary with all intravenous Opioid Infusions<\/p><p>Morphine Infusion    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>0.5mg/kg into 50mls<\/td><td>(1ml = 10mcg/kg)<\/td><\/tr><tr><td>Background Infusion<\/td><td>0-4ml/hr<\/td><td>(0-40mcg/kg/hr)<\/td><\/tr><\/table><p>Fentanyl Infusion    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>20mcg/kg into 50mls<\/td><td>(1ml = 0.4mcg/kg)<\/td><\/tr><tr><td>Background Infusion<\/td><td>0-4ml/hr<\/td><td>(0-1.6mcg/kg/hr)<\/td><\/tr><\/table><p>These are the recommended infusion regimes and may be varied at the discretion of the<\/p><p>Anaesthetic Staff according to the individual patient\u2019s needs.<\/p><p>Children younger than 3 months:<\/p><ul><li>\u2022<\/li><\/ul><p>Infusion rates and boluses should be halved i.e. 0-2.0ml/hr<\/p><p>Their metabolic pathways may be very immature, (especially preterm infants) and<\/p><p>of major concern is the risk of opioid induced respiratory depression. The method<\/p><p>of analgesia must be discussed with senior medical staff.<\/p><p>Managing IV infusions:<\/p><p>Prior to commencing the infusion the patient should be titrated to comfort by a doctor with<\/p><p>intravenous boluses of the same opioid. Infusions should be started at 2.0ml/hr (syringe<\/p><p>pump) and can then be varied at the discretion of the ward nursing staff according to the<\/p><p>degree of analgesia or sedation of the patient (within the prescribed limits).<\/p><p>Bolus doses with opioid infusions:<\/p><p>Morphine:    10-20 mcg/kg (1-2mls of solution) at intervals no less than 10mins<\/p><p>Fentanyl:    0.4 mcg/kg (1ml of solution) at intervals no less than 5mins<\/p><p>Bolus doses can be given in two situations:<\/p><ul><li>\u2022<\/li><\/ul><p>If pain relief is inadequate, a prescribed bolus dose should be administered<\/p><p>followed by an increasing infusion rate by 1ml/hr<\/p><ul><li>\u2022<\/li><\/ul><p>To cover anticipated \u201cincident pain\u201d (e.g. pulling out drain, physiotherapy<\/p><p>movement, procedures, dressings etc) we suggest that a bolus dose be given 10-<\/p><p>15 minutes prior to the anticipated painful procedure<\/p><p>Page 15 of 57<\/p><p>Before bolus doses are given:<\/p><ul><li>\u2022<\/li><\/ul><p>Exclude alternative causes of pain eg, urinary retention, compartment syndrome<\/p><ul><li>\u2022<\/li><\/ul><p>The patient should be awake and coherent<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Children &lt; 6 months old must have continuous oximetry.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p><p>4.3 Protocol for Nurse Controlled Analgesia (NCA)<\/p><p>Introduction:<\/p><p>If a child receiving an opioid infusion is in pain, the only adjustment the nurses may<\/p><p>make is to increase the rate of infusion within the prescribed range. Pharmacokinetically<\/p><p>what the child needs is a bolus dose, but in order to give this medical staff have to be<\/p><p>involved. NCA takes the equipment and principals of PCA and puts the control in the<\/p><p>hands of the nurses. NCA allows continuous low dose background infusion and<\/p><p>intermittent boluses at specified intervals. The patient is protected from over dose by<\/p><p>routine monitoring, a longer lockout interval and the principal of assess-intervene-<\/p><p>reassess. There is no place for a parent or guardian to press the button.<\/p><p>NCA is appropriate for the control of pain in infants, pre-verbal children and children that<\/p><p>cannot use a PCA. It is useful for moderate to severe pain that has a significant incident/<\/p><p>movement component.<\/p><p>Prescription:<\/p><p>NCA orders are prescribed on the PAPS Prescription Form by the Department of<\/p><p>Anaesthesia only. Syringe changes are recorded in the Drug Administration Record of the<\/p><p>PAPS Prescription Form.<\/p><p>Protocol:<\/p><p>Use CADD Solis pump<\/p><p>Mix drug into 50ml bag of Normal Saline or Dextrose 5%<\/p><p>An anti-reflux valve is necessary with all intravenous NCA<\/p><p>Page 16 of 57<\/p><p>Morphine NCA    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>0.5mg/kg into 50mls<\/td><td>(1ml = 10mcg/kg)<\/td><\/tr><tr><td>Bolus Dose<\/td><td>1-2ml<\/td><td>(10-20mcg/kg)<\/td><\/tr><\/table><p>Lockout    10-30mins<\/p><table><tr><td>Background Infusion<\/td><td>0-2ml/hr<\/td><td>(0-20mcg/kg/hr)<\/td><\/tr><tr><td>Hourly Dose Limit<\/td><td>8ml<\/td><td>(80mcg/kg)<\/td><\/tr><\/table><p>Fentanyl NCA    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>20mcg/kg into 50mls<\/td><td>(1ml = 0.4mcg/kg)<\/td><\/tr><tr><td>Bolus Dose<\/td><td>1-2ml<\/td><td>(0.4-0.8mcg/kg)<\/td><\/tr><\/table><p>Lockout    10-30mins<\/p><table><tr><td>Background Infusion<\/td><td>0-2ml/hr<\/td><td>(0-0.8mcg/kg/hr )<\/td><\/tr><tr><td>Hourly Dose Limit<\/td><td>8ml<\/td><td>(3.2mcg/kg )<\/td><\/tr><\/table><p>In children weighing close to 50 kg it is suggested you use the \u2018Adolescent protocol\u2019 which<\/p><p>uses the \u2018Adult\u2019 100ml premix bags (Morpine 100mg in 100mls, or Fentanyl 1000mcg in<\/p><p>100mls).<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Children &lt; 6 months old must have continuous oximetry.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p><p>4.4 Protocol for Patient Controlled Analgesia (PCA)<\/p><p>Introduction:<\/p><p>PCA is a technique of managing acute pain which utilises a programmable syringe-pump<\/p><p>to allow patients to self-administer their own intravenous opioid analgesics. It can be used<\/p><p>by any child who is able to understand the concept of pressing a button when it hurts.<\/p><p>Pre-operative education is very worthwhile.<\/p><p>Prescription of PCA:<\/p><p>PCA orders are prescribed on the PAPS Prescription Form by the Department of<\/p><p>Anaesthesia only. Syringe changes are recorded in the Drug Administration Record of the<\/p><p>PAPS Prescription Form.<\/p><p>Protocol:<\/p><p>Use CADD Solis pump<\/p><p>Mix drug into 50ml bag of Normal Saline or Dextrose 5%<\/p><p>An anti-reflux valve is necessary with all intravenous PCA<\/p><p>Page 17 of 57<\/p><p>Morphine PCA    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>0.5mg/kg into 50mls<\/td><td>(1ml = 10mcg/kg)<\/td><\/tr><tr><td>Bolus Dose<\/td><td>1-2ml<\/td><td>(10-20mcg/kg)<\/td><\/tr><\/table><p>Lockout    5-10mins<\/p><table><tr><td>Background Infusion<\/td><td>0-1ml/hr<\/td><td>(0-10mcg/kg/hr)<\/td><\/tr><tr><td>Hourly Dose Limit<\/td><td>10ml<\/td><td>(100mcg/kg)<\/td><\/tr><\/table><p>Fentanyl PCA    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>20mcg/kg into 50mls<\/td><td>(1ml = 0.4mcg/kg)<\/td><\/tr><tr><td>Bolus Dose<\/td><td>1ml<\/td><td>(0.4mcg/kg)<\/td><\/tr><\/table><p>Lockout    5mins<\/p><table><tr><td>Background Infusion<\/td><td>0.5ml/hr<\/td><td>(0.2mcg/kg/hr )<\/td><\/tr><tr><td>Hourly Dose Limit<\/td><td>10ml<\/td><td>(4mcg/kg )<\/td><\/tr><\/table><p>Morphine is usually the first choice \u2013 Fentanyl is used for patients who are unable to<\/p><p>tolerate Morphine or have renal impairment.<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p><p>Adolescent PCA:<\/p><p>In children weighing close to 50 kg it is suggested you use the \u2018Adolescent protocol\u2019 which<\/p><p>uses the \u2018Adult\u2019 100ml premix bags (Morphine 100mg in 100mls, or Fentanyl 1000mcg in<\/p><p>100mls).<\/p><p>4.5 Protocol for Subcutaneous Morphine Boluses<\/p><p>Introduction:<\/p><p>This is ideally avoided because of the irritant nature of subcutaneous (SC) Morphine, but it<\/p><p>may be useful for post-operative pain of short duration in the older child. A narrow gauge<\/p><p>plastic cannula can be left in position usually just below the clavicle, obviating the need for<\/p><p>repeated skin puncture. Morphine is the drug of choice because:<\/p><ul><li>\u2022<\/li><\/ul><p>It has longer duration of action than Pethidine<\/p><ul><li>\u2022<\/li><\/ul><p>It is not irritant and hence not as painful as Pethidine<\/p><ul><li>\u2022<\/li><\/ul><p>It is available in a more concentrated solution than Pethidine and hence a smaller<\/p><p>volume can be given for the same effect<\/p><p>Page 18 of 57<\/p><p>In the shocked patient the absorption from the SC (and IM) site is erratic and this form of<\/p><p>analgesia should not be used. Because it is necessary to prime the line with Morphine<\/p><p>prior to the first injection, it is important to use Morphine of the same concentrations for all<\/p><p>injections.<\/p><p>Prescription:<\/p><p>This is prescribed on the Inpatient Medication Chart.<\/p><p>Dosage:<\/p><p>Morphine 0.1mg/kg SC 1-2 hourly prn<\/p><p>:<\/p><p>Equipment<\/p><ul><li>\u2022<\/li><\/ul><p>24g BD Saf-T-Intima cannula<\/p><ul><li>\u2022<\/li><\/ul><p>Alcohol swabs<\/p><ul><li>\u2022<\/li><\/ul><p>Small transparent dressing e.g. Opsite, Tegaderm<\/p><p>Insertion of SC cannula: (may already be in situ from theatre)<\/p><ul><li>\u2022<\/li><\/ul><p>Prime the infusion line with Morphine (concentration 10mg/ml)<\/p><ul><li>\u2022<\/li><\/ul><p>Clean the site in the subclavicular region thoroughly with alcohol swab<\/p><ul><li>\u2022<\/li><\/ul><p>Insert the cannula through the skin at shallow angle. It is best to pinch up a fold of<\/p><p>skin to do this<\/p><ul><li>\u2022<\/li><\/ul><p>Cover with the transparent dressing<\/p><ul><li>\u2022<\/li><\/ul><p>All patients should have IV access<\/p><p>Injection procedures:<\/p><ul><li>\u2022<\/li><\/ul><p>Check the drug order for the dose of Morphine (0.1 mg/kg or less)<\/p><ul><li>\u2022<\/li><\/ul><p>Draw the appropriate dose of Morphine into a 1ml syringe.<\/p><p>Do not dilute<\/p><ul><li>\u2022<\/li><\/ul><p>Wipe the bung with an alcohol swab and then inject. The slower the rate of<\/p><p>injection the less discomfort the patient experiences (give over 1-2 minutes)<\/p><ul><li>\u2022<\/li><\/ul><p>the cannula either before or after the injection<\/p><p>Do not flush<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p><p>Page 19 of 57<\/p><p>5. MANAGING PAIN USING EPIDURALS<\/p><p>Introduction:<\/p><p>Mixtures of diluted local anaesthetic (LA) and opioids infused into the epidural space can<\/p><p>provide virtually complete analgesia for selected procedures, especially in patients with<\/p><p>compromised or potentially compromised respiratory function. Epidural catheters can be<\/p><p>placed either via the thoracic, lumbar, caudal or trans-sacral routes. The catheter is inserted<\/p><p>by the Anaesthetist at the time of surgery.<\/p><p>Advantages:<\/p><ul><li>\u2022<\/li><\/ul><p>Almost complete pain relief<\/p><ul><li>\u2022<\/li><\/ul><p>Reduced analgesic requirement<\/p><ul><li>\u2022<\/li><\/ul><p>Less sedation/ opioid side effects<\/p><ul><li>\u2022<\/li><\/ul><p>Suitable for all age groups<\/p><p>Disadvantages:<\/p><ul><li>\u2022<\/li><\/ul><p>Requires epidural catheter<\/p><ul><li>\u2022<\/li><\/ul><p>No patient participation<\/p><ul><li>\u2022<\/li><\/ul><p>Urinary retention and pruritus may increase<\/p><p>Contraindications:<\/p><ul><li>\u2022<\/li><\/ul><p>Head injury/raised ICP<\/p><ul><li>\u2022<\/li><\/ul><p>Coagulopathy<\/p><ul><li>\u2022<\/li><\/ul><p>Local or systemic infection<\/p><ul><li>\u2022<\/li><\/ul><p>Progressive neurological deficit<\/p><ul><li>\u2022<\/li><\/ul><p>Patient/parent refusal<\/p><p>Local anaesthetic pharmacokinetics in children:<\/p><p>Children are more at risk of local anaesthetic toxicity than adults for a number of reasons:<\/p><ul><li>\u2022<\/li><\/ul><p>Reduced intrinsic clearance. Local anaesthetics are metabolized by cytochrome<\/p><p>P450 \u2013 lignocaine and bupivacaine mainly CYP3A4, and Ropivacaine by CYP1A2.<\/p><p>These enzymes are immature in early life \u2013 at 1 month of age the clearance of<\/p><p>bupivacaine is one-third of that of adults, and 2-thirds at 6 months, and the<\/p><p>clearance of Ropivacaine is not mature until 8 years of age.<\/p><ul><li>\u2022<\/li><\/ul><p>Faster vascular absorption. Children have higher cardiac outputs than adults,<\/p><p>which results in faster vascular absorption from vascular tissue. This produces<\/p><p>higher initial plasma concentrations and decreased durations of action.<\/p><ul><li>\u2022<\/li><\/ul><p>Reduced protein binding. Alpha-1 acid glycoprotein is the major protein that binds<\/p><p>LAs \u2013 levels are very low at birth and rise throughout the first year of life.<\/p><p>Page 20 of 57<\/p><p>Toxicity Summary<\/p><p>Children &lt; 2 years \u2013 higher risk of cardiac toxicity due to higher baseline heart rates<\/p><p>Children &lt; 1 year \u2013 even higher risk of systemic toxicity due to decreased protein binding<\/p><p>Children &lt; 6 months \u2013 even higher risk of systemic toxicity due to immature liver enzymes<\/p><ul><li>\u2022<\/li><\/ul><p>Risk of high plasma drug conc is increased with infusions or repeated injections<\/p><ul><li>\u2022<\/li><\/ul><p>Risk of high plasma drug conc somewhat lessened following single injection<\/p><p>Volumes of distribution of LAs in neonates and infants are larger than adults<\/p><p>o<\/p><p>duration is shorter in infants than in adults (most noticeable in<\/p><p>Spinal anaesthesia<\/p><p>preterm infants). Reasons:<\/p><ul><li>\u2022<\/li><\/ul><p>larger volume of cerebrospinal fluid (CSF)<\/p><ul><li>\u2022<\/li><\/ul><p>faster drug uptake from CSF \u2013 infants have a greater blood flow to the spinal cord.<\/p><p>Drugs:<\/p><p>Local Anaesthetics:<\/p><p>Bupivacaine (racemic) has historically been the most popular epidural LA. Ropivacaine is a<\/p><p>newer LA. It is a single stereoisomer amino amide agent which, in adults, is thought to<\/p><p>produce less motor blockade and be less cardiotoxic than standard Bupivacaine<\/p><p>There still remains very little high quality evidence on what doses of local anaesthetic may be<\/p><p>safely used in paediatric practice. Dosages recommended by the ESRA and ASRA Joint<\/p><p>Committee (2018) are:<\/p><p>0.1-0.3 mg/kg/hr (Bupivacaine or Ropivacaine)<\/p><p>Multicentre studies show a large variation in dosages used by practitioners and the above is<\/p><p>a guideline only. As new evidence becomes available this guideline may need to be updated.<\/p><p>Additives:<\/p><p>Other drugs may be used in the epidural infusion to supplement the LA.<\/p><p>Fentanyl:<\/p><ul><li>\u2022<\/li><\/ul><p>Opioid commonly used to supplement epidural LA analgesia<\/p><ul><li>\u2022<\/li><\/ul><p>At high doses sedation and respiratory depression may occur<\/p><p>Clonidine:<\/p><ul><li>\u2022<\/li><\/ul><p>Partial agonist at alpha 2 receptors<\/p><ul><li>\u2022<\/li><\/ul><p>Sedative, analgesic and antihypertensive properties<\/p><ul><li>\u2022<\/li><\/ul><p>Affects conduction in peripheral nociceptive nerves<\/p><ul><li>\u2022<\/li><\/ul><p>Used for supplementing epidurals/ regional blocks and as a premedication<\/p><ul><li>\u2022<\/li><\/ul><p>Side effects include sedation and hypotension<\/p><p>Page 21 of 57<\/p><p>Prescription:<\/p><p>Epidural orders are prescribed on the PAPS Prescription Form by the Department of<\/p><p>Anaesthesia only. Bag changes are recorded on the Drug Administration Record of the<\/p><p>PAPS Prescription Form.<\/p><p>Epidural Infusions Protocol:<\/p><p>Use CADD Solis pump<\/p><p>Mix drug into 50ml bag<\/p><p>Infusions can be managed within the prescribed rates by certificated Nursing Staff according<\/p><p>to patient comfort.<\/p><p>Drugs:<\/p><p>is standard<\/p><p>Bupivacaine 0.1%<\/p><ul><li>\u2022<\/li><\/ul><p>Mix 20mls of 0.25% Bupivacaine (50mg) and 100 mcg of Fentanyl (2mls) and<\/p><p>28mls of Normal Saline to total volume of 50mls<\/p><ul><li>\u2022<\/li><\/ul><p>In order to avoid LA toxicity maximum doses must not be exceeded<\/p><ul><li>\u2022<\/li><\/ul><p>Think in mg/kg not ml/kg<\/p><ul><li>\u2022<\/li><\/ul><p>Bupivacaine 0.1% = 1mg/ml<\/p><table><tr><td>Age<\/td><td>Max Infusion<\/td><td>Duration<\/td><\/tr><tr><td>&lt; 6 months<\/td><td>0.2mg/kg/hr<\/td><td>0-0.2ml/kg/hr<\/td><td>24-36hrs<\/td><\/tr><tr><td>&gt; 6 months<\/td><td>0.4mg/kg/hr<\/td><td>0-0.4ml/kg/hr<\/td><td>36-48hrs<\/td><\/tr><\/table><p>Suggested initial setting range 0-0.3 ml/kg/hr for children &gt; 6 months<\/p><p>(Maximum rate not to exceed 15 ml/hr)<\/p><p>Fentanyl:<\/p><ul><li>\u2022<\/li><\/ul><p>May be added to epidural infusions to improve the quality of analgesia<\/p><ul><li>\u2022<\/li><\/ul><p>May cause sedation<\/p><ul><li>\u2022<\/li><\/ul><p>Added to Bupivacaine 0.1% to give concentration of Fentanyl 1-2 mcg/ml<\/p><ul><li>\u2022<\/li><\/ul><p>Suggest reduced to Fentanyl 0-1 mcg/ml in children &lt; 6 months old<\/p><p>Clonidine:<\/p><ul><li>\u2022<\/li><\/ul><p>May be added to epidural infusions to improve the quality of analgesia without<\/p><p>increasing the side-effects of epidural opioids (itching, nausea/ vomiting,<\/p><p>respiratory depression)<\/p><ul><li>\u2022<\/li><\/ul><p>May be useful in postoperative spasticity (eg, cerebral palsy)<\/p><ul><li>\u2022<\/li><\/ul><p>May cause sedation<\/p><ul><li>\u2022<\/li><\/ul><p>Use preservative free solution (eg, Catapress150 mcg/ml)<\/p><ul><li>\u2022<\/li><\/ul><p>Added to Bupivacaine 0.1% to give concentration of Clonidine 0.5-1 mcg/ml<\/p><ul><li>\u2022<\/li><\/ul><p>This would result in the following doses of Clonidine<\/p><p>Conc 0.5 mcg/ml    0.1-0.3ml/kg/hr -&gt; 0.05-0.15mcg/kg/hr<\/p><p>Conc 1 mcg/ml    0.1-0.3ml/kg/hr -&gt; 0.1-0.3mcg/kg/hr<\/p><ul><li>\u2022<\/li><\/ul><p>Literature suggests generally aiming for 0.12-0.16 mcg/kg/hr.<\/p><ul><li>\u2022<\/li><\/ul><p>Suggest reduced to Clonidine 0.5 mcg/ml in children &lt; 6 months old<\/p><p>Page 22 of 57<\/p><p>Epidural Boluses Protocol:<\/p><p>There may be occasions when there is inadequate analgesia while using an epidural<\/p><p>infusion. A top-up bolus may improve the analgesia and should be considered before<\/p><p>resorting to some other form of analgesia.<\/p><ul><li>\u2022<\/li><\/ul><p>Bolus orders are prescribed by the Department of Anaesthesia only.<\/p><p>The size of the bolus (in mls) may be equal to the hourly rate (in mls).<\/p><p>o<\/p><p>The rate of the bolus is to be administered over 10 minutes.<\/p><p>o<\/p><p>If this does not resolve the pain then a review of the pain management should<\/p><p>o<\/p><p>be sought.<\/p><ul><li>\u2022<\/li><\/ul><p>Following a bolus, observations should be performed quarter hourly for one hour.<\/p><p>See Section 9 of the Handbook.<\/p><p>Epidural Catheter Care and Removal:<\/p><p>The catheter should be secured with a combination of Tegaderm/ Opsite and Hypafix/ Sleek<\/p><p>tape or similar. If a catheter requires redressing the Department of Anaesthesia should be<\/p><p>contacted. All children must have IV access.<\/p><p>The tubing from the syringe to the epidural catheter will incorporate an antibacterial filter.<\/p><p>There are to be no 3-way taps or injection ports in this line. Antiseptic agents such as<\/p><p>Chlorhexidine, Betadine or alcohol are not to come in contact with the epidural catheter or<\/p><p>tubing as they are neurotoxic.<\/p><p>Important:<\/p><ul><li>\u2022<\/li><\/ul><p>Before removing the catheter it is important to check that the patient is not<\/p><p>coagulapathic or receiving anticoagulants<\/p><p>(eg Heparin, Clexane, Fragmin, Warfarin or Clopidogrel)<\/p><ul><li>\u2022<\/li><\/ul><p>Removal of the catheter is performed by certificated ward nursing staff<\/p><ul><li>\u2022<\/li><\/ul><p>The adhesive tapes and dressing are removed and the catheter is simply withdrawn<\/p><ul><li>\u2022<\/li><\/ul><p>It is important to confirm that the whole catheter has been removed intact. A Band-aid<\/p><p>is optional.<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Following bolus administration quarter hourly observations should be done for one hour.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p><p>Page 23 of 57<\/p><p>6. MANAGING PAIN USING REGIONAL INFUSIONS<\/p><p>Introduction:<\/p><p>The introduction of ultrasound guided regional anaesthesia has seen an increase in the<\/p><p>popularity of paediatric nerve blocks and fascial plane blocks. This is achieved by delivering<\/p><p>local anaesthetic around major nerves or in fascial planes. An infusion catheter is usually<\/p><p>sited when the patient is anaesthetised, and may be used for postoperative analgesia. These<\/p><p>techniques not only help to reduce some of the stress response of surgery, but may also<\/p><p>provide excellent analgesia with less systemic effects than may occur with opioid analgesia.<\/p><p>Common types of regional infusions:<\/p><p>Interpleural    catheter in the intrapleural space<\/p><p>Extrapleural    catheter external to the parietal pleura (usually across rib necks)<\/p><p>Paravertebral    catheter in the paravertebral space, next to the vertebral column<\/p><p>Brachial plexus catheter in the perineural sheath around the brachial plexus<\/p><p>Femoral nerve    catheter in the perineural sheath around the femoral nerve<\/p><p>Sciatic nerve    catheter in the perineural sheath around the sciatic nerve<\/p><p>Paravertebral blocks may be used for surgery entailing unilateral incisions above T12 (eg<\/p><p>thoracotomy, renal surgery, cholecystectomy). They may still be suitable in situations where<\/p><p>epidurals are contraindicated (\u2191ICP, coagulopathy etc).<\/p><p>Local anaesthetic pharmacokinetics in children:<\/p><p>Children are more at risk of local anaesthetic toxicity than adults for a number of reasons:<\/p><ul><li>\u2022<\/li><\/ul><p>Reduced intrinsic clearance. Local anaesthetics are metabolized by cytochrome<\/p><p>P450 \u2013 lignocaine and bupivacaine mainly CYP3A4, and Ropivacaine by CYP1A2.<\/p><p>These enzymes are immature in early life \u2013 at 1 month of age the clearance of<\/p><p>bupivacaine is one-third of that of adults, and 2-thirds at 6 months, and the<\/p><p>clearance of Ropivacaine is not mature until 8 years of age.<\/p><ul><li>\u2022<\/li><\/ul><p>Faster vascular absorption. Children have higher cardiac outputs than adults,<\/p><p>which results in faster vascular absorption from vascular tissue. This produces<\/p><p>higher initial plasma concentrations and decreased durations of action.<\/p><ul><li>\u2022<\/li><\/ul><p>Reduced protein binding. Alpha-1 acid glycoprotein is the major protein that binds<\/p><p>LAs \u2013 levels are very low at birth and rise throughout the first year of life.<\/p><p>Toxicity Summary<\/p><p>Children &lt; 2 years \u2013 higher risk of cardiac toxicity due to higher baseline heart rates<\/p><p>Children &lt; 1 year \u2013 even higher risk of systemic toxicity due to decreased protein binding<\/p><p>Children &lt; 6 months \u2013 even higher risk of systemic toxicity due to immature liver enzymes<\/p><ul><li>\u2022<\/li><\/ul><p>Risk of high plasma drug conc is increased with infusions or repeated injections<\/p><ul><li>\u2022<\/li><\/ul><p>Risk of high plasma drug conc somewhat lessened following single injection<\/p><p>Volumes of distribution of LAs in neonates and infants are larger than adults<\/p><p>o<\/p><p>Page 24 of 57<\/p><p>Drugs:<\/p><p>Bupivacaine (racemic) has historically been the most popular LA. Ropivacaine is a newer LA.<\/p><p>It is a single stereoisomer amino amide agent which, in adults, is thought to produce less<\/p><p>motor blockade and be less cardiotoxic than standard Bupivacaine.<\/p><p>There still remains very little high quality evidence on what doses of local anaesthetic may be<\/p><p>safely used in paediatric practice. Dosages recommended by the ESRA and ASRA Joint<\/p><p>Committee (2018) are:<\/p><p>0.1-0.3 mg/kg/hr (Bupivacaine or Ropivacaine)<\/p><p>Multicentre studies show a large variation in dosages used by practitioners and the above is<\/p><p>a guideline only. As new evidence becomes available this guideline may need to be updated.<\/p><p>Prescription:<\/p><p>Regional infusions are prescribed on the PAPS Prescription Form by the Department of<\/p><p>Anaesthesia only. Bag changes are recorded on the Drug Administration Record of the<\/p><p>PAPS Prescription Form.<\/p><p>Regional Infusion Protocols:<\/p><p>Use CADD Solis pump<\/p><p>Mix drug into 50ml bag<\/p><p>Infusions can be managed within the prescribed rates by certificated ward Nursing Staff<\/p><p>according to patient comfort.<\/p><p>Drugs:<\/p><p>is standard<\/p><p>Bupivacaine 0.125%<\/p><ul><li>\u2022<\/li><\/ul><p>This is higher concentration than in epidural<\/p><ul><li>\u2022<\/li><\/ul><p>Mix 25mls of 0.25% Bupivacaine and 25mls of Normal Saline to total volume of<\/p><p>50mls<\/p><ul><li>\u2022<\/li><\/ul><p>In order to avoid LA toxicity maximum doses must not be exceeded<\/p><ul><li>\u2022<\/li><\/ul><p>Think in mg/kg not ml/kg<\/p><ul><li>\u2022<\/li><\/ul><p>Bupivacaine 0.125% = 1.25mg/ml<\/p><table><tr><td>Age<\/td><td>Max Infusion<\/td><td>Duration<\/td><\/tr><tr><td>&lt; 6 months<\/td><td>0.2mg/kg/hr<\/td><td>0.16ml/kg/hr<\/td><td>24-36hrs<\/td><\/tr><tr><td>&gt; 6 months<\/td><td>0.4mg/kg/hr<\/td><td>0.32ml/kg/hr<\/td><td>36-48hrs<\/td><\/tr><\/table><p>Suggested initial setting range 0-0.25 ml/kg/hr for children &gt; 6 months<\/p><p>(Maximum rate not to exceed 5 ml/hr)<\/p><p>Infusion Catheter Care and Removal:<\/p><p>The tubing from the syringe to the infusion catheter will incorporate an antibacterial filter.<\/p><p>There are to be no 3-way taps or injection ports in this line. Antiseptic agents such as<\/p><p>Chlorhexidine, Betadine or alcohol are not to come in contact with the infusion catheter or<\/p><p>tubing as they are neurotoxic.<\/p><p>Page 25 of 57<\/p><p>Removal of the catheter is performed by certificated Nursing Staff. The adhesive tapes and<\/p><p>dressing are removed and the catheter is simply withdrawn. It is important to confirm that the<\/p><p>whole catheter has been removed intact. A Band-aid is optional.<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Following bolus administration quarter hourly observations should be done for one hour.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p><p>Page 26 of 57<\/p><p>7. MANAGING PAIN USING ENTONOX<\/p><p>Introduction:<\/p><p>Entonox is a 50% mixture of nitrous oxide and oxygen. It is an odourless, colourless gas<\/p><p>which can provide potent short-term analgesia for painful procedures. It has a quick onset of<\/p><p>action (30-60 seconds) and wears off almost as quickly. It is unsuitable for chronic, long-term<\/p><p>administration because of the risk of bone-marrow toxicity.<\/p><p>Apparatus:<\/p><p>Entonox is self-administered via a demand-apparatus.<\/p><p>The apparatus consists of:<\/p><ul><li>\u2022<\/li><\/ul><p>A 4000 litre (size E) OR 1600 litre (size D) cylinder<\/p><ul><li>\u2022<\/li><\/ul><p>A small pressure (contents) gauge<\/p><ul><li>\u2022<\/li><\/ul><p>A reducing valve which reduces the pressure from the cylinder to one suitable for<\/p><p>inhalation<\/p><ul><li>\u2022<\/li><\/ul><p>A demand valve which allows gas to flow only when the patient inhales from the face-<\/p><p>mask or mouth-piece. For this to occur, the face-mask or mouth-piece must be well<\/p><p>sealed and a characteristic sound is heard when the Entonox is being inhaled<\/p><ul><li>\u2022<\/li><\/ul><p>Black tubing leading to the face mask<\/p><ul><li>\u2022<\/li><\/ul><p>An expiratory valve near the face mask vents expired gas to the atmosphere<\/p><ul><li>\u2022<\/li><\/ul><p>New mask/mouthpiece and filter for each patient<\/p><p>Contraindications:<\/p><ul><li>\u2022<\/li><\/ul><p>Children aged &lt;2 years<\/p><ul><li>\u2022<\/li><\/ul><p>Children unwilling or unable to use Entonox<\/p><ul><li>\u2022<\/li><\/ul><p>Intoxication with alcohol or other drugs<\/p><ul><li>\u2022<\/li><\/ul><p>Closed head injury or unconsciousness<\/p><ul><li>\u2022<\/li><\/ul><p>Airway obstruction or airway burns<\/p><ul><li>\u2022<\/li><\/ul><p>Pneumothorax (nitrous oxide diffuses into air filled cavities and expands them)<\/p><ul><li>\u2022<\/li><\/ul><p>Recent Eye/ ENT/ Maxillofacial surgery or injury<\/p><ul><li>\u2022<\/li><\/ul><p>Head injury, raised intracranial pressure or depressed level of consciousness<\/p><ul><li>\u2022<\/li><\/ul><p>Bowel obstruction<\/p><ul><li>\u2022<\/li><\/ul><p>Respiratory distress and hypoxia<\/p><ul><li>\u2022<\/li><\/ul><p>Decompression sickness and air embolism<\/p><ul><li>\u2022<\/li><\/ul><p>Haematologic illness<\/p><p>These contraindications may be relative, in which case, the Duty Anaesthetist should be<\/p><p>consulted prior to the use of Entonox.<\/p><p>Page 27 of 57<\/p><p>Side Effects:<\/p><ul><li>\u2022<\/li><\/ul><p>Sedation. If the child becomes sedated the seal around the mask or mouth-piece will be<\/p><p>lost and the flow of Entonox will stop if the child has been holding the mask themselves.<\/p><p>This mechanism is responsible for the inherent safety of Entonox<\/p><ul><li>\u2022<\/li><\/ul><p>Nausea will occasionally occur<\/p><ul><li>\u2022<\/li><\/ul><p>Bone marrow depression with prolonged use. Ward patients should be limited to no more<\/p><p>than 1.5 hours administration per day. Children requiring Entonox for longer than 2<\/p><p>weeks should be prescribed folic acid 15mg orally daily<\/p><p>Administration of Entonox:<\/p><p>Entonox is prescribed on the Inpatient Prescription Sheet for ward patients.<\/p><p>The duration of<\/p><p>administration is recorded and signed for with each use.<\/p><p>For outpatients, Entonox is administered at the discretion of the attending nursing or medical<\/p><p>staff but its use is recorded in the Outpatient Notes.<\/p><p>Where practical, the child should be fasted (food and fluids) for 2 hours prior to<\/p><p>administration.<\/p><p>Entonox may be administered by any Registered Nurse or Medical Staff<\/p><p>who have been trained in the safe administration of Entonox.<\/p><p>Method of administration:<\/p><ul><li>\u2022<\/li><\/ul><p>Make sure there is a new mask/mouthpiece and filter for each patient.<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure cylinder is upright.<\/p><ul><li>\u2022<\/li><\/ul><p>Turn the key to open the cylinder and check the contents of the cylinder. Change if &lt;<\/p><p>5000 kPa.<\/p><ul><li>\u2022<\/li><\/ul><p>Explain how to use the Entonox and allow the child time to become familiar with the<\/p><p>equipment and the noise it makes.<\/p><ul><li>\u2022<\/li><\/ul><p>Instruct the child how to hold the face-mask or mouth-piece to ensure a good fit. The<\/p><p>child should self-administer Entonox wherever possible. If the child is unable to do so<\/p><p>(eg. burns or fractured arms) then the nurse should provide assistance holding the mask<\/p><p>and creating a seal. Verbal contact should be maintained with the patient and the mask<\/p><p>should be removed temporarily should over sedation occur.<\/p><ul><li>\u2022<\/li><\/ul><p>Administration should commence several minutes prior to the painful procedure.<\/p><ul><li>\u2022<\/li><\/ul><p>The child continues to breathe normally from the apparatus. The noise indicates<\/p><p>satisfactory delivery of Entonox. The expiratory valve should be observed for movemen<\/p><p>Page 28 of 57<\/p><p>8. MANAGING ADVERSE EFFECTS &amp; TROUBLESHOOTING<\/p><p>8.1 LA Toxicity<\/p><p>Local anaesthetics (LA) achieve their clinical effect by reversibly blocking voltage-gated<\/p><p>sodium channels. Blockade of small fibre afferents is responsible for analgesia while<\/p><p>blockade of larger (myelinated) fibres can result in motor blockade. At toxic levels LA may<\/p><p>interfere with nerve conduction in the central nervous system (CNS) and heart \u2013 again<\/p><p>blockade of voltage-gated sodium channels is involved, although recently many<\/p><p>alternative sites have also been considered.<\/p><p>LA toxicity can occur following drug overdose, intravascular injection or drug accumulation<\/p><p>following infusion. Toxicity is related to the unbound fraction of the drug. Both neonates<\/p><p>and acidotic patients are at increased risk of toxicity due to decreased protein binding of<\/p><p>the drug. Neonates and infants have lower plasma levels of \u03b1 acid glycoprotein which is<\/p><p>1<\/p><p>largely responsible for protein binding of the drug, and acidosis causes dissociation of the<\/p><p>drug from protein binding.<\/p><p>LA toxicity is rare, but it can have catastrophic consequences. If plasma levels rise slowly<\/p><p>the CNS is affected first. Symptoms are initially excitatory \u2013 circumoral and tongue<\/p><p>paraesthesia, metallic taste, and dizziness, followed by slurred speech, diplopia, tinnitus,<\/p><p>confusion, restlessness, muscle twitching and seizures. Higher plasma concentrations<\/p><p>result in impaired cardiac conduction, arrhythmia and cardiac arrest. Cardiac arrest due to<\/p><p>local anaesthetic toxicity is notoriously refractory to standard resuscitation techniques.<\/p><p>8.1.1 Management of Impending LA Toxicity<\/p><p>Suspect local anaesthetic toxicity if:<\/p><ul><li>\u2022<\/li><\/ul><p>Recognised inadvertent overdose<\/p><ul><li>\u2022<\/li><\/ul><p>Symptoms of CNS toxicity<\/p><p>(circumoral paraesthesia, dizziness, disorientation, agitation or tremor)<\/p><ul><li>\u2022<\/li><\/ul><p>Seizure<\/p><ul><li>\u2022<\/li><\/ul><p>Stop LA infusion<\/p><ul><li>\u2022<\/li><\/ul><p>Give Oxygen<\/p><ul><li>\u2022<\/li><\/ul><p>Notify PAPS and Medical Staff \u2013 call Arrest Team if required<\/p><ul><li>\u2022<\/li><\/ul><p>Consider Lipid Emulsion (Intralipid 20%) infusion concurrently with<\/p><p>management of symptoms<\/p><p>Page 29 of 57<\/p><p>8.1.2 Cardiac Resuscitation in the Event of Suspected LA Toxicity<\/p><ul><li>\u2022<\/li><\/ul><p>Commence APLS according to current protocols<\/p><ul><li>\u2022<\/li><\/ul><p>Call Arrest Team<\/p><ul><li>\u2022<\/li><\/ul><p>Give IV Lipid Emulsion (Intralipid 20%) as soon as practical<\/p><p>1ml/kg over 1 minute<\/p><p>o<\/p><p>Repeat if necessary every 3 minutes (up to 3ml/kg)<\/p><p>o<\/p><p>Follow with an infusion of 0.25ml/kg/min until haemodynamic stability<\/p><p>o<\/p><p>(increase to 0.5ml/kg/min if hypotensive)<\/p><p>8.2 Management of Common Opioid Side-Effects<\/p><p>8.2.1 Management of Overdose<\/p><p>Opioid overdose may be suspected if there are slow shallow respirations and deep<\/p><p>sedation or loss of consciousness.<\/p><ul><li>\u2022<\/li><\/ul><p>Stop Opioid infusion<\/p><ul><li>\u2022<\/li><\/ul><p>Give Oxygen, assist ventilation if necessary<\/p><ul><li>\u2022<\/li><\/ul><p>Give Naloxone 2 mcg/kg IV prn 1-2 minutes, if required<\/p><p>Stimulation and encouragement to breathe may be all that is required<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS and Medical Staff<\/p><ul><li>\u2022<\/li><\/ul><p>5 minute observations<\/p><ul><li>\u2022<\/li><\/ul><p>If cardiorespiratory arrest/ minimal respirations/ or unconscious<\/p><p>Give Oxygen, and assist ventilation<\/p><p>o<\/p><p>Give Naloxone 10 mcg/kg IV prn 1-2 minutes<\/p><p>o<\/p><p>Call Arrest team, and commence APLS<\/p><p>o<\/p><p>8.2.2 Management of Pruritus<\/p><p>This is a very common symptom in infants and children receiving opioid analgesia.<\/p><p>Recommendations to attempt to reduce distress:<\/p><ul><li>\u2022<\/li><\/ul><p>Optimize general skin care i.e. change old dressings, adequate skin washing,<\/p><p>use skin moisturisers etc<\/p><ul><li>\u2022<\/li><\/ul><p>Try antihistamine<\/p><p>Promethazine 0.5mg/kg IV/ IM/ PO 8 hourly prn (max 10-25mg) or<\/p><p>o<\/p><p>Trimeprazine 0.5mg/kg PO 8 hourly prn<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Try Ondansetron 100mcg/kg IV or PO (max 4mg) \u2013 if effective, it may be<\/p><p>repeated 8 hourly (max 3 doses for pruritus)<\/p><ul><li>\u2022<\/li><\/ul><p>Change opioid i.e. Morphine to Fentanyl<\/p><ul><li>\u2022<\/li><\/ul><p>Try Naloxone<\/p><p>Bolus 0.5mcg/kg IV up to 3 doses over 15 minutes<\/p><p>o<\/p><p>Infusion 1mcg/kg/hr if successful<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Stop opioid altogether<\/p><p>Page 30 of 57<\/p><p>8.3 Management of Nausea &amp; Vomiting<\/p><p>Introduction:<\/p><p>Antiemetics may be used prophylactically in theatre if the patient is considered to be<\/p><p>significantly at risk of postoperative nausea and vomiting (PONV), or they may be used to<\/p><p>treat patients with PONV.<\/p><p>Studies suggest that independent risk factors for PONV in children include:<\/p><ul><li>\u2022<\/li><\/ul><p>History of PONV in patient, sibling, or parent<\/p><ul><li>\u2022<\/li><\/ul><p>Age \u2265 3 years<\/p><ul><li>\u2022<\/li><\/ul><p>Surgery \u2265 30mins<\/p><ul><li>\u2022<\/li><\/ul><p>Strabismus surgery (others include adenotonsillectomy)<\/p><p>When 0, 1, 2, 3, or 4 factors are present, risk equates to 10%, 10%, 30%, 55%, or 70%<\/p><p>Drugs and doses:<\/p><table><tr><td>Antiemetic<\/td><td>Dose<\/td><td>Maximum<\/td><td>Frequency<\/td><td>Class<\/td><\/tr><tr><td>Ondansetron<\/td><td>50-100mcg/kg<\/td><td>Max 4mg<\/td><td>8hrly prn<\/td><td>5 HT3 antagonist<\/td><\/tr><tr><td>Dexamethasone 150-200mcg/kg Max 8mg<\/td><td>Once only<\/td><td>Steroid<\/td><\/tr><tr><td>Droperidol<\/td><td>10-20mcg/kg<\/td><td>Max 500mcg<\/td><td>8hrly prn<\/td><td>Butyrophenone<\/td><\/tr><tr><td>Cyclizine<\/td><td>0.5-1mg/kg<\/td><td>Max 50mg<\/td><td>6hrly prn<\/td><td>Histamine antagonist<\/td><\/tr><tr><td>Metoclopramide 150mcg/kg<\/td><td>Max 10mg<\/td><td>8hrly prn<\/td><td>Dopamine antagonist<\/td><\/tr><\/table><p>8.3.1 PONV Prophylaxis<\/p><p>In children at moderate or high risk of PONV, combination therapy with 2 or 3<\/p><p>antiemetics from different classes should be used. Combination therapy may also be<\/p><p>appropriate for patients in whom PONV poses a particular morbidity (jaws wired, raised<\/p><p>intracranial pressure, gastric/ oesophageal surgery, or day surgery)<\/p><p>Antiemetics are not all equal in their effectiveness.<\/p><p>Numbers needed to treat (NNT) for POV prophylaxis in children:<\/p><p>Dose    NNT<\/p><table><tr><td>Ondansetron<\/td><td>50-100 mcg/kg<\/td><td>2-3 (early &amp; late POV)<\/td><\/tr><\/table><p>Dexamethasone 150 mcg/kg    4 (early &amp; late POV)<\/p><table><tr><td>Droperidol<\/td><td>50-75 mcg/kg<\/td><td>4-5 (early &amp; late POV)<\/td><\/tr><\/table><p>Metoclopramide 150 mcg/kg    Little evidence to show useful<\/p><p>Taken from Gan 2007    Early POV = postoperative vomiting 0-6hrs<\/p><p>Late POV = postoperative vomiting 0-24hrs<\/p><p>Page 31 of 57<\/p><p>Recommendations for PONV Prophylaxis:<\/p><ul><li>\u2022<\/li><\/ul><p>Ondansetron and Dexamethasone<\/p><p>First line combination<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Droperidol<\/p><p>Potential for extrapyramidal symptoms and high levels of sedation<\/p><p>o<\/p><p>Should probably be reserved for children who have failed other<\/p><p>o<\/p><p>therapies and are being admitted overnight<\/p><ul><li>\u2022<\/li><\/ul><p>Cyclizine<\/p><p>May cause sedation, caution if &lt;2 years old<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Metoclopramide<\/p><p>Combinations with Metoclopramide are no better than monotherapy<\/p><p>o<\/p><p>8.3.2 PONV Treatment<\/p><p>When PONV occurs treatment should be given with an antiemetic from a different class<\/p><p>than any prophylactic agents already used.<\/p><p>Recommendations for PONV Treatment:<\/p><ul><li>\u2022<\/li><\/ul><p>Ondansetron<\/p><p>First line agent if not already given<\/p><p>o<\/p><p>Doses for treatment are lower than doses required for prophylaxis<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>May give a repeat dose of an antiemetic if greater than 6 hours since last dose<\/p><p>Do not give repeat dose of Dexamethasone<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>May consider small dose of Propofol if still in PACU (effect probably brief)<\/p><p>Recommendations for Persistent PONV:<\/p><ul><li>\u2022<\/li><\/ul><p>Exclude correctable causes (eg, unnecessary opioids, ingested blood,<\/p><p>abdominal obstruction, hypotension).<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure adequate hydration, analgesia, blood pressure, blood sugar<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure triple therapy (Ondansetron, Dexamethasone, Droperidol)<\/p><p>Give Dexamethasone slowly if conscious \u2013 may cause discomfort<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Consider:<\/p><p>Cyclizine \u2013 may cause sedation, caution if &lt;2yrs old<\/p><p>o<\/p><p>Metoclopramide<\/p><p>o<\/p><p>Page 32 of 57<\/p><p>8.4 Management of Common Epidural Problems<\/p><p>8.4.1 Epidural Disconnection<\/p><p>As soon as an epidural catheter disconnection has been discovered:<\/p><ul><li>\u2022<\/li><\/ul><p>Keep catheter tip clean eg hold with a sterile glove or wrap in sterile gauze<\/p><ul><li>\u2022<\/li><\/ul><p>Clamp catheter tip (or tie a knot next to tip)<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS who will manage further<\/p><ul><li>\u2022<\/li><\/ul><p>The PAPS will then review the indication for epidural analgesia<\/p><ul><li>\u2022<\/li><\/ul><p>With a witnessed disconnection the Anaesthetist may decide that it is reasonable<\/p><p>to continue with the epidural infusion without removing the existing catheter:<\/p><p>Using aseptic technique clean the epidural catheter end with Chlorhexidine/<\/p><p>o<\/p><p>alcohol 70%<\/p><p>(wait until dry)<\/p><p>Cut approximately 3-4cm off the distal end of the catheter.<\/p><p>o<\/p><p>Reconnect to a new sterile epidural filter and secure carefully<\/p><p>o<\/p><p>Change the epidural infusion set<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>With a disconnection that is unwitnessed and thus of an uncertain time frame, the<\/p><p>Anaesthetist may:<\/p><p>Review the indication for the epidural analgesia \u2013 consider the advantages<\/p><p>o<\/p><p>and disadvantages of leaving the existing catheter in situ<\/p><p>Consider removing the catheter and:<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Resiting an epidural in the usual manner with full asepsis<\/p><ul><li>\u2022<\/li><\/ul><p>Offering an alternative analgesic technique eg PCA / NCA<\/p><p>Additional analgesia may be required if the epidural infusion has been<\/p><p>o<\/p><p>disrupted for some time<\/p><p>8.4.2 Inadequate Analgesia<\/p><p>Occasionally epidural analgesia alone may be inadequate.<\/p><p>In this situation it may be worth continuing epidural analgesia but with LA only (ie<\/p><p>without additives) and adding IV opioid (ie, NCA or PCA). Before doing this:<\/p><ul><li>\u2022<\/li><\/ul><p>Exclude epidural disconnection and dislodgement<\/p><ul><li>\u2022<\/li><\/ul><p>Consider epidural bolus<\/p><p>These changes may be made by the Department of Anaesthesia only.<\/p><p>Page 33 of 57<\/p><p>8.5 Troubleshooting<\/p><p>Note:    Medical staff = House Surgeon, Medical/ Surgical Registrar<\/p><p>PAPS    = Paediatric Acute Pain Service<\/p><p>Sedation Score 3 or 4 or Respirations &lt; minimum for age:<\/p><p>Suspect opioid overdose:<\/p><ul><li>\u2022<\/li><\/ul><p>Stop Opioid infusion<\/p><ul><li>\u2022<\/li><\/ul><p>Give Oxygen, assist ventilation if necessary<\/p><ul><li>\u2022<\/li><\/ul><p>Give Naloxone 2 mcg/kg IV prn 1-2 minutes, if required<\/p><p>Stimulation and encouragement to breathe may be all that is required<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS and Medical Staff<\/p><ul><li>\u2022<\/li><\/ul><p>5 minute observations<\/p><ul><li>\u2022<\/li><\/ul><p>If cardiorespiratory arrest/ minimal respirations/ or unconscious<\/p><p>Give Oxygen, and assist ventilation<\/p><p>o<\/p><p>Give Naloxone 10 mcg/kg IV prn 1-2 minutes<\/p><p>o<\/p><p>Call Arrest team, and commence APLS<\/p><p>o<\/p><p>Trouble breathing and or numbness in fingers, upper limbs:<\/p><p>Suspect epidural block too high:<\/p><ul><li>\u2022<\/li><\/ul><p>Stop epidural<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS and Medical Staff<\/p><ul><li>\u2022<\/li><\/ul><p>5 minute observations<\/p><p>Pain score of 3 or more on two consecutive recordings:<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS<\/p><p>Hypotension or heart rate extremes:<\/p><ul><li>\u2022<\/li><\/ul><p>Stop infusion<\/p><ul><li>\u2022<\/li><\/ul><p>Give Oxygen<\/p><ul><li>\u2022<\/li><\/ul><p>Call Medical Staff for opioid infusions/ NCA/ PCA<\/p><p>Call Medical Staff and PAPS for epidural<\/p><ul><li>\u2022<\/li><\/ul><p>5 minute observations<\/p><p>Nausea, Vomiting, Pruritus:<\/p><ul><li>\u2022<\/li><\/ul><p>Call Medical Staff<\/p><ul><li>\u2022<\/li><\/ul><p>Refer to Sections 8.2 and 8.3 for drug recommendations and dosages<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS if unrelieved<\/p><p>Page 34 of 57<\/p><p>9. MONITORING<\/p><p>9.1 Pain Assessment &amp; Measurement<\/p><p>Children of all age groups experience pain and there are significant physiological and<\/p><p>behavioural consequences of inadequately treated pain.<\/p><p>The function of pain assessment is to detect pain, estimate its severity and test the<\/p><p>effectiveness of the intervention. It should be routine and one component of the holistic<\/p><p>approach to the child. The cause of pain should be sought.<\/p><p>In general, pain assessment instruments in children can be categorised as observational,<\/p><p>self-report and physiological. Pain assessment should take place against a background<\/p><p>experience of this child\u2019s recovery compared to other children at the same stage of<\/p><p>recovery.<\/p><p>Pain management should be proactive but when confronted with pain an assessment-<\/p><p>intervention-reassessment approach is used. Children can be divided into the preverbal,<\/p><p>the cognitively impaired and the verbal.<\/p><p>Preverbal &amp; Cognitively Impaired<\/p><p>This is the most difficult group and they are most at risk of under treatment as they are<\/p><p>unable to communicate pain. There are many well validated behavioural and physiological<\/p><p>pain score systems (CRIES, CHEOPS) that are used in pain research but are difficult to<\/p><p>apply in the ward setting.<\/p><p>We prefer the Instinctive Behavioural Observation approach in this group eg. if<\/p><p>experienced staff think the child is in pain we will intervene and then reassess.<\/p><p>Verbal<\/p><p>Children older than 3 years are able to communicate pain. Initially it is an all-or-nothing<\/p><p>type of response. Self-reporting with words or visual aids can be used successfully<\/p><p>provided the number of choices is limited to around 4 words, faces or \u2018pieces of hurt\u2019.<\/p><p>Visual linear analogues can be used from age 5 years (eg. face pain scale rating). Vertical<\/p><p>pain scales are better in children less than 7 years and horizontal pain scales can be used<\/p><p>in children older than 7 years. The numerical rating scale (NRS), can usually be<\/p><p>comprehended by children older than 10 years.<\/p><p>Page 35 of 57<\/p><p>9.2 Monitoring<\/p><p>Observations are to be recorded on the PAPS Pain Recording Chart.<\/p><p>9.2.1 Opioids<\/p><p>Children taking opioids by any route require the following recordings:<\/p><p>BP    Sedation score<\/p><p>Pulse    Pain assessment<\/p><p>Respiratory rate    Oxygen saturation<\/p><p>Opioid Observation Protocol<\/p><ul><li>\u2022<\/li><\/ul><p>\u2192 Baseline recordings<\/p><p>Before opioid<\/p><ul><li>\u2022<\/li><\/ul><p>\u2192 Every 15 minutes for one hour<\/p><p>Following opioid<\/p><ul><li>\u2022<\/li><\/ul><p>\u2192 Every hour (BP can be done every 2 hours)<\/p><p>Then<\/p><p>For opioid infusions, NCA, PCA and single dose opioids (PO, IV, SC, or IM)<\/p><p>recordings may stop 2 hours after discontinuing/ last dose<\/p><p>For controlled release oral opioids recordings may stop 12 hours after last dose<\/p><p>Children &lt; 6 months old must have continuous oximetry if on infusion/ NCA<\/p><p>Pain assessment<\/p><p>1    No pain<\/p><p>2    A little pain<\/p><p>3    Moderate<\/p><p>4    Very sore<\/p><p>5    Too much pain<\/p><p>Sedation score<\/p><p>1    Alert<\/p><p>2    Rousable to voice<\/p><p>3    Rousable to light pain<\/p><p>4    Unrousable<\/p><p>9.2.2 Epidurals and Regional Infusions<\/p><p>Epidurals and Regional Infusions require the same monitoring as for opioids with the<\/p><p>addition of hourly motor scores.<\/p><p>Motor score<\/p><p>1    Hip, knee ankle movement<\/p><p>2    Ankle and knee movement<\/p><p>3    Ankle only<\/p><p>4    No movement<\/p><p>All patients with indwelling catheters/ lines (including epidural and regional catheters)<\/p><p>must have their temperature documented at least every 4 hours.<\/p><p>Page 36 of 57<\/p><p>9.3 Some Normal Physiological Values for Children 0-16 Years<\/p><table><tr><td>0 \u2013 3 months<\/td><td>Heart rate<\/td><td>&gt; 110 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 65 mmHg<\/p><p>Respirations    &gt; 25 /min<\/p><table><tr><td>3 \u2013 6 months<\/td><td>Heart rate<\/td><td>&gt; 100 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 75 mmHg<\/p><p>Respirations    &gt; 20 /min<\/p><table><tr><td>6 months \u2013 2 years<\/td><td>Heart rate<\/td><td>&gt; 85 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 80 mmHg<\/p><p>Respirations    &gt; 20 /min<\/p><table><tr><td>2 years \u2013 10 years<\/td><td>Heart rate<\/td><td>&gt; 80 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 90 mmHg<\/p><p>Respirations    &gt; 15 /min<\/p><table><tr><td>10 years \u2013 16 years<\/td><td>Heart rate<\/td><td>&gt; 60 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 100 mmHg<\/p><p>Respirations    &gt; 12 /min<\/p><p>Page 37 of 57<\/p><p>10. MANAGING PAIN FROM BURNS<\/p><p>Analgesia and sedation for dressing changes:<\/p><p>Dressing changes can be painful and distressing, and consequently may lead to<\/p><p>considerable anxiety if managed inadequately. To minimise distress and discomfort it is<\/p><p>important for the dressing team to have everything planned and prepared in advance.<\/p><p>Preparation will also include appropriate fasting and medication of the child, and importantly,<\/p><p>communication and explanation with the child and family about the procedure. The use of<\/p><p>distraction techniques involving Play Therapists and family may be helpful. Burns are often<\/p><p>painful when exposed, and so it is important to ensure the dressing change does not become<\/p><p>protracted - it is important to have enough staff and everything ready, if necessary photos<\/p><p>should be taken if surgical staff can not attend in a timely fashion.<\/p><p>Most dressing changes should be appropriately managed without the need for intravenous<\/p><p>medication \u2013 dressing changes for big or complicated burns, especially in infants or unwell<\/p><p>children, may require general anaesthesia, and should be discussed with the Paediatric<\/p><p>Anaesthetist or Duty Anaesthetist.<\/p><p>Medication:<\/p><p>Depending on the size of the burn and the age of the child, a combination of the following is<\/p><p>often required:<\/p><ul><li>\u2022<\/li><\/ul><p>Paracetamol    15mg/kg orally, give 45mins before procedure<\/p><ul><li>\u2022<\/li><\/ul><p>Morphine    0.3-0.5mg/kg orally, give 45mins before procedure<\/p><ul><li>\u2022<\/li><\/ul><p>Midazolam    0.3mg/kg orally if combined with Morphine, (otherwise 0.5mg/kg with<\/p><p>max 15mg), give 30mins before procedure<\/p><p>Other:<\/p><ul><li>\u2022<\/li><\/ul><p>N2O 30-70%    Consider for: first dressing/ removal staples/ deroofing blisters/<\/p><p>large debridement/ tricky areas (eg hands). This requires<\/p><p>appropriately trained nurse/ doctor and fasting. Not appropriate for<\/p><p>children aged &lt;2 years. See Section 7 of the Handbook. (Managing<\/p><p>Pain Using Entonox)<\/p><ul><li>\u2022<\/li><\/ul><p>Ketamine    3-5mg/kg orally if combined with drugs above, give 30mins before<\/p><p>procedure, (caution if less than 2years old). Charted by<\/p><p>Anaesthetist.<\/p><p>Page 38 of 57<\/p><p>Rescue Analgesia/ Sedation:<\/p><table><tr><td>Option<\/td><td>Indication<\/td><td>Dose<\/td><td>Limitations<\/td><\/tr><tr><td>N2O<\/td><td>Inadequate<\/td><td>30-70%<\/td><td>Appropriate training &amp; fasting<\/td><\/tr><\/table><p>analgesia/    Vomiting (prolonged conc.&gt;50%)<\/p><p>sedation<\/p><table><tr><td>Intranasal<\/td><td>Inadequate<\/td><td>0.5-1mcg/kg<\/td><td>Unpleasant, stings<\/td><\/tr><tr><td>Fentanyl<\/td><td>analgesia<\/td><td>Repeat Q5mins Oversedation &amp; nausea/ vomiting<\/td><\/tr><\/table><p>Max 3mcg/kg    (Onset &amp; potency similar to IV)<\/p><p>If a child is distressed and other appropriate measures have been tried it may be necessary<\/p><p>to abandon and try again with a different approach or a general anaesthestic. Children<\/p><p>should not be undergoing prolonged or distressing dressing changes \u2013 if there is any<\/p><p>uncertainty discuss with the Paediatric Anaesthetist.<\/p><p>Fasting:<\/p><p>Oral sedation alone    2 hours<\/p><p>N2O sedation alone    2 hours<\/p><p>Combined oral and N2O sedation    4 hours solids/ breast milk<\/p><p>2 hours clear fluids<\/p><p>Monitoring for dressing changes:<\/p><p>Children taking opioids require baseline and regular recording of vital observations every<\/p><p>15mins. See section 9.2.1 of the Handbook. (Monitoring) In addition to this, children requiring<\/p><p>sedation with Midazolam, N2O, or Ketamine should also have continuous oximetry and<\/p><p>supervision during the dressing change, and until they have woken fully.<\/p><p>Ongoing pain management:<\/p><p>Consider simple analgesics (paracetamol and NSAIDS), although caution is advised with<\/p><p>prolonged use, particularly in the presence of poor nutritional status. Reduced daily dosing<\/p><p>may be wise, along with surveillance of liver function.<\/p><p>Opioids are frequently required in burns management, and often in high doses. In patients<\/p><p>requiring regular opioids, a controlled release preparation is often charted (this will usually be<\/p><p>after a few days, at which point the dose can be calculated from the 24 hour usage). As the<\/p><p>burns recover, the opioid dose will need to be reduced in a fashion so as to avoid opioid<\/p><p>withdrawal.<\/p><p>Page 39 of 57<\/p><p>11. OTHER ANALGESIC MEDICATIONS<\/p><p>11.1 Fentanyl Patches<\/p><p>These are used for patients with chronic or cancer pain, requiring high dosage Fentanyl,<\/p><p>that are opioid tolerant. There is marked inter-patient variability in blood concentrations<\/p><p>reached. The patch provides the background infusion and incident pain is managed by<\/p><p>alternative means, e.g. PCA or oral opioid.<\/p><p>Patches (12.5, 25, 50, 75, 100 mcg/hr)<\/p><p>Preparation:<\/p><p>If the patient is on a Fentanyl PCA, then the patch is selected by<\/p><p>Dose:<\/p><p>calculating the Fentanyl consumption per day and then calculating the<\/p><p>average hourly consumption \u2013 the patch selected should not exceed this<\/p><p>hourly consumption.<\/p><p>Eg, If patient is using 2000 mcg Fentanyl IV per day this equates to<\/p><p>average hourly use of 2000/ 24 = 83.3 mcg/ hr so charting 75 mcg/hr<\/p><p>patch would be reasonable.<\/p><p>Alternatively calculate the patients 24 hour oral morphine dose and<\/p><p>convert this to the appropriate Fentanyl patch dose using the table below<\/p><p>(from Medsafe data).<\/p><p>Oral 24-hour Morphine dose    Fentanyl patch dose<\/p><p>&lt;60 mg    12.5mcg/hour<\/p><p>60 \u2013 134 mg    25<\/p><p>135 \u2013 224 mg    50<\/p><p>225 \u2013 314 mg    75<\/p><p>315 \u2013 404 mg    100<\/p><p>If the patient is taking a medicine other than oral Morphine, then calculate the<\/p><p>total daily dose and multiply by the following conversion factors to get the<\/p><p>Morphine equivalent dose:<\/p><p>oral Oxycodone 2, intravenous Morphine 3,<\/p><p>intravenous Fentanyl 0.15<\/p><p>Eg, If patient is using 2000 mcg Fentanyl IV per day this equates to 2000<\/p><p>x 0.15 = 300 mg of oral 24-hour Morphine dose, so (from the table<\/p><p>above) charting a Fentanyl 75 mcg/hr patch would be reasonable.<\/p><p>Observations:<\/p><p>The risk of opioid over dose mandates that the patient remain on PCA/ NCA<\/p><p>monitoring. The signs of over dosage include sedation, slow weak respirations and<\/p><p>pin point pupils.<\/p><p>See Section 9 of the Handbook<\/p><p>Page 40 of 57<\/p><p>Note:<\/p><ul><li>\u2022<\/li><\/ul><p>A new patch is required every 72 hours. It is applied to different areas of hairless,<\/p><p>healthy and undamaged skin with thirty seconds of pressure. The onset time to full<\/p><p>effect is 12-24 hours.<\/p><p>As the requirement for incident pain intervention falls the<\/p><p>patch strength can be weaned.<\/p><ul><li>\u2022<\/li><\/ul><p>The opioid tolerant patient requires a weaning regime to avoid opioid withdrawal. Off<\/p><p>set time is 12-24 hours. Incident pain can be managed without delay following<\/p><p>stopping Fentanyl patches.<\/p><ul><li>\u2022<\/li><\/ul><p>Patients should not be discharged home on Fentanyl patches without discussion<\/p><p>with PAPs. On the rare occasion that a child is discharged home on Fentanyl<\/p><p>patches, then the care givers must be educated on the signs of Fentanyl overdose<\/p><p>and on the safe storage of the patches (out of reach of children, preferably in a<\/p><p>locked cupboard).<\/p><p>11.2 Gabapentin<\/p><p>Gabapentin is a relatively new anticonvulsant which acts mostly on the \u03b12\u03b4 subunit of the<\/p><p>Ca channel. It has also been shown to be useful in the management of pain.<\/p><ul><li>FDA approval for:<\/li><\/ul><p>Chronic pain<\/p><ul><li>\u2022<\/li><\/ul><p>Post herpetic neuralgia<\/p><ul><li>\u2022<\/li><\/ul><p>Diabetic neuropathy<\/p><ul><li>increased use in this setting as an adjunct, particularly in<\/li><\/ul><p>Perioperative acute pain<\/p><p>operations associated with a high incidence of chronic pain or with a significant<\/p><p>neuropathic component:<\/p><ul><li>\u2022<\/li><\/ul><p>Amputations<\/p><ul><li>\u2022<\/li><\/ul><p>Multilevel orthopaedic surgery<\/p><ul><li>\u2022<\/li><\/ul><p>Spinal surgery (scoliosis)<\/p><ul><li>\u2022<\/li><\/ul><p>Thoracotomy<\/p><ul><li>\u2022<\/li><\/ul><p>High anxiety and significant pain prior to surgery<\/p><p>Other painful conditions<\/p><ul><li>\u2022<\/li><\/ul><p>Burns<\/p><p>Side effects commonly include: sedation, tiredness, dizziness and ataxia.<\/p><p>Currently Gabapentin is not licensed for use in children, but several large centres are<\/p><p>using it for specific indications.<\/p><p>Capsules (100, 300, 400 and 600 mg)<\/p><p>Preparation:<\/p><p>Oral suspension<\/p><ul><li>Currently not available in NZ<\/li><li>Pharmacy can make up an oral suspension<\/li><\/ul><p>(ideally need half a day notice)<\/p><p>Page 41 of 57<\/p><p>(see indications above)<\/p><p>Dose:    Perioperative acute pain<\/p><ul><li>\u2022<\/li><\/ul><p>Dose:    5-10mg/kg PO TDS starting 2-12 hours preop<\/p><ul><li>\u2022<\/li><\/ul><p>Duration: 3-5 days or until pain settles<\/p><ul><li>\u2022<\/li><\/ul><p>Wean if &gt;1 week use \u2013 to avoid acute withdrawal<\/p><p>(children &gt;2 years old)<\/p><p>Chronic pain<\/p><ul><li>\u2022<\/li><\/ul><p>Day 1: 10mg/kg/day, as single dose    (max 300mg)<\/p><ul><li>\u2022<\/li><\/ul><p>Day 2: 20mg/kg/day, divided BD    (max 600mg/day)<\/p><ul><li>\u2022<\/li><\/ul><p>Day 3: 30mg/kg/day, divided dose TDS    (max 900mg/day)<\/p><ul><li>\u2022<\/li><\/ul><p>Maintenance: -reassess day 7<\/p><ul><li>titrate to clinical effect<\/li><\/ul><p>Important:<\/p><ul><li>\u2022<\/li><\/ul><p>Titrate to clinical effect (upto 40mg/kg/day in divided dose TDS)<\/p><ul><li>\u2022<\/li><\/ul><p>Recommended maximum 2400mg/day (note usual adult dose 900-3600mg/day)<\/p><ul><li>\u2022<\/li><\/ul><p>In outpatient setting titration is usually slower (every 3 days)<\/p><ul><li>\u2022<\/li><\/ul><p>Clinical benefit is usually seen after 1-2 weeks<\/p><ul><li>\u2022<\/li><\/ul><p>Reduce dose in renal dysfunction \u2013 monitor more carefully for side effects<\/p><ul><li>\u2022<\/li><\/ul><p>Side effects include: sleepiness, dizziness, confusion, dry mouth, ataxia, abnormal<\/p><p>gait and weight gain<\/p><ul><li>\u2022<\/li><\/ul><p>Wean slowly after prolonged use (&gt; 1 week use)<\/p><p>11.3 Amitriptyline<\/p><p>There are few published guidelines on drugs for paediatric neuropathic pain and few are<\/p><p>specifically licensed for paediatric use. Amitriptyline is a Tricylic Antidepressant with<\/p><p>membrane stabilising properties that has been used as one of the main pharmacological<\/p><p>treatments for paediatric neuropathic pain. It is not recommended for paediatric use in<\/p><p>Mims, and should be initially charted by a consultant. A Cochrane review in 2007<\/p><p>confirmed its efficacy in neuropathic pain states. While being best known as an<\/p><p>antidepressant it is charted in much lower doses for pain management. Amitriptyline can<\/p><p>have marked sedative properties even in low doses.<\/p><p>At Waikato hospital it is generally started in low doses at night to facilitate sleep and<\/p><p>minimise daytime sedation. A recent review by Medsafe and the Medicines Adverse<\/p><p>Reactions Committee on the safety of antidepressants suggests that all classes of<\/p><p>antidepressants appear to carry some degree of risk of QT prolongation and potentially<\/p><p>arrhythmia. Patients should be evaluated for the risk factors for QT prolongation before<\/p><p>starting Amitriptyline. An ECG should be considered at baseline, steady state, at the time<\/p><p>of dose increases, and if another QT prolonging medicine is added.<\/p><p>Tablet (10, 25, 50mg)<\/p><p>Preparation:<\/p><p>The starting dose is 0.2 mg/kg orally at night, but no more than 10mg.<\/p><p>Dose:<\/p><p>The onset of effect may take 3-5 days, and it is sensible to reassess<\/p><p>after one week. If necessary the dose may be titrated to effect by<\/p><p>increasing the dose by 0.2mg/kg and waiting 5 days. The dose may be<\/p><p>titrated to a maximum of 1mg/kg daily. Maximum dose 50mg (usual adult<\/p><p>dose 10-50mg).<\/p><p>Page 42 of 57<\/p><p>11.4 Diazepam<\/p><p>Diazepam may be useful for children troubled with postoperative muscle spasms following<\/p><p>multilevel orthopaedic surgery. This surgery involves tenotomies and osteotomies at<\/p><p>different levels on one or both limbs. Diazepam may be prescribed on a regular basis, but<\/p><p>its effect should be reviewed daily and doses adjusted as required. Caution should be<\/p><p>used when charting for children with global developmental delay and particularly children<\/p><p>with hypotonia, (these children may be more vulnerable to sedation and respiratory<\/p><p>compromise).<\/p><p>Syrup (10mg/10ml)<\/p><p>Preparation:<\/p><p>0.1mg/kg TDS<\/p><p>Dose:<\/p><p>11.5 Intranasal Fentanyl<\/p><p>Fentanyl is a short to medium duration opioid commonly used IV for treatment of acute<\/p><p>pain and useful for painful procedures of a short duration. Concerns with IV Fentanyl<\/p><p>outside of a specialist environment when given as a single large bolus include the<\/p><p>potential for respiratory depression and chest wall rigidity. Advantages of Fentanyl via the<\/p><p>nasal route include a slower onset of action, longer duration and the fact it does not<\/p><p>require IV access for administration. Limited studies to date have shown a good safety<\/p><p>profile when used in an appropriate dose. It provides similar analgesia to 0.1mg/kg<\/p><p>Morphine IV. Onset of effect is 5min and duration is greater than 30minutes.<\/p><p>Dose:<\/p><p>A suggested initial dose is 1.5mcg/kg. A second dose of 0.5mcg/kg can be given no<\/p><p>sooner than 10 minutes later. Maximum dose 100mcg.<\/p><p>Administration:<\/p><p>Calculate and draw up the dose (using Fentanyl 100mcg/2ml concentration)<\/p><p>Use 1ml Tuberculin syringe and MAD (Mucosal Atomiser Device)<\/p><p>Recline patient at 45 degrees. Hold the syringe horizontal and expel the contents into the<\/p><p>nostril as a fine mist in one rapid push. Consider dividing doses of more than 1ml between<\/p><p>both nostrils<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Page 43 of 57<\/p><p>12. PREOPERATIVE MEDICATIONS<\/p><p>12.1 Topical Local Anaesthetics<\/p><p>The insertion of intravenous cannulas, performance of lumbar punctures and<\/p><p>administration of IM injections are potentially very distressing procedures for children.<\/p><p>Some of the pain and distress may be reduced by using topical local anaesthetics. The<\/p><p>topical LA should be applied under an occlusive dressing and a secondary dressing such<\/p><p>as a bandage may help reduce dislodgement/ ingestion of the cream or occlusive<\/p><p>dressing.<\/p><p>Amethocaine gel (Ametop or Amgel)<\/p><p>4% Amethocaine gel is an ester type LA suitable for topical anaesthesia in infants and<\/p><p>children prior to painful procedures. Studies in children show a similar success rate for IV<\/p><p>cannulation with Amethocaine or EMLA but lower pain scores with Amethocaine. It<\/p><p>provides good topical anaesthesia in 30-45 minutes. Do not leave for longer than 60<\/p><p>minutes. Effective skin anaesthesia lasts 4-6 hrs after removal. Do not apply to broken<\/p><p>skin. No systemic side effects have been noted in children. Amethocaine tends to cause<\/p><p>erythema secondary to vasodilation. A small number of children may get a marked<\/p><p>erythema that resolves after removal.<\/p><p>EMLA cream<\/p><p>EMLA cream is a eutectic mixture of local anaesthetics. This is a mixture of 2.5%<\/p><p>Lignocaine and 2.5% Prilocaine.<\/p><p>It requires at least 60 minutes to provide topical<\/p><p>. We recommend caution in children less than 3 months of age because of<\/p><p>anaesthesia<\/p><p>the possibility of methaemoglobinaemia from the Prilocaine component. In infants use 2g<\/p><p>or less and do not leave in place for longer than 2 hours. It tends to cause blanching of the<\/p><p>skin secondary to vasoconstriction.<\/p><p>12.2 Premedications<\/p><p>Premedication with sedative drugs is often used in paediatric practice as one of the<\/p><p>modalities to reduce preoperative anxiety in children undergoing surgery. The same<\/p><p>medications may also be used for unpleasant ward procedures, as long as a few basic<\/p><p>safety measures are in place.<\/p><p>Non-pharmacological measures which may contribute to anxiolysis include tablet based<\/p><p>interactive distraction (TBID), video distraction, and performance of \u2018coping promoting<\/p><p>behaviour\u2019 by physicians and parents. These are beyond the scope of this guideline, but<\/p><p>some references are included at the end of this section.<\/p><p>Risk/ benefits:<\/p><p>The following are some conditions where a    assessment must be<\/p><p>careful risk/ benefit<\/p><p>made prior to prescribing a premed:<\/p><ul><li>\u2022<\/li><\/ul><p>Anticipated airway difficulty<\/p><ul><li>\u2022<\/li><\/ul><p>Increased risk of aspiration<\/p><ul><li>\u2022<\/li><\/ul><p>Respiratory/ cardiac/ hepatic/ renal impairment<\/p><p>Page 44 of 57<\/p><ul><li>\u2022<\/li><\/ul><p>Previous allergy/ adverse reaction to premedication<\/p><ul><li>\u2022<\/li><\/ul><p>Central/ obstructive sleep apnoea<\/p><ul><li>\u2022<\/li><\/ul><p>Acute systemic illness e.g. sepsis<\/p><p>Important:<\/p><p>If in any doubt, discuss your plan with the PAPS Specialist beforehand<\/p><p>o<\/p><p>Some children may only be safely sedated in a theatre environment due to<\/p><p>o<\/p><p>their comorbidities<\/p><p>Practical Considerations:<\/p><ul><li>\u2022<\/li><\/ul><p>Consider fasting status<\/p><ul><li>\u2022<\/li><\/ul><p>Obtain informed consent from the parent/ guardian<\/p><ul><li>\u2022<\/li><\/ul><p>Chart the premedication dose, route and time to be given<\/p><ul><li>\u2022<\/li><\/ul><p>Inform the nursing staff of the prescription<\/p><ul><li>\u2022<\/li><\/ul><p>Premeds may be mixed with a small volume of clear fluid if required e.g. apple juice,<\/p><p>or with cordial or paracetamol suspension<\/p><ul><li>\u2022<\/li><\/ul><p>Sedative drugs should be provided in a safe environment where resuscitation<\/p><p>equipment can be readily accessed<\/p><ul><li>\u2022<\/li><\/ul><p>A sedated child should be appropriately monitored at all times, including during<\/p><p>transfer from one clinical area to another<\/p><p>Tips:<\/p><p>Oral premeds:<\/p><p>Midazolam \u2013 has a quick and reliable onset and has been the most frequently used.<\/p><p>o<\/p><p>Its bitter taste may be masked by additives, but some children may not tolerate this<\/p><p>Clonidine \u2013 may be useful in these children but note increased onset time required<\/p><p>o<\/p><p>Intranasal premeds:<\/p><p>Should be administered with the MAD (mucosal atomiser) device<\/p><p>o<\/p><p>May be useful where children have refused oral medications<\/p><p>o<\/p><p>Beware the large dead space in the MAD device and requirement to deliver the<\/p><p>o<\/p><p>drug at 45 degrees to coat the turbinates<\/p><p>(and to a lesser extent Ketamine) \u2013 sore and<\/p><p>Midazolam    not recommended<\/p><p>o<\/p><ul><li>avoid in children with abnormal conduction systems/ on<\/li><\/ul><p>Dexmedetomidine<\/p><p>o<\/p><p>negative chronotropic agents<\/p><p>l \u2013 has a rapid onset, and wide interpatient variability, and should be given<\/p><p>Fentany<\/p><p>o<\/p><p>by medical personnel. A further dose of 1.5 mcg/kg may be given after 10 mins if<\/p><p>required<\/p><p>Combination regimens:<\/p><ul><li>\u2022<\/li><\/ul><p>May be of benefit \u2013 faster onset/ increased efficacy/ attenuation of side effects<\/p><ul><li>\u2022<\/li><\/ul><p>Dose reduction of one or both agents may be appropriate<\/p><ul><li>\u2022<\/li><li>they have<\/li><\/ul><p>Only after discussion and/ or supervision by the PAPS Specialist<\/p><p>a higher risk of over sedation<\/p><p>Page 45 of 57<\/p><table><tr><td>Drug<\/td><td>Route<\/td><td>Dose<\/td><td>Onset<\/td><td>Duration Notes<\/td><td>Comments<\/td><\/tr><\/table><p>(mins)    (hours)<\/p><table><tr><td>Midazolam<\/td><td>Oral<\/td><td>0.5-1 mg/kg<\/td><td>20-30<\/td><td>1-2<\/td><td>Bitter taste Paradoxical<\/td><\/tr><\/table><p>(max 15 mg)    reactions, esp in<\/p><p>children with<\/p><table><tr><td>Intranasal 0.2 mg/kg<\/td><td>10-15<\/td><td>1-2<\/td><td>Stings<\/td><\/tr><\/table><p>high impulsivity,<\/p><table><tr><td>Temazepam<\/td><td>Oral<\/td><td>10-30 mg<\/td><td>45-60<\/td><td>3<\/td><td>Tablet<\/td><\/tr><\/table><p>hiccups<\/p><p>(older children)<\/p><table><tr><td>Ketamine<\/td><td>Oral<\/td><td>5-10 mg/kg<\/td><td>10-20<\/td><td>3<\/td><td>Nystagmus,<\/td><\/tr><\/table><p>(&gt;2 yrs)    analgesia, N&amp;V,<\/p><table><tr><td>Intranasal 3-5 mg/kg<\/td><td>10-15<\/td><td>1-3<\/td><td>Stings<\/td><\/tr><\/table><p>salivation,<\/p><p>hallucinations<\/p><table><tr><td>Clonidine<\/td><td>Oral<\/td><td>4 mcg/kg<\/td><td>60-90<\/td><td>6<\/td><td>Tasteless<\/td><td>Mild<\/td><\/tr><\/table><p>bradycardia/<\/p><table><tr><td>Intranasal 2-4 mcg/kg<\/td><td>30-60<\/td><td>6<\/td><td>Painless<\/td><\/tr><\/table><p>hypotension,<\/p><p>analgesia,<\/p><table><tr><td>Dexmedetomidine<\/td><td>Intranasal 1-2 mcg/kg<\/td><td>Painless<\/td><\/tr><\/table><p>anxiolysis,<\/p><p>antiemesis<\/p><table><tr><td>Fentanyl<\/td><td>Intranasal 1.5 mcg/kg<\/td><td>2-5<\/td><td>0.5-1<\/td><td>Painless<\/td><td>Respiratory<\/td><\/tr><\/table><p>depression,<\/p><p>N&amp;V, pruritus<\/p><p>Page 46 of 57<\/p><p>13. MANAGING PAIN FOLLOWING TONSILLECTOMY<\/p><p>Analgesic options following tonsillectomy include:<\/p><ul><li>\u2022<\/li><\/ul><p>Simple analgesics<\/p><ul><li>\u2022<\/li><\/ul><p>Opioids<\/p><ul><li>\u2022<\/li><\/ul><p>Tramadol<\/p><p>Simple analgesics:<\/p><p>Unless contraindicated all children should have regular:<\/p><ul><li>\u2022<\/li><\/ul><p>Paracetamol 15-20mg/kg QID (maximum    )<\/p><p>75mg/kg/day<\/p><ul><li>\u2022<\/li><\/ul><p>Ibuprofen 5-10mg/kg QID (maximum 40mg/kg/day, max dose 1600mg/day)<\/p><p>Opioids:<\/p><p>For those monitored in hospital consider:<\/p><ul><li>\u2022<\/li><\/ul><p>Morphine 0.2mg/kg orally 2hrly PRN<\/p><ul><li>\u2022<\/li><\/ul><p>Oxycodone 0.05-0.1mg/kg orally 3hrly PRN<\/p><p>Note:<\/p><p>Should<\/p><p>never be used regularly<\/p><p>o<\/p><p>Children with OSA:<\/p><p>o<\/p><p>\uf0a7<\/p><p>Use with    and in a reduced dose<\/p><p>extreme caution<\/p><p>\uf0a7<\/p><p>Have been shown to have 1/3-1/2 the opioid requirements as children without<\/p><p>OSA and a much higher rate of post-operative adverse respiratory events<\/p><p>\uf0a7<\/p><p>Should be monitored overnight in hospital to assess response and sensitivity<\/p><p>to opioids<\/p><p>Tramadol:<\/p><p>Alternative analgesia includes tramadol.<\/p><ul><li>\u2022<\/li><\/ul><p>Initial dose:    Tramadol 0.5mg/kg 6-8hrly<\/p><ul><li>\u2022<\/li><\/ul><p>Maximum:    Tramadol 1mg/kg 6-8hrly (maximum of 400mg/day)<\/p><p>Note:<\/p><p>Associated with less respiratory depression but not confirmed to be safer than<\/p><p>o<\/p><p>morphine after tonsillectomy<\/p><p>Will have an incidence of nausea<\/p><p>o<\/p><p>Recent FDA concerns with the use of Tramadol in children have been largely<\/p><p>o<\/p><p>refuted by SPANZA but as with all potent analgesics a risk benefit analysis should<\/p><p>always be evaluated for individual patients before use. SPANZA<\/p><p>Recommendations:<\/p><p>\uf0a7<\/p><p>Children with OSA should be monitored overnight in hospital to assess<\/p><p>response and sensitivity to Tramadol<\/p><p>\uf0a7<\/p><p>Tramadol dose should be reduced following tonsillectomy<\/p><p>SPANZA Advisory on Tramadol - Warning on tramadol use in children<\/p><p>Page 47 of 57<\/p><p>General comments:<\/p><p>For further information and precautions on use of the above drugs see Section 3 of the<\/p><p>Handbook.<\/p><p>Page 48 of 57<\/p><p>14. MANAGING PAIN FOLLOWING SCOLIOSIS SURGERY<\/p><p>Multi-level spinal surgery is major surgery and is associated with significant postoperative<\/p><p>pain, including the potential for neuropathic pain. Patients may have varying levels of pre-<\/p><p>operative pain. Presently, at Waikato Hospital, we are performing posterior spinal fusion<\/p><p>on patients with idiopathic adolescent scoliosis and, as a general rule, are not including<\/p><p>patients with neuromuscular co-morbidities.<\/p><p>14.1 Intraoperative Analgesia<\/p><p>These children usually receive the following analgesia:<\/p><ul><li>\u2022<\/li><\/ul><p>Intrathecal morphine (ITM)    intravenous methadone<\/p><p>or<\/p><ul><li>\u2022<\/li><\/ul><p>Morphine IV (low dose)<\/p><ul><li>\u2022<\/li><\/ul><p>Parecoxib IV<\/p><ul><li>\u2022<\/li><\/ul><p>Paracetamol IV<\/p><ul><li>\u2022<\/li><\/ul><p>Ketamine IV infusion<\/p><p>14.2 Postoperative Analgesia<\/p><p>Routine:<\/p><ul><li>\u2022<\/li><\/ul><p>Paracetamol 15mg/kg PO/ IV 4 hourly (If given IV max 4 doses in a 24 hour period)<\/p><ul><li>\u2022<\/li><\/ul><p>Ibuprofen 10mg/kg (max 400mg) PO 8 hourly<\/p><ul><li>\u2022<\/li><\/ul><p>Morphine PCA<\/p><p>Note if intraoperative intrathecal morphine used then:<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>First 24 hours low dose PCA and no basal<\/p><ul><li>\u2022<\/li><\/ul><p>Increase parameters to normal levels after 24 hours<\/p><p>Adjuvants:<\/p><ul><li>\u2022<\/li><\/ul><p>Gabapentin 5mg/kg PO TDS x 5 days<\/p><p>The first dose may be given as part of the premedication<\/p><p>o<\/p><p>Usually prescribed for 5 days<\/p><p>o<\/p><p>Watch out for excessive sedation or dizziness<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Parecoxib 1mg/kg IV daily (max 40mg)<\/p><p>Can be given instead of Ibuprofen for the first day or two, especially if patient<\/p><p>o<\/p><p>reluctant to take orally<\/p><ul><li>\u2022<\/li><\/ul><p>Tramadol 1-2mg/kg PO/IV 4 hourly prn<\/p><p>Note recent FDA concerns regarding charting in paediatric patients under 12<\/p><p>o<\/p><p>years and any patients under 18 years with respiratory problems, sleep<\/p><p>disordered breathing or obesity (See Section 3.5 of the Handbook)<\/p><p>Lowers seizure threshold, and can cause significant nausea and vomiting<\/p><p>o<\/p><p>Other adjuvant analgesics to consider:<\/p><ul><li>\u2022<\/li><\/ul><p>Clonidine 1-2 mcg/kg IV/ PO 8hourly prn<\/p><p>Useful as an anxiolytic and analgesic<\/p><p>o<\/p><p>Sedating but generally not a respiratory depressant<\/p><p>o<\/p><p>Can cause a drop in blood pressure and heart rate<\/p><p>o<\/p><p>Page 49 of 57<\/p><ul><li>\u2022<\/li><\/ul><p>Amitriptyline starting at 0.2 mg/kg (max 10mg) PO at night<\/p><p>If struggling to sleep and with significant pain<\/p><p>o<\/p><p>Patients should be evaluated for the risk factors for QT prolongation before<\/p><p>o<\/p><p>starting Amitriptyline. An ECG should be considered at baseline, steady state, at<\/p><p>the time of dose increases and if another QT prolonging medicine is added<\/p><ul><li>\u2022<\/li><\/ul><p>Diazepam<\/p><p>0.1mg/kg PO/IV 8 hourly prn<\/p><p>o<\/p><p>Useful for muscle spasms which may be present<\/p><p>o<\/p><p>Anxiolytic<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Ketamine infusion<\/p><p>0-4 mcg/kg/min \u2013 for 24-48 hours postoperatively<\/p><p>o<\/p><p>General comments:<\/p><p>Care needs to be taken with the multimodal nature of analgesia often used in this setting.<\/p><p>Patients do vary in their response, but over-sedation and dizziness can potentially delay<\/p><p>mobilization.<\/p><p>Page 50 of 57<\/p><p>15. INITIAL TREATMENT OF CHRONIC PAIN IN CHILDREN<\/p><p>A useful definition of chronic pain is \u201cpain that extends beyond the expected time of<\/p><p>healing\u201d and \u201chence lacks the acute warning function of physiological nociception\u201d.<\/p><p>Mechanisms of pain include acute nociceptive pain (i.e., pain arising from the activation of<\/p><p>peripheral nerve endings), neuropathic pain (i.e., resulting from injury to, or dysfunction of,<\/p><p>the somatosensory system), and psycho-social-spiritual-emotional pain. Chronic pain<\/p><p>commonly involves a combination of these mechanisms.<\/p><p>15.1 Types of Chronic Pain in Children<\/p><p>(formerly functional pain syndrome)<\/p><p>Primary pain disorders:<\/p><p>Many different chronic pain syndromes are now considered to be manifestations of an<\/p><p>underlying pain vulnerability or pain spectrum condition, rather than being viewed as<\/p><p>separate disorders. Considerable evidence, points to a role of shared biological sensitivity,<\/p><p>or \u201cpain vulnerability\u201d.<\/p><p>Important features:<\/p><ul><li>\u2022<\/li><\/ul><p>Pain not explained in terms of conventional medical disease<\/p><p>(biochemical or structural abnormalities)<\/p><ul><li>\u2022<\/li><\/ul><p>Significant disruption of everyday life (often leads to incapacitation)<\/p><ul><li>\u2022<\/li><\/ul><p>Unimodal medical therapy typically unsuccessful<\/p><ul><li>\u2022<\/li><\/ul><p>Unimodal medical therapy can consume significant time, resources and finances<\/p><ul><li>\u2022<\/li><\/ul><p>Persistent treatment failures can lead to negative implications eg<\/p><ul><li>patients perceiving their pain is not organic and therefore not real/ serious<\/li><li>stigmatization (i.e. symptoms characterized as fictitious or malingering)<\/li><\/ul><p>The three most common primary pain disorders in paediatrics are:<\/p><ul><li>\u2022<\/li><\/ul><p>Primary headaches: tension headaches and migraines<\/p><ul><li>\u2022<\/li><\/ul><p>Centrally mediated central abdominal pain syndrome<\/p><ul><li>\u2022<\/li><\/ul><p>Musculoskeletal and joint pain<\/p><p>Chronic-on-acute pain<\/p><p>A significant number of children with recurrent nociceptive pain caused by underlying<\/p><p>organic disease (eg, inflammatory bowel disease, sickle cell disease, rheumatoid arthritis<\/p><p>or cancer), may develop pain which becomes complicated to treat, and have what is<\/p><p>known as \u201cchronic-on-acute\u201d disease. In these children primary pain disorders may also<\/p><p>co-exist, or even be triggered by the underlying organic disease, and pain symptoms do<\/p><p>not necessarily represent inadequate treatment, flare-up, or recurrence.<\/p><p>15.2 Management<\/p><p>Many children with chronic pain will benefit from an interdisciplinary rehabilitative pain<\/p><p>program. This requires appropriate resources including: pain specialists and nurses,<\/p><p>psychologists, physiotherapists and occupational therapists and social workers. A lot of<\/p><p>Page 51 of 57<\/p><p>the focus is on restoring function and as this is achieved the pain improves and commonly<\/p><p>resolves \u2013 this may be summarized as \u201clife gets back to normal\u201d and then \u201cthe pain gets<\/p><p>better\u201d. To achieve this an interdisciplinary approach is required which involves a<\/p><p>combination of: (1) physical therapy (eg, range of movement, strength, balance, graded<\/p><p>motor imagery exercises); (2) integrative medicine/active mind-body techniques (eg, self-<\/p><p>relaxation, self-regulation, distraction, guided imagery exercises); (3) psychology (coping<\/p><p>strategies, targeting anxiety and depression); and (4) normalizing daily routine (school<\/p><p>attendance, sports, social life and sleep). Determining which children will benefit from an<\/p><p>interdisciplinary approach will require input from the Chronic Pain Team.<\/p><p>15.2.1 Referal to the Pain Service<\/p><p>If the Home Team decide they would like to refer a child with chronic pain to the Pain<\/p><p>Service then the following basic principles should be adhered to:<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure the child has been reviewed by the admitting Consultant<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure the team have excluded reversible and treatable conditions<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure a written referral documenting relevant imaging and bloods (including a<\/p><p>recent CBC and CRP)<\/p><ul><li>\u2022<\/li><\/ul><p>Over investigation can also be harmful and deflect from confronting the real issues<\/p><ul><li>\u2022<\/li><\/ul><p>Take a thorough pain history including psychological issues<\/p><ul><li>\u2022<\/li><\/ul><p>Use available non-pharmacological treatments<\/p><p>15.2.2 Initial approach and non-drug treatments<\/p><p>It may be useful to start to explain to the child and family the concepts that the pain \u201cis<\/p><p>real\u201d but it \u201chas lost its warning function\u201d and that using the affected part of the body<\/p><p>does not result in greater harm. It is also helpful that the child and family begin to<\/p><p>understand that working towards \u201clife gets back to normal\u201d is important and that this<\/p><p>results in \u201cthe pain gets better\u201d.<\/p><p>At some point it can be helpful discussing pain transmission and how this can be<\/p><p>influenced by down-modulation (which results in decreased pain) or up-modulation<\/p><p>(which results in increased pain). This can help explaining that the pain is real and how<\/p><p>the interdisciplinary (\u201cnon-drug\u201d) treatment modalities work. Down-modulation can be<\/p><p>described as \u201cOFF-switch\u201d modulation which involves descending inhibition from the<\/p><p>\u201ccontrol center\u201d (the peri-aquaductal grey matter). \u201cOFF-switch\u201d modulation (decreases<\/p><p>pain) is triggered by 1) physical therapy/ exercise, and 2) integrative medicine/<\/p><p>distraction. Up-modulation can be described as \u201cON-switch\u201d modulation (increases<\/p><p>pain) which involves activation in the front of the brain (the prefrontal cortex). \u201cON-<\/p><p>switch\u201d modulation is triggered by stress, pessimism, anxiety/ depression, insomnia,<\/p><p>and absenteeism (missing school/ sports/ and social contact). \u201cON-switch\u201d modulation<\/p><p>may be reduced by 1) psychological support, and 2) normalizing the activities of daily<\/p><p>life.<\/p><p>It is also helpful to understand how fear and catastrophizing can affect pain. Both<\/p><p>exacerbate the experience of pain, and both can be experienced by the child and the<\/p><p>parents. Catastrophizing involves cognitive and emotional processes which include<\/p><p>magnification, rumination, pessimism, and feelings of helplessness. Reducing fear of<\/p><p>pain in children is important and is associated with positive functional outcomes in<\/p><p>children with primary pain disorders. It has also been shown that parental<\/p><p>catastrophizing and expectations strongly influence children\u2019s pain memory.<\/p><p>Page 52 of 57<\/p><p>So even before the Chronic Pain Service has been involved, basic non-drug treatment<\/p><p>strategies can be initiated:<\/p><ul><li>\u2022<\/li><\/ul><p>Reassure \u2013 the pain is real, using the affected part of the body will not result in<\/p><p>greater harm<\/p><ul><li>\u2022<\/li><\/ul><p>Explain \u2013 the pain has lost its warning function<\/p><ul><li>\u2022<\/li><\/ul><p>Explain \u2013 the pain can be modulated up and down<\/p><ul><li>\u2022<\/li><\/ul><p>Explain \u2013 working towards \u201clife gets back to normal\u201d is really important and results<\/p><p>in \u201cthe pain gets better\u201d<\/p><ul><li>\u2022<\/li><\/ul><p>Initiate some basic interdisciplinary rehabilitation strategies \u2013 normalizing daily<\/p><p>routine (showering, dressing, eating) and regular sleep<\/p><p>Self-relaxation<\/p><p>o<\/p><p>Distraction<\/p><p>o<\/p><p>Targeting anxiety/ catastrophizing<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Involve ward physiotherapist and play therapist<\/p><p>Online resources (for children/ families and staff):<\/p><ul><li>\u2022<\/li><\/ul><p>The    website in Australia and has some very<\/p><p>\u201cACI Pain Management Network\u201d<\/p><p>useful resources<\/p><p>Follow the link: Chronic pain resources for children and families<\/p><p>o<\/p><p>Then see \u201cFor Youth: PainBytes\u201d for some very helpful episodes<\/p><p>o<\/p><p>Provides information and education to help children/ families begin to<\/p><p>o<\/p><p>understand what is going on in the nervous system, and how to begin to<\/p><p>better manage the pain<\/p><p>15.2.3 Drugs<\/p><p>In the short term, before review by Chronic Pain Service, some pharmacological<\/p><p>treatments may have a role, however evidence of strong efficacy is lacking for any<\/p><p>agents.<\/p><ul><li>Have been shown in many studies to be as efficacious as<\/li><\/ul><p>Paracetamol and NSAIDS<\/p><p>more \u201cpotent\u201d analgesics for reducing pain scores despite not being pursued as much<\/p><p>by patients. They have the advantage of a good side effect profile and not exacerbating<\/p><p>chronic pain states.<\/p><ul><li>Has a very idiosyncratic profile and may be very effective for some<\/li><\/ul><p>Tramadol<\/p><p>patients. It is often worth trialling.<\/p><ul><li>Have little role in primary pain disorders, i.e. those not related to tissue<\/li><\/ul><p>Opioids<\/p><p>damage. However, they are effective in persistent pain conditions with nociceptive pain<\/p><p>caused by tissue damage.<\/p><p>Key points:<\/p><ul><li>\u2022<\/li><\/ul><p>Opioids administered for primary pain disorders have low long long-term efficacy, a<\/p><p>poor safety profile, and commonly a worse clinical outcome<\/p><ul><li>\u2022<\/li><\/ul><p>Opioids should not be administered to paediatric patients with primary pain<\/p><ul><li>in these patients they are likely to cause more harm than benefit.<\/li><\/ul><p>disorders<\/p><p>These disorders include:<\/p><p>Primary headaches: tension headaches and migraines<\/p><p>o<\/p><p>Centrally mediated central abdominal pain syndrome<\/p><p>o<\/p><p>Chronic musculoskeletal and joint pain<\/p><p>o<\/p><p>\u201cChronic sickle cell pain\u201d (pain that extends beyond the expected time of<\/p><p>o<\/p><p>acute vaso-occlusive crisis)<\/p><p>Page 53 of 57<\/p><ul><li>\u2022<\/li><\/ul><p>Opioids are important and effective for long-term analgesic management in<\/p><p>persistent pain conditions (i.e., long-lasting and/or repetitive nociceptive pain<\/p><p>caused by tissue injury), such as:<\/p><p>Junctional epidermolysis bullosa<\/p><p>o<\/p><p>Osteogenesis imperfecta<\/p><p>o<\/p><p>Advanced metastasized bone tumours (e.g., Ewing sarcoma)<\/p><p>o<\/p><p>(Chronic Pain in Children and Adolescents: Diagnosis and Treatment of Primary Pain<\/p><p>Disorders in Head, Abdomen, Muscles and Joints. Stefan J Friedrichsdorf et al.<\/p><p>Children    , 3, 24)<\/p><p>2016<\/p><ul><li>May be useful if sleep disturbance and pain. (Children &gt;6 years old).<\/li><\/ul><p>Amitriptyline<\/p><p>The starting dose is 0.2 mg/kg orally at night, but no more than 10mg.<\/p><p>The onset of effect may take 3-5 days, and it is sensible to reassess after one week.<\/p><p>Maintenance: -titrate to effect by increasing the dose by 0.2mg/kg and waiting 5 days<\/p><ul><li>may be titrated to a maximum of 1mg/kg daily (max dose 50mg)<\/li><\/ul><p>(usual adult dose 10-50mg)<\/p><ul><li>\u2022<\/li><\/ul><p>Patients should be evaluated for the risk factors for QT prolongation before starting<\/p><ul><li>\u2022<\/li><\/ul><p>An ECG should be considered at baseline, steady state, at the time of dose<\/p><p>increases and if another QT prolonging medicine is added<\/p><p>If you expect the Paediatric Pain Service to be involved, please discuss this before<\/p><p>commencing.<\/p><ul><li>Maybe useful for neuropathic pain. (Children &gt;2 years old)<\/li><\/ul><p>Gabapentin<\/p><p>Day 1: 10mg/kg/day, as single dose (max 300mg)<\/p><p>Day 2: 20mg/kg/day, divided BD (max 600mg/day)<\/p><p>Day 3: 30mg/kg/day, divided dose TDS (max 900mg/day), until day 7 then reassess<\/p><p>Maintenance: titrate to clinical effect (upto 40mg/kg/day in divided dose TDS)<\/p><ul><li>\u2022<\/li><\/ul><p>Recommended maximum 2400mg/day (note usual adult dose 900-3600mg/day)<\/p><ul><li>\u2022<\/li><\/ul><p>In the outpatient setting titration is usually slower (every 3 days)<\/p><ul><li>\u2022<\/li><\/ul><p>Clinical benefit is usually seen after 1-2 weeks<\/p><ul><li>\u2022<\/li><\/ul><p>Side effects include: sleepiness, dizziness, confusion, dry mouth, ataxia, abnormal<\/p><p>gait and weight gain.<\/p><p>If you expect the Paediatric Pain Service to be involved, please discuss this before<\/p><p>commencing.<\/p><ul><li>May be useful if anxiety and pain. May cause significant sedation, and<\/li><\/ul><p>Clonidine<\/p><p>may cause reduction in heart rate and blood pressure.<\/p><p>Start at 1-2mcg/kg BD PO.<\/p><ul><li>Has been suggested as being useful in some studies and has the<\/li><\/ul><p>Melatonin<\/p><p>advantages of augmenting sleep and a good side effect profile.<\/p><p>Important Note:<\/p><p>Prior to discharge, a management plan must be made for the ongoing management of<\/p><p>these drugs. It must be clear in the discharge letter whether the GP or Outpatient Clinic<\/p><p>will be responsible, and when the follow-up will occur.<\/p><p>Page 54 of 57<\/p><p>16. PALLIATIVE CARE, TERMINAL ILLNESS AND END-OF-LIFE<\/p><p>Specialist Paediatric Palliative Care is an extremely limited resource in New Zealand and<\/p><p>is currently available only through Starship Hospital.<\/p><p>However, good quality end-of-life care and symptom management can still be achieved<\/p><p>through a multidisciplinary approach as required. The lead clinician will be a Paediatrician,<\/p><p>who will typically seek Specialist Paediatric Palliative Care advice from Starship Hospital.<\/p><p>However, if required, the Paediatric Pain Service at Waikato is happy to provide advice on<\/p><p>the management of pain related issues in this patient group (including outpatients),<\/p><p>accepting that we are not Palliative Specialists. This advice is generally in the form of<\/p><p>bridging options &amp; may include admission until the primary team can seek a definitive<\/p><p>strategy from the Paediatric Palliative Service at Starship Hospital at the earliest possible<\/p><p>opportunity.<\/p><p>16.1 Key Aspects of Care<\/p><p>For the child with a life-limiting or life-threatening illness include it is important to<\/p><p>remember the following principles:<\/p><ul><li>\u2022<\/li><\/ul><p>Recognising the situation<\/p><ul><li>\u2022<\/li><\/ul><p>Recognising high levels of anxiety are common for the child/ family and professionals<\/p><ul><li>\u2022<\/li><\/ul><p>Appropriate and open communication with the child and family<\/p><ul><li>\u2022<\/li><\/ul><p>Minimising or avoiding interventions that are futile or add limited benefit<\/p><ul><li>\u2022<\/li><\/ul><p>Planning is important, ie an end-of-life care plan<\/p><p>Initiated by senior clinician, involves family and child<\/p><p>o<\/p><p>Includes advanced care plan (ceiling of care, place of care/ death, donation)<\/p><p>o<\/p><p>Includes management plan (flexible plan, symptom management goals,<\/p><p>o<\/p><p>psychosocial spiritual support, people and equipment, contacts 24/7)<\/p><p>16.2 Symptom Management<\/p><p>16.2.1 General Approach<\/p><p>As already outlined above, caring for the dying child involves more than just symptom<\/p><p>control \u2013 emotional, psychological, and spiritual support of the child and the family are<\/p><p>essential.<\/p><p>The following may be helpful:<\/p><ul><li>\u2022<\/li><\/ul><p>Don\u2019t panic \u2013 stop and gather information:<\/p><p>Read the notes<\/p><p>o<\/p><p>Talk to the parents \u2013 they play a pivotal role in care<\/p><p>o<\/p><p>Talk to the child \u2013 they may be old enough to describe their symptoms<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Document and discuss the plan<\/p><ul><li>\u2022<\/li><\/ul><p>Beware of emotional burnout \u2013 maintain professional compassion and care<\/p><p>Page 55 of 57<\/p><p>16.2.2 Pain Management<\/p><p>Pain is a feared and common symptom in children receiving end-of-life care. There are<\/p><p>many varied causes of pain, and in this group of children the cause of the pain is often<\/p><p>multi-factorial. Most of the time the pain is simple to manage. Management is based on<\/p><p>a good assessment and understanding of the disease process, good communication<\/p><p>and an empiric approach with regular reviews of the response to treatment.<\/p><p>It is also important to remember that management should include \u2018non-drug\u2019 treatment.<\/p><p>Without addressing the child\u2019s emotional, psychological, and spiritual needs drug<\/p><p>treatment alone will not be completely successful.<\/p><p>Remember:<\/p><ul><li>\u2022<\/li><\/ul><p>Effective treatment requires a trusting relationship which requires good<\/p><p>communication<\/p><ul><li>\u2022<\/li><\/ul><p>Determine what the pain means to the child and parent \u2013 what do they understand<\/p><ul><li>\u2022<\/li><\/ul><p>What children think, feel and do with their pain influences their pain experience<\/p><p>Eg, worsening physical function, sleep deprivation, upset parents, and feeling<\/p><p>o<\/p><p>scared may all effect pain<\/p><ul><li>\u2022<\/li><\/ul><p>Myths/ misunderstandings can cause:<\/p><p>Increased anxiety<\/p><p>o<\/p><p>Poor compliance<\/p><p>o<\/p><p>Poor reporting eg, if people know I\u2019m in pain I\u2019ll have to stay in hospital<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Honest and age-appropriate explanations and options help the child and family<\/p><p>Prescribing:<\/p><p>The oral route is the simplest but may not always be appropriate:<\/p><ul><li>\u2022<\/li><\/ul><p>Pain crisis requiring rapid titration of IV opioids<\/p><ul><li>\u2022<\/li><\/ul><p>Poor absorption: vomiting, disordered GI motility<\/p><ul><li>\u2022<\/li><\/ul><p>Inability to comply: unconscious, severe nausea, poor swallow/ aspiration risk,<\/p><p>mediaction refusal<\/p><p>In this case consider the role of the subcutaneous route. Subcutaneous infusions are<\/p><p>frequently and incorrectly viewed as both a painful intervention and an option only<\/p><p>when the child is actively dying. Instead they can be utilised over long term periods and<\/p><p>minimise both the trauma of repeated cannulation and the risks associated with central<\/p><p>access.<\/p><p>Opioids:<\/p><p>There are 3 phases in finding the \u2018right dose\u2019:<\/p><ul><li>\u2022<\/li><\/ul><p>Initiation \u2013 charted according to weight/ age (mindful of other charted drugs)<\/p><ul><li>\u2022<\/li><\/ul><p>Titration \u2013 remember don\u2019t increase daily amount by more than 30-50%<\/p><ul><li>\u2022<\/li><\/ul><p>Maintenance \u2013 LA opioids are started once a stable effective daily dose has been<\/p><p>found<\/p><p>Transdermal fentanyl takes 12-24hours to be effective so it is only used once<\/p><p>o<\/p><p>child is stabilized on morphine or equivalent<\/p><p>th    th<\/p><p>to 1/10 daily dose<\/p><p>Chart PRN \u2018rescue dose\u2019 \u2013 1/5<\/p><p>o<\/p><p>Opioid switch and rotation:<\/p><ul><li>\u2022<\/li><\/ul><p>Switch \u2013 change in opioid early on because opioid relatively ineffective or trouble<\/p><p>with side-effects. Consider when:<\/p><p>Analgesia inadequate<\/p><p>o<\/p><p>Page 56 of 57<\/p><p>Dose-limiting side-effects<\/p><p>o<\/p><p>Adequate analgesia but unpleasant side-effects<\/p><p>o<\/p><p>Alternative opioid has specific advantages<\/p><p>o<\/p><p>(eg change from enteral morphine to transdermal fentanyl)<\/p><ul><li>\u2022<\/li><\/ul><p>Rotation \u2013 change in opioid after a period of benefit because tolerance appears to<\/p><p>be developing<\/p><ul><li>\u2022<\/li><\/ul><p>The new dose is calculated as follows:<\/p><p>Calculate oral morphine equivalent<\/p><p>o<\/p><p>Reduce dose of new opioid by 25-30%<\/p><p>o<\/p><p>(This allows for incomplete cross-tolerance - thus reduces the risk of toxicity)<\/p><p>16.3 Resources<\/p><p>Services:<\/p><ul><li>\u2022<\/li><\/ul><p>Paediatric Medicine \u2013 the lead clinician should be a Paediatrician<\/p><p>(<\/p><p>One of the Paediatricians at Waikato Hospital will be the assigned the role as \u2018link<\/p><p>Paediatrician\u2019 for Paediatric Palliative Care in our region)<\/p><ul><li>\u2022<\/li><\/ul><p>Adult Palliative Care \u2013 some of the specialists may be comfortable to be consulted<\/p><p>Online resources:<\/p><ul><li>\u2022<\/li><\/ul><p>The \u201c    \u201d website in the UK has some very useful resources<\/p><p>Together for Short Lives<\/p><p>Follow the link: Palliative care resources for professionals<\/p><p>o<\/p><p>Then see \u201cBasic Symptom Control in Paediatric Palliative Care\u201d<\/p><p>o<\/p><p>\uf0a7<\/p><p>Pain p108<\/p><p>\uf0a7<\/p><p>Pain management p110<\/p><ul><li>\u2022<\/li><\/ul><p>The \u201c    \u201d website is also very useful<\/p><p>Starship Paediatric Palliative Care Network<\/p><p>Follow the link: Starship Paediatric Palliative Care Network<\/p><p>o<\/p><p>Then see \u201cPaediatric Palliative Care Clinical Guidelines\u201d:<\/p><p>o<\/p><p>\uf0a7<\/p><p>Pain management<\/p><p>\uf0a7<\/p><p>Various symptom managements<\/p><p>\uf0a7<\/p><p>Palliative care emergencies<\/p><p>Page 57 of 57<\/p>", "children": [{"id": 2, "page": 2, "top": 99.4, "level": 2, "font_size": 13.980000000000018, "text": "CONTENTS", "content_html": "<p>1. Introduction ....................................................................................................................... 4<\/p><p>2. Principles Of Analgesic Administration In Children ........................................................... 5<\/p><p>3. Managing pain using simple and oral analgesics .............................................................. 6<\/p><p>3.1 Paracetamol .............................................................................................................. 6<\/p><p>3.2 Diclofenac (Voltaren)................................................................................................. 7<\/p><p>3.3 Ibuprofen (Brufen) ..................................................................................................... 7<\/p><p>3.4 Parecoxib (Dynastat)................................................................................................. 8<\/p><p>3.3 Celecoxib .................................................................................................................. 9<\/p><p>3.5 Tramadol ................................................................................................................... 9<\/p><p>3.6 Oral Morphine Preparations .................................................................................... 10<\/p><p>3.7 Oxycodone .............................................................................................................. 11<\/p><p>3.8 Codeine Phosphate ................................................................................................ 13<\/p><p>4. Managing Pain Using Parenteral Analgesics .................................................................. 14<\/p><p>4.1 Protocol for Intermittent IV Opioids ......................................................................... 14<\/p><p>4.2 Protocol for Intravenous Opioid Infusions ............................................................... 14<\/p><p>4.3 Protocol for Nurse Controlled Analgesia (NCA) ...................................................... 16<\/p><p>4.4 Protocol for Patient Controlled Analgesia (PCA) ..................................................... 17<\/p><p>4.5 Protocol for Subcutaneous Morphine Boluses ........................................................ 18<\/p><p>5. Managing Pain Using Epidurals ...................................................................................... 20<\/p><p>6. Managing Pain Using Regional Infusions ....................................................................... 24<\/p><p>7. Managing Pain Using Entonox ........................................................................................ 27<\/p><p>8. Managing Adverse Effects &amp; Troubleshooting ................................................................ 29<\/p><p>8.1 LA Toxicity .............................................................................................................. 29<\/p><p>8.1.1 Management of Impending LA Toxicity ........................................................... 29<\/p><p>8.1.2 Cardiac Resuscitation in the Event of Suspected LA Toxicity ......................... 30<\/p><p>8.2 Management of Common Opioid Side-Effects ........................................................ 30<\/p><p>8.2.1 Management of Overdose ............................................................................... 30<\/p><p>8.2.2 Management of Pruritus .................................................................................. 30<\/p><p>8.3 Management of Nausea &amp; Vomiting ....................................................................... 31<\/p><p>8.4 Management of Common Epidural Problems ......................................................... 33<\/p><p>8.4.1 Epidural Disconnection .................................................................................... 33<\/p><p>8.4.2 Inadequate Analgesia ...................................................................................... 33<\/p><p>Page 2 of 57<\/p><p>8.5 Troubleshooting ...................................................................................................... 34<\/p><p>9. Monitoring ....................................................................................................................... 35<\/p><p>9.1 Pain Assessment &amp; Measurement .......................................................................... 35<\/p><p>9.2 Monitoring ............................................................................................................... 36<\/p><p>9.3 Some Normal Physiological Values for Children 0-16 Years .................................. 37<\/p><p>10. Managing Pain from Burns .............................................................................................. 38<\/p><p>11. Other Analgesic Medications .......................................................................................... 40<\/p><p>11.1 Fentanyl Patches .................................................................................................. 40<\/p><p>11.2 Gabapentin ........................................................................................................... 41<\/p><p>11.3 Amitriptyline .......................................................................................................... 42<\/p><p>11.4 Diazepam .............................................................................................................. 43<\/p><p>11.5 Intranasal Fentanyl................................................................................................ 43<\/p><p>12. Preoperative Medications ................................................................................................ 44<\/p><p>12.1 Topical Local Anaesthetics ................................................................................... 44<\/p><p>12.2 Premedications ..................................................................................................... 44<\/p><p>13. Managing Pain Following Tonsillectomy ......................................................................... 47<\/p><p>14. Managing pain following scoliosis surgery ...................................................................... 49<\/p><p>14.1 Intraoperative Analgesia ....................................................................................... 49<\/p><p>14.2 Postoperative Analgesia ....................................................................................... 49<\/p><p>15. Initial treatment of chronic pain in children ...................................................................... 51<\/p><p>15.1 Types of Chronic Pain in Children......................................................................... 51<\/p><p>15.2 Management ......................................................................................................... 51<\/p><p>15.2.1 Referal to the Pain Service ............................................................................ 52<\/p><p>15.2.2 Initial approach and non-drug treatments ...................................................... 52<\/p><p>15.2.3 Drugs ............................................................................................................. 53<\/p><p>16. Palliative Care, Terminal Illness And End-Of-Life ........................................................... 55<\/p><p>16.1 Key Aspects of Care ............................................................................................. 55<\/p><p>16.2 Symptom Management ......................................................................................... 55<\/p><p>16.2.1 General Approach ......................................................................................... 55<\/p><p>16.2.2 Pain Management ......................................................................................... 56<\/p><p>16.3 Resources ............................................................................................................. 57<\/p><p>Page 3 of 57<\/p>", "children": []}, {"id": 3, "page": 4, "top": 115.4, "level": 2, "font_size": 13.980000000000018, "text": "1. INTRODUCTION", "content_html": "<p>The purpose of this handbook is to assist with the education of hospital staff in the commonly<\/p><p>available methods of acute pain relief at Waikato Hospital.<\/p><p>It is intended to be a guide which medical and nursing staff can refer to when prescribing and<\/p><p>managing pain relief in children.<\/p><p>It is not intended to be exhaustive or to restrict the way individuals practice, but children<\/p><p>admitted to hospital may benefit from a more co-ordinated approach to pain management.<\/p><p>Referrals and advice:<\/p><p>The Department of Anaesthesia provides a Paediatric Acute Pain Management Service<\/p><p>(PAPS) which is involved in the treatment of all types of acute pain. For in-hours<\/p><p>consultation, refer to the \u2018Amion Rostering\u2019 page on the intranet (Look on the Anaesthetics<\/p><p>roster for \u2018Paed Pain\u2019). If this is unsuccessful, phone the Duty Anaesthetist (23322), who will<\/p><p>direct you to the Paediatric Anaesthetist covering pain for the week. The Anaesthetist is likely<\/p><p>to be working in a theatre, but bearing this in mind they will respond to phone calls as soon<\/p><p>as possible. For out-of-hours problems, phone the Anaesthetic Registrar covering Obstetrics<\/p><p>(23470) who will consult with the on-call Paediatric Anaesthetist if unable to resolve the<\/p><p>problem.<\/p><p>Referrals from within the Department of Anaesthesia:<\/p><p>When referring children to the PAPS, it would be appreciated if the Anaesthetist could<\/p><p>please:<\/p><ul><li>\u2022<\/li><\/ul><p>In-hours \u2013 phone the Paediatric Anaesthetist covering pain for the week<\/p><ul><li>\u2022<\/li><\/ul><p>Out-of-hours \u2013 phone the on-call Paediatric Anaesthetist at a reasonable hour<\/p><ul><li>\u2022<\/li><\/ul><p>Place a patient sticker in the PAPS book (Red A4) found in Level 2 PACU<\/p><p>(document the procedure, type of pain relief and ward)<\/p><ul><li>\u2022<\/li><\/ul><p>Please DO NOT fill out an Adult Pain Referral form<\/p><p>Page 4 of 57<\/p>", "children": []}, {"id": 4, "page": 5, "top": 77.6, "level": 2, "font_size": 13.980000000000018, "text": "2. PRINCIPLES OF ANALGESIC ADMINISTRATION IN CHILDREN", "content_html": "<p>There are some major differences between paediatric pain relief and adult pain relief, and<\/p><p>this may not be readily appreciated by medical and nursing staff who rotate from adult areas.<\/p><p>Some general principles apply in children:<\/p><ul><li>\u2022<\/li><\/ul><p>Paediatric analgesia needs to be calculated on a mg/kg basis and these dosages need to<\/p><p>be rounded off to make volume calculations easy.<\/p><ul><li>\u2022<\/li><\/ul><p>Children do not like intramuscular (IM) injections and they should not be used<\/p><p>IM injections are unpredictable, largely ineffective<\/p><p>unless special circumstances exist.<\/p><p>and many children will deny having pain to avoid injections. Intravenous, oral and rectal<\/p><p>are the preferred routes of administration.<\/p><ul><li>\u2022<\/li><\/ul><p>Techniques such as opioid infusions, Nurse Controlled Analgesia (NCA), Patient<\/p><p>Controlled Analgesia (PCA), epidural infusions, regional infusions and Entonox are freely<\/p><p>available and should be used if indicated.<\/p><ul><li>\u2022<\/li><\/ul><p>Following the administration of oral, subcutaneous (or IM) opioids, 60 minutes should<\/p><p>elapse before starting opioid infusions, NCA, PCA, or epidurals.<\/p><p>No other opioids or<\/p><p>sedatives should be given while using these techniques unless ordered by PAPS.<\/p><ul><li>\u2022<\/li><\/ul><p>Pain is best treated with continuous methods of analgesic administration (e.g. infusions<\/p><p>or PCA). Mild pain can usually be adequately controlled with intermittent bolus dose<\/p><p>administration.<\/p><ul><li>\u2022<\/li><\/ul><p>Neonates and some ex-premature infants (up to 60 weeks post-conceptual age) may be<\/p><p>sensitive to opioids. If they require opioid analgesics then the method and doses should<\/p><p>be discussed with the Consultant involved.<\/p><ul><li>\u2022<\/li><\/ul><p>When faced with unusually high or increasing requirements of pain relief think of<\/p><p>alternative causes of pain (e.g. compartment syndrome, pressure necrosis or other<\/p><p>surgical complications).<\/p><ul><li>\u2022<\/li><\/ul><p>Hospital approved protocols are available for all the common methods and are included<\/p><p>in this handbook.<\/p><p>Page 5 of 57<\/p>", "children": []}, {"id": 5, "page": 6, "top": 77.6, "level": 2, "font_size": 13.980000000000018, "text": "3. MANAGING PAIN USING SIMPLE AND ORAL ANALGESICS", "content_html": "<p>3.1 Paracetamol<\/p><p>Paracetamol is an analgesic suitable for mild pain or in conjunction with other analgesics<\/p><p>for more severe pain. Its mechanism of action is not clear. Paracetamol\u2019s main strength is<\/p><p>its excellent side effect profile, with serious complications being very rare despite<\/p><p>extensive worldwide use over a long period of time.<\/p><p>Liver damage from Paracetamol is a very rare problem despite its widespread use. Risk<\/p><p>factors include, prolonged fasting, febrile illness, use of P450 inducing drugs (eg isoniazid)<\/p><p>and probably most importantly a unique genetic predisposition. If children are considered<\/p><p>at risk, consideration should be given to decreasing the dose of Paracetamol if given for<\/p><p>more than 1-2 days. Dosing limits will always be controversial.<\/p><p>Tablets (500mg)<\/p><p>Preparations:<\/p><p>Syrup (120mg/5ml and 250mg/5ml)<\/p><p>Suppositories (50, 125, 250, and 500mg)<\/p><p>Intravenous (Perfalgan 1000mg/100ml)<\/p><p>Dosage:<\/p><p>Oral:<\/p><table><tr><td>Neonates 32 weeks \u2013 44 weeks<\/td><td>10mg/kg 6hrly prn<\/td><td>- max 40mg/kg/day<\/td><\/tr><tr><td>Neonates 44 weeks \u2013 6 months<\/td><td>15mg/kg 6hrly prn<\/td><td>- max 60mg/kg/day<\/td><\/tr><tr><td>&gt; 6 months old<\/td><td>15mg/kg 4-6hrly prn<\/td><td>- max 60-90mg/kg/day<\/td><\/tr><\/table><ul><li>\u2022<\/li><\/ul><p>In neonates a single loading dose of 20mg/kg may be given if the neonatologist is<\/p><p>in agreement (paracetamol has a large volume of distribution in neonates)<\/p><ul><li>\u2022<\/li><\/ul><p>Anaesthetist may chart 120 mg/kg/day for a short time period in selected patients<\/p><ul><li>\u2022<\/li><\/ul><p>Review Paracetamol dose after 48 hours<\/p><ul><li>\u2022<\/li><\/ul><p>Suggestions for extended use:<\/p><p>After 8 days:    reduce dose to max 45mg/kg/day<\/p><p>After 14 days:    reduce dose to max 30mg/kg/day<\/p><p>Rectal:<\/p><ul><li>\u2022<\/li><\/ul><p>Absorption is slow and variable \u2013 the oral route should be used when possible<\/p><ul><li>\u2022<\/li><\/ul><p>Max daily dose is same as oral route<\/p><p>Intravenous (Perfalgan):<\/p><table><tr><td>Neonates 32 weeks \u2013 44 weeks<\/td><td>7.5mg/kg 6hrly prn<\/td><td>- max 30mg/kg/day<\/td><\/tr><tr><td>Neonates 44 weeks \u2013 3 months<\/td><td>10mg/kg 6hrly prn<\/td><td>- max 40mg/kg/day<\/td><\/tr><tr><td>&gt; 3 months old<\/td><td>15mg/kg 6hrly prn<\/td><td>- max 60mg/kg/day<\/td><\/tr><\/table><ul><li>\u2022<\/li><\/ul><p>Chart only for 2 days then review<\/p><ul><li>\u2022<\/li><\/ul><p>Convert to oral as soon as possible<\/p><p>Page 6 of 57<\/p><ul><li>\u2022<\/li><\/ul><p>IV Paracetamol may be considered in patients unable to take or absorb oral<\/p><p>Paracetamol. Following major surgery it provides better analgesia and opioid<\/p><p>sparing effect than rectal Paracetamol which has slow, poor and very variable<\/p><p>absorption<\/p><p>3.2 Diclofenac (Voltaren)<\/p><p>Diclofenac is an NSAID that has a low dose suppository preparation that is licensed for<\/p><p>use in children more than 1 year of age. Caution is required in patients with<\/p><p>hypovolaemia, renal dysfunction, coagulopathy, GI bleeding, aminoglycosides and in the<\/p><p>immediate post-operative period.<\/p><p>Tablets (25, 50mg, and 75SRmg)<\/p><p>Preparation:<\/p><p>Suppository (12.5, 25, 50mg)<\/p><p>0.5-1.0mg/kg 12 hourly prn<\/p><p>Dosage:<\/p><p>3.3 Ibuprofen (Brufen)<\/p><p>Ibuprofen is an NSAID that has a syrup preparation and can be used in children older than<\/p><p>6 months. NSAIDS differ in their nociceptive, anti-inflammatory and side effect profiles.<\/p><p>Ibuprofen has been well validated as an analgesic. The usual cautions apply in patients<\/p><p>with hypovolaemia, renal dysfunction, coagulopathy, GI bleeding, aminoglycosides and<\/p><p>the immediate post-operative period.<\/p><p>Syrup (100mg/5ml)<\/p><p>Preparation:<\/p><p>Tablets (200, 400mg)<\/p><p>5-10mg/kg 6 hourly prn (max 40mg/kg/day)<\/p><p>Dosage:<\/p><p>Ibuprofen is an NSAID that is available as a syrup or tablet. It has been well validated as<\/p><p>an analgesic in children. Studies show a safety profile that is at least as good as<\/p><p>paracetamol when used in patients as young as 3 months old. Some centres are using<\/p><p>Ibuprofen down to 1 month of age, however this cannot be recommended at this time.<\/p><p>(There is also limited safety data from studies looking at its use for patent ductus<\/p><p>arteriosus closure in premature neonates - 7% of neonates had renal impairment which<\/p><p>was completely reversible).<\/p><p>There are some developmental concerns when using Ibuprofen in young babies. Like all<\/p><p>NSAIDs, Ibuprofen disrupts prostaglandin production, and prostaglandins are involved in<\/p><p>regulation of cerebral and renal blood flow, non-REM sleep and ductus arteriosus closure.<\/p><p>In addition, it should be remembered that renal maturity is not reached until 6-12 months.<\/p><p>There are also other pharmacokinetic differences in infants which are complex and may<\/p><p>affect dosing.<\/p><p>hypovolaemia, renal dysfunction,<\/p><p>NSAIDs precautions for all children include:<\/p><p>coagulopathy, jaundice, GI bleeding, aminoglycosides and the immediate post-operative<\/p><p>period. Most asthmatic children tolerate NSAIDs well, but caution should be exercised in<\/p><p>older children with severe asthma and nasal polyp disease, where the rate of severe<\/p><p>exacerbation may be as high as 30%.<\/p><p>Suspension (100 mg/5 ml)<\/p><p>Preparation:<\/p><p>Tablets (200 mg, 400 mg)<\/p><p>Page 7 of 57<\/p><p>Dosage:<\/p><p>3-6 months    5mg/kg 8-12 hourly prn (may use 10mg/kg loading dose)<\/p><p>&gt;6 months old    5-10mg/kg 6-8 hourly prn<\/p><ul><li>\u2022<\/li><\/ul><p>Review Ibuprofen dose after 3 days and for consider reducing dose to 5mg/kg<\/p><p>3.4 Parecoxib (Dynastat)<\/p><p>Parecoxib is an NSAID that specifically inhibits the enzyme cyclooxygenase-2 (COX 2).<\/p><p>Paediatric trial data is very limited. It is given intravenously, and in adults, it has been<\/p><p>shown to be as effective or more effective than the older NSAIDs for treatment of acute<\/p><p>pain. It is opioid sparing and associated with less post-operative nausea and vomiting post<\/p><p>tonsillectomy. Advantages of parecoxib over other NSAIDs are that it does not impair<\/p><p>platelet function, and gastrointestinal ulceration is less likely. In addition, the ability to give<\/p><p>the drug intravenously means a more reliable NSAID dose (ie 100% bioavailability in<\/p><p>children with an IV cannula in place), compared with traditional perioperative rectal<\/p><p>NSAID, or where oral dosing is inappropriate. Parecoxib is not licensed for use in children.<\/p><p>However, it may on occasion be a useful analgesic in the paediatric setting. It should only<\/p><p>be charted by PAPS.<\/p><p>The adverse effects of intravenous Parecoxib in adult clinical trials are similar to those for<\/p><p>NSAIDs, with serious adverse effects such as acute renal failure, Stevens-Johnson<\/p><p>syndrome, and hypersensitivity reactions including anaphylaxis and angioedema<\/p><p>occurring at low incidence. The usual cautions apply in patients with hypovolaemia, renal<\/p><p>dysfunction, coagulopathy and GI bleeding.<\/p><p>Contraindications:<\/p><ul><li>\u2022<\/li><\/ul><p>Sulphur allergy<\/p><ul><li>\u2022<\/li><\/ul><p>Severe hepatic impairment<\/p><ul><li>\u2022<\/li><\/ul><p>Concurrent use of another NSAID<\/p><p>Cautions:<\/p><ul><li>\u2022<\/li><\/ul><p>Allergic like reactions with NSAIDs/ aspirin<\/p><p>According to adult data, COX-2 inhibitors are considered safe in most of<\/p><p>o<\/p><p>these patients, but a small percentage have cross-sensitivity, so an oral<\/p><p>challenge under medical supervision is advisable<\/p><p>Considered safe in paediatric patients with NSAID exacerbated respiratory<\/p><p>o<\/p><p>disease<\/p><p>:    Intravenous (Dynastat)<\/p><p>Preparations<\/p><p>2 yrs and older (no studies looking at safety in younger age to date)<\/p><p>Dosage:<\/p><p>1 mg/kg (max 40mg) once daily IV<\/p><ul><li>\u2022<\/li><\/ul><p>Chart only for 2 days then review<\/p><ul><li>\u2022<\/li><\/ul><p>Convert to oral as soon as possible<\/p><p>Page 8 of 57<\/p><p>3.3 Celecoxib<\/p><p>Celecoxib is a COX 2 inhibitor \u2013 it is an NSAID that selectively inhibits the enzyme<\/p><p>cyclooxygenase-2 (COX 2). Being a selective inhibitor it has the same advantages as<\/p><p>Parecoxib, except that Celecoxib is an oral drug. Paediatric trial data is very limited.<\/p><p>See Parecoxib above<\/p><p>Contraindications:<\/p><p>See Parecoxib above<\/p><p>Cautions:<\/p><p>Capsule (100mg, 200mg)<\/p><p>Preparation:<\/p><p>Solution (10mg/ml \u2013 disperse 100mg capsule in 10ml water)<\/p><p>12 months and older<\/p><p>Dosage:<\/p><p>4 mg/kg (max 200mg per dose) BD prn<\/p><p>3.5 Tramadol<\/p><p>Tramadol is used for treatment of moderate to severe pain. Its action is by both opioid and<\/p><p>non-opioid monoaminergic mechanisms (serotoninergic, noradrenergic), and it may also<\/p><p>have some local anaesthetic action on peripheral nerves. It may be given orally and IV,<\/p><p>although both PR and IM preparations have also been used. Advantages over opioids<\/p><p>such as Morphine may include less sedation, less respiratory depression and less<\/p><p>constipation. Tramadol may not be as suitable as opioids for more severe pain.<\/p><p>In New Zealand Tramadol is currently licensed for use in children aged 2 years and older.<\/p><p>However, it has been used internationally for many years in children as young as<\/p><p>newborn.<\/p><p>The risks and benefits of Tramadol use in early life are not straightforward \u2013 there are a<\/p><p>number of important considerations. Both Tramadol and its M1 metabolite (formed by<\/p><p>CYP2D6 liver enzyme) are active and provide analgesia via different pathways. Tramadol<\/p><p>parent drug causes sedation (but does not cause respiratory depression), however the M1<\/p><p>\u00b5<\/p><p>metabolite has is a opioid agonist (200 x more receptor affinity than Tramadol itself) and<\/p><p>may cause both sedation and respiratory depression.<\/p><p>At term, the newborn\u2019s CYP2D6 activity is still immature and the ability to convert<\/p><p>Tramadol to M1 is 50% compared to adult levels. The newborn\u2019s ability to renally excrete<\/p><p>M1 is also reduced, and is 70% compared to adults. However, as a result of the slow<\/p><p>maturation of CYP2D6, the plasma concentrations of M1 are low until infants are 3<\/p><p>months old \u2013 at this point in time the immature renal elimination becomes relevant and<\/p><p>higher M1 levels may occur. Renal excretion and M1 clearance reaches 90% adult levels<\/p><p>by age 1 year.<\/p><p>In addition, it must be remembered that the descending pain tracts in the neonate may not<\/p><p>be functionally mature, hence the serotoninergic/ noradrenergic advantages of the drug<\/p><p>\u00b5<\/p><p>over conventional opioids may not apply, with agonism predominating.<\/p><p>In 2017 in the United Sates, the FDA in started restricting the use of both Tramadol and<\/p><p>codeine in children, after identifying cases involving serious breathing problems and<\/p><p>death. Among other groups, their restrictions and warnings have included: children with<\/p><p>obesity, sleep disordered breathing, and other breathing problems, post-tonsillectomy and<\/p><p>breast feeding mothers.<\/p><p>In response to this, SPANZA (the Society of Paediatric Anaesthesia of New Zealand and<\/p><p>Page 9 of 57<\/p><p>Australia) put out two statements in 2017 regarding Tramadol use. Genetic variation in<\/p><p>CYP2D6 exists and ultra-rapid metabolisers may be more at risk in certain situations,<\/p><p>although this is less certain with Tramadol than with Codeine. Readers are directed to<\/p><p>these statements in the references; their content is acknowledged in the cautions/ dosage<\/p><p>recommendations below.<\/p><p>Key points:<\/p><p>Tramadol is safer than opioids in breast feeding mothers<\/p><p>Tramadol doses should be limited for acute pain after tonsillectomy<\/p><p>Children with obstructive sleep apnea who have undergone tonsillectomy should be<\/p><p>observed overnight to assess response and sensitivity to opioids<\/p><p>SPANZA Advisory on Tramadol - Use during breast feeding and the neonate<\/p><p>SPANZA Advisory on Tramadol - Warning on tramadol use in children<\/p><p>Caution must be used with certain \u201cat risk\u201d patients:<\/p><ul><li>\u2022<\/li><\/ul><p>Day surgery patients<\/p><ul><li>\u2022<\/li><\/ul><p>Post-tonsillectomy patients<\/p><ul><li>\u2022<\/li><\/ul><p>Patients with obstructive sleep apnoea or obesity or severe lung disease<\/p><ul><li>\u2022<\/li><\/ul><p>Patients with severe hepatic and renal impairment<\/p><ul><li>\u2022<\/li><\/ul><p>Patients susceptible to seizures<\/p><ul><li>\u2022<\/li><\/ul><p>Patients on psychotropic medication (SSRI)<\/p><p>Side effects:<\/p><ul><li>\u2022<\/li><\/ul><p>Nausea and vomiting \u2013 around 10% of children<\/p><ul><li>\u2022<\/li><\/ul><p>Dizziness<\/p><ul><li>\u2022<\/li><\/ul><p>Sedation<\/p><ul><li>\u2022<\/li><\/ul><p>Respiratory depression (rare)<\/p><p>Tablets (50mg, and 100SRmg)<\/p><p>Preparation:<\/p><p>Oral solution (10mg/ml)<\/p><p>Intravenous (50mg/ml)<\/p><p>Drops 100 mg/ml delisted in NZ during 2017 after several unintentional overdoses<\/p><p>worldwide<\/p><p>1.5-2mg/kg 6 hourly prn PO<\/p><p>Dosage:<\/p><p>1-2mg/kg 4-6 hourly prn IV in general population (up to 400 mg daily)<\/p><p>0.5-1 mg/kg 6-8 hourly prn IV/PO in post tonsillectomy/at risk patients<\/p><p>Note that Tramadol and Ondansetron may decrease each other\u2019s efficacy to a mild<\/p><p>degree.<\/p><p>3.6 Oral Morphine Preparations<\/p><p>Oral Morphine is widely used and highly effective for acute and chronic severe pain but<\/p><p>requires a functional gastrointestinal tract. It has a low bioavailability (30-40%) and thus<\/p><p>requires higher doses than parenteral Morphine. All oral opioid prescriptions should be for<\/p><p>limited duration. Monitoring of patients is required following doses of oral opioids. (See<\/p><p>Section 9 of the Handbook)<\/p><p>Page 10 of 57<\/p><p>Morphine Elixir<\/p><p>Indicated for children unable to swallow tablets.<\/p><p>Syrup (1mg/ml only)<\/p><p>Preparation:<\/p><p>0.3mg/kg 4 hourly prn<\/p><p>Dosage:<\/p><p>Morphine Tabs \u2013 Immediate Release (Sevredol)<\/p><p>Indicated for children that are comfortable with swallowing tablets.<\/p><p>Tablets (10, 20mg)<\/p><p>Preparation:<\/p><p>0.1-0.3mg/kg 2-4 hourly prn<\/p><p>Dose:<\/p><p>Morphine Tabs \u2013 Controlled Release (LA Morph)<\/p><p>Indicated for children that are able to swallow tablets that have prolonged severe opioid<\/p><p>responsive pain e.g. cancer pain or post-operative pain.<\/p><p>Once swallowed LA Morph is<\/p><p>like an infusion that cannot be stopped!<\/p><p>Tablets (10, 30, 60 &amp; 100mg)<\/p><p>Preparation:<\/p><p>Calculate the amount of parenteral Morphine used in the previous 24<\/p><p>Dose:<\/p><p>hrs, then chart this orally as a divided dose (BD).<\/p><p>Eg, if the patient used 60mg of IV Morphine in the previous 24hrs then<\/p><p>chart LA Morph (controlled release morphine) 30mg BD.<\/p><p>Observations:<\/p><p>Following doses of oral controlled release Morphine, monitoring must continue<\/p><p>until 12 hours after last dose administered.<\/p><p>See Section 9 of the Handbook.<\/p><p>Whenever prescribing slow release preparations, it is useful to prescribe an<\/p><p>immediate release opioid on a PRN basis for \u201cbreak-through pain\u201d. This dose is<\/p><p>usually equal to 10% of the daily Morphine requirement.<\/p><p>3.7 Oxycodone<\/p><p>Oxycodone is a semi-synthetic opioid, useful for treatment of moderate to severe pain.<\/p><p>The analgesic effects of Oxycodone are similar to Morphine, though in adults it is said to<\/p><p>have a more rapid onset and longer duration. Both drugs, Morphine and Oxycodone,<\/p><p>cause typical opioid side-effects but several reports suggest that hallucinations may be<\/p><p>Page 11 of 57<\/p><p>less frequent with Oxycodone. Oxycodone releases significantly less histamine than<\/p><p>Morphine. Oxycodone syrup is not as bitter/ unpleasant tasting as Morphine elixir.<\/p><p>Oxycodone has a good oral bioavailability (80%; compared to Morphine 25% and Codeine<\/p><p>50-60%). Oxycodone is eliminated more slowly (t 3 hrs) than Morphine. Metabolism of<\/p><p>1/2<\/p><p>Oxycodone does not produce significant levels of active metabolites, however clearance<\/p><p>of Oxycodone may be reduced in renal and hepatic impairment. In renal failure clearance<\/p><p>is reduced, with a resultant increase in half-life (t 3.9 hrs in uraemic patients). In liver<\/p><p>1/2<\/p><p>failure changes in clearance and half-life are more marked.<\/p><p>Oxycodone like Morphine comes in both immediate release (Oxynorm/ Endone) and<\/p><p>controlled release (Oxycontin) preparations \u2013<\/p><p>it is important that the two preparations<\/p><p>are not confused.<\/p><p>Oxycodone \u2013 Immediate Release (Oxynorm, Endone)<\/p><p>Syrup (5mg/5ml)<\/p><p>Preparation:<\/p><p>Tablets (5, 10, 20mg)<\/p><p>1-12months 0.05-0.1 mg/kg 4 hourly prn<\/p><p>Dose:<\/p><p>&gt;12months    0.1-0.25mg/kg 4 hourly prn<\/p><p>Suggested uses:<\/p><p>Inpatients - Oxycodone is a useful analgesic for acute post-operative pain and may be<\/p><p>used as an alternative to codeine and for \u2018stepping down\u2019 from intravenous opioids.<\/p><p>Day-stay surgery - Oxycodone may be useful in infants and children who have moderate<\/p><p>to severe pain and who are likely to need only one dose of oral opioids (it should not be<\/p><p>dispensed for \u201cout of hospital use\u201d following day surgery). Typically:<\/p><ul><li>\u2022<\/li><\/ul><p>Hypospadias repair<\/p><ul><li>\u2022<\/li><\/ul><p>Tonsillectomy<\/p><p>Converting to Oxycodone<\/p><p>Total mg/ day Oxycodone = Total mg/ day of Previous Opioid x f<\/p><p>Previous Opioid    Conversion factor ( f )<\/p><p>Intravenous    Oral<\/p><table><tr><td>Morphine<\/td><td>2<\/td><td>0.5<\/td><\/tr><tr><td>Fentanyl<\/td><td>100<\/td><td>NA<\/td><\/tr><tr><td>Codeine<\/td><td>NA<\/td><td>0.1<\/td><\/tr><tr><td>Tramadol<\/td><td>0.2<\/td><td>0.2<\/td><\/tr><tr><td>Methadone<\/td><td>2<\/td><td>1.3<\/td><\/tr><\/table><p>Eg, if the patient used 60mg of IV Morphine in the previous 24hrs then chart Total of<\/p><p>120mg/ day of Oxycodone ie, 60 x ( f = 2) = 120. This could be charted as Oxycodone<\/p><p>(immediate release) 20mg 4 hourly prn, orally.<\/p><p>Page 12 of 57<\/p><p>Oxycodone    Codeine<\/p><p>Parent drug is active \u2013 all patients    Prodrug (must be metabolised to<\/p><p>receive analgesia. Metabolised by    morphine in order to provide analgesia)<\/p><p>CYP3A4 and to lesser extent CYP2D6.    \u2013 not all patients are able to this.<\/p><p>Unclear how much CYP2D6    Metabolised by CYP2D6, which is<\/p><p>polymorphism affects pharmacokinetics.    polymorphic \u2013 some patients (5-10%<\/p><p>Caucasians) poor/ no activity therefore<\/p><p>limited analgesia, while some have<\/p><p>increased activity and therefore<\/p><p>increased morphine levels.<\/p><p>Duration action 3-4 hrs    Duration action 3-4 hrs<\/p><p>Onset action 45 mins    Onset action 1 hr<\/p><p>Oral bioavailability 70-80%    Oral bioavailability 50-60%<\/p><p>(cf morphine 25%)<\/p><p>Lower incidence of hallucinations than    Higher incidence of nausea and<\/p><p>other opioids; kappa action may provide    vomiting than other opioids<\/p><p>good visceral analgesia<\/p><p>3.8 Codeine Phosphate<\/p><p>Codeine is no longer a routine analgesic \u2013 numerous healthy agencies make warnings<\/p><p>about its use in children, and it is very rarely used by PAPS.<\/p><p>Codeine is a partial opioid agonist which is most effective when given with Paracetamol.<\/p><p>Codeine is a pro-drug with variable metabolism (5-15%) to morphine. Some ultra-rapid<\/p><p>metabolisers will achieve higher than average levels of morphine (which has resulted in<\/p><p>mortality and morbidity), while at the other extreme 5-10% of Caucasian patients are<\/p><p>unable to metabolise codeine to its active form i.e. it will not work.<\/p><p>Tablets (30mg)<\/p><p>Preparations:<\/p><p>Syrup (5mg/5ml)<\/p><p>0.5-1.0mg/kg 4 hourly prn<\/p><p>Dosage:<\/p><p>Page 13 of 57<\/p>", "children": [{"id": 6, "page": 6, "top": 129.3, "level": 3, "font_size": 13.980000000000018, "text": "3.1 Paracetamol", "content_html": "<p>Paracetamol is an analgesic suitable for mild pain or in conjunction with other analgesics<\/p><p>for more severe pain. Its mechanism of action is not clear. Paracetamol\u2019s main strength is<\/p><p>its excellent side effect profile, with serious complications being very rare despite<\/p><p>extensive worldwide use over a long period of time.<\/p><p>Liver damage from Paracetamol is a very rare problem despite its widespread use. Risk<\/p><p>factors include, prolonged fasting, febrile illness, use of P450 inducing drugs (eg isoniazid)<\/p><p>and probably most importantly a unique genetic predisposition. If children are considered<\/p><p>at risk, consideration should be given to decreasing the dose of Paracetamol if given for<\/p><p>more than 1-2 days. Dosing limits will always be controversial.<\/p><p>Tablets (500mg)<\/p><p>Preparations:<\/p><p>Syrup (120mg/5ml and 250mg/5ml)<\/p><p>Suppositories (50, 125, 250, and 500mg)<\/p><p>Intravenous (Perfalgan 1000mg/100ml)<\/p><p>Dosage:<\/p><p>Oral:<\/p><table><tr><td>Neonates 32 weeks \u2013 44 weeks<\/td><td>10mg/kg 6hrly prn<\/td><td>- max 40mg/kg/day<\/td><\/tr><tr><td>Neonates 44 weeks \u2013 6 months<\/td><td>15mg/kg 6hrly prn<\/td><td>- max 60mg/kg/day<\/td><\/tr><tr><td>&gt; 6 months old<\/td><td>15mg/kg 4-6hrly prn<\/td><td>- max 60-90mg/kg/day<\/td><\/tr><\/table><ul><li>\u2022<\/li><\/ul><p>In neonates a single loading dose of 20mg/kg may be given if the neonatologist is<\/p><p>in agreement (paracetamol has a large volume of distribution in neonates)<\/p><ul><li>\u2022<\/li><\/ul><p>Anaesthetist may chart 120 mg/kg/day for a short time period in selected patients<\/p><ul><li>\u2022<\/li><\/ul><p>Review Paracetamol dose after 48 hours<\/p><ul><li>\u2022<\/li><\/ul><p>Suggestions for extended use:<\/p><p>After 8 days:    reduce dose to max 45mg/kg/day<\/p><p>After 14 days:    reduce dose to max 30mg/kg/day<\/p><p>Rectal:<\/p><ul><li>\u2022<\/li><\/ul><p>Absorption is slow and variable \u2013 the oral route should be used when possible<\/p><ul><li>\u2022<\/li><\/ul><p>Max daily dose is same as oral route<\/p><p>Intravenous (Perfalgan):<\/p><table><tr><td>Neonates 32 weeks \u2013 44 weeks<\/td><td>7.5mg/kg 6hrly prn<\/td><td>- max 30mg/kg/day<\/td><\/tr><tr><td>Neonates 44 weeks \u2013 3 months<\/td><td>10mg/kg 6hrly prn<\/td><td>- max 40mg/kg/day<\/td><\/tr><tr><td>&gt; 3 months old<\/td><td>15mg/kg 6hrly prn<\/td><td>- max 60mg/kg/day<\/td><\/tr><\/table><ul><li>\u2022<\/li><\/ul><p>Chart only for 2 days then review<\/p><ul><li>\u2022<\/li><\/ul><p>Convert to oral as soon as possible<\/p><p>Page 6 of 57<\/p><ul><li>\u2022<\/li><\/ul><p>IV Paracetamol may be considered in patients unable to take or absorb oral<\/p><p>Paracetamol. Following major surgery it provides better analgesia and opioid<\/p><p>sparing effect than rectal Paracetamol which has slow, poor and very variable<\/p><p>absorption<\/p>", "children": []}, {"id": 7, "page": 7, "top": 145.1, "level": 3, "font_size": 13.980000000000018, "text": "3.2 Diclofenac (Voltaren)", "content_html": "<p>Diclofenac is an NSAID that has a low dose suppository preparation that is licensed for<\/p><p>use in children more than 1 year of age. Caution is required in patients with<\/p><p>hypovolaemia, renal dysfunction, coagulopathy, GI bleeding, aminoglycosides and in the<\/p><p>immediate post-operative period.<\/p><p>Tablets (25, 50mg, and 75SRmg)<\/p><p>Preparation:<\/p><p>Suppository (12.5, 25, 50mg)<\/p><p>0.5-1.0mg/kg 12 hourly prn<\/p><p>Dosage:<\/p>", "children": []}, {"id": 8, "page": 7, "top": 314.1, "level": 3, "font_size": 13.980000000000018, "text": "3.3 Ibuprofen (Brufen)", "content_html": "<p>Ibuprofen is an NSAID that has a syrup preparation and can be used in children older than<\/p><p>6 months. NSAIDS differ in their nociceptive, anti-inflammatory and side effect profiles.<\/p><p>Ibuprofen has been well validated as an analgesic. The usual cautions apply in patients<\/p><p>with hypovolaemia, renal dysfunction, coagulopathy, GI bleeding, aminoglycosides and<\/p><p>the immediate post-operative period.<\/p><p>Syrup (100mg/5ml)<\/p><p>Preparation:<\/p><p>Tablets (200, 400mg)<\/p><p>5-10mg/kg 6 hourly prn (max 40mg/kg/day)<\/p><p>Dosage:<\/p><p>Ibuprofen is an NSAID that is available as a syrup or tablet. It has been well validated as<\/p><p>an analgesic in children. Studies show a safety profile that is at least as good as<\/p><p>paracetamol when used in patients as young as 3 months old. Some centres are using<\/p><p>Ibuprofen down to 1 month of age, however this cannot be recommended at this time.<\/p><p>(There is also limited safety data from studies looking at its use for patent ductus<\/p><p>arteriosus closure in premature neonates - 7% of neonates had renal impairment which<\/p><p>was completely reversible).<\/p><p>There are some developmental concerns when using Ibuprofen in young babies. Like all<\/p><p>NSAIDs, Ibuprofen disrupts prostaglandin production, and prostaglandins are involved in<\/p><p>regulation of cerebral and renal blood flow, non-REM sleep and ductus arteriosus closure.<\/p><p>In addition, it should be remembered that renal maturity is not reached until 6-12 months.<\/p><p>There are also other pharmacokinetic differences in infants which are complex and may<\/p><p>affect dosing.<\/p><p>hypovolaemia, renal dysfunction,<\/p><p>NSAIDs precautions for all children include:<\/p><p>coagulopathy, jaundice, GI bleeding, aminoglycosides and the immediate post-operative<\/p><p>period. Most asthmatic children tolerate NSAIDs well, but caution should be exercised in<\/p><p>older children with severe asthma and nasal polyp disease, where the rate of severe<\/p><p>exacerbation may be as high as 30%.<\/p><p>Suspension (100 mg/5 ml)<\/p><p>Preparation:<\/p><p>Tablets (200 mg, 400 mg)<\/p><p>Page 7 of 57<\/p><p>Dosage:<\/p><p>3-6 months    5mg/kg 8-12 hourly prn (may use 10mg/kg loading dose)<\/p><p>&gt;6 months old    5-10mg/kg 6-8 hourly prn<\/p><ul><li>\u2022<\/li><\/ul><p>Review Ibuprofen dose after 3 days and for consider reducing dose to 5mg/kg<\/p>", "children": []}, {"id": 9, "page": 8, "top": 183.0, "level": 3, "font_size": 13.980000000000018, "text": "3.4 Parecoxib (Dynastat)", "content_html": "<p>Parecoxib is an NSAID that specifically inhibits the enzyme cyclooxygenase-2 (COX 2).<\/p><p>Paediatric trial data is very limited. It is given intravenously, and in adults, it has been<\/p><p>shown to be as effective or more effective than the older NSAIDs for treatment of acute<\/p><p>pain. It is opioid sparing and associated with less post-operative nausea and vomiting post<\/p><p>tonsillectomy. Advantages of parecoxib over other NSAIDs are that it does not impair<\/p><p>platelet function, and gastrointestinal ulceration is less likely. In addition, the ability to give<\/p><p>the drug intravenously means a more reliable NSAID dose (ie 100% bioavailability in<\/p><p>children with an IV cannula in place), compared with traditional perioperative rectal<\/p><p>NSAID, or where oral dosing is inappropriate. Parecoxib is not licensed for use in children.<\/p><p>However, it may on occasion be a useful analgesic in the paediatric setting. It should only<\/p><p>be charted by PAPS.<\/p><p>The adverse effects of intravenous Parecoxib in adult clinical trials are similar to those for<\/p><p>NSAIDs, with serious adverse effects such as acute renal failure, Stevens-Johnson<\/p><p>syndrome, and hypersensitivity reactions including anaphylaxis and angioedema<\/p><p>occurring at low incidence. The usual cautions apply in patients with hypovolaemia, renal<\/p><p>dysfunction, coagulopathy and GI bleeding.<\/p><p>Contraindications:<\/p><ul><li>\u2022<\/li><\/ul><p>Sulphur allergy<\/p><ul><li>\u2022<\/li><\/ul><p>Severe hepatic impairment<\/p><ul><li>\u2022<\/li><\/ul><p>Concurrent use of another NSAID<\/p><p>Cautions:<\/p><ul><li>\u2022<\/li><\/ul><p>Allergic like reactions with NSAIDs/ aspirin<\/p><p>According to adult data, COX-2 inhibitors are considered safe in most of<\/p><p>o<\/p><p>these patients, but a small percentage have cross-sensitivity, so an oral<\/p><p>challenge under medical supervision is advisable<\/p><p>Considered safe in paediatric patients with NSAID exacerbated respiratory<\/p><p>o<\/p><p>disease<\/p><p>:    Intravenous (Dynastat)<\/p><p>Preparations<\/p><p>2 yrs and older (no studies looking at safety in younger age to date)<\/p><p>Dosage:<\/p><p>1 mg/kg (max 40mg) once daily IV<\/p><ul><li>\u2022<\/li><\/ul><p>Chart only for 2 days then review<\/p><ul><li>\u2022<\/li><\/ul><p>Convert to oral as soon as possible<\/p><p>Page 8 of 57<\/p>", "children": []}, {"id": 10, "page": 9, "top": 67.3, "level": 3, "font_size": 13.980000000000018, "text": "3.3 Celecoxib", "content_html": "<p>Celecoxib is a COX 2 inhibitor \u2013 it is an NSAID that selectively inhibits the enzyme<\/p><p>cyclooxygenase-2 (COX 2). Being a selective inhibitor it has the same advantages as<\/p><p>Parecoxib, except that Celecoxib is an oral drug. Paediatric trial data is very limited.<\/p><p>See Parecoxib above<\/p><p>Contraindications:<\/p><p>See Parecoxib above<\/p><p>Cautions:<\/p><p>Capsule (100mg, 200mg)<\/p><p>Preparation:<\/p><p>Solution (10mg/ml \u2013 disperse 100mg capsule in 10ml water)<\/p><p>12 months and older<\/p><p>Dosage:<\/p><p>4 mg/kg (max 200mg per dose) BD prn<\/p>", "children": []}, {"id": 11, "page": 9, "top": 274.3, "level": 3, "font_size": 13.980000000000018, "text": "3.5 Tramadol", "content_html": "<p>Tramadol is used for treatment of moderate to severe pain. Its action is by both opioid and<\/p><p>non-opioid monoaminergic mechanisms (serotoninergic, noradrenergic), and it may also<\/p><p>have some local anaesthetic action on peripheral nerves. It may be given orally and IV,<\/p><p>although both PR and IM preparations have also been used. Advantages over opioids<\/p><p>such as Morphine may include less sedation, less respiratory depression and less<\/p><p>constipation. Tramadol may not be as suitable as opioids for more severe pain.<\/p><p>In New Zealand Tramadol is currently licensed for use in children aged 2 years and older.<\/p><p>However, it has been used internationally for many years in children as young as<\/p><p>newborn.<\/p><p>The risks and benefits of Tramadol use in early life are not straightforward \u2013 there are a<\/p><p>number of important considerations. Both Tramadol and its M1 metabolite (formed by<\/p><p>CYP2D6 liver enzyme) are active and provide analgesia via different pathways. Tramadol<\/p><p>parent drug causes sedation (but does not cause respiratory depression), however the M1<\/p><p>\u00b5<\/p><p>metabolite has is a opioid agonist (200 x more receptor affinity than Tramadol itself) and<\/p><p>may cause both sedation and respiratory depression.<\/p><p>At term, the newborn\u2019s CYP2D6 activity is still immature and the ability to convert<\/p><p>Tramadol to M1 is 50% compared to adult levels. The newborn\u2019s ability to renally excrete<\/p><p>M1 is also reduced, and is 70% compared to adults. However, as a result of the slow<\/p><p>maturation of CYP2D6, the plasma concentrations of M1 are low until infants are 3<\/p><p>months old \u2013 at this point in time the immature renal elimination becomes relevant and<\/p><p>higher M1 levels may occur. Renal excretion and M1 clearance reaches 90% adult levels<\/p><p>by age 1 year.<\/p><p>In addition, it must be remembered that the descending pain tracts in the neonate may not<\/p><p>be functionally mature, hence the serotoninergic/ noradrenergic advantages of the drug<\/p><p>\u00b5<\/p><p>over conventional opioids may not apply, with agonism predominating.<\/p><p>In 2017 in the United Sates, the FDA in started restricting the use of both Tramadol and<\/p><p>codeine in children, after identifying cases involving serious breathing problems and<\/p><p>death. Among other groups, their restrictions and warnings have included: children with<\/p><p>obesity, sleep disordered breathing, and other breathing problems, post-tonsillectomy and<\/p><p>breast feeding mothers.<\/p><p>In response to this, SPANZA (the Society of Paediatric Anaesthesia of New Zealand and<\/p><p>Page 9 of 57<\/p><p>Australia) put out two statements in 2017 regarding Tramadol use. Genetic variation in<\/p><p>CYP2D6 exists and ultra-rapid metabolisers may be more at risk in certain situations,<\/p><p>although this is less certain with Tramadol than with Codeine. Readers are directed to<\/p><p>these statements in the references; their content is acknowledged in the cautions/ dosage<\/p><p>recommendations below.<\/p><p>Key points:<\/p><p>Tramadol is safer than opioids in breast feeding mothers<\/p><p>Tramadol doses should be limited for acute pain after tonsillectomy<\/p><p>Children with obstructive sleep apnea who have undergone tonsillectomy should be<\/p><p>observed overnight to assess response and sensitivity to opioids<\/p><p>SPANZA Advisory on Tramadol - Use during breast feeding and the neonate<\/p><p>SPANZA Advisory on Tramadol - Warning on tramadol use in children<\/p><p>Caution must be used with certain \u201cat risk\u201d patients:<\/p><ul><li>\u2022<\/li><\/ul><p>Day surgery patients<\/p><ul><li>\u2022<\/li><\/ul><p>Post-tonsillectomy patients<\/p><ul><li>\u2022<\/li><\/ul><p>Patients with obstructive sleep apnoea or obesity or severe lung disease<\/p><ul><li>\u2022<\/li><\/ul><p>Patients with severe hepatic and renal impairment<\/p><ul><li>\u2022<\/li><\/ul><p>Patients susceptible to seizures<\/p><ul><li>\u2022<\/li><\/ul><p>Patients on psychotropic medication (SSRI)<\/p><p>Side effects:<\/p><ul><li>\u2022<\/li><\/ul><p>Nausea and vomiting \u2013 around 10% of children<\/p><ul><li>\u2022<\/li><\/ul><p>Dizziness<\/p><ul><li>\u2022<\/li><\/ul><p>Sedation<\/p><ul><li>\u2022<\/li><\/ul><p>Respiratory depression (rare)<\/p><p>Tablets (50mg, and 100SRmg)<\/p><p>Preparation:<\/p><p>Oral solution (10mg/ml)<\/p><p>Intravenous (50mg/ml)<\/p><p>Drops 100 mg/ml delisted in NZ during 2017 after several unintentional overdoses<\/p><p>worldwide<\/p><p>1.5-2mg/kg 6 hourly prn PO<\/p><p>Dosage:<\/p><p>1-2mg/kg 4-6 hourly prn IV in general population (up to 400 mg daily)<\/p><p>0.5-1 mg/kg 6-8 hourly prn IV/PO in post tonsillectomy/at risk patients<\/p><p>Note that Tramadol and Ondansetron may decrease each other\u2019s efficacy to a mild<\/p><p>degree.<\/p>", "children": []}, {"id": 12, "page": 10, "top": 683.0, "level": 3, "font_size": 13.980000000000018, "text": "3.6 Oral Morphine Preparations", "content_html": "<p>Oral Morphine is widely used and highly effective for acute and chronic severe pain but<\/p><p>requires a functional gastrointestinal tract. It has a low bioavailability (30-40%) and thus<\/p><p>requires higher doses than parenteral Morphine. All oral opioid prescriptions should be for<\/p><p>limited duration. Monitoring of patients is required following doses of oral opioids. (See<\/p><p>Section 9 of the Handbook)<\/p><p>Page 10 of 57<\/p>", "children": []}, {"id": 13, "page": 11, "top": 94.3, "level": 3, "font_size": 12.0, "text": "Morphine Elixir", "content_html": "<p>Indicated for children unable to swallow tablets.<\/p><p>Syrup (1mg/ml only)<\/p><p>Preparation:<\/p><p>0.3mg/kg 4 hourly prn<\/p><p>Dosage:<\/p>", "children": []}, {"id": 14, "page": 11, "top": 212.7, "level": 3, "font_size": 12.0, "text": "Morphine Tabs \u2013 Immediate Release (Sevredol)", "content_html": "<p>Indicated for children that are comfortable with swallowing tablets.<\/p><p>Tablets (10, 20mg)<\/p><p>Preparation:<\/p><p>0.1-0.3mg/kg 2-4 hourly prn<\/p><p>Dose:<\/p>", "children": []}, {"id": 15, "page": 11, "top": 331.2, "level": 3, "font_size": 12.0, "text": "Morphine Tabs \u2013 Controlled Release (LA Morph)", "content_html": "<p>Indicated for children that are able to swallow tablets that have prolonged severe opioid<\/p><p>responsive pain e.g. cancer pain or post-operative pain.<\/p><p>Once swallowed LA Morph is<\/p><p>like an infusion that cannot be stopped!<\/p><p>Tablets (10, 30, 60 &amp; 100mg)<\/p><p>Preparation:<\/p><p>Calculate the amount of parenteral Morphine used in the previous 24<\/p><p>Dose:<\/p><p>hrs, then chart this orally as a divided dose (BD).<\/p><p>Eg, if the patient used 60mg of IV Morphine in the previous 24hrs then<\/p><p>chart LA Morph (controlled release morphine) 30mg BD.<\/p><p>Observations:<\/p><p>Following doses of oral controlled release Morphine, monitoring must continue<\/p><p>until 12 hours after last dose administered.<\/p><p>See Section 9 of the Handbook.<\/p><p>Whenever prescribing slow release preparations, it is useful to prescribe an<\/p><p>immediate release opioid on a PRN basis for \u201cbreak-through pain\u201d. This dose is<\/p><p>usually equal to 10% of the daily Morphine requirement.<\/p>", "children": []}, {"id": 16, "page": 11, "top": 687.0, "level": 3, "font_size": 13.980000000000018, "text": "3.7 Oxycodone", "content_html": "<p>Oxycodone is a semi-synthetic opioid, useful for treatment of moderate to severe pain.<\/p><p>The analgesic effects of Oxycodone are similar to Morphine, though in adults it is said to<\/p><p>have a more rapid onset and longer duration. Both drugs, Morphine and Oxycodone,<\/p><p>cause typical opioid side-effects but several reports suggest that hallucinations may be<\/p><p>Page 11 of 57<\/p><p>less frequent with Oxycodone. Oxycodone releases significantly less histamine than<\/p><p>Morphine. Oxycodone syrup is not as bitter/ unpleasant tasting as Morphine elixir.<\/p><p>Oxycodone has a good oral bioavailability (80%; compared to Morphine 25% and Codeine<\/p><p>50-60%). Oxycodone is eliminated more slowly (t 3 hrs) than Morphine. Metabolism of<\/p><p>1/2<\/p><p>Oxycodone does not produce significant levels of active metabolites, however clearance<\/p><p>of Oxycodone may be reduced in renal and hepatic impairment. In renal failure clearance<\/p><p>is reduced, with a resultant increase in half-life (t 3.9 hrs in uraemic patients). In liver<\/p><p>1/2<\/p><p>failure changes in clearance and half-life are more marked.<\/p><p>Oxycodone like Morphine comes in both immediate release (Oxynorm/ Endone) and<\/p><p>controlled release (Oxycontin) preparations \u2013<\/p><p>it is important that the two preparations<\/p><p>are not confused.<\/p>", "children": []}, {"id": 17, "page": 12, "top": 233.4, "level": 3, "font_size": 12.0, "text": "Oxycodone \u2013 Immediate Release (Oxynorm, Endone)", "content_html": "<p>Syrup (5mg/5ml)<\/p><p>Preparation:<\/p><p>Tablets (5, 10, 20mg)<\/p><p>1-12months 0.05-0.1 mg/kg 4 hourly prn<\/p><p>Dose:<\/p><p>&gt;12months    0.1-0.25mg/kg 4 hourly prn<\/p><p>Suggested uses:<\/p><p>Inpatients - Oxycodone is a useful analgesic for acute post-operative pain and may be<\/p><p>used as an alternative to codeine and for \u2018stepping down\u2019 from intravenous opioids.<\/p><p>Day-stay surgery - Oxycodone may be useful in infants and children who have moderate<\/p><p>to severe pain and who are likely to need only one dose of oral opioids (it should not be<\/p><p>dispensed for \u201cout of hospital use\u201d following day surgery). Typically:<\/p><ul><li>\u2022<\/li><\/ul><p>Hypospadias repair<\/p><ul><li>\u2022<\/li><\/ul><p>Tonsillectomy<\/p><p>Converting to Oxycodone<\/p><p>Total mg/ day Oxycodone = Total mg/ day of Previous Opioid x f<\/p><p>Previous Opioid    Conversion factor ( f )<\/p><p>Intravenous    Oral<\/p><table><tr><td>Morphine<\/td><td>2<\/td><td>0.5<\/td><\/tr><tr><td>Fentanyl<\/td><td>100<\/td><td>NA<\/td><\/tr><tr><td>Codeine<\/td><td>NA<\/td><td>0.1<\/td><\/tr><tr><td>Tramadol<\/td><td>0.2<\/td><td>0.2<\/td><\/tr><tr><td>Methadone<\/td><td>2<\/td><td>1.3<\/td><\/tr><\/table><p>Eg, if the patient used 60mg of IV Morphine in the previous 24hrs then chart Total of<\/p><p>120mg/ day of Oxycodone ie, 60 x ( f = 2) = 120. This could be charted as Oxycodone<\/p><p>(immediate release) 20mg 4 hourly prn, orally.<\/p><p>Page 12 of 57<\/p><p>Oxycodone    Codeine<\/p><p>Parent drug is active \u2013 all patients    Prodrug (must be metabolised to<\/p><p>receive analgesia. Metabolised by    morphine in order to provide analgesia)<\/p><p>CYP3A4 and to lesser extent CYP2D6.    \u2013 not all patients are able to this.<\/p><p>Unclear how much CYP2D6    Metabolised by CYP2D6, which is<\/p><p>polymorphism affects pharmacokinetics.    polymorphic \u2013 some patients (5-10%<\/p><p>Caucasians) poor/ no activity therefore<\/p><p>limited analgesia, while some have<\/p><p>increased activity and therefore<\/p><p>increased morphine levels.<\/p><p>Duration action 3-4 hrs    Duration action 3-4 hrs<\/p><p>Onset action 45 mins    Onset action 1 hr<\/p><p>Oral bioavailability 70-80%    Oral bioavailability 50-60%<\/p><p>(cf morphine 25%)<\/p><p>Lower incidence of hallucinations than    Higher incidence of nausea and<\/p><p>other opioids; kappa action may provide    vomiting than other opioids<\/p><p>good visceral analgesia<\/p>", "children": []}, {"id": 18, "page": 13, "top": 373.2, "level": 3, "font_size": 13.980000000000018, "text": "3.8 Codeine Phosphate", "content_html": "<p>Codeine is no longer a routine analgesic \u2013 numerous healthy agencies make warnings<\/p><p>about its use in children, and it is very rarely used by PAPS.<\/p><p>Codeine is a partial opioid agonist which is most effective when given with Paracetamol.<\/p><p>Codeine is a pro-drug with variable metabolism (5-15%) to morphine. Some ultra-rapid<\/p><p>metabolisers will achieve higher than average levels of morphine (which has resulted in<\/p><p>mortality and morbidity), while at the other extreme 5-10% of Caucasian patients are<\/p><p>unable to metabolise codeine to its active form i.e. it will not work.<\/p><p>Tablets (30mg)<\/p><p>Preparations:<\/p><p>Syrup (5mg/5ml)<\/p><p>0.5-1.0mg/kg 4 hourly prn<\/p><p>Dosage:<\/p><p>Page 13 of 57<\/p>", "children": []}]}, {"id": 19, "page": 14, "top": 77.6, "level": 2, "font_size": 13.980000000000018, "text": "4. MANAGING PAIN USING PARENTERAL ANALGESICS", "content_html": "<p>4.1 Protocol for Intermittent IV Opioids<\/p><p>Introduction:<\/p><p>This technique of analgesia is suitable for minor surgery where there is a need for short<\/p><p>term intravenous analgesic therapy. This is prescribed by medical staff. Administration is<\/p><p>by medical staff or by nursing staff in PACU or PICU.<\/p><p>Prescription:<\/p><p>This is prescribed on the Inpatient Medication Chart.<\/p><p>Protocol:<\/p><p>Morphine 0.025mg/kg IV every 5 minutes until comfortable.<\/p><p>If the patient is in moderate or severe pain, this dose can be given over 5 minutes directly<\/p><p>into the IV port of a running drip and the patient observed closely for the next 15 minutes.<\/p><p>Alternatively if the need is less urgent then the dose should be given in the burette to be<\/p><p>infused.<\/p><p>For patients unable to tolerate Morphine contact PAPS (Fentanyl or Oxycodone may be<\/p><p>used).<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>4.2 Protocol for Intravenous Opioid Infusions<\/p><p>Introduction:<\/p><p>Infusions of Morphine or Fentanyl can provide continuous analgesia without the \u201cups and<\/p><p>downs\u201d of intermittent bolus administration. They are suitable for children of any age<\/p><p>particularly those who are unsuitable for patient controlled analgesia.<\/p><p>Additional prescribed bolus doses may be required to cover additional \u201cincident\u201d pain<\/p><p>which occurs during movement or when the patient is subjected to painful procedures.<\/p><p>Intravenous infusions need close observation as the patient is always receiving the drug<\/p><p>and accumulations may occur.<\/p><p>Prescription:<\/p><p>Opioid infusion orders are prescribed on the PAPS Prescription Form by the Department<\/p><p>of Anaesthesia only. Syringe changes are recorded in the Drug Administration Record of<\/p><p>the PAPS Prescription Form.<\/p><p>Page 14 of 57<\/p><p>Protocol:<\/p><p>Use CADD Solis pump<\/p><p>Mix drug into 50ml bag of Normal Saline or Dextrose 5%<\/p><p>An anti-reflux valve is necessary with all intravenous Opioid Infusions<\/p><p>Morphine Infusion    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>0.5mg/kg into 50mls<\/td><td>(1ml = 10mcg/kg)<\/td><\/tr><tr><td>Background Infusion<\/td><td>0-4ml/hr<\/td><td>(0-40mcg/kg/hr)<\/td><\/tr><\/table><p>Fentanyl Infusion    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>20mcg/kg into 50mls<\/td><td>(1ml = 0.4mcg/kg)<\/td><\/tr><tr><td>Background Infusion<\/td><td>0-4ml/hr<\/td><td>(0-1.6mcg/kg/hr)<\/td><\/tr><\/table><p>These are the recommended infusion regimes and may be varied at the discretion of the<\/p><p>Anaesthetic Staff according to the individual patient\u2019s needs.<\/p><p>Children younger than 3 months:<\/p><ul><li>\u2022<\/li><\/ul><p>Infusion rates and boluses should be halved i.e. 0-2.0ml/hr<\/p><p>Their metabolic pathways may be very immature, (especially preterm infants) and<\/p><p>of major concern is the risk of opioid induced respiratory depression. The method<\/p><p>of analgesia must be discussed with senior medical staff.<\/p><p>Managing IV infusions:<\/p><p>Prior to commencing the infusion the patient should be titrated to comfort by a doctor with<\/p><p>intravenous boluses of the same opioid. Infusions should be started at 2.0ml/hr (syringe<\/p><p>pump) and can then be varied at the discretion of the ward nursing staff according to the<\/p><p>degree of analgesia or sedation of the patient (within the prescribed limits).<\/p><p>Bolus doses with opioid infusions:<\/p><p>Morphine:    10-20 mcg/kg (1-2mls of solution) at intervals no less than 10mins<\/p><p>Fentanyl:    0.4 mcg/kg (1ml of solution) at intervals no less than 5mins<\/p><p>Bolus doses can be given in two situations:<\/p><ul><li>\u2022<\/li><\/ul><p>If pain relief is inadequate, a prescribed bolus dose should be administered<\/p><p>followed by an increasing infusion rate by 1ml/hr<\/p><ul><li>\u2022<\/li><\/ul><p>To cover anticipated \u201cincident pain\u201d (e.g. pulling out drain, physiotherapy<\/p><p>movement, procedures, dressings etc) we suggest that a bolus dose be given 10-<\/p><p>15 minutes prior to the anticipated painful procedure<\/p><p>Page 15 of 57<\/p><p>Before bolus doses are given:<\/p><ul><li>\u2022<\/li><\/ul><p>Exclude alternative causes of pain eg, urinary retention, compartment syndrome<\/p><ul><li>\u2022<\/li><\/ul><p>The patient should be awake and coherent<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Children &lt; 6 months old must have continuous oximetry.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p><p>4.3 Protocol for Nurse Controlled Analgesia (NCA)<\/p><p>Introduction:<\/p><p>If a child receiving an opioid infusion is in pain, the only adjustment the nurses may<\/p><p>make is to increase the rate of infusion within the prescribed range. Pharmacokinetically<\/p><p>what the child needs is a bolus dose, but in order to give this medical staff have to be<\/p><p>involved. NCA takes the equipment and principals of PCA and puts the control in the<\/p><p>hands of the nurses. NCA allows continuous low dose background infusion and<\/p><p>intermittent boluses at specified intervals. The patient is protected from over dose by<\/p><p>routine monitoring, a longer lockout interval and the principal of assess-intervene-<\/p><p>reassess. There is no place for a parent or guardian to press the button.<\/p><p>NCA is appropriate for the control of pain in infants, pre-verbal children and children that<\/p><p>cannot use a PCA. It is useful for moderate to severe pain that has a significant incident/<\/p><p>movement component.<\/p><p>Prescription:<\/p><p>NCA orders are prescribed on the PAPS Prescription Form by the Department of<\/p><p>Anaesthesia only. Syringe changes are recorded in the Drug Administration Record of the<\/p><p>PAPS Prescription Form.<\/p><p>Protocol:<\/p><p>Use CADD Solis pump<\/p><p>Mix drug into 50ml bag of Normal Saline or Dextrose 5%<\/p><p>An anti-reflux valve is necessary with all intravenous NCA<\/p><p>Page 16 of 57<\/p><p>Morphine NCA    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>0.5mg/kg into 50mls<\/td><td>(1ml = 10mcg/kg)<\/td><\/tr><tr><td>Bolus Dose<\/td><td>1-2ml<\/td><td>(10-20mcg/kg)<\/td><\/tr><\/table><p>Lockout    10-30mins<\/p><table><tr><td>Background Infusion<\/td><td>0-2ml/hr<\/td><td>(0-20mcg/kg/hr)<\/td><\/tr><tr><td>Hourly Dose Limit<\/td><td>8ml<\/td><td>(80mcg/kg)<\/td><\/tr><\/table><p>Fentanyl NCA    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>20mcg/kg into 50mls<\/td><td>(1ml = 0.4mcg/kg)<\/td><\/tr><tr><td>Bolus Dose<\/td><td>1-2ml<\/td><td>(0.4-0.8mcg/kg)<\/td><\/tr><\/table><p>Lockout    10-30mins<\/p><table><tr><td>Background Infusion<\/td><td>0-2ml/hr<\/td><td>(0-0.8mcg/kg/hr )<\/td><\/tr><tr><td>Hourly Dose Limit<\/td><td>8ml<\/td><td>(3.2mcg/kg )<\/td><\/tr><\/table><p>In children weighing close to 50 kg it is suggested you use the \u2018Adolescent protocol\u2019 which<\/p><p>uses the \u2018Adult\u2019 100ml premix bags (Morpine 100mg in 100mls, or Fentanyl 1000mcg in<\/p><p>100mls).<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Children &lt; 6 months old must have continuous oximetry.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p><p>4.4 Protocol for Patient Controlled Analgesia (PCA)<\/p><p>Introduction:<\/p><p>PCA is a technique of managing acute pain which utilises a programmable syringe-pump<\/p><p>to allow patients to self-administer their own intravenous opioid analgesics. It can be used<\/p><p>by any child who is able to understand the concept of pressing a button when it hurts.<\/p><p>Pre-operative education is very worthwhile.<\/p><p>Prescription of PCA:<\/p><p>PCA orders are prescribed on the PAPS Prescription Form by the Department of<\/p><p>Anaesthesia only. Syringe changes are recorded in the Drug Administration Record of the<\/p><p>PAPS Prescription Form.<\/p><p>Protocol:<\/p><p>Use CADD Solis pump<\/p><p>Mix drug into 50ml bag of Normal Saline or Dextrose 5%<\/p><p>An anti-reflux valve is necessary with all intravenous PCA<\/p><p>Page 17 of 57<\/p><p>Morphine PCA    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>0.5mg/kg into 50mls<\/td><td>(1ml = 10mcg/kg)<\/td><\/tr><tr><td>Bolus Dose<\/td><td>1-2ml<\/td><td>(10-20mcg/kg)<\/td><\/tr><\/table><p>Lockout    5-10mins<\/p><table><tr><td>Background Infusion<\/td><td>0-1ml/hr<\/td><td>(0-10mcg/kg/hr)<\/td><\/tr><tr><td>Hourly Dose Limit<\/td><td>10ml<\/td><td>(100mcg/kg)<\/td><\/tr><\/table><p>Fentanyl PCA    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>20mcg/kg into 50mls<\/td><td>(1ml = 0.4mcg/kg)<\/td><\/tr><tr><td>Bolus Dose<\/td><td>1ml<\/td><td>(0.4mcg/kg)<\/td><\/tr><\/table><p>Lockout    5mins<\/p><table><tr><td>Background Infusion<\/td><td>0.5ml/hr<\/td><td>(0.2mcg/kg/hr )<\/td><\/tr><tr><td>Hourly Dose Limit<\/td><td>10ml<\/td><td>(4mcg/kg )<\/td><\/tr><\/table><p>Morphine is usually the first choice \u2013 Fentanyl is used for patients who are unable to<\/p><p>tolerate Morphine or have renal impairment.<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p><p>Adolescent PCA:<\/p><p>In children weighing close to 50 kg it is suggested you use the \u2018Adolescent protocol\u2019 which<\/p><p>uses the \u2018Adult\u2019 100ml premix bags (Morphine 100mg in 100mls, or Fentanyl 1000mcg in<\/p><p>100mls).<\/p><p>4.5 Protocol for Subcutaneous Morphine Boluses<\/p><p>Introduction:<\/p><p>This is ideally avoided because of the irritant nature of subcutaneous (SC) Morphine, but it<\/p><p>may be useful for post-operative pain of short duration in the older child. A narrow gauge<\/p><p>plastic cannula can be left in position usually just below the clavicle, obviating the need for<\/p><p>repeated skin puncture. Morphine is the drug of choice because:<\/p><ul><li>\u2022<\/li><\/ul><p>It has longer duration of action than Pethidine<\/p><ul><li>\u2022<\/li><\/ul><p>It is not irritant and hence not as painful as Pethidine<\/p><ul><li>\u2022<\/li><\/ul><p>It is available in a more concentrated solution than Pethidine and hence a smaller<\/p><p>volume can be given for the same effect<\/p><p>Page 18 of 57<\/p><p>In the shocked patient the absorption from the SC (and IM) site is erratic and this form of<\/p><p>analgesia should not be used. Because it is necessary to prime the line with Morphine<\/p><p>prior to the first injection, it is important to use Morphine of the same concentrations for all<\/p><p>injections.<\/p><p>Prescription:<\/p><p>This is prescribed on the Inpatient Medication Chart.<\/p><p>Dosage:<\/p><p>Morphine 0.1mg/kg SC 1-2 hourly prn<\/p><p>:<\/p><p>Equipment<\/p><ul><li>\u2022<\/li><\/ul><p>24g BD Saf-T-Intima cannula<\/p><ul><li>\u2022<\/li><\/ul><p>Alcohol swabs<\/p><ul><li>\u2022<\/li><\/ul><p>Small transparent dressing e.g. Opsite, Tegaderm<\/p><p>Insertion of SC cannula: (may already be in situ from theatre)<\/p><ul><li>\u2022<\/li><\/ul><p>Prime the infusion line with Morphine (concentration 10mg/ml)<\/p><ul><li>\u2022<\/li><\/ul><p>Clean the site in the subclavicular region thoroughly with alcohol swab<\/p><ul><li>\u2022<\/li><\/ul><p>Insert the cannula through the skin at shallow angle. It is best to pinch up a fold of<\/p><p>skin to do this<\/p><ul><li>\u2022<\/li><\/ul><p>Cover with the transparent dressing<\/p><ul><li>\u2022<\/li><\/ul><p>All patients should have IV access<\/p><p>Injection procedures:<\/p><ul><li>\u2022<\/li><\/ul><p>Check the drug order for the dose of Morphine (0.1 mg/kg or less)<\/p><ul><li>\u2022<\/li><\/ul><p>Draw the appropriate dose of Morphine into a 1ml syringe.<\/p><p>Do not dilute<\/p><ul><li>\u2022<\/li><\/ul><p>Wipe the bung with an alcohol swab and then inject. The slower the rate of<\/p><p>injection the less discomfort the patient experiences (give over 1-2 minutes)<\/p><ul><li>\u2022<\/li><\/ul><p>the cannula either before or after the injection<\/p><p>Do not flush<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p><p>Page 19 of 57<\/p>", "children": [{"id": 20, "page": 14, "top": 129.3, "level": 3, "font_size": 13.980000000000018, "text": "4.1 Protocol for Intermittent IV Opioids", "content_html": "<p>Introduction:<\/p><p>This technique of analgesia is suitable for minor surgery where there is a need for short<\/p><p>term intravenous analgesic therapy. This is prescribed by medical staff. Administration is<\/p><p>by medical staff or by nursing staff in PACU or PICU.<\/p><p>Prescription:<\/p><p>This is prescribed on the Inpatient Medication Chart.<\/p><p>Protocol:<\/p><p>Morphine 0.025mg/kg IV every 5 minutes until comfortable.<\/p><p>If the patient is in moderate or severe pain, this dose can be given over 5 minutes directly<\/p><p>into the IV port of a running drip and the patient observed closely for the next 15 minutes.<\/p><p>Alternatively if the need is less urgent then the dose should be given in the burette to be<\/p><p>infused.<\/p><p>For patients unable to tolerate Morphine contact PAPS (Fentanyl or Oxycodone may be<\/p><p>used).<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p>", "children": []}, {"id": 21, "page": 14, "top": 541.0, "level": 3, "font_size": 13.980000000000018, "text": "4.2 Protocol for Intravenous Opioid Infusions", "content_html": "<p>Introduction:<\/p><p>Infusions of Morphine or Fentanyl can provide continuous analgesia without the \u201cups and<\/p><p>downs\u201d of intermittent bolus administration. They are suitable for children of any age<\/p><p>particularly those who are unsuitable for patient controlled analgesia.<\/p><p>Additional prescribed bolus doses may be required to cover additional \u201cincident\u201d pain<\/p><p>which occurs during movement or when the patient is subjected to painful procedures.<\/p><p>Intravenous infusions need close observation as the patient is always receiving the drug<\/p><p>and accumulations may occur.<\/p><p>Prescription:<\/p><p>Opioid infusion orders are prescribed on the PAPS Prescription Form by the Department<\/p><p>of Anaesthesia only. Syringe changes are recorded in the Drug Administration Record of<\/p><p>the PAPS Prescription Form.<\/p><p>Page 14 of 57<\/p><p>Protocol:<\/p><p>Use CADD Solis pump<\/p><p>Mix drug into 50ml bag of Normal Saline or Dextrose 5%<\/p><p>An anti-reflux valve is necessary with all intravenous Opioid Infusions<\/p><p>Morphine Infusion    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>0.5mg/kg into 50mls<\/td><td>(1ml = 10mcg/kg)<\/td><\/tr><tr><td>Background Infusion<\/td><td>0-4ml/hr<\/td><td>(0-40mcg/kg/hr)<\/td><\/tr><\/table><p>Fentanyl Infusion    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>20mcg/kg into 50mls<\/td><td>(1ml = 0.4mcg/kg)<\/td><\/tr><tr><td>Background Infusion<\/td><td>0-4ml/hr<\/td><td>(0-1.6mcg/kg/hr)<\/td><\/tr><\/table><p>These are the recommended infusion regimes and may be varied at the discretion of the<\/p><p>Anaesthetic Staff according to the individual patient\u2019s needs.<\/p><p>Children younger than 3 months:<\/p><ul><li>\u2022<\/li><\/ul><p>Infusion rates and boluses should be halved i.e. 0-2.0ml/hr<\/p><p>Their metabolic pathways may be very immature, (especially preterm infants) and<\/p><p>of major concern is the risk of opioid induced respiratory depression. The method<\/p><p>of analgesia must be discussed with senior medical staff.<\/p><p>Managing IV infusions:<\/p><p>Prior to commencing the infusion the patient should be titrated to comfort by a doctor with<\/p><p>intravenous boluses of the same opioid. Infusions should be started at 2.0ml/hr (syringe<\/p><p>pump) and can then be varied at the discretion of the ward nursing staff according to the<\/p><p>degree of analgesia or sedation of the patient (within the prescribed limits).<\/p><p>Bolus doses with opioid infusions:<\/p><p>Morphine:    10-20 mcg/kg (1-2mls of solution) at intervals no less than 10mins<\/p><p>Fentanyl:    0.4 mcg/kg (1ml of solution) at intervals no less than 5mins<\/p><p>Bolus doses can be given in two situations:<\/p><ul><li>\u2022<\/li><\/ul><p>If pain relief is inadequate, a prescribed bolus dose should be administered<\/p><p>followed by an increasing infusion rate by 1ml/hr<\/p><ul><li>\u2022<\/li><\/ul><p>To cover anticipated \u201cincident pain\u201d (e.g. pulling out drain, physiotherapy<\/p><p>movement, procedures, dressings etc) we suggest that a bolus dose be given 10-<\/p><p>15 minutes prior to the anticipated painful procedure<\/p><p>Page 15 of 57<\/p><p>Before bolus doses are given:<\/p><ul><li>\u2022<\/li><\/ul><p>Exclude alternative causes of pain eg, urinary retention, compartment syndrome<\/p><ul><li>\u2022<\/li><\/ul><p>The patient should be awake and coherent<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Children &lt; 6 months old must have continuous oximetry.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p>", "children": []}, {"id": 22, "page": 16, "top": 324.1, "level": 3, "font_size": 13.980000000000018, "text": "4.3 Protocol for Nurse Controlled Analgesia (NCA)", "content_html": "<p>Introduction:<\/p><p>If a child receiving an opioid infusion is in pain, the only adjustment the nurses may<\/p><p>make is to increase the rate of infusion within the prescribed range. Pharmacokinetically<\/p><p>what the child needs is a bolus dose, but in order to give this medical staff have to be<\/p><p>involved. NCA takes the equipment and principals of PCA and puts the control in the<\/p><p>hands of the nurses. NCA allows continuous low dose background infusion and<\/p><p>intermittent boluses at specified intervals. The patient is protected from over dose by<\/p><p>routine monitoring, a longer lockout interval and the principal of assess-intervene-<\/p><p>reassess. There is no place for a parent or guardian to press the button.<\/p><p>NCA is appropriate for the control of pain in infants, pre-verbal children and children that<\/p><p>cannot use a PCA. It is useful for moderate to severe pain that has a significant incident/<\/p><p>movement component.<\/p><p>Prescription:<\/p><p>NCA orders are prescribed on the PAPS Prescription Form by the Department of<\/p><p>Anaesthesia only. Syringe changes are recorded in the Drug Administration Record of the<\/p><p>PAPS Prescription Form.<\/p><p>Protocol:<\/p><p>Use CADD Solis pump<\/p><p>Mix drug into 50ml bag of Normal Saline or Dextrose 5%<\/p><p>An anti-reflux valve is necessary with all intravenous NCA<\/p><p>Page 16 of 57<\/p><p>Morphine NCA    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>0.5mg/kg into 50mls<\/td><td>(1ml = 10mcg/kg)<\/td><\/tr><tr><td>Bolus Dose<\/td><td>1-2ml<\/td><td>(10-20mcg/kg)<\/td><\/tr><\/table><p>Lockout    10-30mins<\/p><table><tr><td>Background Infusion<\/td><td>0-2ml/hr<\/td><td>(0-20mcg/kg/hr)<\/td><\/tr><tr><td>Hourly Dose Limit<\/td><td>8ml<\/td><td>(80mcg/kg)<\/td><\/tr><\/table><p>Fentanyl NCA    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>20mcg/kg into 50mls<\/td><td>(1ml = 0.4mcg/kg)<\/td><\/tr><tr><td>Bolus Dose<\/td><td>1-2ml<\/td><td>(0.4-0.8mcg/kg)<\/td><\/tr><\/table><p>Lockout    10-30mins<\/p><table><tr><td>Background Infusion<\/td><td>0-2ml/hr<\/td><td>(0-0.8mcg/kg/hr )<\/td><\/tr><tr><td>Hourly Dose Limit<\/td><td>8ml<\/td><td>(3.2mcg/kg )<\/td><\/tr><\/table><p>In children weighing close to 50 kg it is suggested you use the \u2018Adolescent protocol\u2019 which<\/p><p>uses the \u2018Adult\u2019 100ml premix bags (Morpine 100mg in 100mls, or Fentanyl 1000mcg in<\/p><p>100mls).<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Children &lt; 6 months old must have continuous oximetry.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p>", "children": []}, {"id": 23, "page": 17, "top": 496.4, "level": 3, "font_size": 13.980000000000018, "text": "4.4 Protocol for Patient Controlled Analgesia (PCA)", "content_html": "<p>Introduction:<\/p><p>PCA is a technique of managing acute pain which utilises a programmable syringe-pump<\/p><p>to allow patients to self-administer their own intravenous opioid analgesics. It can be used<\/p><p>by any child who is able to understand the concept of pressing a button when it hurts.<\/p><p>Pre-operative education is very worthwhile.<\/p><p>Prescription of PCA:<\/p><p>PCA orders are prescribed on the PAPS Prescription Form by the Department of<\/p><p>Anaesthesia only. Syringe changes are recorded in the Drug Administration Record of the<\/p><p>PAPS Prescription Form.<\/p><p>Protocol:<\/p><p>Use CADD Solis pump<\/p><p>Mix drug into 50ml bag of Normal Saline or Dextrose 5%<\/p><p>An anti-reflux valve is necessary with all intravenous PCA<\/p><p>Page 17 of 57<\/p><p>Morphine PCA    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>0.5mg/kg into 50mls<\/td><td>(1ml = 10mcg/kg)<\/td><\/tr><tr><td>Bolus Dose<\/td><td>1-2ml<\/td><td>(10-20mcg/kg)<\/td><\/tr><\/table><p>Lockout    5-10mins<\/p><table><tr><td>Background Infusion<\/td><td>0-1ml/hr<\/td><td>(0-10mcg/kg/hr)<\/td><\/tr><tr><td>Hourly Dose Limit<\/td><td>10ml<\/td><td>(100mcg/kg)<\/td><\/tr><\/table><p>Fentanyl PCA    INITIAL PROGRAMMING<\/p><table><tr><td>Solution<\/td><td>20mcg/kg into 50mls<\/td><td>(1ml = 0.4mcg/kg)<\/td><\/tr><tr><td>Bolus Dose<\/td><td>1ml<\/td><td>(0.4mcg/kg)<\/td><\/tr><\/table><p>Lockout    5mins<\/p><table><tr><td>Background Infusion<\/td><td>0.5ml/hr<\/td><td>(0.2mcg/kg/hr )<\/td><\/tr><tr><td>Hourly Dose Limit<\/td><td>10ml<\/td><td>(4mcg/kg )<\/td><\/tr><\/table><p>Morphine is usually the first choice \u2013 Fentanyl is used for patients who are unable to<\/p><p>tolerate Morphine or have renal impairment.<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p><p>Adolescent PCA:<\/p><p>In children weighing close to 50 kg it is suggested you use the \u2018Adolescent protocol\u2019 which<\/p><p>uses the \u2018Adult\u2019 100ml premix bags (Morphine 100mg in 100mls, or Fentanyl 1000mcg in<\/p><p>100mls).<\/p>", "children": []}, {"id": 24, "page": 18, "top": 597.5, "level": 3, "font_size": 13.980000000000018, "text": "4.5 Protocol for Subcutaneous Morphine Boluses", "content_html": "<p>Introduction:<\/p><p>This is ideally avoided because of the irritant nature of subcutaneous (SC) Morphine, but it<\/p><p>may be useful for post-operative pain of short duration in the older child. A narrow gauge<\/p><p>plastic cannula can be left in position usually just below the clavicle, obviating the need for<\/p><p>repeated skin puncture. Morphine is the drug of choice because:<\/p><ul><li>\u2022<\/li><\/ul><p>It has longer duration of action than Pethidine<\/p><ul><li>\u2022<\/li><\/ul><p>It is not irritant and hence not as painful as Pethidine<\/p><ul><li>\u2022<\/li><\/ul><p>It is available in a more concentrated solution than Pethidine and hence a smaller<\/p><p>volume can be given for the same effect<\/p><p>Page 18 of 57<\/p><p>In the shocked patient the absorption from the SC (and IM) site is erratic and this form of<\/p><p>analgesia should not be used. Because it is necessary to prime the line with Morphine<\/p><p>prior to the first injection, it is important to use Morphine of the same concentrations for all<\/p><p>injections.<\/p><p>Prescription:<\/p><p>This is prescribed on the Inpatient Medication Chart.<\/p><p>Dosage:<\/p><p>Morphine 0.1mg/kg SC 1-2 hourly prn<\/p><p>:<\/p><p>Equipment<\/p><ul><li>\u2022<\/li><\/ul><p>24g BD Saf-T-Intima cannula<\/p><ul><li>\u2022<\/li><\/ul><p>Alcohol swabs<\/p><ul><li>\u2022<\/li><\/ul><p>Small transparent dressing e.g. Opsite, Tegaderm<\/p><p>Insertion of SC cannula: (may already be in situ from theatre)<\/p><ul><li>\u2022<\/li><\/ul><p>Prime the infusion line with Morphine (concentration 10mg/ml)<\/p><ul><li>\u2022<\/li><\/ul><p>Clean the site in the subclavicular region thoroughly with alcohol swab<\/p><ul><li>\u2022<\/li><\/ul><p>Insert the cannula through the skin at shallow angle. It is best to pinch up a fold of<\/p><p>skin to do this<\/p><ul><li>\u2022<\/li><\/ul><p>Cover with the transparent dressing<\/p><ul><li>\u2022<\/li><\/ul><p>All patients should have IV access<\/p><p>Injection procedures:<\/p><ul><li>\u2022<\/li><\/ul><p>Check the drug order for the dose of Morphine (0.1 mg/kg or less)<\/p><ul><li>\u2022<\/li><\/ul><p>Draw the appropriate dose of Morphine into a 1ml syringe.<\/p><p>Do not dilute<\/p><ul><li>\u2022<\/li><\/ul><p>Wipe the bung with an alcohol swab and then inject. The slower the rate of<\/p><p>injection the less discomfort the patient experiences (give over 1-2 minutes)<\/p><ul><li>\u2022<\/li><\/ul><p>the cannula either before or after the injection<\/p><p>Do not flush<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p><p>Page 19 of 57<\/p>", "children": []}]}, {"id": 25, "page": 20, "top": 115.4, "level": 2, "font_size": 13.980000000000018, "text": "5. MANAGING PAIN USING EPIDURALS", "content_html": "<p>Introduction:<\/p><p>Mixtures of diluted local anaesthetic (LA) and opioids infused into the epidural space can<\/p><p>provide virtually complete analgesia for selected procedures, especially in patients with<\/p><p>compromised or potentially compromised respiratory function. Epidural catheters can be<\/p><p>placed either via the thoracic, lumbar, caudal or trans-sacral routes. The catheter is inserted<\/p><p>by the Anaesthetist at the time of surgery.<\/p><p>Advantages:<\/p><ul><li>\u2022<\/li><\/ul><p>Almost complete pain relief<\/p><ul><li>\u2022<\/li><\/ul><p>Reduced analgesic requirement<\/p><ul><li>\u2022<\/li><\/ul><p>Less sedation/ opioid side effects<\/p><ul><li>\u2022<\/li><\/ul><p>Suitable for all age groups<\/p><p>Disadvantages:<\/p><ul><li>\u2022<\/li><\/ul><p>Requires epidural catheter<\/p><ul><li>\u2022<\/li><\/ul><p>No patient participation<\/p><ul><li>\u2022<\/li><\/ul><p>Urinary retention and pruritus may increase<\/p><p>Contraindications:<\/p><ul><li>\u2022<\/li><\/ul><p>Head injury/raised ICP<\/p><ul><li>\u2022<\/li><\/ul><p>Coagulopathy<\/p><ul><li>\u2022<\/li><\/ul><p>Local or systemic infection<\/p><ul><li>\u2022<\/li><\/ul><p>Progressive neurological deficit<\/p><ul><li>\u2022<\/li><\/ul><p>Patient/parent refusal<\/p><p>Local anaesthetic pharmacokinetics in children:<\/p><p>Children are more at risk of local anaesthetic toxicity than adults for a number of reasons:<\/p><ul><li>\u2022<\/li><\/ul><p>Reduced intrinsic clearance. Local anaesthetics are metabolized by cytochrome<\/p><p>P450 \u2013 lignocaine and bupivacaine mainly CYP3A4, and Ropivacaine by CYP1A2.<\/p><p>These enzymes are immature in early life \u2013 at 1 month of age the clearance of<\/p><p>bupivacaine is one-third of that of adults, and 2-thirds at 6 months, and the<\/p><p>clearance of Ropivacaine is not mature until 8 years of age.<\/p><ul><li>\u2022<\/li><\/ul><p>Faster vascular absorption. Children have higher cardiac outputs than adults,<\/p><p>which results in faster vascular absorption from vascular tissue. This produces<\/p><p>higher initial plasma concentrations and decreased durations of action.<\/p><ul><li>\u2022<\/li><\/ul><p>Reduced protein binding. Alpha-1 acid glycoprotein is the major protein that binds<\/p><p>LAs \u2013 levels are very low at birth and rise throughout the first year of life.<\/p><p>Page 20 of 57<\/p><p>Toxicity Summary<\/p><p>Children &lt; 2 years \u2013 higher risk of cardiac toxicity due to higher baseline heart rates<\/p><p>Children &lt; 1 year \u2013 even higher risk of systemic toxicity due to decreased protein binding<\/p><p>Children &lt; 6 months \u2013 even higher risk of systemic toxicity due to immature liver enzymes<\/p><ul><li>\u2022<\/li><\/ul><p>Risk of high plasma drug conc is increased with infusions or repeated injections<\/p><ul><li>\u2022<\/li><\/ul><p>Risk of high plasma drug conc somewhat lessened following single injection<\/p><p>Volumes of distribution of LAs in neonates and infants are larger than adults<\/p><p>o<\/p><p>duration is shorter in infants than in adults (most noticeable in<\/p><p>Spinal anaesthesia<\/p><p>preterm infants). Reasons:<\/p><ul><li>\u2022<\/li><\/ul><p>larger volume of cerebrospinal fluid (CSF)<\/p><ul><li>\u2022<\/li><\/ul><p>faster drug uptake from CSF \u2013 infants have a greater blood flow to the spinal cord.<\/p><p>Drugs:<\/p><p>Local Anaesthetics:<\/p><p>Bupivacaine (racemic) has historically been the most popular epidural LA. Ropivacaine is a<\/p><p>newer LA. It is a single stereoisomer amino amide agent which, in adults, is thought to<\/p><p>produce less motor blockade and be less cardiotoxic than standard Bupivacaine<\/p><p>There still remains very little high quality evidence on what doses of local anaesthetic may be<\/p><p>safely used in paediatric practice. Dosages recommended by the ESRA and ASRA Joint<\/p><p>Committee (2018) are:<\/p><p>0.1-0.3 mg/kg/hr (Bupivacaine or Ropivacaine)<\/p><p>Multicentre studies show a large variation in dosages used by practitioners and the above is<\/p><p>a guideline only. As new evidence becomes available this guideline may need to be updated.<\/p><p>Additives:<\/p><p>Other drugs may be used in the epidural infusion to supplement the LA.<\/p><p>Fentanyl:<\/p><ul><li>\u2022<\/li><\/ul><p>Opioid commonly used to supplement epidural LA analgesia<\/p><ul><li>\u2022<\/li><\/ul><p>At high doses sedation and respiratory depression may occur<\/p><p>Clonidine:<\/p><ul><li>\u2022<\/li><\/ul><p>Partial agonist at alpha 2 receptors<\/p><ul><li>\u2022<\/li><\/ul><p>Sedative, analgesic and antihypertensive properties<\/p><ul><li>\u2022<\/li><\/ul><p>Affects conduction in peripheral nociceptive nerves<\/p><ul><li>\u2022<\/li><\/ul><p>Used for supplementing epidurals/ regional blocks and as a premedication<\/p><ul><li>\u2022<\/li><\/ul><p>Side effects include sedation and hypotension<\/p><p>Page 21 of 57<\/p><p>Prescription:<\/p><p>Epidural orders are prescribed on the PAPS Prescription Form by the Department of<\/p><p>Anaesthesia only. Bag changes are recorded on the Drug Administration Record of the<\/p><p>PAPS Prescription Form.<\/p><p>Epidural Infusions Protocol:<\/p><p>Use CADD Solis pump<\/p><p>Mix drug into 50ml bag<\/p><p>Infusions can be managed within the prescribed rates by certificated Nursing Staff according<\/p><p>to patient comfort.<\/p><p>Drugs:<\/p><p>is standard<\/p><p>Bupivacaine 0.1%<\/p><ul><li>\u2022<\/li><\/ul><p>Mix 20mls of 0.25% Bupivacaine (50mg) and 100 mcg of Fentanyl (2mls) and<\/p><p>28mls of Normal Saline to total volume of 50mls<\/p><ul><li>\u2022<\/li><\/ul><p>In order to avoid LA toxicity maximum doses must not be exceeded<\/p><ul><li>\u2022<\/li><\/ul><p>Think in mg/kg not ml/kg<\/p><ul><li>\u2022<\/li><\/ul><p>Bupivacaine 0.1% = 1mg/ml<\/p><table><tr><td>Age<\/td><td>Max Infusion<\/td><td>Duration<\/td><\/tr><tr><td>&lt; 6 months<\/td><td>0.2mg/kg/hr<\/td><td>0-0.2ml/kg/hr<\/td><td>24-36hrs<\/td><\/tr><tr><td>&gt; 6 months<\/td><td>0.4mg/kg/hr<\/td><td>0-0.4ml/kg/hr<\/td><td>36-48hrs<\/td><\/tr><\/table><p>Suggested initial setting range 0-0.3 ml/kg/hr for children &gt; 6 months<\/p><p>(Maximum rate not to exceed 15 ml/hr)<\/p><p>Fentanyl:<\/p><ul><li>\u2022<\/li><\/ul><p>May be added to epidural infusions to improve the quality of analgesia<\/p><ul><li>\u2022<\/li><\/ul><p>May cause sedation<\/p><ul><li>\u2022<\/li><\/ul><p>Added to Bupivacaine 0.1% to give concentration of Fentanyl 1-2 mcg/ml<\/p><ul><li>\u2022<\/li><\/ul><p>Suggest reduced to Fentanyl 0-1 mcg/ml in children &lt; 6 months old<\/p><p>Clonidine:<\/p><ul><li>\u2022<\/li><\/ul><p>May be added to epidural infusions to improve the quality of analgesia without<\/p><p>increasing the side-effects of epidural opioids (itching, nausea/ vomiting,<\/p><p>respiratory depression)<\/p><ul><li>\u2022<\/li><\/ul><p>May be useful in postoperative spasticity (eg, cerebral palsy)<\/p><ul><li>\u2022<\/li><\/ul><p>May cause sedation<\/p><ul><li>\u2022<\/li><\/ul><p>Use preservative free solution (eg, Catapress150 mcg/ml)<\/p><ul><li>\u2022<\/li><\/ul><p>Added to Bupivacaine 0.1% to give concentration of Clonidine 0.5-1 mcg/ml<\/p><ul><li>\u2022<\/li><\/ul><p>This would result in the following doses of Clonidine<\/p><p>Conc 0.5 mcg/ml    0.1-0.3ml/kg/hr -&gt; 0.05-0.15mcg/kg/hr<\/p><p>Conc 1 mcg/ml    0.1-0.3ml/kg/hr -&gt; 0.1-0.3mcg/kg/hr<\/p><ul><li>\u2022<\/li><\/ul><p>Literature suggests generally aiming for 0.12-0.16 mcg/kg/hr.<\/p><ul><li>\u2022<\/li><\/ul><p>Suggest reduced to Clonidine 0.5 mcg/ml in children &lt; 6 months old<\/p><p>Page 22 of 57<\/p><p>Epidural Boluses Protocol:<\/p><p>There may be occasions when there is inadequate analgesia while using an epidural<\/p><p>infusion. A top-up bolus may improve the analgesia and should be considered before<\/p><p>resorting to some other form of analgesia.<\/p><ul><li>\u2022<\/li><\/ul><p>Bolus orders are prescribed by the Department of Anaesthesia only.<\/p><p>The size of the bolus (in mls) may be equal to the hourly rate (in mls).<\/p><p>o<\/p><p>The rate of the bolus is to be administered over 10 minutes.<\/p><p>o<\/p><p>If this does not resolve the pain then a review of the pain management should<\/p><p>o<\/p><p>be sought.<\/p><ul><li>\u2022<\/li><\/ul><p>Following a bolus, observations should be performed quarter hourly for one hour.<\/p><p>See Section 9 of the Handbook.<\/p><p>Epidural Catheter Care and Removal:<\/p><p>The catheter should be secured with a combination of Tegaderm/ Opsite and Hypafix/ Sleek<\/p><p>tape or similar. If a catheter requires redressing the Department of Anaesthesia should be<\/p><p>contacted. All children must have IV access.<\/p><p>The tubing from the syringe to the epidural catheter will incorporate an antibacterial filter.<\/p><p>There are to be no 3-way taps or injection ports in this line. Antiseptic agents such as<\/p><p>Chlorhexidine, Betadine or alcohol are not to come in contact with the epidural catheter or<\/p><p>tubing as they are neurotoxic.<\/p><p>Important:<\/p><ul><li>\u2022<\/li><\/ul><p>Before removing the catheter it is important to check that the patient is not<\/p><p>coagulapathic or receiving anticoagulants<\/p><p>(eg Heparin, Clexane, Fragmin, Warfarin or Clopidogrel)<\/p><ul><li>\u2022<\/li><\/ul><p>Removal of the catheter is performed by certificated ward nursing staff<\/p><ul><li>\u2022<\/li><\/ul><p>The adhesive tapes and dressing are removed and the catheter is simply withdrawn<\/p><ul><li>\u2022<\/li><\/ul><p>It is important to confirm that the whole catheter has been removed intact. A Band-aid<\/p><p>is optional.<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Following bolus administration quarter hourly observations should be done for one hour.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p><p>Page 23 of 57<\/p>", "children": []}, {"id": 26, "page": 24, "top": 77.6, "level": 2, "font_size": 13.980000000000018, "text": "6. MANAGING PAIN USING REGIONAL INFUSIONS", "content_html": "<p>Introduction:<\/p><p>The introduction of ultrasound guided regional anaesthesia has seen an increase in the<\/p><p>popularity of paediatric nerve blocks and fascial plane blocks. This is achieved by delivering<\/p><p>local anaesthetic around major nerves or in fascial planes. An infusion catheter is usually<\/p><p>sited when the patient is anaesthetised, and may be used for postoperative analgesia. These<\/p><p>techniques not only help to reduce some of the stress response of surgery, but may also<\/p><p>provide excellent analgesia with less systemic effects than may occur with opioid analgesia.<\/p><p>Common types of regional infusions:<\/p><p>Interpleural    catheter in the intrapleural space<\/p><p>Extrapleural    catheter external to the parietal pleura (usually across rib necks)<\/p><p>Paravertebral    catheter in the paravertebral space, next to the vertebral column<\/p><p>Brachial plexus catheter in the perineural sheath around the brachial plexus<\/p><p>Femoral nerve    catheter in the perineural sheath around the femoral nerve<\/p><p>Sciatic nerve    catheter in the perineural sheath around the sciatic nerve<\/p><p>Paravertebral blocks may be used for surgery entailing unilateral incisions above T12 (eg<\/p><p>thoracotomy, renal surgery, cholecystectomy). They may still be suitable in situations where<\/p><p>epidurals are contraindicated (\u2191ICP, coagulopathy etc).<\/p><p>Local anaesthetic pharmacokinetics in children:<\/p><p>Children are more at risk of local anaesthetic toxicity than adults for a number of reasons:<\/p><ul><li>\u2022<\/li><\/ul><p>Reduced intrinsic clearance. Local anaesthetics are metabolized by cytochrome<\/p><p>P450 \u2013 lignocaine and bupivacaine mainly CYP3A4, and Ropivacaine by CYP1A2.<\/p><p>These enzymes are immature in early life \u2013 at 1 month of age the clearance of<\/p><p>bupivacaine is one-third of that of adults, and 2-thirds at 6 months, and the<\/p><p>clearance of Ropivacaine is not mature until 8 years of age.<\/p><ul><li>\u2022<\/li><\/ul><p>Faster vascular absorption. Children have higher cardiac outputs than adults,<\/p><p>which results in faster vascular absorption from vascular tissue. This produces<\/p><p>higher initial plasma concentrations and decreased durations of action.<\/p><ul><li>\u2022<\/li><\/ul><p>Reduced protein binding. Alpha-1 acid glycoprotein is the major protein that binds<\/p><p>LAs \u2013 levels are very low at birth and rise throughout the first year of life.<\/p><p>Toxicity Summary<\/p><p>Children &lt; 2 years \u2013 higher risk of cardiac toxicity due to higher baseline heart rates<\/p><p>Children &lt; 1 year \u2013 even higher risk of systemic toxicity due to decreased protein binding<\/p><p>Children &lt; 6 months \u2013 even higher risk of systemic toxicity due to immature liver enzymes<\/p><ul><li>\u2022<\/li><\/ul><p>Risk of high plasma drug conc is increased with infusions or repeated injections<\/p><ul><li>\u2022<\/li><\/ul><p>Risk of high plasma drug conc somewhat lessened following single injection<\/p><p>Volumes of distribution of LAs in neonates and infants are larger than adults<\/p><p>o<\/p><p>Page 24 of 57<\/p><p>Drugs:<\/p><p>Bupivacaine (racemic) has historically been the most popular LA. Ropivacaine is a newer LA.<\/p><p>It is a single stereoisomer amino amide agent which, in adults, is thought to produce less<\/p><p>motor blockade and be less cardiotoxic than standard Bupivacaine.<\/p><p>There still remains very little high quality evidence on what doses of local anaesthetic may be<\/p><p>safely used in paediatric practice. Dosages recommended by the ESRA and ASRA Joint<\/p><p>Committee (2018) are:<\/p><p>0.1-0.3 mg/kg/hr (Bupivacaine or Ropivacaine)<\/p><p>Multicentre studies show a large variation in dosages used by practitioners and the above is<\/p><p>a guideline only. As new evidence becomes available this guideline may need to be updated.<\/p><p>Prescription:<\/p><p>Regional infusions are prescribed on the PAPS Prescription Form by the Department of<\/p><p>Anaesthesia only. Bag changes are recorded on the Drug Administration Record of the<\/p><p>PAPS Prescription Form.<\/p><p>Regional Infusion Protocols:<\/p><p>Use CADD Solis pump<\/p><p>Mix drug into 50ml bag<\/p><p>Infusions can be managed within the prescribed rates by certificated ward Nursing Staff<\/p><p>according to patient comfort.<\/p><p>Drugs:<\/p><p>is standard<\/p><p>Bupivacaine 0.125%<\/p><ul><li>\u2022<\/li><\/ul><p>This is higher concentration than in epidural<\/p><ul><li>\u2022<\/li><\/ul><p>Mix 25mls of 0.25% Bupivacaine and 25mls of Normal Saline to total volume of<\/p><p>50mls<\/p><ul><li>\u2022<\/li><\/ul><p>In order to avoid LA toxicity maximum doses must not be exceeded<\/p><ul><li>\u2022<\/li><\/ul><p>Think in mg/kg not ml/kg<\/p><ul><li>\u2022<\/li><\/ul><p>Bupivacaine 0.125% = 1.25mg/ml<\/p><table><tr><td>Age<\/td><td>Max Infusion<\/td><td>Duration<\/td><\/tr><tr><td>&lt; 6 months<\/td><td>0.2mg/kg/hr<\/td><td>0.16ml/kg/hr<\/td><td>24-36hrs<\/td><\/tr><tr><td>&gt; 6 months<\/td><td>0.4mg/kg/hr<\/td><td>0.32ml/kg/hr<\/td><td>36-48hrs<\/td><\/tr><\/table><p>Suggested initial setting range 0-0.25 ml/kg/hr for children &gt; 6 months<\/p><p>(Maximum rate not to exceed 5 ml/hr)<\/p><p>Infusion Catheter Care and Removal:<\/p><p>The tubing from the syringe to the infusion catheter will incorporate an antibacterial filter.<\/p><p>There are to be no 3-way taps or injection ports in this line. Antiseptic agents such as<\/p><p>Chlorhexidine, Betadine or alcohol are not to come in contact with the infusion catheter or<\/p><p>tubing as they are neurotoxic.<\/p><p>Page 25 of 57<\/p><p>Removal of the catheter is performed by certificated Nursing Staff. The adhesive tapes and<\/p><p>dressing are removed and the catheter is simply withdrawn. It is important to confirm that the<\/p><p>whole catheter has been removed intact. A Band-aid is optional.<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Observations must be recorded on the Paediatric Pain Recording Chart.<\/p><p>Following bolus administration quarter hourly observations should be done for one hour.<\/p><p>Problems:<\/p><p>See Section 8 of the Handbook or refer to PAPS Prescription Form (Trouble shooting<\/p><p>guidelines).<\/p><p>Page 26 of 57<\/p>", "children": []}, {"id": 27, "page": 27, "top": 77.6, "level": 2, "font_size": 13.980000000000018, "text": "7. MANAGING PAIN USING ENTONOX", "content_html": "<p>Introduction:<\/p><p>Entonox is a 50% mixture of nitrous oxide and oxygen. It is an odourless, colourless gas<\/p><p>which can provide potent short-term analgesia for painful procedures. It has a quick onset of<\/p><p>action (30-60 seconds) and wears off almost as quickly. It is unsuitable for chronic, long-term<\/p><p>administration because of the risk of bone-marrow toxicity.<\/p><p>Apparatus:<\/p><p>Entonox is self-administered via a demand-apparatus.<\/p><p>The apparatus consists of:<\/p><ul><li>\u2022<\/li><\/ul><p>A 4000 litre (size E) OR 1600 litre (size D) cylinder<\/p><ul><li>\u2022<\/li><\/ul><p>A small pressure (contents) gauge<\/p><ul><li>\u2022<\/li><\/ul><p>A reducing valve which reduces the pressure from the cylinder to one suitable for<\/p><p>inhalation<\/p><ul><li>\u2022<\/li><\/ul><p>A demand valve which allows gas to flow only when the patient inhales from the face-<\/p><p>mask or mouth-piece. For this to occur, the face-mask or mouth-piece must be well<\/p><p>sealed and a characteristic sound is heard when the Entonox is being inhaled<\/p><ul><li>\u2022<\/li><\/ul><p>Black tubing leading to the face mask<\/p><ul><li>\u2022<\/li><\/ul><p>An expiratory valve near the face mask vents expired gas to the atmosphere<\/p><ul><li>\u2022<\/li><\/ul><p>New mask/mouthpiece and filter for each patient<\/p><p>Contraindications:<\/p><ul><li>\u2022<\/li><\/ul><p>Children aged &lt;2 years<\/p><ul><li>\u2022<\/li><\/ul><p>Children unwilling or unable to use Entonox<\/p><ul><li>\u2022<\/li><\/ul><p>Intoxication with alcohol or other drugs<\/p><ul><li>\u2022<\/li><\/ul><p>Closed head injury or unconsciousness<\/p><ul><li>\u2022<\/li><\/ul><p>Airway obstruction or airway burns<\/p><ul><li>\u2022<\/li><\/ul><p>Pneumothorax (nitrous oxide diffuses into air filled cavities and expands them)<\/p><ul><li>\u2022<\/li><\/ul><p>Recent Eye/ ENT/ Maxillofacial surgery or injury<\/p><ul><li>\u2022<\/li><\/ul><p>Head injury, raised intracranial pressure or depressed level of consciousness<\/p><ul><li>\u2022<\/li><\/ul><p>Bowel obstruction<\/p><ul><li>\u2022<\/li><\/ul><p>Respiratory distress and hypoxia<\/p><ul><li>\u2022<\/li><\/ul><p>Decompression sickness and air embolism<\/p><ul><li>\u2022<\/li><\/ul><p>Haematologic illness<\/p><p>These contraindications may be relative, in which case, the Duty Anaesthetist should be<\/p><p>consulted prior to the use of Entonox.<\/p><p>Page 27 of 57<\/p><p>Side Effects:<\/p><ul><li>\u2022<\/li><\/ul><p>Sedation. If the child becomes sedated the seal around the mask or mouth-piece will be<\/p><p>lost and the flow of Entonox will stop if the child has been holding the mask themselves.<\/p><p>This mechanism is responsible for the inherent safety of Entonox<\/p><ul><li>\u2022<\/li><\/ul><p>Nausea will occasionally occur<\/p><ul><li>\u2022<\/li><\/ul><p>Bone marrow depression with prolonged use. Ward patients should be limited to no more<\/p><p>than 1.5 hours administration per day. Children requiring Entonox for longer than 2<\/p><p>weeks should be prescribed folic acid 15mg orally daily<\/p><p>Administration of Entonox:<\/p><p>Entonox is prescribed on the Inpatient Prescription Sheet for ward patients.<\/p><p>The duration of<\/p><p>administration is recorded and signed for with each use.<\/p><p>For outpatients, Entonox is administered at the discretion of the attending nursing or medical<\/p><p>staff but its use is recorded in the Outpatient Notes.<\/p><p>Where practical, the child should be fasted (food and fluids) for 2 hours prior to<\/p><p>administration.<\/p><p>Entonox may be administered by any Registered Nurse or Medical Staff<\/p><p>who have been trained in the safe administration of Entonox.<\/p><p>Method of administration:<\/p><ul><li>\u2022<\/li><\/ul><p>Make sure there is a new mask/mouthpiece and filter for each patient.<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure cylinder is upright.<\/p><ul><li>\u2022<\/li><\/ul><p>Turn the key to open the cylinder and check the contents of the cylinder. Change if &lt;<\/p><p>5000 kPa.<\/p><ul><li>\u2022<\/li><\/ul><p>Explain how to use the Entonox and allow the child time to become familiar with the<\/p><p>equipment and the noise it makes.<\/p><ul><li>\u2022<\/li><\/ul><p>Instruct the child how to hold the face-mask or mouth-piece to ensure a good fit. The<\/p><p>child should self-administer Entonox wherever possible. If the child is unable to do so<\/p><p>(eg. burns or fractured arms) then the nurse should provide assistance holding the mask<\/p><p>and creating a seal. Verbal contact should be maintained with the patient and the mask<\/p><p>should be removed temporarily should over sedation occur.<\/p><ul><li>\u2022<\/li><\/ul><p>Administration should commence several minutes prior to the painful procedure.<\/p><ul><li>\u2022<\/li><\/ul><p>The child continues to breathe normally from the apparatus. The noise indicates<\/p><p>satisfactory delivery of Entonox. The expiratory valve should be observed for movemen<\/p><p>Page 28 of 57<\/p>", "children": []}, {"id": 28, "page": 29, "top": 101.6, "level": 2, "font_size": 13.980000000000018, "text": "8. MANAGING ADVERSE EFFECTS & TROUBLESHOOTING", "content_html": "<p>8.1 LA Toxicity<\/p><p>Local anaesthetics (LA) achieve their clinical effect by reversibly blocking voltage-gated<\/p><p>sodium channels. Blockade of small fibre afferents is responsible for analgesia while<\/p><p>blockade of larger (myelinated) fibres can result in motor blockade. At toxic levels LA may<\/p><p>interfere with nerve conduction in the central nervous system (CNS) and heart \u2013 again<\/p><p>blockade of voltage-gated sodium channels is involved, although recently many<\/p><p>alternative sites have also been considered.<\/p><p>LA toxicity can occur following drug overdose, intravascular injection or drug accumulation<\/p><p>following infusion. Toxicity is related to the unbound fraction of the drug. Both neonates<\/p><p>and acidotic patients are at increased risk of toxicity due to decreased protein binding of<\/p><p>the drug. Neonates and infants have lower plasma levels of \u03b1 acid glycoprotein which is<\/p><p>1<\/p><p>largely responsible for protein binding of the drug, and acidosis causes dissociation of the<\/p><p>drug from protein binding.<\/p><p>LA toxicity is rare, but it can have catastrophic consequences. If plasma levels rise slowly<\/p><p>the CNS is affected first. Symptoms are initially excitatory \u2013 circumoral and tongue<\/p><p>paraesthesia, metallic taste, and dizziness, followed by slurred speech, diplopia, tinnitus,<\/p><p>confusion, restlessness, muscle twitching and seizures. Higher plasma concentrations<\/p><p>result in impaired cardiac conduction, arrhythmia and cardiac arrest. Cardiac arrest due to<\/p><p>local anaesthetic toxicity is notoriously refractory to standard resuscitation techniques.<\/p><p>8.1.1 Management of Impending LA Toxicity<\/p><p>Suspect local anaesthetic toxicity if:<\/p><ul><li>\u2022<\/li><\/ul><p>Recognised inadvertent overdose<\/p><ul><li>\u2022<\/li><\/ul><p>Symptoms of CNS toxicity<\/p><p>(circumoral paraesthesia, dizziness, disorientation, agitation or tremor)<\/p><ul><li>\u2022<\/li><\/ul><p>Seizure<\/p><ul><li>\u2022<\/li><\/ul><p>Stop LA infusion<\/p><ul><li>\u2022<\/li><\/ul><p>Give Oxygen<\/p><ul><li>\u2022<\/li><\/ul><p>Notify PAPS and Medical Staff \u2013 call Arrest Team if required<\/p><ul><li>\u2022<\/li><\/ul><p>Consider Lipid Emulsion (Intralipid 20%) infusion concurrently with<\/p><p>management of symptoms<\/p><p>Page 29 of 57<\/p><p>8.1.2 Cardiac Resuscitation in the Event of Suspected LA Toxicity<\/p><ul><li>\u2022<\/li><\/ul><p>Commence APLS according to current protocols<\/p><ul><li>\u2022<\/li><\/ul><p>Call Arrest Team<\/p><ul><li>\u2022<\/li><\/ul><p>Give IV Lipid Emulsion (Intralipid 20%) as soon as practical<\/p><p>1ml/kg over 1 minute<\/p><p>o<\/p><p>Repeat if necessary every 3 minutes (up to 3ml/kg)<\/p><p>o<\/p><p>Follow with an infusion of 0.25ml/kg/min until haemodynamic stability<\/p><p>o<\/p><p>(increase to 0.5ml/kg/min if hypotensive)<\/p><p>8.2 Management of Common Opioid Side-Effects<\/p><p>8.2.1 Management of Overdose<\/p><p>Opioid overdose may be suspected if there are slow shallow respirations and deep<\/p><p>sedation or loss of consciousness.<\/p><ul><li>\u2022<\/li><\/ul><p>Stop Opioid infusion<\/p><ul><li>\u2022<\/li><\/ul><p>Give Oxygen, assist ventilation if necessary<\/p><ul><li>\u2022<\/li><\/ul><p>Give Naloxone 2 mcg/kg IV prn 1-2 minutes, if required<\/p><p>Stimulation and encouragement to breathe may be all that is required<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS and Medical Staff<\/p><ul><li>\u2022<\/li><\/ul><p>5 minute observations<\/p><ul><li>\u2022<\/li><\/ul><p>If cardiorespiratory arrest/ minimal respirations/ or unconscious<\/p><p>Give Oxygen, and assist ventilation<\/p><p>o<\/p><p>Give Naloxone 10 mcg/kg IV prn 1-2 minutes<\/p><p>o<\/p><p>Call Arrest team, and commence APLS<\/p><p>o<\/p><p>8.2.2 Management of Pruritus<\/p><p>This is a very common symptom in infants and children receiving opioid analgesia.<\/p><p>Recommendations to attempt to reduce distress:<\/p><ul><li>\u2022<\/li><\/ul><p>Optimize general skin care i.e. change old dressings, adequate skin washing,<\/p><p>use skin moisturisers etc<\/p><ul><li>\u2022<\/li><\/ul><p>Try antihistamine<\/p><p>Promethazine 0.5mg/kg IV/ IM/ PO 8 hourly prn (max 10-25mg) or<\/p><p>o<\/p><p>Trimeprazine 0.5mg/kg PO 8 hourly prn<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Try Ondansetron 100mcg/kg IV or PO (max 4mg) \u2013 if effective, it may be<\/p><p>repeated 8 hourly (max 3 doses for pruritus)<\/p><ul><li>\u2022<\/li><\/ul><p>Change opioid i.e. Morphine to Fentanyl<\/p><ul><li>\u2022<\/li><\/ul><p>Try Naloxone<\/p><p>Bolus 0.5mcg/kg IV up to 3 doses over 15 minutes<\/p><p>o<\/p><p>Infusion 1mcg/kg/hr if successful<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Stop opioid altogether<\/p><p>Page 30 of 57<\/p><p>8.3 Management of Nausea &amp; Vomiting<\/p><p>Introduction:<\/p><p>Antiemetics may be used prophylactically in theatre if the patient is considered to be<\/p><p>significantly at risk of postoperative nausea and vomiting (PONV), or they may be used to<\/p><p>treat patients with PONV.<\/p><p>Studies suggest that independent risk factors for PONV in children include:<\/p><ul><li>\u2022<\/li><\/ul><p>History of PONV in patient, sibling, or parent<\/p><ul><li>\u2022<\/li><\/ul><p>Age \u2265 3 years<\/p><ul><li>\u2022<\/li><\/ul><p>Surgery \u2265 30mins<\/p><ul><li>\u2022<\/li><\/ul><p>Strabismus surgery (others include adenotonsillectomy)<\/p><p>When 0, 1, 2, 3, or 4 factors are present, risk equates to 10%, 10%, 30%, 55%, or 70%<\/p><p>Drugs and doses:<\/p><table><tr><td>Antiemetic<\/td><td>Dose<\/td><td>Maximum<\/td><td>Frequency<\/td><td>Class<\/td><\/tr><tr><td>Ondansetron<\/td><td>50-100mcg/kg<\/td><td>Max 4mg<\/td><td>8hrly prn<\/td><td>5 HT3 antagonist<\/td><\/tr><tr><td>Dexamethasone 150-200mcg/kg Max 8mg<\/td><td>Once only<\/td><td>Steroid<\/td><\/tr><tr><td>Droperidol<\/td><td>10-20mcg/kg<\/td><td>Max 500mcg<\/td><td>8hrly prn<\/td><td>Butyrophenone<\/td><\/tr><tr><td>Cyclizine<\/td><td>0.5-1mg/kg<\/td><td>Max 50mg<\/td><td>6hrly prn<\/td><td>Histamine antagonist<\/td><\/tr><tr><td>Metoclopramide 150mcg/kg<\/td><td>Max 10mg<\/td><td>8hrly prn<\/td><td>Dopamine antagonist<\/td><\/tr><\/table><p>8.3.1 PONV Prophylaxis<\/p><p>In children at moderate or high risk of PONV, combination therapy with 2 or 3<\/p><p>antiemetics from different classes should be used. Combination therapy may also be<\/p><p>appropriate for patients in whom PONV poses a particular morbidity (jaws wired, raised<\/p><p>intracranial pressure, gastric/ oesophageal surgery, or day surgery)<\/p><p>Antiemetics are not all equal in their effectiveness.<\/p><p>Numbers needed to treat (NNT) for POV prophylaxis in children:<\/p><p>Dose    NNT<\/p><table><tr><td>Ondansetron<\/td><td>50-100 mcg/kg<\/td><td>2-3 (early &amp; late POV)<\/td><\/tr><\/table><p>Dexamethasone 150 mcg/kg    4 (early &amp; late POV)<\/p><table><tr><td>Droperidol<\/td><td>50-75 mcg/kg<\/td><td>4-5 (early &amp; late POV)<\/td><\/tr><\/table><p>Metoclopramide 150 mcg/kg    Little evidence to show useful<\/p><p>Taken from Gan 2007    Early POV = postoperative vomiting 0-6hrs<\/p><p>Late POV = postoperative vomiting 0-24hrs<\/p><p>Page 31 of 57<\/p><p>Recommendations for PONV Prophylaxis:<\/p><ul><li>\u2022<\/li><\/ul><p>Ondansetron and Dexamethasone<\/p><p>First line combination<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Droperidol<\/p><p>Potential for extrapyramidal symptoms and high levels of sedation<\/p><p>o<\/p><p>Should probably be reserved for children who have failed other<\/p><p>o<\/p><p>therapies and are being admitted overnight<\/p><ul><li>\u2022<\/li><\/ul><p>Cyclizine<\/p><p>May cause sedation, caution if &lt;2 years old<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Metoclopramide<\/p><p>Combinations with Metoclopramide are no better than monotherapy<\/p><p>o<\/p><p>8.3.2 PONV Treatment<\/p><p>When PONV occurs treatment should be given with an antiemetic from a different class<\/p><p>than any prophylactic agents already used.<\/p><p>Recommendations for PONV Treatment:<\/p><ul><li>\u2022<\/li><\/ul><p>Ondansetron<\/p><p>First line agent if not already given<\/p><p>o<\/p><p>Doses for treatment are lower than doses required for prophylaxis<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>May give a repeat dose of an antiemetic if greater than 6 hours since last dose<\/p><p>Do not give repeat dose of Dexamethasone<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>May consider small dose of Propofol if still in PACU (effect probably brief)<\/p><p>Recommendations for Persistent PONV:<\/p><ul><li>\u2022<\/li><\/ul><p>Exclude correctable causes (eg, unnecessary opioids, ingested blood,<\/p><p>abdominal obstruction, hypotension).<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure adequate hydration, analgesia, blood pressure, blood sugar<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure triple therapy (Ondansetron, Dexamethasone, Droperidol)<\/p><p>Give Dexamethasone slowly if conscious \u2013 may cause discomfort<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Consider:<\/p><p>Cyclizine \u2013 may cause sedation, caution if &lt;2yrs old<\/p><p>o<\/p><p>Metoclopramide<\/p><p>o<\/p><p>Page 32 of 57<\/p><p>8.4 Management of Common Epidural Problems<\/p><p>8.4.1 Epidural Disconnection<\/p><p>As soon as an epidural catheter disconnection has been discovered:<\/p><ul><li>\u2022<\/li><\/ul><p>Keep catheter tip clean eg hold with a sterile glove or wrap in sterile gauze<\/p><ul><li>\u2022<\/li><\/ul><p>Clamp catheter tip (or tie a knot next to tip)<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS who will manage further<\/p><ul><li>\u2022<\/li><\/ul><p>The PAPS will then review the indication for epidural analgesia<\/p><ul><li>\u2022<\/li><\/ul><p>With a witnessed disconnection the Anaesthetist may decide that it is reasonable<\/p><p>to continue with the epidural infusion without removing the existing catheter:<\/p><p>Using aseptic technique clean the epidural catheter end with Chlorhexidine/<\/p><p>o<\/p><p>alcohol 70%<\/p><p>(wait until dry)<\/p><p>Cut approximately 3-4cm off the distal end of the catheter.<\/p><p>o<\/p><p>Reconnect to a new sterile epidural filter and secure carefully<\/p><p>o<\/p><p>Change the epidural infusion set<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>With a disconnection that is unwitnessed and thus of an uncertain time frame, the<\/p><p>Anaesthetist may:<\/p><p>Review the indication for the epidural analgesia \u2013 consider the advantages<\/p><p>o<\/p><p>and disadvantages of leaving the existing catheter in situ<\/p><p>Consider removing the catheter and:<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Resiting an epidural in the usual manner with full asepsis<\/p><ul><li>\u2022<\/li><\/ul><p>Offering an alternative analgesic technique eg PCA / NCA<\/p><p>Additional analgesia may be required if the epidural infusion has been<\/p><p>o<\/p><p>disrupted for some time<\/p><p>8.4.2 Inadequate Analgesia<\/p><p>Occasionally epidural analgesia alone may be inadequate.<\/p><p>In this situation it may be worth continuing epidural analgesia but with LA only (ie<\/p><p>without additives) and adding IV opioid (ie, NCA or PCA). Before doing this:<\/p><ul><li>\u2022<\/li><\/ul><p>Exclude epidural disconnection and dislodgement<\/p><ul><li>\u2022<\/li><\/ul><p>Consider epidural bolus<\/p><p>These changes may be made by the Department of Anaesthesia only.<\/p><p>Page 33 of 57<\/p><p>8.5 Troubleshooting<\/p><p>Note:    Medical staff = House Surgeon, Medical/ Surgical Registrar<\/p><p>PAPS    = Paediatric Acute Pain Service<\/p><p>Sedation Score 3 or 4 or Respirations &lt; minimum for age:<\/p><p>Suspect opioid overdose:<\/p><ul><li>\u2022<\/li><\/ul><p>Stop Opioid infusion<\/p><ul><li>\u2022<\/li><\/ul><p>Give Oxygen, assist ventilation if necessary<\/p><ul><li>\u2022<\/li><\/ul><p>Give Naloxone 2 mcg/kg IV prn 1-2 minutes, if required<\/p><p>Stimulation and encouragement to breathe may be all that is required<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS and Medical Staff<\/p><ul><li>\u2022<\/li><\/ul><p>5 minute observations<\/p><ul><li>\u2022<\/li><\/ul><p>If cardiorespiratory arrest/ minimal respirations/ or unconscious<\/p><p>Give Oxygen, and assist ventilation<\/p><p>o<\/p><p>Give Naloxone 10 mcg/kg IV prn 1-2 minutes<\/p><p>o<\/p><p>Call Arrest team, and commence APLS<\/p><p>o<\/p><p>Trouble breathing and or numbness in fingers, upper limbs:<\/p><p>Suspect epidural block too high:<\/p><ul><li>\u2022<\/li><\/ul><p>Stop epidural<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS and Medical Staff<\/p><ul><li>\u2022<\/li><\/ul><p>5 minute observations<\/p><p>Pain score of 3 or more on two consecutive recordings:<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS<\/p><p>Hypotension or heart rate extremes:<\/p><ul><li>\u2022<\/li><\/ul><p>Stop infusion<\/p><ul><li>\u2022<\/li><\/ul><p>Give Oxygen<\/p><ul><li>\u2022<\/li><\/ul><p>Call Medical Staff for opioid infusions/ NCA/ PCA<\/p><p>Call Medical Staff and PAPS for epidural<\/p><ul><li>\u2022<\/li><\/ul><p>5 minute observations<\/p><p>Nausea, Vomiting, Pruritus:<\/p><ul><li>\u2022<\/li><\/ul><p>Call Medical Staff<\/p><ul><li>\u2022<\/li><\/ul><p>Refer to Sections 8.2 and 8.3 for drug recommendations and dosages<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS if unrelieved<\/p><p>Page 34 of 57<\/p>", "children": [{"id": 29, "page": 29, "top": 153.3, "level": 3, "font_size": 13.980000000000018, "text": "8.1 LA Toxicity", "content_html": "<p>Local anaesthetics (LA) achieve their clinical effect by reversibly blocking voltage-gated<\/p><p>sodium channels. Blockade of small fibre afferents is responsible for analgesia while<\/p><p>blockade of larger (myelinated) fibres can result in motor blockade. At toxic levels LA may<\/p><p>interfere with nerve conduction in the central nervous system (CNS) and heart \u2013 again<\/p><p>blockade of voltage-gated sodium channels is involved, although recently many<\/p><p>alternative sites have also been considered.<\/p><p>LA toxicity can occur following drug overdose, intravascular injection or drug accumulation<\/p><p>following infusion. Toxicity is related to the unbound fraction of the drug. Both neonates<\/p><p>and acidotic patients are at increased risk of toxicity due to decreased protein binding of<\/p><p>the drug. Neonates and infants have lower plasma levels of \u03b1 acid glycoprotein which is<\/p><p>1<\/p><p>largely responsible for protein binding of the drug, and acidosis causes dissociation of the<\/p><p>drug from protein binding.<\/p><p>LA toxicity is rare, but it can have catastrophic consequences. If plasma levels rise slowly<\/p><p>the CNS is affected first. Symptoms are initially excitatory \u2013 circumoral and tongue<\/p><p>paraesthesia, metallic taste, and dizziness, followed by slurred speech, diplopia, tinnitus,<\/p><p>confusion, restlessness, muscle twitching and seizures. Higher plasma concentrations<\/p><p>result in impaired cardiac conduction, arrhythmia and cardiac arrest. Cardiac arrest due to<\/p><p>local anaesthetic toxicity is notoriously refractory to standard resuscitation techniques.<\/p>", "children": []}, {"id": 30, "page": 29, "top": 462.0, "level": 3, "font_size": 12.0, "text": "8.1.1 Management of Impending LA Toxicity", "content_html": "<p>Suspect local anaesthetic toxicity if:<\/p><ul><li>\u2022<\/li><\/ul><p>Recognised inadvertent overdose<\/p><ul><li>\u2022<\/li><\/ul><p>Symptoms of CNS toxicity<\/p><p>(circumoral paraesthesia, dizziness, disorientation, agitation or tremor)<\/p><ul><li>\u2022<\/li><\/ul><p>Seizure<\/p><ul><li>\u2022<\/li><\/ul><p>Stop LA infusion<\/p><ul><li>\u2022<\/li><\/ul><p>Give Oxygen<\/p><ul><li>\u2022<\/li><\/ul><p>Notify PAPS and Medical Staff \u2013 call Arrest Team if required<\/p><ul><li>\u2022<\/li><\/ul><p>Consider Lipid Emulsion (Intralipid 20%) infusion concurrently with<\/p><p>management of symptoms<\/p><p>Page 29 of 57<\/p>", "children": []}, {"id": 31, "page": 30, "top": 66.7, "level": 3, "font_size": 12.0, "text": "8.1.2 Cardiac Resuscitation in the Event of Suspected LA Toxicity", "content_html": "<ul><li>\u2022<\/li><\/ul><p>Commence APLS according to current protocols<\/p><ul><li>\u2022<\/li><\/ul><p>Call Arrest Team<\/p><ul><li>\u2022<\/li><\/ul><p>Give IV Lipid Emulsion (Intralipid 20%) as soon as practical<\/p><p>1ml/kg over 1 minute<\/p><p>o<\/p><p>Repeat if necessary every 3 minutes (up to 3ml/kg)<\/p><p>o<\/p><p>Follow with an infusion of 0.25ml/kg/min until haemodynamic stability<\/p><p>o<\/p><p>(increase to 0.5ml/kg/min if hypotensive)<\/p>", "children": []}, {"id": 32, "page": 30, "top": 232.7, "level": 3, "font_size": 13.980000000000018, "text": "8.2 Management of Common Opioid Side-Effects", "content_html": "<p class=\"text-muted\">No text detected for this section.<\/p>", "children": []}, {"id": 33, "page": 30, "top": 275.8, "level": 3, "font_size": 12.0, "text": "8.2.1 Management of Overdose", "content_html": "<p>Opioid overdose may be suspected if there are slow shallow respirations and deep<\/p><p>sedation or loss of consciousness.<\/p><ul><li>\u2022<\/li><\/ul><p>Stop Opioid infusion<\/p><ul><li>\u2022<\/li><\/ul><p>Give Oxygen, assist ventilation if necessary<\/p><ul><li>\u2022<\/li><\/ul><p>Give Naloxone 2 mcg/kg IV prn 1-2 minutes, if required<\/p><p>Stimulation and encouragement to breathe may be all that is required<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS and Medical Staff<\/p><ul><li>\u2022<\/li><\/ul><p>5 minute observations<\/p><ul><li>\u2022<\/li><\/ul><p>If cardiorespiratory arrest/ minimal respirations/ or unconscious<\/p><p>Give Oxygen, and assist ventilation<\/p><p>o<\/p><p>Give Naloxone 10 mcg/kg IV prn 1-2 minutes<\/p><p>o<\/p><p>Call Arrest team, and commence APLS<\/p><p>o<\/p>", "children": []}, {"id": 34, "page": 30, "top": 545.7, "level": 3, "font_size": 12.0, "text": "8.2.2 Management of Pruritus", "content_html": "<p>This is a very common symptom in infants and children receiving opioid analgesia.<\/p><p>Recommendations to attempt to reduce distress:<\/p><ul><li>\u2022<\/li><\/ul><p>Optimize general skin care i.e. change old dressings, adequate skin washing,<\/p><p>use skin moisturisers etc<\/p><ul><li>\u2022<\/li><\/ul><p>Try antihistamine<\/p><p>Promethazine 0.5mg/kg IV/ IM/ PO 8 hourly prn (max 10-25mg) or<\/p><p>o<\/p><p>Trimeprazine 0.5mg/kg PO 8 hourly prn<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Try Ondansetron 100mcg/kg IV or PO (max 4mg) \u2013 if effective, it may be<\/p><p>repeated 8 hourly (max 3 doses for pruritus)<\/p><ul><li>\u2022<\/li><\/ul><p>Change opioid i.e. Morphine to Fentanyl<\/p><ul><li>\u2022<\/li><\/ul><p>Try Naloxone<\/p><p>Bolus 0.5mcg/kg IV up to 3 doses over 15 minutes<\/p><p>o<\/p><p>Infusion 1mcg/kg/hr if successful<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Stop opioid altogether<\/p><p>Page 30 of 57<\/p>", "children": []}, {"id": 35, "page": 31, "top": 94.9, "level": 3, "font_size": 13.980000000000018, "text": "8.3 Management of Nausea & Vomiting", "content_html": "<p>Introduction:<\/p><p>Antiemetics may be used prophylactically in theatre if the patient is considered to be<\/p><p>significantly at risk of postoperative nausea and vomiting (PONV), or they may be used to<\/p><p>treat patients with PONV.<\/p><p>Studies suggest that independent risk factors for PONV in children include:<\/p><ul><li>\u2022<\/li><\/ul><p>History of PONV in patient, sibling, or parent<\/p><ul><li>\u2022<\/li><\/ul><p>Age \u2265 3 years<\/p><ul><li>\u2022<\/li><\/ul><p>Surgery \u2265 30mins<\/p><ul><li>\u2022<\/li><\/ul><p>Strabismus surgery (others include adenotonsillectomy)<\/p><p>When 0, 1, 2, 3, or 4 factors are present, risk equates to 10%, 10%, 30%, 55%, or 70%<\/p><p>Drugs and doses:<\/p><table><tr><td>Antiemetic<\/td><td>Dose<\/td><td>Maximum<\/td><td>Frequency<\/td><td>Class<\/td><\/tr><tr><td>Ondansetron<\/td><td>50-100mcg/kg<\/td><td>Max 4mg<\/td><td>8hrly prn<\/td><td>5 HT3 antagonist<\/td><\/tr><tr><td>Dexamethasone 150-200mcg/kg Max 8mg<\/td><td>Once only<\/td><td>Steroid<\/td><\/tr><tr><td>Droperidol<\/td><td>10-20mcg/kg<\/td><td>Max 500mcg<\/td><td>8hrly prn<\/td><td>Butyrophenone<\/td><\/tr><tr><td>Cyclizine<\/td><td>0.5-1mg/kg<\/td><td>Max 50mg<\/td><td>6hrly prn<\/td><td>Histamine antagonist<\/td><\/tr><tr><td>Metoclopramide 150mcg/kg<\/td><td>Max 10mg<\/td><td>8hrly prn<\/td><td>Dopamine antagonist<\/td><\/tr><\/table>", "children": []}, {"id": 36, "page": 31, "top": 476.8, "level": 3, "font_size": 12.0, "text": "8.3.1 PONV Prophylaxis", "content_html": "<p>In children at moderate or high risk of PONV, combination therapy with 2 or 3<\/p><p>antiemetics from different classes should be used. Combination therapy may also be<\/p><p>appropriate for patients in whom PONV poses a particular morbidity (jaws wired, raised<\/p><p>intracranial pressure, gastric/ oesophageal surgery, or day surgery)<\/p><p>Antiemetics are not all equal in their effectiveness.<\/p><p>Numbers needed to treat (NNT) for POV prophylaxis in children:<\/p><p>Dose    NNT<\/p><table><tr><td>Ondansetron<\/td><td>50-100 mcg/kg<\/td><td>2-3 (early &amp; late POV)<\/td><\/tr><\/table><p>Dexamethasone 150 mcg/kg    4 (early &amp; late POV)<\/p><table><tr><td>Droperidol<\/td><td>50-75 mcg/kg<\/td><td>4-5 (early &amp; late POV)<\/td><\/tr><\/table><p>Metoclopramide 150 mcg/kg    Little evidence to show useful<\/p><p>Taken from Gan 2007    Early POV = postoperative vomiting 0-6hrs<\/p><p>Late POV = postoperative vomiting 0-24hrs<\/p><p>Page 31 of 57<\/p><p>Recommendations for PONV Prophylaxis:<\/p><ul><li>\u2022<\/li><\/ul><p>Ondansetron and Dexamethasone<\/p><p>First line combination<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Droperidol<\/p><p>Potential for extrapyramidal symptoms and high levels of sedation<\/p><p>o<\/p><p>Should probably be reserved for children who have failed other<\/p><p>o<\/p><p>therapies and are being admitted overnight<\/p><ul><li>\u2022<\/li><\/ul><p>Cyclizine<\/p><p>May cause sedation, caution if &lt;2 years old<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Metoclopramide<\/p><p>Combinations with Metoclopramide are no better than monotherapy<\/p><p>o<\/p>", "children": []}, {"id": 37, "page": 32, "top": 268.5, "level": 3, "font_size": 12.0, "text": "8.3.2 PONV Treatment", "content_html": "<p>When PONV occurs treatment should be given with an antiemetic from a different class<\/p><p>than any prophylactic agents already used.<\/p><p>Recommendations for PONV Treatment:<\/p><ul><li>\u2022<\/li><\/ul><p>Ondansetron<\/p><p>First line agent if not already given<\/p><p>o<\/p><p>Doses for treatment are lower than doses required for prophylaxis<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>May give a repeat dose of an antiemetic if greater than 6 hours since last dose<\/p><p>Do not give repeat dose of Dexamethasone<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>May consider small dose of Propofol if still in PACU (effect probably brief)<\/p><p>Recommendations for Persistent PONV:<\/p><ul><li>\u2022<\/li><\/ul><p>Exclude correctable causes (eg, unnecessary opioids, ingested blood,<\/p><p>abdominal obstruction, hypotension).<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure adequate hydration, analgesia, blood pressure, blood sugar<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure triple therapy (Ondansetron, Dexamethasone, Droperidol)<\/p><p>Give Dexamethasone slowly if conscious \u2013 may cause discomfort<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Consider:<\/p><p>Cyclizine \u2013 may cause sedation, caution if &lt;2yrs old<\/p><p>o<\/p><p>Metoclopramide<\/p><p>o<\/p><p>Page 32 of 57<\/p>", "children": []}, {"id": 38, "page": 33, "top": 67.3, "level": 3, "font_size": 13.980000000000018, "text": "8.4 Management of Common Epidural Problems", "content_html": "<p class=\"text-muted\">No text detected for this section.<\/p>", "children": []}, {"id": 39, "page": 33, "top": 110.4, "level": 3, "font_size": 12.0, "text": "8.4.1 Epidural Disconnection", "content_html": "<p>As soon as an epidural catheter disconnection has been discovered:<\/p><ul><li>\u2022<\/li><\/ul><p>Keep catheter tip clean eg hold with a sterile glove or wrap in sterile gauze<\/p><ul><li>\u2022<\/li><\/ul><p>Clamp catheter tip (or tie a knot next to tip)<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS who will manage further<\/p><ul><li>\u2022<\/li><\/ul><p>The PAPS will then review the indication for epidural analgesia<\/p><ul><li>\u2022<\/li><\/ul><p>With a witnessed disconnection the Anaesthetist may decide that it is reasonable<\/p><p>to continue with the epidural infusion without removing the existing catheter:<\/p><p>Using aseptic technique clean the epidural catheter end with Chlorhexidine/<\/p><p>o<\/p><p>alcohol 70%<\/p><p>(wait until dry)<\/p><p>Cut approximately 3-4cm off the distal end of the catheter.<\/p><p>o<\/p><p>Reconnect to a new sterile epidural filter and secure carefully<\/p><p>o<\/p><p>Change the epidural infusion set<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>With a disconnection that is unwitnessed and thus of an uncertain time frame, the<\/p><p>Anaesthetist may:<\/p><p>Review the indication for the epidural analgesia \u2013 consider the advantages<\/p><p>o<\/p><p>and disadvantages of leaving the existing catheter in situ<\/p><p>Consider removing the catheter and:<\/p><p>o<\/p>", "children": []}, {"id": 40, "page": 33, "top": 381.0, "level": 3, "font_size": 12.0, "text": "\u2022", "content_html": "<p>Resiting an epidural in the usual manner with full asepsis<\/p>", "children": []}, {"id": 41, "page": 33, "top": 394.8, "level": 3, "font_size": 12.0, "text": "\u2022", "content_html": "<p>Offering an alternative analgesic technique eg PCA / NCA<\/p><p>Additional analgesia may be required if the epidural infusion has been<\/p><p>o<\/p><p>disrupted for some time<\/p>", "children": []}, {"id": 42, "page": 33, "top": 462.1, "level": 3, "font_size": 12.0, "text": "8.4.2 Inadequate Analgesia", "content_html": "<p>Occasionally epidural analgesia alone may be inadequate.<\/p><p>In this situation it may be worth continuing epidural analgesia but with LA only (ie<\/p><p>without additives) and adding IV opioid (ie, NCA or PCA). Before doing this:<\/p><ul><li>\u2022<\/li><\/ul><p>Exclude epidural disconnection and dislodgement<\/p><ul><li>\u2022<\/li><\/ul><p>Consider epidural bolus<\/p><p>These changes may be made by the Department of Anaesthesia only.<\/p><p>Page 33 of 57<\/p>", "children": []}, {"id": 43, "page": 34, "top": 67.3, "level": 3, "font_size": 13.980000000000018, "text": "8.5 Troubleshooting", "content_html": "<p>Note:    Medical staff = House Surgeon, Medical/ Surgical Registrar<\/p><p>PAPS    = Paediatric Acute Pain Service<\/p><p>Sedation Score 3 or 4 or Respirations &lt; minimum for age:<\/p><p>Suspect opioid overdose:<\/p><ul><li>\u2022<\/li><\/ul><p>Stop Opioid infusion<\/p><ul><li>\u2022<\/li><\/ul><p>Give Oxygen, assist ventilation if necessary<\/p><ul><li>\u2022<\/li><\/ul><p>Give Naloxone 2 mcg/kg IV prn 1-2 minutes, if required<\/p><p>Stimulation and encouragement to breathe may be all that is required<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS and Medical Staff<\/p><ul><li>\u2022<\/li><\/ul><p>5 minute observations<\/p><ul><li>\u2022<\/li><\/ul><p>If cardiorespiratory arrest/ minimal respirations/ or unconscious<\/p><p>Give Oxygen, and assist ventilation<\/p><p>o<\/p><p>Give Naloxone 10 mcg/kg IV prn 1-2 minutes<\/p><p>o<\/p><p>Call Arrest team, and commence APLS<\/p><p>o<\/p><p>Trouble breathing and or numbness in fingers, upper limbs:<\/p><p>Suspect epidural block too high:<\/p><ul><li>\u2022<\/li><\/ul><p>Stop epidural<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS and Medical Staff<\/p><ul><li>\u2022<\/li><\/ul><p>5 minute observations<\/p><p>Pain score of 3 or more on two consecutive recordings:<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS<\/p><p>Hypotension or heart rate extremes:<\/p><ul><li>\u2022<\/li><\/ul><p>Stop infusion<\/p><ul><li>\u2022<\/li><\/ul><p>Give Oxygen<\/p><ul><li>\u2022<\/li><\/ul><p>Call Medical Staff for opioid infusions/ NCA/ PCA<\/p><p>Call Medical Staff and PAPS for epidural<\/p><ul><li>\u2022<\/li><\/ul><p>5 minute observations<\/p><p>Nausea, Vomiting, Pruritus:<\/p><ul><li>\u2022<\/li><\/ul><p>Call Medical Staff<\/p><ul><li>\u2022<\/li><\/ul><p>Refer to Sections 8.2 and 8.3 for drug recommendations and dosages<\/p><ul><li>\u2022<\/li><\/ul><p>Call PAPS if unrelieved<\/p><p>Page 34 of 57<\/p>", "children": []}]}, {"id": 44, "page": 35, "top": 77.6, "level": 2, "font_size": 13.980000000000018, "text": "9. MONITORING", "content_html": "<p>9.1 Pain Assessment &amp; Measurement<\/p><p>Children of all age groups experience pain and there are significant physiological and<\/p><p>behavioural consequences of inadequately treated pain.<\/p><p>The function of pain assessment is to detect pain, estimate its severity and test the<\/p><p>effectiveness of the intervention. It should be routine and one component of the holistic<\/p><p>approach to the child. The cause of pain should be sought.<\/p><p>In general, pain assessment instruments in children can be categorised as observational,<\/p><p>self-report and physiological. Pain assessment should take place against a background<\/p><p>experience of this child\u2019s recovery compared to other children at the same stage of<\/p><p>recovery.<\/p><p>Pain management should be proactive but when confronted with pain an assessment-<\/p><p>intervention-reassessment approach is used. Children can be divided into the preverbal,<\/p><p>the cognitively impaired and the verbal.<\/p><p>Preverbal &amp; Cognitively Impaired<\/p><p>This is the most difficult group and they are most at risk of under treatment as they are<\/p><p>unable to communicate pain. There are many well validated behavioural and physiological<\/p><p>pain score systems (CRIES, CHEOPS) that are used in pain research but are difficult to<\/p><p>apply in the ward setting.<\/p><p>We prefer the Instinctive Behavioural Observation approach in this group eg. if<\/p><p>experienced staff think the child is in pain we will intervene and then reassess.<\/p><p>Verbal<\/p><p>Children older than 3 years are able to communicate pain. Initially it is an all-or-nothing<\/p><p>type of response. Self-reporting with words or visual aids can be used successfully<\/p><p>provided the number of choices is limited to around 4 words, faces or \u2018pieces of hurt\u2019.<\/p><p>Visual linear analogues can be used from age 5 years (eg. face pain scale rating). Vertical<\/p><p>pain scales are better in children less than 7 years and horizontal pain scales can be used<\/p><p>in children older than 7 years. The numerical rating scale (NRS), can usually be<\/p><p>comprehended by children older than 10 years.<\/p><p>Page 35 of 57<\/p><p>9.2 Monitoring<\/p><p>Observations are to be recorded on the PAPS Pain Recording Chart.<\/p><p>9.2.1 Opioids<\/p><p>Children taking opioids by any route require the following recordings:<\/p><p>BP    Sedation score<\/p><p>Pulse    Pain assessment<\/p><p>Respiratory rate    Oxygen saturation<\/p><p>Opioid Observation Protocol<\/p><ul><li>\u2022<\/li><\/ul><p>\u2192 Baseline recordings<\/p><p>Before opioid<\/p><ul><li>\u2022<\/li><\/ul><p>\u2192 Every 15 minutes for one hour<\/p><p>Following opioid<\/p><ul><li>\u2022<\/li><\/ul><p>\u2192 Every hour (BP can be done every 2 hours)<\/p><p>Then<\/p><p>For opioid infusions, NCA, PCA and single dose opioids (PO, IV, SC, or IM)<\/p><p>recordings may stop 2 hours after discontinuing/ last dose<\/p><p>For controlled release oral opioids recordings may stop 12 hours after last dose<\/p><p>Children &lt; 6 months old must have continuous oximetry if on infusion/ NCA<\/p><p>Pain assessment<\/p><p>1    No pain<\/p><p>2    A little pain<\/p><p>3    Moderate<\/p><p>4    Very sore<\/p><p>5    Too much pain<\/p><p>Sedation score<\/p><p>1    Alert<\/p><p>2    Rousable to voice<\/p><p>3    Rousable to light pain<\/p><p>4    Unrousable<\/p><p>9.2.2 Epidurals and Regional Infusions<\/p><p>Epidurals and Regional Infusions require the same monitoring as for opioids with the<\/p><p>addition of hourly motor scores.<\/p><p>Motor score<\/p><p>1    Hip, knee ankle movement<\/p><p>2    Ankle and knee movement<\/p><p>3    Ankle only<\/p><p>4    No movement<\/p><p>All patients with indwelling catheters/ lines (including epidural and regional catheters)<\/p><p>must have their temperature documented at least every 4 hours.<\/p><p>Page 36 of 57<\/p><p>9.3 Some Normal Physiological Values for Children 0-16 Years<\/p><table><tr><td>0 \u2013 3 months<\/td><td>Heart rate<\/td><td>&gt; 110 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 65 mmHg<\/p><p>Respirations    &gt; 25 /min<\/p><table><tr><td>3 \u2013 6 months<\/td><td>Heart rate<\/td><td>&gt; 100 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 75 mmHg<\/p><p>Respirations    &gt; 20 /min<\/p><table><tr><td>6 months \u2013 2 years<\/td><td>Heart rate<\/td><td>&gt; 85 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 80 mmHg<\/p><p>Respirations    &gt; 20 /min<\/p><table><tr><td>2 years \u2013 10 years<\/td><td>Heart rate<\/td><td>&gt; 80 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 90 mmHg<\/p><p>Respirations    &gt; 15 /min<\/p><table><tr><td>10 years \u2013 16 years<\/td><td>Heart rate<\/td><td>&gt; 60 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 100 mmHg<\/p><p>Respirations    &gt; 12 /min<\/p><p>Page 37 of 57<\/p>", "children": [{"id": 45, "page": 35, "top": 129.3, "level": 3, "font_size": 13.980000000000018, "text": "9.1 Pain Assessment & Measurement", "content_html": "<p>Children of all age groups experience pain and there are significant physiological and<\/p><p>behavioural consequences of inadequately treated pain.<\/p><p>The function of pain assessment is to detect pain, estimate its severity and test the<\/p><p>effectiveness of the intervention. It should be routine and one component of the holistic<\/p><p>approach to the child. The cause of pain should be sought.<\/p><p>In general, pain assessment instruments in children can be categorised as observational,<\/p><p>self-report and physiological. Pain assessment should take place against a background<\/p><p>experience of this child\u2019s recovery compared to other children at the same stage of<\/p><p>recovery.<\/p><p>Pain management should be proactive but when confronted with pain an assessment-<\/p><p>intervention-reassessment approach is used. Children can be divided into the preverbal,<\/p><p>the cognitively impaired and the verbal.<\/p><p>Preverbal &amp; Cognitively Impaired<\/p><p>This is the most difficult group and they are most at risk of under treatment as they are<\/p><p>unable to communicate pain. There are many well validated behavioural and physiological<\/p><p>pain score systems (CRIES, CHEOPS) that are used in pain research but are difficult to<\/p><p>apply in the ward setting.<\/p><p>We prefer the Instinctive Behavioural Observation approach in this group eg. if<\/p><p>experienced staff think the child is in pain we will intervene and then reassess.<\/p><p>Verbal<\/p><p>Children older than 3 years are able to communicate pain. Initially it is an all-or-nothing<\/p><p>type of response. Self-reporting with words or visual aids can be used successfully<\/p><p>provided the number of choices is limited to around 4 words, faces or \u2018pieces of hurt\u2019.<\/p><p>Visual linear analogues can be used from age 5 years (eg. face pain scale rating). Vertical<\/p><p>pain scales are better in children less than 7 years and horizontal pain scales can be used<\/p><p>in children older than 7 years. The numerical rating scale (NRS), can usually be<\/p><p>comprehended by children older than 10 years.<\/p><p>Page 35 of 57<\/p>", "children": []}, {"id": 46, "page": 36, "top": 81.1, "level": 3, "font_size": 13.980000000000018, "text": "9.2 Monitoring", "content_html": "<p>Observations are to be recorded on the PAPS Pain Recording Chart.<\/p>", "children": []}, {"id": 47, "page": 36, "top": 150.6, "level": 3, "font_size": 12.0, "text": "9.2.1 Opioids", "content_html": "<p>Children taking opioids by any route require the following recordings:<\/p><p>BP    Sedation score<\/p><p>Pulse    Pain assessment<\/p><p>Respiratory rate    Oxygen saturation<\/p><p>Opioid Observation Protocol<\/p><ul><li>\u2022<\/li><\/ul><p>\u2192 Baseline recordings<\/p><p>Before opioid<\/p><ul><li>\u2022<\/li><\/ul><p>\u2192 Every 15 minutes for one hour<\/p><p>Following opioid<\/p><ul><li>\u2022<\/li><\/ul><p>\u2192 Every hour (BP can be done every 2 hours)<\/p><p>Then<\/p><p>For opioid infusions, NCA, PCA and single dose opioids (PO, IV, SC, or IM)<\/p><p>recordings may stop 2 hours after discontinuing/ last dose<\/p><p>For controlled release oral opioids recordings may stop 12 hours after last dose<\/p><p>Children &lt; 6 months old must have continuous oximetry if on infusion/ NCA<\/p><p>Pain assessment<\/p><p>1    No pain<\/p><p>2    A little pain<\/p><p>3    Moderate<\/p><p>4    Very sore<\/p><p>5    Too much pain<\/p><p>Sedation score<\/p><p>1    Alert<\/p><p>2    Rousable to voice<\/p><p>3    Rousable to light pain<\/p><p>4    Unrousable<\/p>", "children": []}, {"id": 48, "page": 36, "top": 590.4, "level": 3, "font_size": 12.0, "text": "9.2.2 Epidurals and Regional Infusions", "content_html": "<p>Epidurals and Regional Infusions require the same monitoring as for opioids with the<\/p><p>addition of hourly motor scores.<\/p><p>Motor score<\/p><p>1    Hip, knee ankle movement<\/p><p>2    Ankle and knee movement<\/p><p>3    Ankle only<\/p><p>4    No movement<\/p><p>All patients with indwelling catheters/ lines (including epidural and regional catheters)<\/p><p>must have their temperature documented at least every 4 hours.<\/p><p>Page 36 of 57<\/p>", "children": []}, {"id": 49, "page": 37, "top": 81.1, "level": 3, "font_size": 13.980000000000018, "text": "9.3 Some Normal Physiological Values for Children 0-16 Years", "content_html": "<table><tr><td>0 \u2013 3 months<\/td><td>Heart rate<\/td><td>&gt; 110 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 65 mmHg<\/p><p>Respirations    &gt; 25 /min<\/p><table><tr><td>3 \u2013 6 months<\/td><td>Heart rate<\/td><td>&gt; 100 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 75 mmHg<\/p><p>Respirations    &gt; 20 /min<\/p><table><tr><td>6 months \u2013 2 years<\/td><td>Heart rate<\/td><td>&gt; 85 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 80 mmHg<\/p><p>Respirations    &gt; 20 /min<\/p><table><tr><td>2 years \u2013 10 years<\/td><td>Heart rate<\/td><td>&gt; 80 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 90 mmHg<\/p><p>Respirations    &gt; 15 /min<\/p><table><tr><td>10 years \u2013 16 years<\/td><td>Heart rate<\/td><td>&gt; 60 /min<\/td><\/tr><\/table><p>Systolic BP    &gt; 100 mmHg<\/p><p>Respirations    &gt; 12 /min<\/p><p>Page 37 of 57<\/p>", "children": []}]}, {"id": 50, "page": 38, "top": 77.6, "level": 2, "font_size": 13.980000000000018, "text": "10. MANAGING PAIN FROM BURNS", "content_html": "<p>Analgesia and sedation for dressing changes:<\/p><p>Dressing changes can be painful and distressing, and consequently may lead to<\/p><p>considerable anxiety if managed inadequately. To minimise distress and discomfort it is<\/p><p>important for the dressing team to have everything planned and prepared in advance.<\/p><p>Preparation will also include appropriate fasting and medication of the child, and importantly,<\/p><p>communication and explanation with the child and family about the procedure. The use of<\/p><p>distraction techniques involving Play Therapists and family may be helpful. Burns are often<\/p><p>painful when exposed, and so it is important to ensure the dressing change does not become<\/p><p>protracted - it is important to have enough staff and everything ready, if necessary photos<\/p><p>should be taken if surgical staff can not attend in a timely fashion.<\/p><p>Most dressing changes should be appropriately managed without the need for intravenous<\/p><p>medication \u2013 dressing changes for big or complicated burns, especially in infants or unwell<\/p><p>children, may require general anaesthesia, and should be discussed with the Paediatric<\/p><p>Anaesthetist or Duty Anaesthetist.<\/p><p>Medication:<\/p><p>Depending on the size of the burn and the age of the child, a combination of the following is<\/p><p>often required:<\/p><ul><li>\u2022<\/li><\/ul><p>Paracetamol    15mg/kg orally, give 45mins before procedure<\/p><ul><li>\u2022<\/li><\/ul><p>Morphine    0.3-0.5mg/kg orally, give 45mins before procedure<\/p><ul><li>\u2022<\/li><\/ul><p>Midazolam    0.3mg/kg orally if combined with Morphine, (otherwise 0.5mg/kg with<\/p><p>max 15mg), give 30mins before procedure<\/p><p>Other:<\/p><ul><li>\u2022<\/li><\/ul><p>N2O 30-70%    Consider for: first dressing/ removal staples/ deroofing blisters/<\/p><p>large debridement/ tricky areas (eg hands). This requires<\/p><p>appropriately trained nurse/ doctor and fasting. Not appropriate for<\/p><p>children aged &lt;2 years. See Section 7 of the Handbook. (Managing<\/p><p>Pain Using Entonox)<\/p><ul><li>\u2022<\/li><\/ul><p>Ketamine    3-5mg/kg orally if combined with drugs above, give 30mins before<\/p><p>procedure, (caution if less than 2years old). Charted by<\/p><p>Anaesthetist.<\/p><p>Page 38 of 57<\/p><p>Rescue Analgesia/ Sedation:<\/p><table><tr><td>Option<\/td><td>Indication<\/td><td>Dose<\/td><td>Limitations<\/td><\/tr><tr><td>N2O<\/td><td>Inadequate<\/td><td>30-70%<\/td><td>Appropriate training &amp; fasting<\/td><\/tr><\/table><p>analgesia/    Vomiting (prolonged conc.&gt;50%)<\/p><p>sedation<\/p><table><tr><td>Intranasal<\/td><td>Inadequate<\/td><td>0.5-1mcg/kg<\/td><td>Unpleasant, stings<\/td><\/tr><tr><td>Fentanyl<\/td><td>analgesia<\/td><td>Repeat Q5mins Oversedation &amp; nausea/ vomiting<\/td><\/tr><\/table><p>Max 3mcg/kg    (Onset &amp; potency similar to IV)<\/p><p>If a child is distressed and other appropriate measures have been tried it may be necessary<\/p><p>to abandon and try again with a different approach or a general anaesthestic. Children<\/p><p>should not be undergoing prolonged or distressing dressing changes \u2013 if there is any<\/p><p>uncertainty discuss with the Paediatric Anaesthetist.<\/p><p>Fasting:<\/p><p>Oral sedation alone    2 hours<\/p><p>N2O sedation alone    2 hours<\/p><p>Combined oral and N2O sedation    4 hours solids/ breast milk<\/p><p>2 hours clear fluids<\/p><p>Monitoring for dressing changes:<\/p><p>Children taking opioids require baseline and regular recording of vital observations every<\/p><p>15mins. See section 9.2.1 of the Handbook. (Monitoring) In addition to this, children requiring<\/p><p>sedation with Midazolam, N2O, or Ketamine should also have continuous oximetry and<\/p><p>supervision during the dressing change, and until they have woken fully.<\/p><p>Ongoing pain management:<\/p><p>Consider simple analgesics (paracetamol and NSAIDS), although caution is advised with<\/p><p>prolonged use, particularly in the presence of poor nutritional status. Reduced daily dosing<\/p><p>may be wise, along with surveillance of liver function.<\/p><p>Opioids are frequently required in burns management, and often in high doses. In patients<\/p><p>requiring regular opioids, a controlled release preparation is often charted (this will usually be<\/p><p>after a few days, at which point the dose can be calculated from the 24 hour usage). As the<\/p><p>burns recover, the opioid dose will need to be reduced in a fashion so as to avoid opioid<\/p><p>withdrawal.<\/p><p>Page 39 of 57<\/p>", "children": []}, {"id": 51, "page": 40, "top": 77.6, "level": 2, "font_size": 13.980000000000018, "text": "11. OTHER ANALGESIC MEDICATIONS", "content_html": "<p>11.1 Fentanyl Patches<\/p><p>These are used for patients with chronic or cancer pain, requiring high dosage Fentanyl,<\/p><p>that are opioid tolerant. There is marked inter-patient variability in blood concentrations<\/p><p>reached. The patch provides the background infusion and incident pain is managed by<\/p><p>alternative means, e.g. PCA or oral opioid.<\/p><p>Patches (12.5, 25, 50, 75, 100 mcg/hr)<\/p><p>Preparation:<\/p><p>If the patient is on a Fentanyl PCA, then the patch is selected by<\/p><p>Dose:<\/p><p>calculating the Fentanyl consumption per day and then calculating the<\/p><p>average hourly consumption \u2013 the patch selected should not exceed this<\/p><p>hourly consumption.<\/p><p>Eg, If patient is using 2000 mcg Fentanyl IV per day this equates to<\/p><p>average hourly use of 2000/ 24 = 83.3 mcg/ hr so charting 75 mcg/hr<\/p><p>patch would be reasonable.<\/p><p>Alternatively calculate the patients 24 hour oral morphine dose and<\/p><p>convert this to the appropriate Fentanyl patch dose using the table below<\/p><p>(from Medsafe data).<\/p><p>Oral 24-hour Morphine dose    Fentanyl patch dose<\/p><p>&lt;60 mg    12.5mcg/hour<\/p><p>60 \u2013 134 mg    25<\/p><p>135 \u2013 224 mg    50<\/p><p>225 \u2013 314 mg    75<\/p><p>315 \u2013 404 mg    100<\/p><p>If the patient is taking a medicine other than oral Morphine, then calculate the<\/p><p>total daily dose and multiply by the following conversion factors to get the<\/p><p>Morphine equivalent dose:<\/p><p>oral Oxycodone 2, intravenous Morphine 3,<\/p><p>intravenous Fentanyl 0.15<\/p><p>Eg, If patient is using 2000 mcg Fentanyl IV per day this equates to 2000<\/p><p>x 0.15 = 300 mg of oral 24-hour Morphine dose, so (from the table<\/p><p>above) charting a Fentanyl 75 mcg/hr patch would be reasonable.<\/p><p>Observations:<\/p><p>The risk of opioid over dose mandates that the patient remain on PCA/ NCA<\/p><p>monitoring. The signs of over dosage include sedation, slow weak respirations and<\/p><p>pin point pupils.<\/p><p>See Section 9 of the Handbook<\/p><p>Page 40 of 57<\/p><p>Note:<\/p><ul><li>\u2022<\/li><\/ul><p>A new patch is required every 72 hours. It is applied to different areas of hairless,<\/p><p>healthy and undamaged skin with thirty seconds of pressure. The onset time to full<\/p><p>effect is 12-24 hours.<\/p><p>As the requirement for incident pain intervention falls the<\/p><p>patch strength can be weaned.<\/p><ul><li>\u2022<\/li><\/ul><p>The opioid tolerant patient requires a weaning regime to avoid opioid withdrawal. Off<\/p><p>set time is 12-24 hours. Incident pain can be managed without delay following<\/p><p>stopping Fentanyl patches.<\/p><ul><li>\u2022<\/li><\/ul><p>Patients should not be discharged home on Fentanyl patches without discussion<\/p><p>with PAPs. On the rare occasion that a child is discharged home on Fentanyl<\/p><p>patches, then the care givers must be educated on the signs of Fentanyl overdose<\/p><p>and on the safe storage of the patches (out of reach of children, preferably in a<\/p><p>locked cupboard).<\/p><p>11.2 Gabapentin<\/p><p>Gabapentin is a relatively new anticonvulsant which acts mostly on the \u03b12\u03b4 subunit of the<\/p><p>Ca channel. It has also been shown to be useful in the management of pain.<\/p><ul><li>FDA approval for:<\/li><\/ul><p>Chronic pain<\/p><ul><li>\u2022<\/li><\/ul><p>Post herpetic neuralgia<\/p><ul><li>\u2022<\/li><\/ul><p>Diabetic neuropathy<\/p><ul><li>increased use in this setting as an adjunct, particularly in<\/li><\/ul><p>Perioperative acute pain<\/p><p>operations associated with a high incidence of chronic pain or with a significant<\/p><p>neuropathic component:<\/p><ul><li>\u2022<\/li><\/ul><p>Amputations<\/p><ul><li>\u2022<\/li><\/ul><p>Multilevel orthopaedic surgery<\/p><ul><li>\u2022<\/li><\/ul><p>Spinal surgery (scoliosis)<\/p><ul><li>\u2022<\/li><\/ul><p>Thoracotomy<\/p><ul><li>\u2022<\/li><\/ul><p>High anxiety and significant pain prior to surgery<\/p><p>Other painful conditions<\/p><ul><li>\u2022<\/li><\/ul><p>Burns<\/p><p>Side effects commonly include: sedation, tiredness, dizziness and ataxia.<\/p><p>Currently Gabapentin is not licensed for use in children, but several large centres are<\/p><p>using it for specific indications.<\/p><p>Capsules (100, 300, 400 and 600 mg)<\/p><p>Preparation:<\/p><p>Oral suspension<\/p><ul><li>Currently not available in NZ<\/li><li>Pharmacy can make up an oral suspension<\/li><\/ul><p>(ideally need half a day notice)<\/p><p>Page 41 of 57<\/p><p>(see indications above)<\/p><p>Dose:    Perioperative acute pain<\/p><ul><li>\u2022<\/li><\/ul><p>Dose:    5-10mg/kg PO TDS starting 2-12 hours preop<\/p><ul><li>\u2022<\/li><\/ul><p>Duration: 3-5 days or until pain settles<\/p><ul><li>\u2022<\/li><\/ul><p>Wean if &gt;1 week use \u2013 to avoid acute withdrawal<\/p><p>(children &gt;2 years old)<\/p><p>Chronic pain<\/p><ul><li>\u2022<\/li><\/ul><p>Day 1: 10mg/kg/day, as single dose    (max 300mg)<\/p><ul><li>\u2022<\/li><\/ul><p>Day 2: 20mg/kg/day, divided BD    (max 600mg/day)<\/p><ul><li>\u2022<\/li><\/ul><p>Day 3: 30mg/kg/day, divided dose TDS    (max 900mg/day)<\/p><ul><li>\u2022<\/li><\/ul><p>Maintenance: -reassess day 7<\/p><ul><li>titrate to clinical effect<\/li><\/ul><p>Important:<\/p><ul><li>\u2022<\/li><\/ul><p>Titrate to clinical effect (upto 40mg/kg/day in divided dose TDS)<\/p><ul><li>\u2022<\/li><\/ul><p>Recommended maximum 2400mg/day (note usual adult dose 900-3600mg/day)<\/p><ul><li>\u2022<\/li><\/ul><p>In outpatient setting titration is usually slower (every 3 days)<\/p><ul><li>\u2022<\/li><\/ul><p>Clinical benefit is usually seen after 1-2 weeks<\/p><ul><li>\u2022<\/li><\/ul><p>Reduce dose in renal dysfunction \u2013 monitor more carefully for side effects<\/p><ul><li>\u2022<\/li><\/ul><p>Side effects include: sleepiness, dizziness, confusion, dry mouth, ataxia, abnormal<\/p><p>gait and weight gain<\/p><ul><li>\u2022<\/li><\/ul><p>Wean slowly after prolonged use (&gt; 1 week use)<\/p><p>11.3 Amitriptyline<\/p><p>There are few published guidelines on drugs for paediatric neuropathic pain and few are<\/p><p>specifically licensed for paediatric use. Amitriptyline is a Tricylic Antidepressant with<\/p><p>membrane stabilising properties that has been used as one of the main pharmacological<\/p><p>treatments for paediatric neuropathic pain. It is not recommended for paediatric use in<\/p><p>Mims, and should be initially charted by a consultant. A Cochrane review in 2007<\/p><p>confirmed its efficacy in neuropathic pain states. While being best known as an<\/p><p>antidepressant it is charted in much lower doses for pain management. Amitriptyline can<\/p><p>have marked sedative properties even in low doses.<\/p><p>At Waikato hospital it is generally started in low doses at night to facilitate sleep and<\/p><p>minimise daytime sedation. A recent review by Medsafe and the Medicines Adverse<\/p><p>Reactions Committee on the safety of antidepressants suggests that all classes of<\/p><p>antidepressants appear to carry some degree of risk of QT prolongation and potentially<\/p><p>arrhythmia. Patients should be evaluated for the risk factors for QT prolongation before<\/p><p>starting Amitriptyline. An ECG should be considered at baseline, steady state, at the time<\/p><p>of dose increases, and if another QT prolonging medicine is added.<\/p><p>Tablet (10, 25, 50mg)<\/p><p>Preparation:<\/p><p>The starting dose is 0.2 mg/kg orally at night, but no more than 10mg.<\/p><p>Dose:<\/p><p>The onset of effect may take 3-5 days, and it is sensible to reassess<\/p><p>after one week. If necessary the dose may be titrated to effect by<\/p><p>increasing the dose by 0.2mg/kg and waiting 5 days. The dose may be<\/p><p>titrated to a maximum of 1mg/kg daily. Maximum dose 50mg (usual adult<\/p><p>dose 10-50mg).<\/p><p>Page 42 of 57<\/p><p>11.4 Diazepam<\/p><p>Diazepam may be useful for children troubled with postoperative muscle spasms following<\/p><p>multilevel orthopaedic surgery. This surgery involves tenotomies and osteotomies at<\/p><p>different levels on one or both limbs. Diazepam may be prescribed on a regular basis, but<\/p><p>its effect should be reviewed daily and doses adjusted as required. Caution should be<\/p><p>used when charting for children with global developmental delay and particularly children<\/p><p>with hypotonia, (these children may be more vulnerable to sedation and respiratory<\/p><p>compromise).<\/p><p>Syrup (10mg/10ml)<\/p><p>Preparation:<\/p><p>0.1mg/kg TDS<\/p><p>Dose:<\/p><p>11.5 Intranasal Fentanyl<\/p><p>Fentanyl is a short to medium duration opioid commonly used IV for treatment of acute<\/p><p>pain and useful for painful procedures of a short duration. Concerns with IV Fentanyl<\/p><p>outside of a specialist environment when given as a single large bolus include the<\/p><p>potential for respiratory depression and chest wall rigidity. Advantages of Fentanyl via the<\/p><p>nasal route include a slower onset of action, longer duration and the fact it does not<\/p><p>require IV access for administration. Limited studies to date have shown a good safety<\/p><p>profile when used in an appropriate dose. It provides similar analgesia to 0.1mg/kg<\/p><p>Morphine IV. Onset of effect is 5min and duration is greater than 30minutes.<\/p><p>Dose:<\/p><p>A suggested initial dose is 1.5mcg/kg. A second dose of 0.5mcg/kg can be given no<\/p><p>sooner than 10 minutes later. Maximum dose 100mcg.<\/p><p>Administration:<\/p><p>Calculate and draw up the dose (using Fentanyl 100mcg/2ml concentration)<\/p><p>Use 1ml Tuberculin syringe and MAD (Mucosal Atomiser Device)<\/p><p>Recline patient at 45 degrees. Hold the syringe horizontal and expel the contents into the<\/p><p>nostril as a fine mist in one rapid push. Consider dividing doses of more than 1ml between<\/p><p>both nostrils<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Page 43 of 57<\/p>", "children": [{"id": 52, "page": 40, "top": 129.3, "level": 3, "font_size": 13.980000000000018, "text": "11.1 Fentanyl Patches", "content_html": "<p>These are used for patients with chronic or cancer pain, requiring high dosage Fentanyl,<\/p><p>that are opioid tolerant. There is marked inter-patient variability in blood concentrations<\/p><p>reached. The patch provides the background infusion and incident pain is managed by<\/p><p>alternative means, e.g. PCA or oral opioid.<\/p><p>Patches (12.5, 25, 50, 75, 100 mcg/hr)<\/p><p>Preparation:<\/p><p>If the patient is on a Fentanyl PCA, then the patch is selected by<\/p><p>Dose:<\/p><p>calculating the Fentanyl consumption per day and then calculating the<\/p><p>average hourly consumption \u2013 the patch selected should not exceed this<\/p><p>hourly consumption.<\/p><p>Eg, If patient is using 2000 mcg Fentanyl IV per day this equates to<\/p><p>average hourly use of 2000/ 24 = 83.3 mcg/ hr so charting 75 mcg/hr<\/p><p>patch would be reasonable.<\/p><p>Alternatively calculate the patients 24 hour oral morphine dose and<\/p><p>convert this to the appropriate Fentanyl patch dose using the table below<\/p><p>(from Medsafe data).<\/p><p>Oral 24-hour Morphine dose    Fentanyl patch dose<\/p><p>&lt;60 mg    12.5mcg/hour<\/p><p>60 \u2013 134 mg    25<\/p><p>135 \u2013 224 mg    50<\/p><p>225 \u2013 314 mg    75<\/p><p>315 \u2013 404 mg    100<\/p><p>If the patient is taking a medicine other than oral Morphine, then calculate the<\/p><p>total daily dose and multiply by the following conversion factors to get the<\/p><p>Morphine equivalent dose:<\/p><p>oral Oxycodone 2, intravenous Morphine 3,<\/p><p>intravenous Fentanyl 0.15<\/p><p>Eg, If patient is using 2000 mcg Fentanyl IV per day this equates to 2000<\/p><p>x 0.15 = 300 mg of oral 24-hour Morphine dose, so (from the table<\/p><p>above) charting a Fentanyl 75 mcg/hr patch would be reasonable.<\/p><p>Observations:<\/p><p>The risk of opioid over dose mandates that the patient remain on PCA/ NCA<\/p><p>monitoring. The signs of over dosage include sedation, slow weak respirations and<\/p><p>pin point pupils.<\/p><p>See Section 9 of the Handbook<\/p><p>Page 40 of 57<\/p><p>Note:<\/p><ul><li>\u2022<\/li><\/ul><p>A new patch is required every 72 hours. It is applied to different areas of hairless,<\/p><p>healthy and undamaged skin with thirty seconds of pressure. The onset time to full<\/p><p>effect is 12-24 hours.<\/p><p>As the requirement for incident pain intervention falls the<\/p><p>patch strength can be weaned.<\/p><ul><li>\u2022<\/li><\/ul><p>The opioid tolerant patient requires a weaning regime to avoid opioid withdrawal. Off<\/p><p>set time is 12-24 hours. Incident pain can be managed without delay following<\/p><p>stopping Fentanyl patches.<\/p><ul><li>\u2022<\/li><\/ul><p>Patients should not be discharged home on Fentanyl patches without discussion<\/p><p>with PAPs. On the rare occasion that a child is discharged home on Fentanyl<\/p><p>patches, then the care givers must be educated on the signs of Fentanyl overdose<\/p><p>and on the safe storage of the patches (out of reach of children, preferably in a<\/p><p>locked cupboard).<\/p>", "children": []}, {"id": 53, "page": 41, "top": 283.2, "level": 3, "font_size": 13.980000000000018, "text": "11.2 Gabapentin", "content_html": "<p>Gabapentin is a relatively new anticonvulsant which acts mostly on the \u03b12\u03b4 subunit of the<\/p><p>Ca channel. It has also been shown to be useful in the management of pain.<\/p><ul><li>FDA approval for:<\/li><\/ul><p>Chronic pain<\/p><ul><li>\u2022<\/li><\/ul><p>Post herpetic neuralgia<\/p><ul><li>\u2022<\/li><\/ul><p>Diabetic neuropathy<\/p><ul><li>increased use in this setting as an adjunct, particularly in<\/li><\/ul><p>Perioperative acute pain<\/p><p>operations associated with a high incidence of chronic pain or with a significant<\/p><p>neuropathic component:<\/p><ul><li>\u2022<\/li><\/ul><p>Amputations<\/p><ul><li>\u2022<\/li><\/ul><p>Multilevel orthopaedic surgery<\/p><ul><li>\u2022<\/li><\/ul><p>Spinal surgery (scoliosis)<\/p><ul><li>\u2022<\/li><\/ul><p>Thoracotomy<\/p><ul><li>\u2022<\/li><\/ul><p>High anxiety and significant pain prior to surgery<\/p><p>Other painful conditions<\/p><ul><li>\u2022<\/li><\/ul><p>Burns<\/p><p>Side effects commonly include: sedation, tiredness, dizziness and ataxia.<\/p><p>Currently Gabapentin is not licensed for use in children, but several large centres are<\/p><p>using it for specific indications.<\/p><p>Capsules (100, 300, 400 and 600 mg)<\/p><p>Preparation:<\/p><p>Oral suspension<\/p><ul><li>Currently not available in NZ<\/li><li>Pharmacy can make up an oral suspension<\/li><\/ul><p>(ideally need half a day notice)<\/p><p>Page 41 of 57<\/p><p>(see indications above)<\/p><p>Dose:    Perioperative acute pain<\/p><ul><li>\u2022<\/li><\/ul><p>Dose:    5-10mg/kg PO TDS starting 2-12 hours preop<\/p><ul><li>\u2022<\/li><\/ul><p>Duration: 3-5 days or until pain settles<\/p><ul><li>\u2022<\/li><\/ul><p>Wean if &gt;1 week use \u2013 to avoid acute withdrawal<\/p><p>(children &gt;2 years old)<\/p><p>Chronic pain<\/p><ul><li>\u2022<\/li><\/ul><p>Day 1: 10mg/kg/day, as single dose    (max 300mg)<\/p><ul><li>\u2022<\/li><\/ul><p>Day 2: 20mg/kg/day, divided BD    (max 600mg/day)<\/p><ul><li>\u2022<\/li><\/ul><p>Day 3: 30mg/kg/day, divided dose TDS    (max 900mg/day)<\/p><ul><li>\u2022<\/li><\/ul><p>Maintenance: -reassess day 7<\/p><ul><li>titrate to clinical effect<\/li><\/ul><p>Important:<\/p><ul><li>\u2022<\/li><\/ul><p>Titrate to clinical effect (upto 40mg/kg/day in divided dose TDS)<\/p><ul><li>\u2022<\/li><\/ul><p>Recommended maximum 2400mg/day (note usual adult dose 900-3600mg/day)<\/p><ul><li>\u2022<\/li><\/ul><p>In outpatient setting titration is usually slower (every 3 days)<\/p><ul><li>\u2022<\/li><\/ul><p>Clinical benefit is usually seen after 1-2 weeks<\/p><ul><li>\u2022<\/li><\/ul><p>Reduce dose in renal dysfunction \u2013 monitor more carefully for side effects<\/p><ul><li>\u2022<\/li><\/ul><p>Side effects include: sleepiness, dizziness, confusion, dry mouth, ataxia, abnormal<\/p><p>gait and weight gain<\/p><ul><li>\u2022<\/li><\/ul><p>Wean slowly after prolonged use (&gt; 1 week use)<\/p>", "children": []}, {"id": 54, "page": 42, "top": 416.3, "level": 3, "font_size": 13.980000000000018, "text": "11.3 Amitriptyline", "content_html": "<p>There are few published guidelines on drugs for paediatric neuropathic pain and few are<\/p><p>specifically licensed for paediatric use. Amitriptyline is a Tricylic Antidepressant with<\/p><p>membrane stabilising properties that has been used as one of the main pharmacological<\/p><p>treatments for paediatric neuropathic pain. It is not recommended for paediatric use in<\/p><p>Mims, and should be initially charted by a consultant. A Cochrane review in 2007<\/p><p>confirmed its efficacy in neuropathic pain states. While being best known as an<\/p><p>antidepressant it is charted in much lower doses for pain management. Amitriptyline can<\/p><p>have marked sedative properties even in low doses.<\/p><p>At Waikato hospital it is generally started in low doses at night to facilitate sleep and<\/p><p>minimise daytime sedation. A recent review by Medsafe and the Medicines Adverse<\/p><p>Reactions Committee on the safety of antidepressants suggests that all classes of<\/p><p>antidepressants appear to carry some degree of risk of QT prolongation and potentially<\/p><p>arrhythmia. Patients should be evaluated for the risk factors for QT prolongation before<\/p><p>starting Amitriptyline. An ECG should be considered at baseline, steady state, at the time<\/p><p>of dose increases, and if another QT prolonging medicine is added.<\/p><p>Tablet (10, 25, 50mg)<\/p><p>Preparation:<\/p><p>The starting dose is 0.2 mg/kg orally at night, but no more than 10mg.<\/p><p>Dose:<\/p><p>The onset of effect may take 3-5 days, and it is sensible to reassess<\/p><p>after one week. If necessary the dose may be titrated to effect by<\/p><p>increasing the dose by 0.2mg/kg and waiting 5 days. The dose may be<\/p><p>titrated to a maximum of 1mg/kg daily. Maximum dose 50mg (usual adult<\/p><p>dose 10-50mg).<\/p><p>Page 42 of 57<\/p>", "children": []}, {"id": 55, "page": 43, "top": 94.9, "level": 3, "font_size": 13.980000000000018, "text": "11.4 Diazepam", "content_html": "<p>Diazepam may be useful for children troubled with postoperative muscle spasms following<\/p><p>multilevel orthopaedic surgery. This surgery involves tenotomies and osteotomies at<\/p><p>different levels on one or both limbs. Diazepam may be prescribed on a regular basis, but<\/p><p>its effect should be reviewed daily and doses adjusted as required. Caution should be<\/p><p>used when charting for children with global developmental delay and particularly children<\/p><p>with hypotonia, (these children may be more vulnerable to sedation and respiratory<\/p><p>compromise).<\/p><p>Syrup (10mg/10ml)<\/p><p>Preparation:<\/p><p>0.1mg/kg TDS<\/p><p>Dose:<\/p>", "children": []}, {"id": 56, "page": 43, "top": 316.8, "level": 3, "font_size": 13.980000000000018, "text": "11.5 Intranasal Fentanyl", "content_html": "<p>Fentanyl is a short to medium duration opioid commonly used IV for treatment of acute<\/p><p>pain and useful for painful procedures of a short duration. Concerns with IV Fentanyl<\/p><p>outside of a specialist environment when given as a single large bolus include the<\/p><p>potential for respiratory depression and chest wall rigidity. Advantages of Fentanyl via the<\/p><p>nasal route include a slower onset of action, longer duration and the fact it does not<\/p><p>require IV access for administration. Limited studies to date have shown a good safety<\/p><p>profile when used in an appropriate dose. It provides similar analgesia to 0.1mg/kg<\/p><p>Morphine IV. Onset of effect is 5min and duration is greater than 30minutes.<\/p><p>Dose:<\/p><p>A suggested initial dose is 1.5mcg/kg. A second dose of 0.5mcg/kg can be given no<\/p><p>sooner than 10 minutes later. Maximum dose 100mcg.<\/p><p>Administration:<\/p><p>Calculate and draw up the dose (using Fentanyl 100mcg/2ml concentration)<\/p><p>Use 1ml Tuberculin syringe and MAD (Mucosal Atomiser Device)<\/p><p>Recline patient at 45 degrees. Hold the syringe horizontal and expel the contents into the<\/p><p>nostril as a fine mist in one rapid push. Consider dividing doses of more than 1ml between<\/p><p>both nostrils<\/p><p>Observations:<\/p><p>See Section 9 of the Handbook.<\/p><p>Page 43 of 57<\/p>", "children": []}]}, {"id": 57, "page": 44, "top": 77.6, "level": 2, "font_size": 13.980000000000018, "text": "12. PREOPERATIVE MEDICATIONS", "content_html": "<p>12.1 Topical Local Anaesthetics<\/p><p>The insertion of intravenous cannulas, performance of lumbar punctures and<\/p><p>administration of IM injections are potentially very distressing procedures for children.<\/p><p>Some of the pain and distress may be reduced by using topical local anaesthetics. The<\/p><p>topical LA should be applied under an occlusive dressing and a secondary dressing such<\/p><p>as a bandage may help reduce dislodgement/ ingestion of the cream or occlusive<\/p><p>dressing.<\/p><p>Amethocaine gel (Ametop or Amgel)<\/p><p>4% Amethocaine gel is an ester type LA suitable for topical anaesthesia in infants and<\/p><p>children prior to painful procedures. Studies in children show a similar success rate for IV<\/p><p>cannulation with Amethocaine or EMLA but lower pain scores with Amethocaine. It<\/p><p>provides good topical anaesthesia in 30-45 minutes. Do not leave for longer than 60<\/p><p>minutes. Effective skin anaesthesia lasts 4-6 hrs after removal. Do not apply to broken<\/p><p>skin. No systemic side effects have been noted in children. Amethocaine tends to cause<\/p><p>erythema secondary to vasodilation. A small number of children may get a marked<\/p><p>erythema that resolves after removal.<\/p><p>EMLA cream<\/p><p>EMLA cream is a eutectic mixture of local anaesthetics. This is a mixture of 2.5%<\/p><p>Lignocaine and 2.5% Prilocaine.<\/p><p>It requires at least 60 minutes to provide topical<\/p><p>. We recommend caution in children less than 3 months of age because of<\/p><p>anaesthesia<\/p><p>the possibility of methaemoglobinaemia from the Prilocaine component. In infants use 2g<\/p><p>or less and do not leave in place for longer than 2 hours. It tends to cause blanching of the<\/p><p>skin secondary to vasoconstriction.<\/p><p>12.2 Premedications<\/p><p>Premedication with sedative drugs is often used in paediatric practice as one of the<\/p><p>modalities to reduce preoperative anxiety in children undergoing surgery. The same<\/p><p>medications may also be used for unpleasant ward procedures, as long as a few basic<\/p><p>safety measures are in place.<\/p><p>Non-pharmacological measures which may contribute to anxiolysis include tablet based<\/p><p>interactive distraction (TBID), video distraction, and performance of \u2018coping promoting<\/p><p>behaviour\u2019 by physicians and parents. These are beyond the scope of this guideline, but<\/p><p>some references are included at the end of this section.<\/p><p>Risk/ benefits:<\/p><p>The following are some conditions where a    assessment must be<\/p><p>careful risk/ benefit<\/p><p>made prior to prescribing a premed:<\/p><ul><li>\u2022<\/li><\/ul><p>Anticipated airway difficulty<\/p><ul><li>\u2022<\/li><\/ul><p>Increased risk of aspiration<\/p><ul><li>\u2022<\/li><\/ul><p>Respiratory/ cardiac/ hepatic/ renal impairment<\/p><p>Page 44 of 57<\/p><ul><li>\u2022<\/li><\/ul><p>Previous allergy/ adverse reaction to premedication<\/p><ul><li>\u2022<\/li><\/ul><p>Central/ obstructive sleep apnoea<\/p><ul><li>\u2022<\/li><\/ul><p>Acute systemic illness e.g. sepsis<\/p><p>Important:<\/p><p>If in any doubt, discuss your plan with the PAPS Specialist beforehand<\/p><p>o<\/p><p>Some children may only be safely sedated in a theatre environment due to<\/p><p>o<\/p><p>their comorbidities<\/p><p>Practical Considerations:<\/p><ul><li>\u2022<\/li><\/ul><p>Consider fasting status<\/p><ul><li>\u2022<\/li><\/ul><p>Obtain informed consent from the parent/ guardian<\/p><ul><li>\u2022<\/li><\/ul><p>Chart the premedication dose, route and time to be given<\/p><ul><li>\u2022<\/li><\/ul><p>Inform the nursing staff of the prescription<\/p><ul><li>\u2022<\/li><\/ul><p>Premeds may be mixed with a small volume of clear fluid if required e.g. apple juice,<\/p><p>or with cordial or paracetamol suspension<\/p><ul><li>\u2022<\/li><\/ul><p>Sedative drugs should be provided in a safe environment where resuscitation<\/p><p>equipment can be readily accessed<\/p><ul><li>\u2022<\/li><\/ul><p>A sedated child should be appropriately monitored at all times, including during<\/p><p>transfer from one clinical area to another<\/p><p>Tips:<\/p><p>Oral premeds:<\/p><p>Midazolam \u2013 has a quick and reliable onset and has been the most frequently used.<\/p><p>o<\/p><p>Its bitter taste may be masked by additives, but some children may not tolerate this<\/p><p>Clonidine \u2013 may be useful in these children but note increased onset time required<\/p><p>o<\/p><p>Intranasal premeds:<\/p><p>Should be administered with the MAD (mucosal atomiser) device<\/p><p>o<\/p><p>May be useful where children have refused oral medications<\/p><p>o<\/p><p>Beware the large dead space in the MAD device and requirement to deliver the<\/p><p>o<\/p><p>drug at 45 degrees to coat the turbinates<\/p><p>(and to a lesser extent Ketamine) \u2013 sore and<\/p><p>Midazolam    not recommended<\/p><p>o<\/p><ul><li>avoid in children with abnormal conduction systems/ on<\/li><\/ul><p>Dexmedetomidine<\/p><p>o<\/p><p>negative chronotropic agents<\/p><p>l \u2013 has a rapid onset, and wide interpatient variability, and should be given<\/p><p>Fentany<\/p><p>o<\/p><p>by medical personnel. A further dose of 1.5 mcg/kg may be given after 10 mins if<\/p><p>required<\/p><p>Combination regimens:<\/p><ul><li>\u2022<\/li><\/ul><p>May be of benefit \u2013 faster onset/ increased efficacy/ attenuation of side effects<\/p><ul><li>\u2022<\/li><\/ul><p>Dose reduction of one or both agents may be appropriate<\/p><ul><li>\u2022<\/li><li>they have<\/li><\/ul><p>Only after discussion and/ or supervision by the PAPS Specialist<\/p><p>a higher risk of over sedation<\/p><p>Page 45 of 57<\/p><table><tr><td>Drug<\/td><td>Route<\/td><td>Dose<\/td><td>Onset<\/td><td>Duration Notes<\/td><td>Comments<\/td><\/tr><\/table><p>(mins)    (hours)<\/p><table><tr><td>Midazolam<\/td><td>Oral<\/td><td>0.5-1 mg/kg<\/td><td>20-30<\/td><td>1-2<\/td><td>Bitter taste Paradoxical<\/td><\/tr><\/table><p>(max 15 mg)    reactions, esp in<\/p><p>children with<\/p><table><tr><td>Intranasal 0.2 mg/kg<\/td><td>10-15<\/td><td>1-2<\/td><td>Stings<\/td><\/tr><\/table><p>high impulsivity,<\/p><table><tr><td>Temazepam<\/td><td>Oral<\/td><td>10-30 mg<\/td><td>45-60<\/td><td>3<\/td><td>Tablet<\/td><\/tr><\/table><p>hiccups<\/p><p>(older children)<\/p><table><tr><td>Ketamine<\/td><td>Oral<\/td><td>5-10 mg/kg<\/td><td>10-20<\/td><td>3<\/td><td>Nystagmus,<\/td><\/tr><\/table><p>(&gt;2 yrs)    analgesia, N&amp;V,<\/p><table><tr><td>Intranasal 3-5 mg/kg<\/td><td>10-15<\/td><td>1-3<\/td><td>Stings<\/td><\/tr><\/table><p>salivation,<\/p><p>hallucinations<\/p><table><tr><td>Clonidine<\/td><td>Oral<\/td><td>4 mcg/kg<\/td><td>60-90<\/td><td>6<\/td><td>Tasteless<\/td><td>Mild<\/td><\/tr><\/table><p>bradycardia/<\/p><table><tr><td>Intranasal 2-4 mcg/kg<\/td><td>30-60<\/td><td>6<\/td><td>Painless<\/td><\/tr><\/table><p>hypotension,<\/p><p>analgesia,<\/p><table><tr><td>Dexmedetomidine<\/td><td>Intranasal 1-2 mcg/kg<\/td><td>Painless<\/td><\/tr><\/table><p>anxiolysis,<\/p><p>antiemesis<\/p><table><tr><td>Fentanyl<\/td><td>Intranasal 1.5 mcg/kg<\/td><td>2-5<\/td><td>0.5-1<\/td><td>Painless<\/td><td>Respiratory<\/td><\/tr><\/table><p>depression,<\/p><p>N&amp;V, pruritus<\/p><p>Page 46 of 57<\/p>", "children": [{"id": 58, "page": 44, "top": 129.3, "level": 3, "font_size": 13.980000000000018, "text": "12.1 Topical Local Anaesthetics", "content_html": "<p>The insertion of intravenous cannulas, performance of lumbar punctures and<\/p><p>administration of IM injections are potentially very distressing procedures for children.<\/p><p>Some of the pain and distress may be reduced by using topical local anaesthetics. The<\/p><p>topical LA should be applied under an occlusive dressing and a secondary dressing such<\/p><p>as a bandage may help reduce dislodgement/ ingestion of the cream or occlusive<\/p><p>dressing.<\/p><p>Amethocaine gel (Ametop or Amgel)<\/p><p>4% Amethocaine gel is an ester type LA suitable for topical anaesthesia in infants and<\/p><p>children prior to painful procedures. Studies in children show a similar success rate for IV<\/p><p>cannulation with Amethocaine or EMLA but lower pain scores with Amethocaine. It<\/p><p>provides good topical anaesthesia in 30-45 minutes. Do not leave for longer than 60<\/p><p>minutes. Effective skin anaesthesia lasts 4-6 hrs after removal. Do not apply to broken<\/p><p>skin. No systemic side effects have been noted in children. Amethocaine tends to cause<\/p><p>erythema secondary to vasodilation. A small number of children may get a marked<\/p><p>erythema that resolves after removal.<\/p><p>EMLA cream<\/p><p>EMLA cream is a eutectic mixture of local anaesthetics. This is a mixture of 2.5%<\/p><p>Lignocaine and 2.5% Prilocaine.<\/p><p>It requires at least 60 minutes to provide topical<\/p><p>. We recommend caution in children less than 3 months of age because of<\/p><p>anaesthesia<\/p><p>the possibility of methaemoglobinaemia from the Prilocaine component. In infants use 2g<\/p><p>or less and do not leave in place for longer than 2 hours. It tends to cause blanching of the<\/p><p>skin secondary to vasoconstriction.<\/p>", "children": []}, {"id": 59, "page": 44, "top": 515.7, "level": 3, "font_size": 13.980000000000018, "text": "12.2 Premedications", "content_html": "<p>Premedication with sedative drugs is often used in paediatric practice as one of the<\/p><p>modalities to reduce preoperative anxiety in children undergoing surgery. The same<\/p><p>medications may also be used for unpleasant ward procedures, as long as a few basic<\/p><p>safety measures are in place.<\/p><p>Non-pharmacological measures which may contribute to anxiolysis include tablet based<\/p><p>interactive distraction (TBID), video distraction, and performance of \u2018coping promoting<\/p><p>behaviour\u2019 by physicians and parents. These are beyond the scope of this guideline, but<\/p><p>some references are included at the end of this section.<\/p><p>Risk/ benefits:<\/p><p>The following are some conditions where a    assessment must be<\/p><p>careful risk/ benefit<\/p><p>made prior to prescribing a premed:<\/p><ul><li>\u2022<\/li><\/ul><p>Anticipated airway difficulty<\/p><ul><li>\u2022<\/li><\/ul><p>Increased risk of aspiration<\/p><ul><li>\u2022<\/li><\/ul><p>Respiratory/ cardiac/ hepatic/ renal impairment<\/p><p>Page 44 of 57<\/p><ul><li>\u2022<\/li><\/ul><p>Previous allergy/ adverse reaction to premedication<\/p><ul><li>\u2022<\/li><\/ul><p>Central/ obstructive sleep apnoea<\/p><ul><li>\u2022<\/li><\/ul><p>Acute systemic illness e.g. sepsis<\/p><p>Important:<\/p><p>If in any doubt, discuss your plan with the PAPS Specialist beforehand<\/p><p>o<\/p><p>Some children may only be safely sedated in a theatre environment due to<\/p><p>o<\/p><p>their comorbidities<\/p><p>Practical Considerations:<\/p><ul><li>\u2022<\/li><\/ul><p>Consider fasting status<\/p><ul><li>\u2022<\/li><\/ul><p>Obtain informed consent from the parent/ guardian<\/p><ul><li>\u2022<\/li><\/ul><p>Chart the premedication dose, route and time to be given<\/p><ul><li>\u2022<\/li><\/ul><p>Inform the nursing staff of the prescription<\/p><ul><li>\u2022<\/li><\/ul><p>Premeds may be mixed with a small volume of clear fluid if required e.g. apple juice,<\/p><p>or with cordial or paracetamol suspension<\/p><ul><li>\u2022<\/li><\/ul><p>Sedative drugs should be provided in a safe environment where resuscitation<\/p><p>equipment can be readily accessed<\/p><ul><li>\u2022<\/li><\/ul><p>A sedated child should be appropriately monitored at all times, including during<\/p><p>transfer from one clinical area to another<\/p><p>Tips:<\/p><p>Oral premeds:<\/p><p>Midazolam \u2013 has a quick and reliable onset and has been the most frequently used.<\/p><p>o<\/p><p>Its bitter taste may be masked by additives, but some children may not tolerate this<\/p><p>Clonidine \u2013 may be useful in these children but note increased onset time required<\/p><p>o<\/p><p>Intranasal premeds:<\/p><p>Should be administered with the MAD (mucosal atomiser) device<\/p><p>o<\/p><p>May be useful where children have refused oral medications<\/p><p>o<\/p><p>Beware the large dead space in the MAD device and requirement to deliver the<\/p><p>o<\/p><p>drug at 45 degrees to coat the turbinates<\/p><p>(and to a lesser extent Ketamine) \u2013 sore and<\/p><p>Midazolam    not recommended<\/p><p>o<\/p><ul><li>avoid in children with abnormal conduction systems/ on<\/li><\/ul><p>Dexmedetomidine<\/p><p>o<\/p><p>negative chronotropic agents<\/p><p>l \u2013 has a rapid onset, and wide interpatient variability, and should be given<\/p><p>Fentany<\/p><p>o<\/p><p>by medical personnel. A further dose of 1.5 mcg/kg may be given after 10 mins if<\/p><p>required<\/p><p>Combination regimens:<\/p><ul><li>\u2022<\/li><\/ul><p>May be of benefit \u2013 faster onset/ increased efficacy/ attenuation of side effects<\/p><ul><li>\u2022<\/li><\/ul><p>Dose reduction of one or both agents may be appropriate<\/p><ul><li>\u2022<\/li><li>they have<\/li><\/ul><p>Only after discussion and/ or supervision by the PAPS Specialist<\/p><p>a higher risk of over sedation<\/p><p>Page 45 of 57<\/p><table><tr><td>Drug<\/td><td>Route<\/td><td>Dose<\/td><td>Onset<\/td><td>Duration Notes<\/td><td>Comments<\/td><\/tr><\/table><p>(mins)    (hours)<\/p><table><tr><td>Midazolam<\/td><td>Oral<\/td><td>0.5-1 mg/kg<\/td><td>20-30<\/td><td>1-2<\/td><td>Bitter taste Paradoxical<\/td><\/tr><\/table><p>(max 15 mg)    reactions, esp in<\/p><p>children with<\/p><table><tr><td>Intranasal 0.2 mg/kg<\/td><td>10-15<\/td><td>1-2<\/td><td>Stings<\/td><\/tr><\/table><p>high impulsivity,<\/p><table><tr><td>Temazepam<\/td><td>Oral<\/td><td>10-30 mg<\/td><td>45-60<\/td><td>3<\/td><td>Tablet<\/td><\/tr><\/table><p>hiccups<\/p><p>(older children)<\/p><table><tr><td>Ketamine<\/td><td>Oral<\/td><td>5-10 mg/kg<\/td><td>10-20<\/td><td>3<\/td><td>Nystagmus,<\/td><\/tr><\/table><p>(&gt;2 yrs)    analgesia, N&amp;V,<\/p><table><tr><td>Intranasal 3-5 mg/kg<\/td><td>10-15<\/td><td>1-3<\/td><td>Stings<\/td><\/tr><\/table><p>salivation,<\/p><p>hallucinations<\/p><table><tr><td>Clonidine<\/td><td>Oral<\/td><td>4 mcg/kg<\/td><td>60-90<\/td><td>6<\/td><td>Tasteless<\/td><td>Mild<\/td><\/tr><\/table><p>bradycardia/<\/p><table><tr><td>Intranasal 2-4 mcg/kg<\/td><td>30-60<\/td><td>6<\/td><td>Painless<\/td><\/tr><\/table><p>hypotension,<\/p><p>analgesia,<\/p><table><tr><td>Dexmedetomidine<\/td><td>Intranasal 1-2 mcg/kg<\/td><td>Painless<\/td><\/tr><\/table><p>anxiolysis,<\/p><p>antiemesis<\/p><table><tr><td>Fentanyl<\/td><td>Intranasal 1.5 mcg/kg<\/td><td>2-5<\/td><td>0.5-1<\/td><td>Painless<\/td><td>Respiratory<\/td><\/tr><\/table><p>depression,<\/p><p>N&amp;V, pruritus<\/p><p>Page 46 of 57<\/p>", "children": []}]}, {"id": 60, "page": 47, "top": 77.6, "level": 2, "font_size": 13.980000000000018, "text": "13. MANAGING PAIN FOLLOWING TONSILLECTOMY", "content_html": "<p>Analgesic options following tonsillectomy include:<\/p><ul><li>\u2022<\/li><\/ul><p>Simple analgesics<\/p><ul><li>\u2022<\/li><\/ul><p>Opioids<\/p><ul><li>\u2022<\/li><\/ul><p>Tramadol<\/p><p>Simple analgesics:<\/p><p>Unless contraindicated all children should have regular:<\/p><ul><li>\u2022<\/li><\/ul><p>Paracetamol 15-20mg/kg QID (maximum    )<\/p><p>75mg/kg/day<\/p><ul><li>\u2022<\/li><\/ul><p>Ibuprofen 5-10mg/kg QID (maximum 40mg/kg/day, max dose 1600mg/day)<\/p><p>Opioids:<\/p><p>For those monitored in hospital consider:<\/p><ul><li>\u2022<\/li><\/ul><p>Morphine 0.2mg/kg orally 2hrly PRN<\/p><ul><li>\u2022<\/li><\/ul><p>Oxycodone 0.05-0.1mg/kg orally 3hrly PRN<\/p><p>Note:<\/p><p>Should<\/p><p>never be used regularly<\/p><p>o<\/p><p>Children with OSA:<\/p><p>o<\/p><p>\uf0a7<\/p><p>Use with    and in a reduced dose<\/p><p>extreme caution<\/p><p>\uf0a7<\/p><p>Have been shown to have 1/3-1/2 the opioid requirements as children without<\/p><p>OSA and a much higher rate of post-operative adverse respiratory events<\/p><p>\uf0a7<\/p><p>Should be monitored overnight in hospital to assess response and sensitivity<\/p><p>to opioids<\/p><p>Tramadol:<\/p><p>Alternative analgesia includes tramadol.<\/p><ul><li>\u2022<\/li><\/ul><p>Initial dose:    Tramadol 0.5mg/kg 6-8hrly<\/p><ul><li>\u2022<\/li><\/ul><p>Maximum:    Tramadol 1mg/kg 6-8hrly (maximum of 400mg/day)<\/p><p>Note:<\/p><p>Associated with less respiratory depression but not confirmed to be safer than<\/p><p>o<\/p><p>morphine after tonsillectomy<\/p><p>Will have an incidence of nausea<\/p><p>o<\/p><p>Recent FDA concerns with the use of Tramadol in children have been largely<\/p><p>o<\/p><p>refuted by SPANZA but as with all potent analgesics a risk benefit analysis should<\/p><p>always be evaluated for individual patients before use. SPANZA<\/p><p>Recommendations:<\/p><p>\uf0a7<\/p><p>Children with OSA should be monitored overnight in hospital to assess<\/p><p>response and sensitivity to Tramadol<\/p><p>\uf0a7<\/p><p>Tramadol dose should be reduced following tonsillectomy<\/p><p>SPANZA Advisory on Tramadol - Warning on tramadol use in children<\/p><p>Page 47 of 57<\/p><p>General comments:<\/p><p>For further information and precautions on use of the above drugs see Section 3 of the<\/p><p>Handbook.<\/p><p>Page 48 of 57<\/p>", "children": [{"id": 61, "page": 47, "top": 594.9, "level": 3, "font_size": 12.0, "text": "Note:", "content_html": "<p>Associated with less respiratory depression but not confirmed to be safer than<\/p><p>o<\/p><p>morphine after tonsillectomy<\/p><p>Will have an incidence of nausea<\/p><p>o<\/p><p>Recent FDA concerns with the use of Tramadol in children have been largely<\/p><p>o<\/p><p>refuted by SPANZA but as with all potent analgesics a risk benefit analysis should<\/p><p>always be evaluated for individual patients before use. SPANZA<\/p><p>Recommendations:<\/p><p>\uf0a7<\/p><p>Children with OSA should be monitored overnight in hospital to assess<\/p><p>response and sensitivity to Tramadol<\/p><p>\uf0a7<\/p><p>Tramadol dose should be reduced following tonsillectomy<\/p><p>SPANZA Advisory on Tramadol - Warning on tramadol use in children<\/p><p>Page 47 of 57<\/p><p>General comments:<\/p><p>For further information and precautions on use of the above drugs see Section 3 of the<\/p><p>Handbook.<\/p><p>Page 48 of 57<\/p>", "children": []}]}, {"id": 62, "page": 49, "top": 77.6, "level": 2, "font_size": 13.980000000000018, "text": "14. MANAGING PAIN FOLLOWING SCOLIOSIS SURGERY", "content_html": "<p>Multi-level spinal surgery is major surgery and is associated with significant postoperative<\/p><p>pain, including the potential for neuropathic pain. Patients may have varying levels of pre-<\/p><p>operative pain. Presently, at Waikato Hospital, we are performing posterior spinal fusion<\/p><p>on patients with idiopathic adolescent scoliosis and, as a general rule, are not including<\/p><p>patients with neuromuscular co-morbidities.<\/p><p>14.1 Intraoperative Analgesia<\/p><p>These children usually receive the following analgesia:<\/p><ul><li>\u2022<\/li><\/ul><p>Intrathecal morphine (ITM)    intravenous methadone<\/p><p>or<\/p><ul><li>\u2022<\/li><\/ul><p>Morphine IV (low dose)<\/p><ul><li>\u2022<\/li><\/ul><p>Parecoxib IV<\/p><ul><li>\u2022<\/li><\/ul><p>Paracetamol IV<\/p><ul><li>\u2022<\/li><\/ul><p>Ketamine IV infusion<\/p><p>14.2 Postoperative Analgesia<\/p><p>Routine:<\/p><ul><li>\u2022<\/li><\/ul><p>Paracetamol 15mg/kg PO/ IV 4 hourly (If given IV max 4 doses in a 24 hour period)<\/p><ul><li>\u2022<\/li><\/ul><p>Ibuprofen 10mg/kg (max 400mg) PO 8 hourly<\/p><ul><li>\u2022<\/li><\/ul><p>Morphine PCA<\/p><p>Note if intraoperative intrathecal morphine used then:<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>First 24 hours low dose PCA and no basal<\/p><ul><li>\u2022<\/li><\/ul><p>Increase parameters to normal levels after 24 hours<\/p><p>Adjuvants:<\/p><ul><li>\u2022<\/li><\/ul><p>Gabapentin 5mg/kg PO TDS x 5 days<\/p><p>The first dose may be given as part of the premedication<\/p><p>o<\/p><p>Usually prescribed for 5 days<\/p><p>o<\/p><p>Watch out for excessive sedation or dizziness<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Parecoxib 1mg/kg IV daily (max 40mg)<\/p><p>Can be given instead of Ibuprofen for the first day or two, especially if patient<\/p><p>o<\/p><p>reluctant to take orally<\/p><ul><li>\u2022<\/li><\/ul><p>Tramadol 1-2mg/kg PO/IV 4 hourly prn<\/p><p>Note recent FDA concerns regarding charting in paediatric patients under 12<\/p><p>o<\/p><p>years and any patients under 18 years with respiratory problems, sleep<\/p><p>disordered breathing or obesity (See Section 3.5 of the Handbook)<\/p><p>Lowers seizure threshold, and can cause significant nausea and vomiting<\/p><p>o<\/p><p>Other adjuvant analgesics to consider:<\/p><ul><li>\u2022<\/li><\/ul><p>Clonidine 1-2 mcg/kg IV/ PO 8hourly prn<\/p><p>Useful as an anxiolytic and analgesic<\/p><p>o<\/p><p>Sedating but generally not a respiratory depressant<\/p><p>o<\/p><p>Can cause a drop in blood pressure and heart rate<\/p><p>o<\/p><p>Page 49 of 57<\/p><ul><li>\u2022<\/li><\/ul><p>Amitriptyline starting at 0.2 mg/kg (max 10mg) PO at night<\/p><p>If struggling to sleep and with significant pain<\/p><p>o<\/p><p>Patients should be evaluated for the risk factors for QT prolongation before<\/p><p>o<\/p><p>starting Amitriptyline. An ECG should be considered at baseline, steady state, at<\/p><p>the time of dose increases and if another QT prolonging medicine is added<\/p><ul><li>\u2022<\/li><\/ul><p>Diazepam<\/p><p>0.1mg/kg PO/IV 8 hourly prn<\/p><p>o<\/p><p>Useful for muscle spasms which may be present<\/p><p>o<\/p><p>Anxiolytic<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Ketamine infusion<\/p><p>0-4 mcg/kg/min \u2013 for 24-48 hours postoperatively<\/p><p>o<\/p><p>General comments:<\/p><p>Care needs to be taken with the multimodal nature of analgesia often used in this setting.<\/p><p>Patients do vary in their response, but over-sedation and dizziness can potentially delay<\/p><p>mobilization.<\/p><p>Page 50 of 57<\/p>", "children": [{"id": 63, "page": 49, "top": 219.0, "level": 3, "font_size": 13.980000000000018, "text": "14.1 Intraoperative Analgesia", "content_html": "<p>These children usually receive the following analgesia:<\/p><ul><li>\u2022<\/li><\/ul><p>Intrathecal morphine (ITM)    intravenous methadone<\/p><p>or<\/p><ul><li>\u2022<\/li><\/ul><p>Morphine IV (low dose)<\/p><ul><li>\u2022<\/li><\/ul><p>Parecoxib IV<\/p><ul><li>\u2022<\/li><\/ul><p>Paracetamol IV<\/p><ul><li>\u2022<\/li><\/ul><p>Ketamine IV infusion<\/p>", "children": []}, {"id": 64, "page": 49, "top": 365.3, "level": 3, "font_size": 13.980000000000018, "text": "14.2 Postoperative Analgesia", "content_html": "<p>Routine:<\/p><ul><li>\u2022<\/li><\/ul><p>Paracetamol 15mg/kg PO/ IV 4 hourly (If given IV max 4 doses in a 24 hour period)<\/p><ul><li>\u2022<\/li><\/ul><p>Ibuprofen 10mg/kg (max 400mg) PO 8 hourly<\/p><ul><li>\u2022<\/li><\/ul><p>Morphine PCA<\/p><p>Note if intraoperative intrathecal morphine used then:<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>First 24 hours low dose PCA and no basal<\/p><ul><li>\u2022<\/li><\/ul><p>Increase parameters to normal levels after 24 hours<\/p><p>Adjuvants:<\/p><ul><li>\u2022<\/li><\/ul><p>Gabapentin 5mg/kg PO TDS x 5 days<\/p><p>The first dose may be given as part of the premedication<\/p><p>o<\/p><p>Usually prescribed for 5 days<\/p><p>o<\/p><p>Watch out for excessive sedation or dizziness<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Parecoxib 1mg/kg IV daily (max 40mg)<\/p><p>Can be given instead of Ibuprofen for the first day or two, especially if patient<\/p><p>o<\/p><p>reluctant to take orally<\/p><ul><li>\u2022<\/li><\/ul><p>Tramadol 1-2mg/kg PO/IV 4 hourly prn<\/p><p>Note recent FDA concerns regarding charting in paediatric patients under 12<\/p><p>o<\/p><p>years and any patients under 18 years with respiratory problems, sleep<\/p><p>disordered breathing or obesity (See Section 3.5 of the Handbook)<\/p><p>Lowers seizure threshold, and can cause significant nausea and vomiting<\/p><p>o<\/p><p>Other adjuvant analgesics to consider:<\/p><ul><li>\u2022<\/li><\/ul><p>Clonidine 1-2 mcg/kg IV/ PO 8hourly prn<\/p><p>Useful as an anxiolytic and analgesic<\/p><p>o<\/p><p>Sedating but generally not a respiratory depressant<\/p><p>o<\/p><p>Can cause a drop in blood pressure and heart rate<\/p><p>o<\/p><p>Page 49 of 57<\/p><ul><li>\u2022<\/li><\/ul><p>Amitriptyline starting at 0.2 mg/kg (max 10mg) PO at night<\/p><p>If struggling to sleep and with significant pain<\/p><p>o<\/p><p>Patients should be evaluated for the risk factors for QT prolongation before<\/p><p>o<\/p><p>starting Amitriptyline. An ECG should be considered at baseline, steady state, at<\/p><p>the time of dose increases and if another QT prolonging medicine is added<\/p><ul><li>\u2022<\/li><\/ul><p>Diazepam<\/p><p>0.1mg/kg PO/IV 8 hourly prn<\/p><p>o<\/p><p>Useful for muscle spasms which may be present<\/p><p>o<\/p><p>Anxiolytic<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Ketamine infusion<\/p><p>0-4 mcg/kg/min \u2013 for 24-48 hours postoperatively<\/p><p>o<\/p><p>General comments:<\/p><p>Care needs to be taken with the multimodal nature of analgesia often used in this setting.<\/p><p>Patients do vary in their response, but over-sedation and dizziness can potentially delay<\/p><p>mobilization.<\/p><p>Page 50 of 57<\/p>", "children": []}]}, {"id": 65, "page": 51, "top": 77.6, "level": 2, "font_size": 13.980000000000018, "text": "15. INITIAL TREATMENT OF CHRONIC PAIN IN CHILDREN", "content_html": "<p>A useful definition of chronic pain is \u201cpain that extends beyond the expected time of<\/p><p>healing\u201d and \u201chence lacks the acute warning function of physiological nociception\u201d.<\/p><p>Mechanisms of pain include acute nociceptive pain (i.e., pain arising from the activation of<\/p><p>peripheral nerve endings), neuropathic pain (i.e., resulting from injury to, or dysfunction of,<\/p><p>the somatosensory system), and psycho-social-spiritual-emotional pain. Chronic pain<\/p><p>commonly involves a combination of these mechanisms.<\/p><p>15.1 Types of Chronic Pain in Children<\/p><p>(formerly functional pain syndrome)<\/p><p>Primary pain disorders:<\/p><p>Many different chronic pain syndromes are now considered to be manifestations of an<\/p><p>underlying pain vulnerability or pain spectrum condition, rather than being viewed as<\/p><p>separate disorders. Considerable evidence, points to a role of shared biological sensitivity,<\/p><p>or \u201cpain vulnerability\u201d.<\/p><p>Important features:<\/p><ul><li>\u2022<\/li><\/ul><p>Pain not explained in terms of conventional medical disease<\/p><p>(biochemical or structural abnormalities)<\/p><ul><li>\u2022<\/li><\/ul><p>Significant disruption of everyday life (often leads to incapacitation)<\/p><ul><li>\u2022<\/li><\/ul><p>Unimodal medical therapy typically unsuccessful<\/p><ul><li>\u2022<\/li><\/ul><p>Unimodal medical therapy can consume significant time, resources and finances<\/p><ul><li>\u2022<\/li><\/ul><p>Persistent treatment failures can lead to negative implications eg<\/p><ul><li>patients perceiving their pain is not organic and therefore not real/ serious<\/li><li>stigmatization (i.e. symptoms characterized as fictitious or malingering)<\/li><\/ul><p>The three most common primary pain disorders in paediatrics are:<\/p><ul><li>\u2022<\/li><\/ul><p>Primary headaches: tension headaches and migraines<\/p><ul><li>\u2022<\/li><\/ul><p>Centrally mediated central abdominal pain syndrome<\/p><ul><li>\u2022<\/li><\/ul><p>Musculoskeletal and joint pain<\/p><p>Chronic-on-acute pain<\/p><p>A significant number of children with recurrent nociceptive pain caused by underlying<\/p><p>organic disease (eg, inflammatory bowel disease, sickle cell disease, rheumatoid arthritis<\/p><p>or cancer), may develop pain which becomes complicated to treat, and have what is<\/p><p>known as \u201cchronic-on-acute\u201d disease. In these children primary pain disorders may also<\/p><p>co-exist, or even be triggered by the underlying organic disease, and pain symptoms do<\/p><p>not necessarily represent inadequate treatment, flare-up, or recurrence.<\/p><p>15.2 Management<\/p><p>Many children with chronic pain will benefit from an interdisciplinary rehabilitative pain<\/p><p>program. This requires appropriate resources including: pain specialists and nurses,<\/p><p>psychologists, physiotherapists and occupational therapists and social workers. A lot of<\/p><p>Page 51 of 57<\/p><p>the focus is on restoring function and as this is achieved the pain improves and commonly<\/p><p>resolves \u2013 this may be summarized as \u201clife gets back to normal\u201d and then \u201cthe pain gets<\/p><p>better\u201d. To achieve this an interdisciplinary approach is required which involves a<\/p><p>combination of: (1) physical therapy (eg, range of movement, strength, balance, graded<\/p><p>motor imagery exercises); (2) integrative medicine/active mind-body techniques (eg, self-<\/p><p>relaxation, self-regulation, distraction, guided imagery exercises); (3) psychology (coping<\/p><p>strategies, targeting anxiety and depression); and (4) normalizing daily routine (school<\/p><p>attendance, sports, social life and sleep). Determining which children will benefit from an<\/p><p>interdisciplinary approach will require input from the Chronic Pain Team.<\/p><p>15.2.1 Referal to the Pain Service<\/p><p>If the Home Team decide they would like to refer a child with chronic pain to the Pain<\/p><p>Service then the following basic principles should be adhered to:<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure the child has been reviewed by the admitting Consultant<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure the team have excluded reversible and treatable conditions<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure a written referral documenting relevant imaging and bloods (including a<\/p><p>recent CBC and CRP)<\/p><ul><li>\u2022<\/li><\/ul><p>Over investigation can also be harmful and deflect from confronting the real issues<\/p><ul><li>\u2022<\/li><\/ul><p>Take a thorough pain history including psychological issues<\/p><ul><li>\u2022<\/li><\/ul><p>Use available non-pharmacological treatments<\/p><p>15.2.2 Initial approach and non-drug treatments<\/p><p>It may be useful to start to explain to the child and family the concepts that the pain \u201cis<\/p><p>real\u201d but it \u201chas lost its warning function\u201d and that using the affected part of the body<\/p><p>does not result in greater harm. It is also helpful that the child and family begin to<\/p><p>understand that working towards \u201clife gets back to normal\u201d is important and that this<\/p><p>results in \u201cthe pain gets better\u201d.<\/p><p>At some point it can be helpful discussing pain transmission and how this can be<\/p><p>influenced by down-modulation (which results in decreased pain) or up-modulation<\/p><p>(which results in increased pain). This can help explaining that the pain is real and how<\/p><p>the interdisciplinary (\u201cnon-drug\u201d) treatment modalities work. Down-modulation can be<\/p><p>described as \u201cOFF-switch\u201d modulation which involves descending inhibition from the<\/p><p>\u201ccontrol center\u201d (the peri-aquaductal grey matter). \u201cOFF-switch\u201d modulation (decreases<\/p><p>pain) is triggered by 1) physical therapy/ exercise, and 2) integrative medicine/<\/p><p>distraction. Up-modulation can be described as \u201cON-switch\u201d modulation (increases<\/p><p>pain) which involves activation in the front of the brain (the prefrontal cortex). \u201cON-<\/p><p>switch\u201d modulation is triggered by stress, pessimism, anxiety/ depression, insomnia,<\/p><p>and absenteeism (missing school/ sports/ and social contact). \u201cON-switch\u201d modulation<\/p><p>may be reduced by 1) psychological support, and 2) normalizing the activities of daily<\/p><p>life.<\/p><p>It is also helpful to understand how fear and catastrophizing can affect pain. Both<\/p><p>exacerbate the experience of pain, and both can be experienced by the child and the<\/p><p>parents. Catastrophizing involves cognitive and emotional processes which include<\/p><p>magnification, rumination, pessimism, and feelings of helplessness. Reducing fear of<\/p><p>pain in children is important and is associated with positive functional outcomes in<\/p><p>children with primary pain disorders. It has also been shown that parental<\/p><p>catastrophizing and expectations strongly influence children\u2019s pain memory.<\/p><p>Page 52 of 57<\/p><p>So even before the Chronic Pain Service has been involved, basic non-drug treatment<\/p><p>strategies can be initiated:<\/p><ul><li>\u2022<\/li><\/ul><p>Reassure \u2013 the pain is real, using the affected part of the body will not result in<\/p><p>greater harm<\/p><ul><li>\u2022<\/li><\/ul><p>Explain \u2013 the pain has lost its warning function<\/p><ul><li>\u2022<\/li><\/ul><p>Explain \u2013 the pain can be modulated up and down<\/p><ul><li>\u2022<\/li><\/ul><p>Explain \u2013 working towards \u201clife gets back to normal\u201d is really important and results<\/p><p>in \u201cthe pain gets better\u201d<\/p><ul><li>\u2022<\/li><\/ul><p>Initiate some basic interdisciplinary rehabilitation strategies \u2013 normalizing daily<\/p><p>routine (showering, dressing, eating) and regular sleep<\/p><p>Self-relaxation<\/p><p>o<\/p><p>Distraction<\/p><p>o<\/p><p>Targeting anxiety/ catastrophizing<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Involve ward physiotherapist and play therapist<\/p><p>Online resources (for children/ families and staff):<\/p><ul><li>\u2022<\/li><\/ul><p>The    website in Australia and has some very<\/p><p>\u201cACI Pain Management Network\u201d<\/p><p>useful resources<\/p><p>Follow the link: Chronic pain resources for children and families<\/p><p>o<\/p><p>Then see \u201cFor Youth: PainBytes\u201d for some very helpful episodes<\/p><p>o<\/p><p>Provides information and education to help children/ families begin to<\/p><p>o<\/p><p>understand what is going on in the nervous system, and how to begin to<\/p><p>better manage the pain<\/p><p>15.2.3 Drugs<\/p><p>In the short term, before review by Chronic Pain Service, some pharmacological<\/p><p>treatments may have a role, however evidence of strong efficacy is lacking for any<\/p><p>agents.<\/p><ul><li>Have been shown in many studies to be as efficacious as<\/li><\/ul><p>Paracetamol and NSAIDS<\/p><p>more \u201cpotent\u201d analgesics for reducing pain scores despite not being pursued as much<\/p><p>by patients. They have the advantage of a good side effect profile and not exacerbating<\/p><p>chronic pain states.<\/p><ul><li>Has a very idiosyncratic profile and may be very effective for some<\/li><\/ul><p>Tramadol<\/p><p>patients. It is often worth trialling.<\/p><ul><li>Have little role in primary pain disorders, i.e. those not related to tissue<\/li><\/ul><p>Opioids<\/p><p>damage. However, they are effective in persistent pain conditions with nociceptive pain<\/p><p>caused by tissue damage.<\/p><p>Key points:<\/p><ul><li>\u2022<\/li><\/ul><p>Opioids administered for primary pain disorders have low long long-term efficacy, a<\/p><p>poor safety profile, and commonly a worse clinical outcome<\/p><ul><li>\u2022<\/li><\/ul><p>Opioids should not be administered to paediatric patients with primary pain<\/p><ul><li>in these patients they are likely to cause more harm than benefit.<\/li><\/ul><p>disorders<\/p><p>These disorders include:<\/p><p>Primary headaches: tension headaches and migraines<\/p><p>o<\/p><p>Centrally mediated central abdominal pain syndrome<\/p><p>o<\/p><p>Chronic musculoskeletal and joint pain<\/p><p>o<\/p><p>\u201cChronic sickle cell pain\u201d (pain that extends beyond the expected time of<\/p><p>o<\/p><p>acute vaso-occlusive crisis)<\/p><p>Page 53 of 57<\/p><ul><li>\u2022<\/li><\/ul><p>Opioids are important and effective for long-term analgesic management in<\/p><p>persistent pain conditions (i.e., long-lasting and/or repetitive nociceptive pain<\/p><p>caused by tissue injury), such as:<\/p><p>Junctional epidermolysis bullosa<\/p><p>o<\/p><p>Osteogenesis imperfecta<\/p><p>o<\/p><p>Advanced metastasized bone tumours (e.g., Ewing sarcoma)<\/p><p>o<\/p><p>(Chronic Pain in Children and Adolescents: Diagnosis and Treatment of Primary Pain<\/p><p>Disorders in Head, Abdomen, Muscles and Joints. Stefan J Friedrichsdorf et al.<\/p><p>Children    , 3, 24)<\/p><p>2016<\/p><ul><li>May be useful if sleep disturbance and pain. (Children &gt;6 years old).<\/li><\/ul><p>Amitriptyline<\/p><p>The starting dose is 0.2 mg/kg orally at night, but no more than 10mg.<\/p><p>The onset of effect may take 3-5 days, and it is sensible to reassess after one week.<\/p><p>Maintenance: -titrate to effect by increasing the dose by 0.2mg/kg and waiting 5 days<\/p><ul><li>may be titrated to a maximum of 1mg/kg daily (max dose 50mg)<\/li><\/ul><p>(usual adult dose 10-50mg)<\/p><ul><li>\u2022<\/li><\/ul><p>Patients should be evaluated for the risk factors for QT prolongation before starting<\/p><ul><li>\u2022<\/li><\/ul><p>An ECG should be considered at baseline, steady state, at the time of dose<\/p><p>increases and if another QT prolonging medicine is added<\/p><p>If you expect the Paediatric Pain Service to be involved, please discuss this before<\/p><p>commencing.<\/p><ul><li>Maybe useful for neuropathic pain. (Children &gt;2 years old)<\/li><\/ul><p>Gabapentin<\/p><p>Day 1: 10mg/kg/day, as single dose (max 300mg)<\/p><p>Day 2: 20mg/kg/day, divided BD (max 600mg/day)<\/p><p>Day 3: 30mg/kg/day, divided dose TDS (max 900mg/day), until day 7 then reassess<\/p><p>Maintenance: titrate to clinical effect (upto 40mg/kg/day in divided dose TDS)<\/p><ul><li>\u2022<\/li><\/ul><p>Recommended maximum 2400mg/day (note usual adult dose 900-3600mg/day)<\/p><ul><li>\u2022<\/li><\/ul><p>In the outpatient setting titration is usually slower (every 3 days)<\/p><ul><li>\u2022<\/li><\/ul><p>Clinical benefit is usually seen after 1-2 weeks<\/p><ul><li>\u2022<\/li><\/ul><p>Side effects include: sleepiness, dizziness, confusion, dry mouth, ataxia, abnormal<\/p><p>gait and weight gain.<\/p><p>If you expect the Paediatric Pain Service to be involved, please discuss this before<\/p><p>commencing.<\/p><ul><li>May be useful if anxiety and pain. May cause significant sedation, and<\/li><\/ul><p>Clonidine<\/p><p>may cause reduction in heart rate and blood pressure.<\/p><p>Start at 1-2mcg/kg BD PO.<\/p><ul><li>Has been suggested as being useful in some studies and has the<\/li><\/ul><p>Melatonin<\/p><p>advantages of augmenting sleep and a good side effect profile.<\/p><p>Important Note:<\/p><p>Prior to discharge, a management plan must be made for the ongoing management of<\/p><p>these drugs. It must be clear in the discharge letter whether the GP or Outpatient Clinic<\/p><p>will be responsible, and when the follow-up will occur.<\/p><p>Page 54 of 57<\/p>", "children": [{"id": 66, "page": 51, "top": 244.3, "level": 3, "font_size": 13.980000000000018, "text": "15.1 Types of Chronic Pain in Children", "content_html": "<p>(formerly functional pain syndrome)<\/p><p>Primary pain disorders:<\/p><p>Many different chronic pain syndromes are now considered to be manifestations of an<\/p><p>underlying pain vulnerability or pain spectrum condition, rather than being viewed as<\/p><p>separate disorders. Considerable evidence, points to a role of shared biological sensitivity,<\/p><p>or \u201cpain vulnerability\u201d.<\/p><p>Important features:<\/p><ul><li>\u2022<\/li><\/ul><p>Pain not explained in terms of conventional medical disease<\/p><p>(biochemical or structural abnormalities)<\/p><ul><li>\u2022<\/li><\/ul><p>Significant disruption of everyday life (often leads to incapacitation)<\/p><ul><li>\u2022<\/li><\/ul><p>Unimodal medical therapy typically unsuccessful<\/p><ul><li>\u2022<\/li><\/ul><p>Unimodal medical therapy can consume significant time, resources and finances<\/p><ul><li>\u2022<\/li><\/ul><p>Persistent treatment failures can lead to negative implications eg<\/p><ul><li>patients perceiving their pain is not organic and therefore not real/ serious<\/li><li>stigmatization (i.e. symptoms characterized as fictitious or malingering)<\/li><\/ul><p>The three most common primary pain disorders in paediatrics are:<\/p><ul><li>\u2022<\/li><\/ul><p>Primary headaches: tension headaches and migraines<\/p><ul><li>\u2022<\/li><\/ul><p>Centrally mediated central abdominal pain syndrome<\/p><ul><li>\u2022<\/li><\/ul><p>Musculoskeletal and joint pain<\/p><p>Chronic-on-acute pain<\/p><p>A significant number of children with recurrent nociceptive pain caused by underlying<\/p><p>organic disease (eg, inflammatory bowel disease, sickle cell disease, rheumatoid arthritis<\/p><p>or cancer), may develop pain which becomes complicated to treat, and have what is<\/p><p>known as \u201cchronic-on-acute\u201d disease. In these children primary pain disorders may also<\/p><p>co-exist, or even be triggered by the underlying organic disease, and pain symptoms do<\/p><p>not necessarily represent inadequate treatment, flare-up, or recurrence.<\/p>", "children": []}, {"id": 67, "page": 51, "top": 709.1, "level": 3, "font_size": 13.97999999999999, "text": "15.2 Management", "content_html": "<p>Many children with chronic pain will benefit from an interdisciplinary rehabilitative pain<\/p><p>program. This requires appropriate resources including: pain specialists and nurses,<\/p><p>psychologists, physiotherapists and occupational therapists and social workers. A lot of<\/p><p>Page 51 of 57<\/p><p>the focus is on restoring function and as this is achieved the pain improves and commonly<\/p><p>resolves \u2013 this may be summarized as \u201clife gets back to normal\u201d and then \u201cthe pain gets<\/p><p>better\u201d. To achieve this an interdisciplinary approach is required which involves a<\/p><p>combination of: (1) physical therapy (eg, range of movement, strength, balance, graded<\/p><p>motor imagery exercises); (2) integrative medicine/active mind-body techniques (eg, self-<\/p><p>relaxation, self-regulation, distraction, guided imagery exercises); (3) psychology (coping<\/p><p>strategies, targeting anxiety and depression); and (4) normalizing daily routine (school<\/p><p>attendance, sports, social life and sleep). Determining which children will benefit from an<\/p><p>interdisciplinary approach will require input from the Chronic Pain Team.<\/p>", "children": []}, {"id": 68, "page": 52, "top": 205.8, "level": 3, "font_size": 12.0, "text": "15.2.1 Referal to the Pain Service", "content_html": "<p>If the Home Team decide they would like to refer a child with chronic pain to the Pain<\/p><p>Service then the following basic principles should be adhered to:<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure the child has been reviewed by the admitting Consultant<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure the team have excluded reversible and treatable conditions<\/p><ul><li>\u2022<\/li><\/ul><p>Ensure a written referral documenting relevant imaging and bloods (including a<\/p><p>recent CBC and CRP)<\/p><ul><li>\u2022<\/li><\/ul><p>Over investigation can also be harmful and deflect from confronting the real issues<\/p><ul><li>\u2022<\/li><\/ul><p>Take a thorough pain history including psychological issues<\/p><ul><li>\u2022<\/li><\/ul><p>Use available non-pharmacological treatments<\/p>", "children": []}, {"id": 69, "page": 52, "top": 390.5, "level": 3, "font_size": 12.0, "text": "15.2.2 Initial approach and non-drug treatments", "content_html": "<p>It may be useful to start to explain to the child and family the concepts that the pain \u201cis<\/p><p>real\u201d but it \u201chas lost its warning function\u201d and that using the affected part of the body<\/p><p>does not result in greater harm. It is also helpful that the child and family begin to<\/p><p>understand that working towards \u201clife gets back to normal\u201d is important and that this<\/p><p>results in \u201cthe pain gets better\u201d.<\/p><p>At some point it can be helpful discussing pain transmission and how this can be<\/p><p>influenced by down-modulation (which results in decreased pain) or up-modulation<\/p><p>(which results in increased pain). This can help explaining that the pain is real and how<\/p><p>the interdisciplinary (\u201cnon-drug\u201d) treatment modalities work. Down-modulation can be<\/p><p>described as \u201cOFF-switch\u201d modulation which involves descending inhibition from the<\/p><p>\u201ccontrol center\u201d (the peri-aquaductal grey matter). \u201cOFF-switch\u201d modulation (decreases<\/p><p>pain) is triggered by 1) physical therapy/ exercise, and 2) integrative medicine/<\/p><p>distraction. Up-modulation can be described as \u201cON-switch\u201d modulation (increases<\/p><p>pain) which involves activation in the front of the brain (the prefrontal cortex). \u201cON-<\/p><p>switch\u201d modulation is triggered by stress, pessimism, anxiety/ depression, insomnia,<\/p><p>and absenteeism (missing school/ sports/ and social contact). \u201cON-switch\u201d modulation<\/p><p>may be reduced by 1) psychological support, and 2) normalizing the activities of daily<\/p><p>life.<\/p><p>It is also helpful to understand how fear and catastrophizing can affect pain. Both<\/p><p>exacerbate the experience of pain, and both can be experienced by the child and the<\/p><p>parents. Catastrophizing involves cognitive and emotional processes which include<\/p><p>magnification, rumination, pessimism, and feelings of helplessness. Reducing fear of<\/p><p>pain in children is important and is associated with positive functional outcomes in<\/p><p>children with primary pain disorders. It has also been shown that parental<\/p><p>catastrophizing and expectations strongly influence children\u2019s pain memory.<\/p><p>Page 52 of 57<\/p><p>So even before the Chronic Pain Service has been involved, basic non-drug treatment<\/p><p>strategies can be initiated:<\/p><ul><li>\u2022<\/li><\/ul><p>Reassure \u2013 the pain is real, using the affected part of the body will not result in<\/p><p>greater harm<\/p><ul><li>\u2022<\/li><\/ul><p>Explain \u2013 the pain has lost its warning function<\/p><ul><li>\u2022<\/li><\/ul><p>Explain \u2013 the pain can be modulated up and down<\/p><ul><li>\u2022<\/li><\/ul><p>Explain \u2013 working towards \u201clife gets back to normal\u201d is really important and results<\/p><p>in \u201cthe pain gets better\u201d<\/p><ul><li>\u2022<\/li><\/ul><p>Initiate some basic interdisciplinary rehabilitation strategies \u2013 normalizing daily<\/p><p>routine (showering, dressing, eating) and regular sleep<\/p><p>Self-relaxation<\/p><p>o<\/p><p>Distraction<\/p><p>o<\/p><p>Targeting anxiety/ catastrophizing<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Involve ward physiotherapist and play therapist<\/p><p>Online resources (for children/ families and staff):<\/p><ul><li>\u2022<\/li><\/ul><p>The    website in Australia and has some very<\/p><p>\u201cACI Pain Management Network\u201d<\/p><p>useful resources<\/p><p>Follow the link: Chronic pain resources for children and families<\/p><p>o<\/p><p>Then see \u201cFor Youth: PainBytes\u201d for some very helpful episodes<\/p><p>o<\/p><p>Provides information and education to help children/ families begin to<\/p><p>o<\/p><p>understand what is going on in the nervous system, and how to begin to<\/p><p>better manage the pain<\/p>", "children": []}, {"id": 70, "page": 53, "top": 413.4, "level": 3, "font_size": 12.0, "text": "15.2.3 Drugs", "content_html": "<p>In the short term, before review by Chronic Pain Service, some pharmacological<\/p><p>treatments may have a role, however evidence of strong efficacy is lacking for any<\/p><p>agents.<\/p><ul><li>Have been shown in many studies to be as efficacious as<\/li><\/ul><p>Paracetamol and NSAIDS<\/p><p>more \u201cpotent\u201d analgesics for reducing pain scores despite not being pursued as much<\/p><p>by patients. They have the advantage of a good side effect profile and not exacerbating<\/p><p>chronic pain states.<\/p><ul><li>Has a very idiosyncratic profile and may be very effective for some<\/li><\/ul><p>Tramadol<\/p><p>patients. It is often worth trialling.<\/p><ul><li>Have little role in primary pain disorders, i.e. those not related to tissue<\/li><\/ul><p>Opioids<\/p><p>damage. However, they are effective in persistent pain conditions with nociceptive pain<\/p><p>caused by tissue damage.<\/p><p>Key points:<\/p><ul><li>\u2022<\/li><\/ul><p>Opioids administered for primary pain disorders have low long long-term efficacy, a<\/p><p>poor safety profile, and commonly a worse clinical outcome<\/p><ul><li>\u2022<\/li><\/ul><p>Opioids should not be administered to paediatric patients with primary pain<\/p><ul><li>in these patients they are likely to cause more harm than benefit.<\/li><\/ul><p>disorders<\/p><p>These disorders include:<\/p><p>Primary headaches: tension headaches and migraines<\/p><p>o<\/p><p>Centrally mediated central abdominal pain syndrome<\/p><p>o<\/p><p>Chronic musculoskeletal and joint pain<\/p><p>o<\/p><p>\u201cChronic sickle cell pain\u201d (pain that extends beyond the expected time of<\/p><p>o<\/p><p>acute vaso-occlusive crisis)<\/p><p>Page 53 of 57<\/p><ul><li>\u2022<\/li><\/ul><p>Opioids are important and effective for long-term analgesic management in<\/p><p>persistent pain conditions (i.e., long-lasting and/or repetitive nociceptive pain<\/p><p>caused by tissue injury), such as:<\/p><p>Junctional epidermolysis bullosa<\/p><p>o<\/p><p>Osteogenesis imperfecta<\/p><p>o<\/p><p>Advanced metastasized bone tumours (e.g., Ewing sarcoma)<\/p><p>o<\/p><p>(Chronic Pain in Children and Adolescents: Diagnosis and Treatment of Primary Pain<\/p><p>Disorders in Head, Abdomen, Muscles and Joints. Stefan J Friedrichsdorf et al.<\/p><p>Children    , 3, 24)<\/p><p>2016<\/p><ul><li>May be useful if sleep disturbance and pain. (Children &gt;6 years old).<\/li><\/ul><p>Amitriptyline<\/p><p>The starting dose is 0.2 mg/kg orally at night, but no more than 10mg.<\/p><p>The onset of effect may take 3-5 days, and it is sensible to reassess after one week.<\/p><p>Maintenance: -titrate to effect by increasing the dose by 0.2mg/kg and waiting 5 days<\/p><ul><li>may be titrated to a maximum of 1mg/kg daily (max dose 50mg)<\/li><\/ul><p>(usual adult dose 10-50mg)<\/p><ul><li>\u2022<\/li><\/ul><p>Patients should be evaluated for the risk factors for QT prolongation before starting<\/p><ul><li>\u2022<\/li><\/ul><p>An ECG should be considered at baseline, steady state, at the time of dose<\/p><p>increases and if another QT prolonging medicine is added<\/p><p>If you expect the Paediatric Pain Service to be involved, please discuss this before<\/p><p>commencing.<\/p><ul><li>Maybe useful for neuropathic pain. (Children &gt;2 years old)<\/li><\/ul><p>Gabapentin<\/p><p>Day 1: 10mg/kg/day, as single dose (max 300mg)<\/p><p>Day 2: 20mg/kg/day, divided BD (max 600mg/day)<\/p><p>Day 3: 30mg/kg/day, divided dose TDS (max 900mg/day), until day 7 then reassess<\/p><p>Maintenance: titrate to clinical effect (upto 40mg/kg/day in divided dose TDS)<\/p><ul><li>\u2022<\/li><\/ul><p>Recommended maximum 2400mg/day (note usual adult dose 900-3600mg/day)<\/p><ul><li>\u2022<\/li><\/ul><p>In the outpatient setting titration is usually slower (every 3 days)<\/p><ul><li>\u2022<\/li><\/ul><p>Clinical benefit is usually seen after 1-2 weeks<\/p><ul><li>\u2022<\/li><\/ul><p>Side effects include: sleepiness, dizziness, confusion, dry mouth, ataxia, abnormal<\/p><p>gait and weight gain.<\/p><p>If you expect the Paediatric Pain Service to be involved, please discuss this before<\/p><p>commencing.<\/p><ul><li>May be useful if anxiety and pain. May cause significant sedation, and<\/li><\/ul><p>Clonidine<\/p><p>may cause reduction in heart rate and blood pressure.<\/p><p>Start at 1-2mcg/kg BD PO.<\/p><ul><li>Has been suggested as being useful in some studies and has the<\/li><\/ul><p>Melatonin<\/p><p>advantages of augmenting sleep and a good side effect profile.<\/p><p>Important Note:<\/p><p>Prior to discharge, a management plan must be made for the ongoing management of<\/p><p>these drugs. It must be clear in the discharge letter whether the GP or Outpatient Clinic<\/p><p>will be responsible, and when the follow-up will occur.<\/p><p>Page 54 of 57<\/p>", "children": []}]}, {"id": 71, "page": 55, "top": 77.6, "level": 2, "font_size": 13.980000000000018, "text": "16. PALLIATIVE CARE, TERMINAL ILLNESS AND END-OF-LIFE", "content_html": "<p>Specialist Paediatric Palliative Care is an extremely limited resource in New Zealand and<\/p><p>is currently available only through Starship Hospital.<\/p><p>However, good quality end-of-life care and symptom management can still be achieved<\/p><p>through a multidisciplinary approach as required. The lead clinician will be a Paediatrician,<\/p><p>who will typically seek Specialist Paediatric Palliative Care advice from Starship Hospital.<\/p><p>However, if required, the Paediatric Pain Service at Waikato is happy to provide advice on<\/p><p>the management of pain related issues in this patient group (including outpatients),<\/p><p>accepting that we are not Palliative Specialists. This advice is generally in the form of<\/p><p>bridging options &amp; may include admission until the primary team can seek a definitive<\/p><p>strategy from the Paediatric Palliative Service at Starship Hospital at the earliest possible<\/p><p>opportunity.<\/p><p>16.1 Key Aspects of Care<\/p><p>For the child with a life-limiting or life-threatening illness include it is important to<\/p><p>remember the following principles:<\/p><ul><li>\u2022<\/li><\/ul><p>Recognising the situation<\/p><ul><li>\u2022<\/li><\/ul><p>Recognising high levels of anxiety are common for the child/ family and professionals<\/p><ul><li>\u2022<\/li><\/ul><p>Appropriate and open communication with the child and family<\/p><ul><li>\u2022<\/li><\/ul><p>Minimising or avoiding interventions that are futile or add limited benefit<\/p><ul><li>\u2022<\/li><\/ul><p>Planning is important, ie an end-of-life care plan<\/p><p>Initiated by senior clinician, involves family and child<\/p><p>o<\/p><p>Includes advanced care plan (ceiling of care, place of care/ death, donation)<\/p><p>o<\/p><p>Includes management plan (flexible plan, symptom management goals,<\/p><p>o<\/p><p>psychosocial spiritual support, people and equipment, contacts 24/7)<\/p><p>16.2 Symptom Management<\/p><p>16.2.1 General Approach<\/p><p>As already outlined above, caring for the dying child involves more than just symptom<\/p><p>control \u2013 emotional, psychological, and spiritual support of the child and the family are<\/p><p>essential.<\/p><p>The following may be helpful:<\/p><ul><li>\u2022<\/li><\/ul><p>Don\u2019t panic \u2013 stop and gather information:<\/p><p>Read the notes<\/p><p>o<\/p><p>Talk to the parents \u2013 they play a pivotal role in care<\/p><p>o<\/p><p>Talk to the child \u2013 they may be old enough to describe their symptoms<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Document and discuss the plan<\/p><ul><li>\u2022<\/li><\/ul><p>Beware of emotional burnout \u2013 maintain professional compassion and care<\/p><p>Page 55 of 57<\/p><p>16.2.2 Pain Management<\/p><p>Pain is a feared and common symptom in children receiving end-of-life care. There are<\/p><p>many varied causes of pain, and in this group of children the cause of the pain is often<\/p><p>multi-factorial. Most of the time the pain is simple to manage. Management is based on<\/p><p>a good assessment and understanding of the disease process, good communication<\/p><p>and an empiric approach with regular reviews of the response to treatment.<\/p><p>It is also important to remember that management should include \u2018non-drug\u2019 treatment.<\/p><p>Without addressing the child\u2019s emotional, psychological, and spiritual needs drug<\/p><p>treatment alone will not be completely successful.<\/p><p>Remember:<\/p><ul><li>\u2022<\/li><\/ul><p>Effective treatment requires a trusting relationship which requires good<\/p><p>communication<\/p><ul><li>\u2022<\/li><\/ul><p>Determine what the pain means to the child and parent \u2013 what do they understand<\/p><ul><li>\u2022<\/li><\/ul><p>What children think, feel and do with their pain influences their pain experience<\/p><p>Eg, worsening physical function, sleep deprivation, upset parents, and feeling<\/p><p>o<\/p><p>scared may all effect pain<\/p><ul><li>\u2022<\/li><\/ul><p>Myths/ misunderstandings can cause:<\/p><p>Increased anxiety<\/p><p>o<\/p><p>Poor compliance<\/p><p>o<\/p><p>Poor reporting eg, if people know I\u2019m in pain I\u2019ll have to stay in hospital<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Honest and age-appropriate explanations and options help the child and family<\/p><p>Prescribing:<\/p><p>The oral route is the simplest but may not always be appropriate:<\/p><ul><li>\u2022<\/li><\/ul><p>Pain crisis requiring rapid titration of IV opioids<\/p><ul><li>\u2022<\/li><\/ul><p>Poor absorption: vomiting, disordered GI motility<\/p><ul><li>\u2022<\/li><\/ul><p>Inability to comply: unconscious, severe nausea, poor swallow/ aspiration risk,<\/p><p>mediaction refusal<\/p><p>In this case consider the role of the subcutaneous route. Subcutaneous infusions are<\/p><p>frequently and incorrectly viewed as both a painful intervention and an option only<\/p><p>when the child is actively dying. Instead they can be utilised over long term periods and<\/p><p>minimise both the trauma of repeated cannulation and the risks associated with central<\/p><p>access.<\/p><p>Opioids:<\/p><p>There are 3 phases in finding the \u2018right dose\u2019:<\/p><ul><li>\u2022<\/li><\/ul><p>Initiation \u2013 charted according to weight/ age (mindful of other charted drugs)<\/p><ul><li>\u2022<\/li><\/ul><p>Titration \u2013 remember don\u2019t increase daily amount by more than 30-50%<\/p><ul><li>\u2022<\/li><\/ul><p>Maintenance \u2013 LA opioids are started once a stable effective daily dose has been<\/p><p>found<\/p><p>Transdermal fentanyl takes 12-24hours to be effective so it is only used once<\/p><p>o<\/p><p>child is stabilized on morphine or equivalent<\/p><p>th    th<\/p><p>to 1/10 daily dose<\/p><p>Chart PRN \u2018rescue dose\u2019 \u2013 1/5<\/p><p>o<\/p><p>Opioid switch and rotation:<\/p><ul><li>\u2022<\/li><\/ul><p>Switch \u2013 change in opioid early on because opioid relatively ineffective or trouble<\/p><p>with side-effects. Consider when:<\/p><p>Analgesia inadequate<\/p><p>o<\/p><p>Page 56 of 57<\/p><p>Dose-limiting side-effects<\/p><p>o<\/p><p>Adequate analgesia but unpleasant side-effects<\/p><p>o<\/p><p>Alternative opioid has specific advantages<\/p><p>o<\/p><p>(eg change from enteral morphine to transdermal fentanyl)<\/p><ul><li>\u2022<\/li><\/ul><p>Rotation \u2013 change in opioid after a period of benefit because tolerance appears to<\/p><p>be developing<\/p><ul><li>\u2022<\/li><\/ul><p>The new dose is calculated as follows:<\/p><p>Calculate oral morphine equivalent<\/p><p>o<\/p><p>Reduce dose of new opioid by 25-30%<\/p><p>o<\/p><p>(This allows for incomplete cross-tolerance - thus reduces the risk of toxicity)<\/p><p>16.3 Resources<\/p><p>Services:<\/p><ul><li>\u2022<\/li><\/ul><p>Paediatric Medicine \u2013 the lead clinician should be a Paediatrician<\/p><p>(<\/p><p>One of the Paediatricians at Waikato Hospital will be the assigned the role as \u2018link<\/p><p>Paediatrician\u2019 for Paediatric Palliative Care in our region)<\/p><ul><li>\u2022<\/li><\/ul><p>Adult Palliative Care \u2013 some of the specialists may be comfortable to be consulted<\/p><p>Online resources:<\/p><ul><li>\u2022<\/li><\/ul><p>The \u201c    \u201d website in the UK has some very useful resources<\/p><p>Together for Short Lives<\/p><p>Follow the link: Palliative care resources for professionals<\/p><p>o<\/p><p>Then see \u201cBasic Symptom Control in Paediatric Palliative Care\u201d<\/p><p>o<\/p><p>\uf0a7<\/p><p>Pain p108<\/p><p>\uf0a7<\/p><p>Pain management p110<\/p><ul><li>\u2022<\/li><\/ul><p>The \u201c    \u201d website is also very useful<\/p><p>Starship Paediatric Palliative Care Network<\/p><p>Follow the link: Starship Paediatric Palliative Care Network<\/p><p>o<\/p><p>Then see \u201cPaediatric Palliative Care Clinical Guidelines\u201d:<\/p><p>o<\/p><p>\uf0a7<\/p><p>Pain management<\/p><p>\uf0a7<\/p><p>Various symptom managements<\/p><p>\uf0a7<\/p><p>Palliative care emergencies<\/p><p>Page 57 of 57<\/p>", "children": [{"id": 72, "page": 55, "top": 320.2, "level": 3, "font_size": 13.980000000000018, "text": "16.1 Key Aspects of Care", "content_html": "<p>For the child with a life-limiting or life-threatening illness include it is important to<\/p><p>remember the following principles:<\/p><ul><li>\u2022<\/li><\/ul><p>Recognising the situation<\/p><ul><li>\u2022<\/li><\/ul><p>Recognising high levels of anxiety are common for the child/ family and professionals<\/p><ul><li>\u2022<\/li><\/ul><p>Appropriate and open communication with the child and family<\/p><ul><li>\u2022<\/li><\/ul><p>Minimising or avoiding interventions that are futile or add limited benefit<\/p><ul><li>\u2022<\/li><\/ul><p>Planning is important, ie an end-of-life care plan<\/p><p>Initiated by senior clinician, involves family and child<\/p><p>o<\/p><p>Includes advanced care plan (ceiling of care, place of care/ death, donation)<\/p><p>o<\/p><p>Includes management plan (flexible plan, symptom management goals,<\/p><p>o<\/p><p>psychosocial spiritual support, people and equipment, contacts 24/7)<\/p>", "children": []}, {"id": 73, "page": 55, "top": 529.7, "level": 3, "font_size": 13.980000000000018, "text": "16.2 Symptom Management", "content_html": "<p class=\"text-muted\">No text detected for this section.<\/p>", "children": []}, {"id": 74, "page": 55, "top": 557.8, "level": 3, "font_size": 12.0, "text": "16.2.1 General Approach", "content_html": "<p>As already outlined above, caring for the dying child involves more than just symptom<\/p><p>control \u2013 emotional, psychological, and spiritual support of the child and the family are<\/p><p>essential.<\/p><p>The following may be helpful:<\/p><ul><li>\u2022<\/li><\/ul><p>Don\u2019t panic \u2013 stop and gather information:<\/p><p>Read the notes<\/p><p>o<\/p><p>Talk to the parents \u2013 they play a pivotal role in care<\/p><p>o<\/p><p>Talk to the child \u2013 they may be old enough to describe their symptoms<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Document and discuss the plan<\/p><ul><li>\u2022<\/li><\/ul><p>Beware of emotional burnout \u2013 maintain professional compassion and care<\/p><p>Page 55 of 57<\/p>", "children": []}, {"id": 75, "page": 56, "top": 66.7, "level": 3, "font_size": 12.0, "text": "16.2.2 Pain Management", "content_html": "<p>Pain is a feared and common symptom in children receiving end-of-life care. There are<\/p><p>many varied causes of pain, and in this group of children the cause of the pain is often<\/p><p>multi-factorial. Most of the time the pain is simple to manage. Management is based on<\/p><p>a good assessment and understanding of the disease process, good communication<\/p><p>and an empiric approach with regular reviews of the response to treatment.<\/p><p>It is also important to remember that management should include \u2018non-drug\u2019 treatment.<\/p><p>Without addressing the child\u2019s emotional, psychological, and spiritual needs drug<\/p><p>treatment alone will not be completely successful.<\/p><p>Remember:<\/p><ul><li>\u2022<\/li><\/ul><p>Effective treatment requires a trusting relationship which requires good<\/p><p>communication<\/p><ul><li>\u2022<\/li><\/ul><p>Determine what the pain means to the child and parent \u2013 what do they understand<\/p><ul><li>\u2022<\/li><\/ul><p>What children think, feel and do with their pain influences their pain experience<\/p><p>Eg, worsening physical function, sleep deprivation, upset parents, and feeling<\/p><p>o<\/p><p>scared may all effect pain<\/p><ul><li>\u2022<\/li><\/ul><p>Myths/ misunderstandings can cause:<\/p><p>Increased anxiety<\/p><p>o<\/p><p>Poor compliance<\/p><p>o<\/p><p>Poor reporting eg, if people know I\u2019m in pain I\u2019ll have to stay in hospital<\/p><p>o<\/p><ul><li>\u2022<\/li><\/ul><p>Honest and age-appropriate explanations and options help the child and family<\/p><p>Prescribing:<\/p><p>The oral route is the simplest but may not always be appropriate:<\/p><ul><li>\u2022<\/li><\/ul><p>Pain crisis requiring rapid titration of IV opioids<\/p><ul><li>\u2022<\/li><\/ul><p>Poor absorption: vomiting, disordered GI motility<\/p><ul><li>\u2022<\/li><\/ul><p>Inability to comply: unconscious, severe nausea, poor swallow/ aspiration risk,<\/p><p>mediaction refusal<\/p><p>In this case consider the role of the subcutaneous route. Subcutaneous infusions are<\/p><p>frequently and incorrectly viewed as both a painful intervention and an option only<\/p><p>when the child is actively dying. Instead they can be utilised over long term periods and<\/p><p>minimise both the trauma of repeated cannulation and the risks associated with central<\/p><p>access.<\/p><p>Opioids:<\/p><p>There are 3 phases in finding the \u2018right dose\u2019:<\/p><ul><li>\u2022<\/li><\/ul><p>Initiation \u2013 charted according to weight/ age (mindful of other charted drugs)<\/p><ul><li>\u2022<\/li><\/ul><p>Titration \u2013 remember don\u2019t increase daily amount by more than 30-50%<\/p><ul><li>\u2022<\/li><\/ul><p>Maintenance \u2013 LA opioids are started once a stable effective daily dose has been<\/p><p>found<\/p><p>Transdermal fentanyl takes 12-24hours to be effective so it is only used once<\/p><p>o<\/p><p>child is stabilized on morphine or equivalent<\/p><p>th    th<\/p><p>to 1/10 daily dose<\/p><p>Chart PRN \u2018rescue dose\u2019 \u2013 1/5<\/p><p>o<\/p><p>Opioid switch and rotation:<\/p><ul><li>\u2022<\/li><\/ul><p>Switch \u2013 change in opioid early on because opioid relatively ineffective or trouble<\/p><p>with side-effects. Consider when:<\/p><p>Analgesia inadequate<\/p><p>o<\/p><p>Page 56 of 57<\/p><p>Dose-limiting side-effects<\/p><p>o<\/p><p>Adequate analgesia but unpleasant side-effects<\/p><p>o<\/p><p>Alternative opioid has specific advantages<\/p><p>o<\/p><p>(eg change from enteral morphine to transdermal fentanyl)<\/p><ul><li>\u2022<\/li><\/ul><p>Rotation \u2013 change in opioid after a period of benefit because tolerance appears to<\/p><p>be developing<\/p><ul><li>\u2022<\/li><\/ul><p>The new dose is calculated as follows:<\/p><p>Calculate oral morphine equivalent<\/p><p>o<\/p><p>Reduce dose of new opioid by 25-30%<\/p><p>o<\/p><p>(This allows for incomplete cross-tolerance - thus reduces the risk of toxicity)<\/p>", "children": []}, {"id": 76, "page": 57, "top": 220.6, "level": 3, "font_size": 13.980000000000018, "text": "16.3 Resources", "content_html": "<p>Services:<\/p><ul><li>\u2022<\/li><\/ul><p>Paediatric Medicine \u2013 the lead clinician should be a Paediatrician<\/p>", "children": []}, {"id": 77, "page": 57, "top": 286.8, "level": 3, "font_size": 12.0, "text": "(", "content_html": "<p>One of the Paediatricians at Waikato Hospital will be the assigned the role as \u2018link<\/p><p>Paediatrician\u2019 for Paediatric Palliative Care in our region)<\/p><ul><li>\u2022<\/li><\/ul><p>Adult Palliative Care \u2013 some of the specialists may be comfortable to be consulted<\/p><p>Online resources:<\/p><ul><li>\u2022<\/li><\/ul><p>The \u201c    \u201d website in the UK has some very useful resources<\/p><p>Together for Short Lives<\/p><p>Follow the link: Palliative care resources for professionals<\/p><p>o<\/p><p>Then see \u201cBasic Symptom Control in Paediatric Palliative Care\u201d<\/p><p>o<\/p><p>\uf0a7<\/p><p>Pain p108<\/p><p>\uf0a7<\/p><p>Pain management p110<\/p><ul><li>\u2022<\/li><\/ul><p>The \u201c    \u201d website is also very useful<\/p><p>Starship Paediatric Palliative Care Network<\/p><p>Follow the link: Starship Paediatric Palliative Care Network<\/p><p>o<\/p><p>Then see \u201cPaediatric Palliative Care Clinical Guidelines\u201d:<\/p><p>o<\/p><p>\uf0a7<\/p><p>Pain management<\/p><p>\uf0a7<\/p><p>Various symptom managements<\/p><p>\uf0a7<\/p><p>Palliative care emergencies<\/p><p>Page 57 of 57<\/p>", "children": []}]}]}]};
    const headingsTree = Array.isArray(headingData) ? headingData : (headingData.headings || []);
    const pdfSource = Array.isArray(headingData)
      ? ''
      : (
          headingData.pdf_path ||
          headingData.pdf ||
          headingData.pdf_filename ||
          headingData.pdfPath ||
          ''
        );

    const sidebarContent = document.getElementById('sidebarContent');
    const content = document.querySelector('.content');
    const searchInput = document.getElementById('searchInput');
    let currentSelectedButton = null;
    let pdfDocPromise = null;

    function collectChapters(tree) {
      const chapters = [];
      function walk(nodes) {
        nodes.forEach(node => {
          if (node.level === 2) {
            chapters.push(node);
          }
          if (node.children && node.children.length) {
            walk(node.children);
          }
        });
      }
      walk(tree);
      return chapters;
    }

    function filterNodesBySearch(term, chapters) {
      if (!term) return chapters;
      term = term.toLowerCase();
      return chapters.map(ch => {
        const matchChapter = ch.text.toLowerCase().includes(term);
        const filteredChildren = (ch.children || []).filter(child =>
          child.text.toLowerCase().includes(term)
        );
        if (matchChapter || filteredChildren.length) {
          return Object.assign({}, ch, { children: filteredChildren.length ? filteredChildren : ch.children });
        }
        return null;
      }).filter(Boolean);
    }

    function renderSidebar(chapters) {
      sidebarContent.innerHTML = "";
      chapters.forEach(chapter => {
        const chapterEl = document.createElement('div');
        chapterEl.classList.add('chapter');   // base class first

        const hasChildren = chapter.children && chapter.children.length > 0;

        // Default state:
        // - With children -> collapsed (hidden, ▸)
        // - Without children -> expanded, no chevron
        if (hasChildren) {
          chapterEl.dataset.expanded = 'false';
          chapterEl.classList.add('collapsed');   // ensure hidden on first render
        } else {
          chapterEl.dataset.expanded = 'true';
        }

        const titleEl = document.createElement('div');
        titleEl.className = 'chapter-title';

        const titleText = document.createElement('span');
        titleText.textContent = chapter.text;
        titleEl.appendChild(titleText);

        let chevron = null;
        if (hasChildren) {
          chevron = document.createElement('span');
          chevron.className = 'chevron';
          chevron.textContent = '▸'; // collapsed by default
          titleEl.appendChild(chevron);
        }

        titleEl.addEventListener('click', () => {
          if (hasChildren) {
            const expanded = chapterEl.dataset.expanded === 'true';
            if (expanded) {
              chapterEl.dataset.expanded = 'false';
              chapterEl.classList.add('collapsed');
              if (chevron) chevron.textContent = '▸';
            } else {
              chapterEl.dataset.expanded = 'true';
              chapterEl.classList.remove('collapsed');
              if (chevron) chevron.textContent = '▾';
            }
          }
          // Show this chapter in the main pane
          showHeading(chapter, chapter);
        });

        chapterEl.appendChild(titleEl);

        if (hasChildren) {
          const listEl = document.createElement('div');
          listEl.className = 'subheading-list';

          chapter.children.forEach(child => {
            const btn = document.createElement('button');
            btn.className = 'subheading-btn';
            btn.textContent = child.text;
            btn.addEventListener('click', (e) => {
              e.stopPropagation();
              selectButton(btn);
              showHeading(child, chapter);
            });
            listEl.appendChild(btn);
          });

          chapterEl.appendChild(listEl);
        }

        sidebarContent.appendChild(chapterEl);
      });
    }

    function selectButton(btn) {
      if (currentSelectedButton) {
        currentSelectedButton.classList.remove('selected');
      }
      currentSelectedButton = btn;
      if (currentSelectedButton) {
        currentSelectedButton.classList.add('selected');
      }
    }

    async function ensurePdfLoaded() {
      if (!pdfSource) {
        throw new Error("No PDF path defined in headings.json");
      }
      if (!window.pdfjsLib) {
        throw new Error("pdf.js failed to load");
      }
      if (!pdfDocPromise) {
        pdfDocPromise = window.pdfjsLib.getDocument(pdfSource).promise;
      }
      return pdfDocPromise;
    }

    async function renderPdfPage(pageNumber, canvas) {
      const pdf = await ensurePdfLoaded();
      const page = await pdf.getPage(pageNumber);
      const viewport = page.getViewport({ scale: 1.2 });
      const ctx = canvas.getContext('2d');
      canvas.width = viewport.width;
      canvas.height = viewport.height;
      await page.render({ canvasContext: ctx, viewport }).promise;
    }

    async function showHeading(node, chapter) {
      content.innerHTML = "";

      const h1 = document.createElement('h1');
      h1.textContent = node.text;

      const meta = document.createElement('p');
      meta.className = 'meta';
      meta.textContent = `Part of "${chapter.text}" • Page ${node.page} • Level L${node.level}`;

      const pills = document.createElement('div');
      const pillChapter = document.createElement('span');
      pillChapter.className = 'pill';
      pillChapter.textContent = 'Chapter: ' + chapter.text;

      const pillPage = document.createElement('span');
      pillPage.className = 'pill';
      pillPage.textContent = 'Page: ' + node.page;

      const pillLevel = document.createElement('span');
      pillLevel.className = 'pill';
      pillLevel.textContent = 'Level: L' + node.level;

      pills.appendChild(pillChapter);
      pills.appendChild(pillPage);
      pills.appendChild(pillLevel);

      content.appendChild(h1);
      content.appendChild(meta);
      content.appendChild(pills);

      const pdfWrapper = document.createElement('div');
      pdfWrapper.className = 'pdf-container';

      const pdfStatus = document.createElement('div');
      pdfStatus.className = 'pdf-status';
      pdfWrapper.appendChild(pdfStatus);

      content.appendChild(pdfWrapper);

      if (!pdfSource) {
        pdfStatus.textContent = 'Add "pdf" to headings.json to preview the file here.';
        pdfWrapper.classList.add('error');
        const textDumpFallback = document.createElement('div');
        textDumpFallback.className = 'section-text';
        textDumpFallback.innerHTML = node.content_html || '<p class="text-muted">No extracted text for this section yet.</p>';
        content.appendChild(textDumpFallback);
        return;
      }

      pdfStatus.textContent = `Loading page ${node.page}…`;

      const canvas = document.createElement('canvas');
      canvas.className = 'pdf-canvas';
      pdfWrapper.appendChild(canvas);

      const controls = document.createElement('div');
      controls.className = 'page-controls';
      const prevBtn = document.createElement('button');
      prevBtn.className = 'page-btn';
      prevBtn.textContent = '← Prev page';
      const pageIndicator = document.createElement('span');
      pageIndicator.className = 'page-indicator';
      const nextBtn = document.createElement('button');
      nextBtn.className = 'page-btn';
      nextBtn.textContent = 'Next page →';
      controls.appendChild(prevBtn);
      controls.appendChild(pageIndicator);
      controls.appendChild(nextBtn);
      content.appendChild(controls);

      const pdfDoc = await ensurePdfLoaded();
      const totalPages = pdfDoc.numPages;
      let activePage = node.page;
      let isRendering = false;

      function updateControls() {
        prevBtn.disabled = activePage <= 1;
        nextBtn.disabled = activePage >= totalPages;
        pageIndicator.textContent = `Page ${activePage} / ${totalPages}`;
      }

      async function goToPage(targetPage) {
        if (targetPage < 1 || targetPage > totalPages || isRendering) {
          return;
        }
        isRendering = true;
        pdfStatus.textContent = `Loading page ${targetPage}…`;
        try {
          await renderPdfPage(targetPage, canvas);
          activePage = targetPage;
          pdfStatus.textContent = `Showing page ${targetPage}`;
        } catch (err) {
          console.error(err);
          pdfWrapper.classList.add('error');
          pdfStatus.textContent = 'Unable to load PDF page. Check console for details.';
        } finally {
          isRendering = false;
          updateControls();
        }
      }

      prevBtn.addEventListener('click', () => goToPage(activePage - 1));
      nextBtn.addEventListener('click', () => goToPage(activePage + 1));

      await goToPage(node.page);

      const textDump = document.createElement('div');
      textDump.className = 'section-text';
      textDump.innerHTML = node.content_html || '<p class="text-muted">No extracted text for this section yet.</p>';
      content.appendChild(textDump);
    }

    const allChapters = collectChapters(headingsTree);

    // Initial render
    renderSidebar(allChapters);

    // Search filter
    searchInput.addEventListener('input', () => {
      const term = searchInput.value;
      const filtered = filterNodesBySearch(term, allChapters);
      renderSidebar(filtered);
      currentSelectedButton = null;
    });
  </script>
</body>
</html>
